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Summary 
For centuries, the threat of prion disease has plagued populations – whether it be in the form of scrapie 
ravaging through the sheep populations of Spain in the eighteenth century, fatal familial insomnia 
afflicting families in Italy, or an outbreak of Creutzfeldt-Jakob disease in the UK triggered by the 
consumption of contaminated beef. The ability of prions to spread with such pathogenic intent whilst 
remaining incurable fuels the fire of public concern - yet delving beyond that classical view of prions 
has led to an enlightened appreciation of the role of such proteins throughout the biota of life.  
Prion-like proteins subvert the dogma of the one-to-one structure-function relationship traditionally held 
onto when considering the physiology of proteins. Instead, these proteins display structural 
polymorphism, capable of adopting different conformations under different conditions; this expands the 
capabilities of protein function and represents a mechanism for epigenetic coding, with protein 
conformation possessing the ability convey and propagate specific states for biological advantage 
without the need for DNA modification. The properties observed in many of these proteins, including 
those of multivalency and low complexity, predispose them towards phase separation, whereby localised 
concentration of biomolecules compartmentalise cellular activity. This ability confers upon an organism 
the ability to respond to stimuli in dynamic and transient fashions without needing to use cumbersome 
membrane-bound organelles. 
Using the Prion-Like Amino Acid Composition program, we have identified the stress-responsive 
protein ABU-13 as a potential prion in the nematode species, Caenorhabditis elegans. Phenotypic 
analysis of ABU-13 knockout animals has identified a non-redundant role for this protein in ER stress 
and innate immune responses – in keeping with previous evidence that this family of proteins is involved 
with a non-canonical unfolded protein response pathway of the endoplasmic reticulum. These knockout 
animals do not display defects in the activation of the stress-response gene hsp-4 upon tunicamycin 
treatment, suggesting that these effects occur independently of the canonical UPR pathway. 
In vivo and in vitro characterisation of ABU-13 has demonstrated a propensity for coalescence, 
reminiscent of a phase-separated organelle. This is further supported by the ability of this protein to bind 
RNA – a common feature of prion-like proteins involved with such transitions. Co-immunoprecipitation 
of ABU-13 confirmed an enrichment of ER and RNA-related protein interactions, supporting a role for 
this protein in ER stress responses. In addition to this, a number of glycosylation related terms were 
identified, pointing towards a role for ABU-13 in the folding quality control of such proteins. 
 vi 
These punctated structures do, however, appear less mobile than traditional liquid-like condensates, as 
demonstrated by a slow FRAP recovery, indicative of a more hydrogel-like structure. To further 
investigate this, we extracted hydrogel-forming proteins from N2 animals using a biotinylated isoxazole 
precipitation, identifying a number of novel proteins that may be involved with in the formation of such 
solid-like structures. ABU-13, however, was not amongst this dataset, suggesting that if it were indeed 
involved in a physiological hydrogel, this transition is driven by another protein component.  
Overall, we propose that ABU-13 represents a phase-separating prion-like protein capable of 
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For centuries, the threat of prion disease has plagued populations – whether it be in the form of scrapie 
ravaging the sheep populations of Spain in the eighteenth century, fatal familial insomnia afflicting 
families in Italy, or an outbreak of Creutzfeldt-Jakob disease in the UK triggered by the consumption of 
contaminated beef. The ability of prions to spread with such pathogenic intent whilst remaining 
incurable fuels the fire of public concern - yet delving beyond that classical view of prions has led to an 
enlightened appreciation of the role of such proteins throughout the biota of life.  
 
Prion-like proteins subvert the dogma of the one-to-one structure-function relationship traditionally held 
onto when considering the physiology of proteins. Instead, these proteins display structural 
polymorphism, capable of adopting different conformations under different conditions; this expands the 
capabilities of protein function and represents a mechanism for epigenetic coding, with protein 
conformation possessing the ability to convey and propagate specific states for biological advantage 
without the need for DNA modification. The properties observed in many of these proteins, including 
those of multivalency and low complexity, predispose them towards phase separation, whereby localised 
concentration of biomolecules compartmentalises cellular activity. This ability confers upon an 
organism the ability to respond to stimuli in dynamic and transient fashions without needing to use 
cumbersome membrane-bound organelles.  
 
In this thesis, the role of a novel prion-like protein will be explored in the nematode species 
Caenorhabditis elegans. During this investigation, the function of this protein in cellular stress and the 
potential molecular mechanisms underlying these functions will be examined. 
 
1.1 Prions 
Whilst the physiological function of the mammalian prion protein remains elusive, its role in the 
development of neurodegenerative pathology is better understood. This protein, encoded by the Prnp 
gene, is endogenously expressed within the nervous system where it is believed to play roles in synaptic 
maintenance, potentially by modulating the voltage-gated potassium channel Kv4.2 and reducing 
neuronal excitability1, or through the inhibition of glutamatergic NMDA receptor subunits2. Under 
healthy conditions, this protein remains in its soluble conformation (PrPC). However, in disease, this 
soluble protein is capable of a conversion into an insoluble, aggregation-prone structure (PrPSc)3–7. In 
this insoluble state, it is then able to seed the conversion of other soluble forms of the protein to the 
same conformation – a transition known as conformational templating (Figure 1.1A-B). 
 
In this insoluble conformation, these proteins expose hydrophobic residues normally retained within the 
core of the protein – as a result, as these misfolded species build up, they begin to fibrilise, forming 
large intracellular deposits that bury these hydrophobic domains within the fibril itself, protected from 
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the solvent environment of the cytoplasm. These oligomeric and fibrillar structures are able to splinter, 
resulting in the production of new seeds capable of triggering the formation of further fibrils within that 
environment.  
 
These seeds are also capable of moving intercellularly, spreading pathology between cells and tissues 
within an organism. A number of pathways have been implicated in this process including tunnelling 
nanotubes between cells8, exosomal release from donor cells9, and macropinocytosis uptake into 
acceptor cells10. Whilst the exact mechanism of transcellular spreading is not fully understood, it is clear 
that these prionogenic seeds can trigger fibril formation in the acceptor cell. It is this affinity for 
intracellular seeding and intercellular spreading that partly gives rise to the canonical properties that 
define the prion protein. 
 
Figure 1.1 Prion-like propagation (A) schematic depicting the prion propagation life cycle from soluble protein to insoluble 
fibrils; (B) structural differences between the soluble PrPC and insoluble PrPSc conformations (adapted from Ruttkay-Nedecky 
et al., 2015) 
 
Whilst in this aggregated, insoluble state, PrPSc becomes resistant to degradation, as illustrated by its 
resistance to heat denaturation, Proteinase K digestion7 and UV irradiation4. It is also difficult for the 
cell to clear these deposits, and they are therefore able to accumulate with time. This build up disrupts 
neuronal cell function and ultimately leads to cell death - however the mechanisms underlying this 
damage are unclear. There are some suggestions that these species are toxic in their oligomeric form 
and thus their fibrillisation is protective12. Whilst this is yet to be fully understood, genetic evidence 
from knockout animals illustrates the necessity for PrPSc aggregation in the development of 
neuropathology including cortical vacuolation and astrogliosis13 – both hallmarks of prion disease. 
 
Akin to traditional infectious agents, prion diseases come in different ‘strains’ and, when propagated 
onto the next host, this strain is then maintained within that organism. In traditional agents, such as 
viruses and bacteria, this strain variation derives from evolutionary selection pressures favouring 
particular nucleotide differences that manifest as advantageous phenotypes in specific environments. 
For prions, however, strains are an entirely distinct concept to this – instead, a variety of misfolded 
conformational states of the prion protein can be found within a single host. Some of these 
Cartoon of structural shift from PrP-C to PrP-Sc 




conformations will make up the majority of the misfolded protein load, whilst others will constitute a 
minor proportion of these. The proportional contributions of each conformation to the overall mix of 
prion structures is what defines a prion ‘strain’ – and these conformational proportions are carried 
through when the infection spreads to another organism14. This strain diversity extends beyond the 
biochemistry of the prion protein too, as different conformations exhibit differential abilities to seed, 
spread and cause disease; this effect is best illustrated by both the varying lag times between infection 
and clinical disease between prion strains, and the maintenance of similar seeding abilities within a 
strain, as measured using in vitro methods such as protein misfolding cyclic amplification15 (PMCA) or 
real-time quaking-induced conversion (RT-QuIC) assays16. As such, although the molecular 
determinants of ‘strain’ variation differ between prions and other infectious agents, they share the ability 
to trigger pathology in different ways.  
 
1.1.1 Prion-like proteins in pathology 
Beyond the actual prion protein, however, there are a range of other proteins that display prion-like 
characteristics. These often encompass aggregation-prone proteins involved with the development of 
neurodegenerative diseases, including tau in Alzheimer’s disease17, and TDP-43 and FUS in 
amyotrophic lateral sclerosis (ALS)18. The term ‘prion-like’ is used to indicate that these proteins display 
some of the distinguishing properties that the bona fide prion protein possesses. These characteristics 
include: the ability to change conformations from a soluble to an insoluble state; the capacity to self-
template this conformation onto naïve proteins; and the capability for cell-to-cell transmission. Prion-
like proteins exist on a spectrum, with some exhibiting minor prionogenic capabilities, and others 
robustly displaying these features.  
 
1.1.1.1 Alpha synuclein 
There is some evidence that alpha synuclein, the pathological protein involved in synucleinopathies such 
as Parkinson’s disease (PD), possesses some prion-like properties, including the ability to spread 
intercellularly. This was demonstrated in human PD patients following neural transplantation trials. 
Foetal ventral mesencephalic tissue grafted into the striatum could integrate into the lost circuit and 
recapitulate lost dopaminergic inputs. However, upon death, these grafted cells showed 
immunoreactivity for Lewy body and Lewy neurite pathology19,20. While there are a number of potential 
causes of this pathology, it is possible that this represents a prionic mechanism at work, with 
pathological alpha synuclein templating its conformation onto the acceptor cells within the graft. 
Alongside PD, alpha synuclein is also involved in the development of multiple systems atrophy (MSA); 
recent evidence has identified that, while brain homogenates from PD patients were unable to stimulate 
the spread of pathology when inoculated into the brains of mice transgenic for human A53T alpha 
synuclein, the brain homogenates from MSA patients were capable of this21,22. This therefore suggests 
that different conformational states of the same aggregation prone protein can determine how 
prionogenic a protein is, even when the secondary structure is identical. This provides support for the 
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cloud hypothesis of prion strains that, as mentioned previously, suggests different conformational states 
alter the prion-like abilities of the protein. 
 
1.1.1.2 Tau 
Tauopathies, including Alzheimer’s disease and progressive supranuclear palsy (PSP), arise from the 
aggregation of misfolded tau, which consequently results in neurodegeneration. This protein, encoded 
by the MAPT gene, normally functions to stabilise microtubules; however, upon disease this function is 
lost. There are 6 isoforms of tau within the CNS produced as a result of alternative splicing of exons 2, 
3 and 10, with exons 2 and 3 found in the N-terminal region, whilst exon 10 represents a 30 amino acid 
repeat sequence within the microtubule binding region. Whilst exons 2 and 3 do not appear to influence 
pathology, alternative splicing of exon 10 - producing either 3 repeat (3R) or 4 repeat (4R) tau - does, 
with evidence pointing towards the latter predisposing individuals to both aggregation and 
neurodegeneration. This is evident in diseases whose tau-positive inclusions have been shown to contain 
the 4R tau isoform only, such as corticobasal degeneration (CBD)17,23,24. 
 
There has been emerging evidence that the tau protein acts as a prion-like protein when involved in 
pathology. This is supported, for example, by the trans-synaptic spread of tau in mouse models of 
Alzheimer’s disease, where induction of pathology in the entorhinal cortex resulted in the spread of 
pathology along anatomically connected circuits, into regions including the subiculum, the CA1 
hippocampal pyramidal neurons, and granule cells of the dentate gyrus25. There is also evidence that tau 
is capable of conformational templating; in vitro data suggests that tau aggregates applied externally can 
be internalised and seed polymerisation in the acceptor cells26. This is further backed up by in vivo data 
showing that when the brain homogenates of animals with different tauopathies are injected into the 
brains of mice expressing non-aggregation-prone forms of human tau, pathology spreads in the injected 
animal, with the resulting inclusions resembling those of the original brain homogenate27. This suggests 
that these proteins are capable of seeding aggregation and templating their specific misfolded 
conformation onto correctly folded counterparts in a prion-like fashion. 
 
Whilst tau does not possess what would be canonically recognised as a prion-like domain, recent work 
on the structure of Alzheimer’s disease filaments has identified a specific beta solenoid fold at the core 
of the fibril. This is of interest as it bears a striking resemblance to the core of a fungal prion, HET-s; 
this beta-solenoid structure has been postulated to act as a prionogenic scaffold, facilitating 
fibrillisation28. If this were indeed the case, it is possible that such a structural conformation could act 
as a non-canonical prion-like domain for the tau protein, driving its prionogenic activity. It is worth 
noting, however, that whilst this structure is seen in Alzheimer’s-related filaments, comprised of both 





1.1.2 Physiological Prion-like Proteins 
Disease-related proteins, however, are not the only proteins with prion-like properties – there are many 
proteins throughout biology that utilise these prion-like characteristics to evolutionarily advantageous 
effect. Many of these were first identified in yeast, where switching to a prionogenic, insoluble state can 
promote increased survival in response to challenging environments. It is interesting to note, however, 
that some of the proteins that possess these functional prion-like properties also overlap with those 
involved with disease, such as TDP-43 in ALS; this suggests that a switch between physiological and 
pathological state may be the driver of pathogenesis. 
 
1.1.2.1 [URE3] 
Under basal conditions, the Ure2p protein in S. cerevisiae acts as a negative regulator of nitrogen 
metabolism32. It achieves this through the regulation of uptake of allantoate33, an intermediate in the 
nitrogen metabolism pathway, by inhibiting the transcription factor Gln3p34,35 and sequestering it in the 
cytoplasm36. In an environment rich with preferable nitrogen sources, such as glutamic acid or 
ammonium sulphate, Ure2p is disinhibited as a downstream consequence of Mks1p inhibition37, thus 
allowing it to bind to this transcription factor and prevent its translocation into the nucleus. However, 
when faced with a non-preferable nitrogen source, such as proline, Mks1p is disinhibited, consequently 
leading to the inhibition of Ure2p38. Due to this inhibition, Gln3p is free to translocate into the nucleus 
where it drives the transcription of Dalp539. This is a transmembrane protein involved with the co-
transport of allantoate and ureidosuccinate into the cell; when its expression is increased, more of these 
intermediates can be imported from the environment into the organism, thus allowing it to continue with 
its nitrogen metabolism cycle, even in the presence of poor nitrogen sources.  
 
Figure 1.2 Summary of the Ure2p related pathways in S. cerevesiae 
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Following a UV mutagenesis screen, several mutants were identified that exhibited urediosuccinate-
related phenotypes, a useful readout for mutations affecting both the pyramidine biosynthesis and the 
nitrogen metabolism pathways, due to the co-transport of intermediates in both of these systems40. The 
majority of those identified displayed recessive, Mendellian genetic inheritance patterns when crossed 
into wild type strains. One of these, ure-1, showed a lack of growth on urediosuccinate-supplemented 
media under nitrogen-rich conditions41; these mutants, shown to derive from a mutation in the ura-2 
gene, coding for the aspartate transcarbamoylase protein, cannot produce their own USA and thus rely 
on its uptake from the environment. However, when ammonium ions or glutamine are present in the 
media, Dal5p production is blocked, inhibiting this uptake from occurring and ultimately preventing 
growth (Figure 1.2). 
 
Further work to delineate this regulatory pathway led to the identification of a further set of mutants 
following mutagenesis of this ura-2-deficient strain. Of these, one mutant, known as ure-3, displayed 
dominant, non-Mendellian genetic traits – this mutant was capable of utilising USA within the 
supplemented media, even in the presence of nitrogen-rich sources. This phenotype, known as [URE3], 
has been shown to be the prionogenic form of Ure2p, conferring evolutionarily beneficial effects by 
triggering the aggregation of the protein and thus preventing it from inhibiting its downstream target, 
Gln3p. As a result, Dalp5 expression is stimulated, and both allantoate and ureidosuccinate can be 
imported from the surroundings, even in a nitrogen-rich environment. 
  
The resulting prion species exhibits many of the same traits as mammalian prions. The propagation of 
[URE3], for example, is dependent on the expression of wild type Ure2p, thus satisfying the need for 
conformational templating – this can be illustrated via cytoduction, whereby the cytoplasmic contents 
of two organisms are mixed without nuclear fusion; in such conditions, the [URE3] phenotype persists 
only when Ure2p is expressed and not in the ure-2 mutants42 thus demonstrating this is a non-genetic 
mode of transmission. Furthermore, overexpression of Ure2p leads to a nearly 100-fold increase in the 
frequency of spontaneous [URE3] development – even when this overexpression is removed, the 
[URE3] phenotype is able to endure thus demonstrating that the phenotype does not rely on a high copy 
number for maintenance. Finally, this conversion to a prion-state has been shown to be reversibly 
curable, as illustrated by treatment of [URE3] strains with 5mM guanidine chloride - however, when 
the conditions are conducive, this phenotype can re-emerge later43. 
 
The molecular driver for this conversion has also been investigated biochemically through targeted 
mutagenesis of the Ure2p protein. By mutating specific residues – namely a single nucleotide deletion 
in codon 44 alongside an addition in 80 – it is possible to frame shift an entire domain of the protein, 
whilst leaving the RNA species relatively unchanged. This manipulation was targeted at the so-called 
prion domain and results in the ability of Ure2p to convert to [URE3] being lost. This is further supported 
by truncation mutations; mutants expressing only the N-terminus, where the prion-domain is located, 
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were sufficient for [URE3] propagation following cytoduction from other [URE3] strains. Those with 
just C-terminus expression, however, were unable to facilitate this propagation44. 
 
[URE3] is one of the first examples of a prion-like protein shown to confer physiological benefits onto 
an organism – in this case, by enabling the uptake and metabolism of ureidosuccinate as part of the 
pyramidine biosynthesis pathway, and allantoate as part of the nitrogen metabolism pathway. This 
represents a species of prion that facilitates its effects through loss of function of the soluble protein. 
There are, however, further examples of prion-like proteins that confer advantageous effects through 
novel functionality when in their prion state. 
 
1.1.2.2 [HET-s] 
Amongst the filamentous fungi family, heterokaryon formation is a process that allows individual fungal 
cells to form a syncytium of connected cells with a shared continuous cytoplasm known as a mycelium45. 
This functional network of fungal hyphae can spread throughout an environment, absorbing and sharing 
nutrients from the surroundings. This process, however, is tightly regulated with a mechanism in place 
to detect self from non-self – this is beneficial as many homogenous heterokaryon combinations are not 
viable, even amongst different wild type isolates of the same species. In the ascomycete fungi Podospora 
anserina, this heterokaryon incompatibility is detected using the prion, HET-s46. 
 
P. anserina can exist in one of two forms – either as [Het-s*] or as [Het-s]47, representing the non-prion 
and prion-states respectively. In addition to these states, HET-s also has a polymorphic variant known 
as HET-S that differs by just 13 amino acids48. Early evidence demonstrated that, whilst fusion of [Het-
s*] and [Het-S] was indeed heterokaryon viable, the fusion of [Het-s] and [Het-S] was not and led to 
cell death. Site-specific mutagenesis of individual residues determined that this incompatibility was a 
consequence of a single amino acid change at position 33 of the HET-s protein. 
 
Similar to other prion-like proteins, the [Het-s] state can only be propagated when there is expression of 
a functional het-s gene, and overexpression of this locus results in an increased frequency of the [Het-
s*] to [Het-s] transition. Furthermore, the protein content of the [Het-s] state displays increased 
proteinase K resistance than that of the [Het-s*] state, reminiscent of insoluble prion states described 
previously. The prionogenic nature of the HET-s protein has been illustrated using HET-s-GFP fusions; 
when expressed at wild-type levels, the protein appears diffuse and soluble in the [Het-s] state however, 
when overexpressed, aggregate formation is visible. Conversely, when the polymorphic variant HET-
S-GFP is visualised, no aggregation formation can be seen in either the wild type or overexpression 
conditions. This is a similar case for HET-s proteins with a double amino acid substitution – namely 
D23A and P33H; these substitutions are known to abolish prion infectivity and, when visualised, show 




Using these GFP fusions, the mechanism of action of these prion states was further elucidated. By co-
expression of HET-s and HET-S, transgenic strains effectively became ‘self incompatible’, 
characterised phenotypically by slow growth and aberrant morphology. This phenotype was variable 
between cells however, with those exhibiting normal growth also showing diffuse cytoplasmic GFP, 
whilst those with incompatibility phenotypes showing a combination of cytoplasmic and vacuolar GFP, 
with no HET-s-GFP aggregates49. It has been suggested that this results from HET-s-GFP aggregation 
being partially suppressed in the presence of HET-S. The mode of toxicity of this incompatibility 
response however, derives from the structural differences between HET-s and HET-S; whilst both have 
the same domain structure, with an N-terminal α-helical globular domain - known as the HeLo domain 
– and a C-terminal prion-forming domain50, there are different functional consequences to their 
fibrillisation. The conversion of HET-s to its prion-state has no specific adverse effects on the cell 
however, when HET-S is converted, it triggers a structural change in the prion-forming domain which 
goes on to induce the refolding and activation of the HeLo domain51. This activation triggers the 
relocalisation of HET-S to the periphery of the cell – a process that is toxic to the cell, with this relocation 
correlating with cell death52.  
 
Akin to other prion-like proteins, these HET-s aggregates form functional amyloid states – as 
demonstrated by biolistic incorporation of these aggregates into [Het-s*] fungi47. Unlike their 
amorphous counterparts, only the amyloidogenic forms of these inclusions are capable of triggering a 
transformation of [Het-s*] to [Het-s]. This also lends credence to the notion of conformational 
templating within this system, with HET-s amyloids triggering a conformational switch within the 
soluble pool of HET-s monomers, as opposed to the presence of aggregate species causing a general 
proteotoxic collapse within the cell and thus leading to spontaneous conversion of the soluble monomers 
to an insoluble state due to dysregulation of protein homeostasis.  
 
Hence, HET-s represents a species of prion-like proteins that confer a specific advantage to Podospora 
anserina through gain of functionality – specifically, by discerning self from non-self and thus 
promoting survival during heterokaryon formation.  
 
1.1.2.3 Cytoplasmic Polyadenylation Element Binding Protein (CPEB) 
Prionic mechanisms have also been implicated in the persistence of long-term memory in a range of 
species, as they are able to facilitate a self-perpetuating state at the level of individual synapses, allowing 
for spatially and temporally regulated potentiation. Early evidence from Aplysia suggested a role for a 
neuronal isoform of the cytoplasmic polyadenylation element binding protein (ApCPEB) in this 
facilitation through the regulation of mRNA translation53. This role is conserved across phyla, with 





Figure 1.3 Summary of the CPEB3 prion-like mechanism of action, resulting in the translation of AMPA receptor subunits 
and the facilitation of long-term potentiation (LTP) 
 
Under basal conditions, this protein is expressed at a low level and is found in its monomeric form, 
however, upon stimulation, its expression is increased and is able to form a multimeric, self-propagating 
active state, as illustrated both in vitro with the formation of GFP-positive puncta in fluorescent 
reconstitution assays59 and in vitro in murine hippocampal extracts following contextual fear 
conditioning and spatial memory tasks60. The formation of such prionogenic puncta is regulated by the 
E3 ubiquitin ligase, Neuralized1 (Neurl1), which monoubiquitinates the N-terminal PrLD of monomeric 
CPEB361, stimulating its prionogenic conversion. Inhibition of this ligase results in a failure to maintain 
long term memory, mimicking the phenotype observed in both ApCPEB inhibition studies57 and in 
CPEB3 conditional knockout studies60 suggesting that, without this ubiquitination, CPEB cannot be 
activated. Conversely, this protein is also negatively regulated via SUMOylation, as illustrated in 
CPEB3, in which activation is correlated with a decrease in SUMOylation. Additionally, chimeric fusion 
proteins of SUMO-2 and CPEB3 are unable to stimulate mRNA translation or form aggregates, neither 
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can they stimulate the same morphological changes observed synaptically downstream of CPEB3 
activation in wild type conditions62. These regulatory mechanisms are particularly interesting as, unlike 
other prion-like proteins that adopt prion states sporadically, the prion-like conversion of CPEB3 has a 
very specific mode of activation.  
 
The activation and subsequent prion-like oligomerisation of CPEB drives RNA binding and 
polyadenylation activity of specific dormant mRNAs53, driving their translation. This mechanism 
ensures that mRNA translation of target transcripts only occurs locally, as a consequence of the spatially 
restricted prion-like activity of CPEB. Of particular interest amongst these transcripts are the AMPA 
receptor subunits GluA1 and GluA2, the increased translation of which help to facilitate the long-term 
persistence of synaptic potentiation (Figure 1.3)60,61,63. 
 
This isoform of CPEB is an example of a ‘functional prion’ as it gains functionality when in its prion 
state – it is particularly interesting due to its tight regulation, with prionogenic conversions being 
triggered in response to specific stimuli, resulting in complex behavioural states.   
 
1.1.3 Prion-like domains 
The discovery of a diverse range of prion-like proteins has facilitated a greater understanding of what 
drives prionogenicity. This activity seemingly derives from specific domains within the protein, known 
as prion-like domains, as demonstrated by their fusion onto other, non-prionogenic proteins. For 
example, fusion of the NM domains of Sup35, which have been demonstrated to be vital for formation 
and maintenance of prion activity in [PSI+] isolates, onto the rat glucocorticoid receptor (GR) confers 
onto the chimera the ability to self-propagate heritable changes within a [PSI+] expression system64. 
This illustrates that the molecular determinant of prion state is both discrete and transferable between 
proteins. 
 
The modular nature of this domain has allowed sequence-specific factors facilitating prion ability to be 
identified. These domains tend to have a low complexity, an intrinsic disorder, and are often rich in low 
hydrophobicity, polar residues, particularly glutamine and asparagine. In fact, if they are scrambled in 
a way as to maintain the same residue frequencies within the region but simply rearranging their order, 
these prion domains are still functional, as illustrated with the scrambled Q/N-rich N-terminus of 
Ure2p65. It is important to note, however, that whilst these proteins maintain their ability to seed and 
propagate their prionogenic states, the frequencies of de novo seeding and efficiencies of propagation 
are altered. This suggests that whilst residue composition is a major factor in driving prion activity, 
residue position within the domain can modulate the efficiency of this system.  
 
Interestingly, there is a significant underrepresentation of hydrophobic residues in prion-like domains 
thought to be due to the ability of such residues to favour amyloid formation. This is reflected in their 
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overrepresentation in the hexapeptide core of many amyloids66. The limited presence of hydrophobic 
amino acids, however, has been shown to enhance prionic activity without promoting amyloid formation 
– for example, insertion of additional residues into the prion domain of Sup35 increases prion 
propensity, whilst removal of the infrequently occurring tyrosine residues decreases this propagation 
ability67. There are, however, differences between the influence that aromatic and non-aromatic 
hydrophobic amino acids exert on these prion domains. Specifically, whilst aromatic hydrophobic 
residues promote prionogenicity by increasing the efficiency of fragmentation and propagation, non-
aromatic hydrophobic residues work instead to promote prion formation. This difference has been 
shown in the Sup35 prion domain, which can be split into subdomains; a nucleation domain (ND) and 
an oligopeptide repeat domain (ORD). Whilst non-aromatic hydrophobic residues are overrepresented 
in the ND, they are underrepresented in the ORD. The differential effects of these residues have been 
demonstrated in amino acid substitution studies, illustrating that non-aromatic hydrophobic residues 
promote prion formation and aggregation, to the detriment of propagation, whilst aromatic residues 
promote propagation68. For the aromatic hydrophobic residues, this is thought to be as a consequence of 
fragmentation ability; fibril fragmentation is key in the life cycle of prion propagation as it allows for 
the formation of new seeds. The presence of these aromatic amino acids, such as tyrosine, facilitates the 
interaction of the chaperone Hsp104 with prion-like polymers, which has been shown to be vital for the 
propagation of Sup35 prions in [PSI+] states69,70. This has been illustrated in tetracycline-inducible 
repression models in yeast, whereby inhibition of HSP104 following doxycycline treatment 
subsequently results in an increase in Sup35 polymer size, and thus a decrease in propagation 
efficiency71. Similar effects have also been shown for other prions as well - for example, there is 
evidence that Hsp104 can reverse the active form of ApCPEB58. This demonstrates the powerful 
influence these underrepresented residues can have on prion-like activity. 
 
The predictable composition of these regions has allowed methods for the bioinformatic identification 
of novel prions to be developed, with mixed success. Initial algorithms, such as DIANA, focused on the 
Q/N-rich nature of these domains but neglected the influence of other residues, thus making it difficult 
to distinguish between prion and non-prion72. Such distinctions have been improved on since the 
development of DIANA. Alberti et al., for example, undertook a bioinformatic proteome-wide screen 
for prionogenic proteins in yeast, identifying and characterising around 100 novel candidates. By 
replacing the Sup35 prion domain with that of the candidate prions, they were able to demonstrate that 
19 of these candidates indeed functioned as prions, capable of transmitting their conformation onto naïve 
counterparts in a [PSI+] state73. Whilst this improved on previous predictions, the false positive rate 
observed in this screen remained high, suggesting that there are other factors influencing prion activity 
– possibility as a result of the systematic exclusion of bioinformatic algorithms to consider the influences 
of hydrophobic residues. Using mutagenesis data, Toombs et al. were able to reduce the false positive 
rate in their PAPA algorithm by quantifying the influence of the residues within these domains74. The 
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success of this algorithm was demonstrated in silico, with the design of synthetic prion forming domains 
(sPFDs), a number of which were shown to reconstitute prion activity to Sup3575.  
 
As a consequence of their stereotyped amino acid composition, it is possible to predict novel prion-like 
domains across a range of species. Thus, such approaches could also be utilised in Caenorhabditis 
elegans to identify and understand the physiology of novel prion-like proteins in a variety of biological 
contexts. 
 
1.1.4 Structure of amyloids and prion-like proteins 
Amongst the broad spectrum of amyloidogenic proteins, there are some commonalities between their 
structures upon fibrillisation, with many adopting ordered β-sheet conformations. Early evidence from 
X-ray diffraction studies demonstrated that amyloid fibrils extracted from the spleens of patients with 
myeloma-associated amyloidosis had a cross-β conformation76. Similar cross-β conformations have also 
been identified in fibrils extracted from patients with a range of other amyloidosis diseases, as well as 
from synthetic transthyretin fibrils77. Such structural motifs can be recognised by a characteristic 4.7 – 
4.8Å meridional diffraction pattern, which denotes hydrogen bonding between β-sheets, as well as a 
10Å equatorial diffraction resulting from the stacking of these sheets. This common structure has led to 
the hypothesis that such conformations are characteristic of amyloidogenic fibrils. Following on from 
their work demonstrating that poly-L-glutamine fibres, akin to those involved in polyglutamine 
expansion disorders such as Huntington’s disease, also had this cross-β conformation, forming a 
nanotube of β-sheets surrounding a water filled cavity, Perutz et al. proposed a universal structure for 
amyloids, based on the thermodynamic properties of these disordered proteins78; they hypothesised that 
the formation of such β-sheet conformations and their subsequent fibrillisation was a result of entropic 
factors, with the high internal degrees of freedom favouring a random coil structure rather than a folded 
state. Within such proteins, stability is gained as hydrogen bonds form between main chain amides as 
the structure turns and creates these nanotube conformations – with each successive turn resulting in the 
formation of another hydrogen bond, stabilising the structure further and reducing its degrees of 
freedom. Eventually, the freedom lost becomes negligible to that of the positive entropy gained by freed 
water in the solvent environment. Such biophysical properties, they speculate, favour a cylindrical β-
sheet conformation for amyloidogenic fibrils.  
 
Recent evidence has also determined the structure of tau filaments using cryoelectron microscopy (cryo-
EM) of fibrils extracted from the post-mortem brain homogenate of a patient with Alzheimer’s disease 
(AD)29. The structures of both straight (SF) and paired-helical (PHF) filaments were shown to contain 
two protofilaments arranged into a cross-β/β-helical conformation (Figure 1.4A). These protofilament 
cores, isolated from the fibril using pronase treatment to remove the non-core ‘fuzzy coat’ without 
structurally damaging the core, were shown to be highly similar between the two types of filament, with 
both containing a series of eight β-sheets arranged in a C-shaped morphology. Within these β-sheets, 
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three formed a triangular β-helix, whilst another two were arranged anti-parallel, forming a cross-β 
structure.  The difference between these fibrils derives from their interface interactions, with the 
protofilaments of PHFs forming an anti-parallel stack with helical symmetry, whilst SFs pack 
asymmetrically. In a similar fashion to other prion-like proteins, the core of these amyloids remains 
consistent. It is important to note, however, that further work using both cryo-EM and immune-gold 
negative strain electron microscopy has determined that, whilst these folds are common amongst both 
sporadic and inherited forms of Alzheimer’s disease79, they are not universal for all tauopathies. Pick’s 
disease, for example, adopts a very distinct fold that lacks these β-helix and cross-β motifs30 whilst the 
fibrils that form in chronic traumatic encephalopathy (CTE) do form a β-helix structure albeit 
conformationally different to those seen in Alzheimer’s disease (Figure 1.4B-C)31. The CTE filaments 
form a much more open β-helix structure, with a hydrophobic cavity not seen in the AD fibrils – this 
cavity is filled by an unidentified cofactor that, once identified, may hint at the differential pathogenesis 
of these two conditions. 
 
The amyloids formed in prion-disease also adopt similar structures – for example, the core of Sup35, 
which forms the prion [PSI] in yeast, is made up of tightly packed β-sheets when in its fibrillar state80,81. 
There is also evidence that this core structure is maintained between prion strains82; residue specific 
information derived from quenched hydrogen/deuterium exchange NMR demonstrates that strain 
divergence between two [PSI] prion strains – namely Sc4 and Sc37 – results from the length of the 
‘core’ region. Whilst the two had an overlapping core of around 40 residues, vital for amyloid formation 
and conformational templating, Sc37 had a much larger expansion of this region. This explains some of 
the molecular differences observed between these strains, with the expanded core of Sc37 potentially 
increasing its stability by occluding chaperone recognition sites. In turn, this limits the formation of new 
seeds and reduces propagation.  
  
Cross β-sheet structures are not the only β-sheet structures observed in these proteins. Solid-state NMR 
of HET-s amyloid fibrils, for example, demonstrated that the prion-forming domain forms a left-handed 
β-solenoid structure made up of a twofold-repeating motif of 4 short β-strands, enclosing a triangular 
hydrophobic core (Figure 1.4D)28. Such a structure has also been observed in other prion species too – 
of particular interest in this context is the FgHET-s prion of the fungal species of Fusarium 
graminearium; despite having only a 38% sequence homology with the P. anserina HET-s in the prion-
forming domain, these proteins are able to cross-seed and reciprocally trigger conformational templating 
and fibrillisation in the other in vitro83. In addition to this, substitution of the FgHET-s prion domain 
into the HET-s protein in vivo is sufficient to functionally recapitulate its prionogenic activity in P. 
anserina, demonstrating the potential universality of this structural motif. It was shown in a yeast co-
expression system however that, whilst able to cross-seed fibrillisation, the fibrils forming after this 
initial seeding mostly segregated out into individual prion species, with preferential formation of 
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homotypic fibrils. This suggests that, even though this amyloid core plays an important role in seeding 
and templating of prion states, other factors are also involved.  
 
Figure 1.4 Structure of amyloid-forming domains (A-C) Schematic of secondary structure of amyloidogenic core of tau 
filaments derived from (A) Alzheimer’s disease (adapted from Fitzpatrick et al., 2018); (B) chronic traumatic encephalopathy 
(adapted from Falcon et al., 2019); and (C) Pick’s disease (adapted from Falcon et al., 2019); (D) Secondary structure of the 
fungal prion HET-s (adapted from Wasmer et al., 2008); (E) X-ray diffraction patterns showing cross β structures from (ii) 
prion cores derived from Syrian hamster samples, showing a 4.8Å meridional diffraction (black arrow); (ii) recombinant prion 
cores, showing a 4.8Å meridional diffraction (black arrow) and a 10Å equatorial diffraction (white arrow) (adapted from Wille 
et al., 2009) 
This β-solenoid structure has also been implicated in mammalian PrPSc fibrils, with recent cryo-EM of 
truncated PrP peptides extracted from mouse brain showing a 4.8Å meridional diffraction, but lacking 
any equatorial diffraction, supporting previous X-ray diffraction work (Figure 1.4Ei)84,85. This led to the 
hypothesis that such fibrils form four-rung β-solenoid structures. Interestingly, recombinant fibrils did 
show a 10.5Å deflection, suggesting that the structure of these fibrils differs from those found in vivo 
(Figure 1.4Eii). 
 
The recurrence of these β-helical and β-solenoid structures in amyloids and prion-like aggregates 
suggests that such motifs are important for conferring prionogenic abilities onto a protein. Whilst prion-
like proteins such as HET-s in P. anserina and tau in humans do not have a canonical prion-like domain, 
they do possess this structural motif – a motif that seems to be acting as a prionogenic scaffold. As such, 
it is possible that these represent a species of prion-like proteins with non-canonical prion-like domains, 
thus demonstrating that low complexity and intrinsic disorder are not necessarily the only molecular 
determinants of prion ability. 
 
1.2 Phase Separation  
Schematic of amyloidogenic 
core of tau filaments in 
Alzheimer’s disease removed. 
Copyright holder is Nature 
(Journal). 
Schematic of amyloidogenic 
core of tau filaments in CTE 
removed. Copyright holder is 
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Schematic of amyloidogenic core of tau filaments in 
Pick’s disease removed. Copyright holder is Nature 
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Schematic of HET-s secondary structure 
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Diffraction patterns of recombinant prion cores removed. Copyright 
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Introduction 
 15 
Many proteins containing prion-like domains have been identified within dynamic, liquid-like 
assemblies within the cell, coalescing in a heterotypic fashion with many other protein and RNA 
components. This process, known as phase separation, compartmentalises cellular function into non-
membrane-bound structures. Instead, weak intermolecular forces between proteins and RNA hold these 
condensates together, separating them out from the surrounding aqueous environment.  These structures 
tend to be dynamic and are capable of responding to specific cellular stimuli – for example, the formation 
of stress granules is triggered in response to cellular stress, after which they are dissolved86.  
 
This process of liquid-liquid phase separation (LLPS) is driven by certain proteins that act as scaffolds 
and can nucleate assembly whilst other proteins act as clients – these clients are unable to induce LLPS 
alone, unlike the scaffold proteins, and instead interact with phase separated organelles after their 
biogenesis. This difference is further demonstrated within these condensates, as client proteins show 
more rapid diffusion than scaffold proteins, as evidenced by the increased recovery time of scaffolds 
compared to clients after FRAP, suggesting that scaffolds interact more transiently with clients than 
they do with other scaffolds87.  
 
The existence of these multiphase states is acutely dependent upon component concentration, with an 
increased diffuse concentration of a scaffold protein driving the formation of these condensates. This 
has been illustrated in numerous overexpression models, whereby the increased expression of a scaffold 
protein can lead to LLPS or even solid-like aggregates. The overexpression of TIA-1, or the artificial 
induction of endogenous hnRNPA1 expression can result in the formation of stress granules, for 
example88,89. Similarly, overexpression of the Processing (P) body component, Lsm4, can drive the 
formation of amyloid-like inclusions90. This concentration dependency has been elegantly investigated 
in the oocytes of C. elegans; these oocytes form as a consequence of the cellularisation of the syncytial 
gonad cytoplasm and show an inverse scaling of nucleolar size (i.e. the larger the oocyte, the smaller 
the nucleolus, and vice versa), as illustrated by manipulating oocyte size via RNAi treatment. This 
inverse correlation derives from the fixed number, rather than concentration, of nucleolar components 
loaded into each maturing oocyte. As a result, larger oocytes have a lower concentration of these 
components and thus smaller nucleoli, whilst smaller oocytes have a higher concentration and larger 
nucleoli.  
 
As alluded to above, these biomolecular condensates exist on a heterogeneous spectrum, with some 
exhibiting liquid-like properties and others forming more solid-like structures. Such differences have 
important physiological implications, but also hint at the pathological potential of such transitions. 
 
1.2.1 Liquid-like Assemblies 
Morphology is a useful readout for the material state of a phase-transitioned system. Liquid-like 
assemblies tend to be spherical, have rapid internal dynamics, and show an ability to fuse with one 
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another and subsequently relax into spherical structures once again91. P-bodies and stress granules 
represent two stimulus-responsive membraneless organelles that are involved in the regulation of 
mRNA following cellular stress events. In mammalian systems, both of these structures fulfil the 
aforementioned criteria, with live imaging of fluorescently-labelled marker proteins highlighting fusion 
events whilst the fast intra-organelle recovery of fluorescence exhibited following an internal ‘half-
bleach’ demonstrates their rapid kinetics90. They can also be dissolved after treatment with 1,6-
hexanediol; this aliphatic alcohol has been shown to disrupt the weak interactions most commonly 
observed in LLPS, and thus has been co-opted as an experimental approach to differentiate between 
liquid and solid transition states. The dissolution of these phase-separated organelles upon treatment 
indicates that they indeed do represent liquid-like assemblies. 
 
Many of these organelles also demonstrate fast exchange of components between the body and the 
surrounding environment, in addition to a high mobility within the structure itself. The nuclear 
condensates, Cajal bodies (CBs) and promyelocytic leukaemia nuclear bodies (PML NBs), exemplify 
these characteristics, with fluorescence recovery after photobleaching (FRAP) illustrating the rapid 
recovery of GFP-fused CB and PML-NB components in vivo92–94. Intriguingly such approaches have 
also been able to determine kinetic differences between components within these condensates; DAXX 
and BLM, for example, are both proteins found within PML nuclear bodies – unlike the PML protein 
itself, which has slow recovery dynamics, these components show rapid exchange dynamics with the 
surrounding nucleoplasm, indicative of the high degree of movement of such components between these 
spaces94. The slower recovery curve of PML, an isoform of which is thought to be a scaffold for the 
formation and maintenance of these structures, suggests it is more constrained within the body, possibly 
as a result of the greater multivalency exhibited by phase separating scaffold proteins compared to their 
clients. 
 
1.2.2 Hydrogel Assemblies 
Hydrogels represent the next stage in the phase transition spectrum, with such structures showing more 
solid-like properties and often being less transient than their liquid-like counterparts. These 
characteristics can be demonstrated by a slow and minimal recovery after photobleaching, 
demonstrating their low mobility and reduced turnover of protein. Many phase separating proteins are 
capable of such transitions: for some, this has been proposed to represent a step in the process towards 
pathological fibril formation95; for others, this hydrogel formation is an end unto itself, with biological 
function being derived from this state.  
 
The nuclear pore complex, for example, is an intelligent example of how hydrogels have been utilised 
in biology to physiological benefit. In this case, nucleoporins that make up this complex, such as Nsp1 
are able to form hydrogels around the nucleus and act as sieve-like meshes, allowing for the selective 
movement of molecules between the nucleus and the cytoplasm. As defined by the ‘selective phase 
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model’, this permeability barrier allows small inert molecules to pass, but prevents the translocation of 
large macromolecules unless they are in complex with an appropriate nuclear transport receptor 
(NTR)96. The gelation behaviour observed is driven by intrinsically disordered97 phenylalanine-glycine 
(FG)-rich repeat regions in the N-terminal region of Nsp1, as a consequence of a number of different 
interactions. Hydrophobic interactions between Phe residues of FG repeats are critical for both binding 
to NTRs and for gel formation, and mutation of these residues to serine prevents any gel formation98. In 
addition to this, solid state NMR has also identified a role for NQST-rich inter-repeat spacer regions in 
gelation – these regions can drive the formation of amyloid-like β-sheet structures. As mentioned 
previously, such structures are akin to the those observed within prion-like protein assemblies; in fact, 
co-incubation of Nsp1 with the prion domain of the yeast prion Sup35, which exhibits a similar 
enrichment of NQ residues, shows incorporation of the Sup35 PrLD into FG-repeat region derived 
hydrogel structures99. Thus, on the whole, this demonstrates how the biophysical properties of low 
complexity, prion-like proteins can also influence phase separation biology to drive hydrogel transitions.  
 
1.2.3 Functional Aggregates 
Whilst aggregation plays a pivotal role in the pathogenesis of many diseases of proteostasis, it can also 
have important physiological functions. Yeast stress granules possess very different material 
characteristics to their mammalian counterparts – they cannot, for example, be dissolved by 1,6-
hexanediol treatment. They are also capable of coalescing with misfolding-prone proteins following 
heat shock90. Such data suggests that these structures have more solid characteristics, reminiscent of 
aggregate-like structures - an idea that is further evidenced by the ability of misfolded proteins to 
nucleate the formation of these stress granules. They do not, however, show any thioflavin-T-positive 
staining or SDS-resistance, suggesting that these aggregates are amorphous rather than amyloids. 
Despite their potential similarities to pathological aggregates, their formation can be readily reversed 
and their components show a greater mobility than their colocalised misfolding-prone protein 
counterparts, thus fulfilling their functionality as dynamic stress-responsive assemblies.  
 
1.2.4 Biophysical properties of phase separated structures 
 
1.2.4.1 Prion-like Domains and Intrinsic Disorder 
There are suggestions that prion-like domains are able to act as scaffolds for the formation of phase-
separated bodies100. This is supported by the huge enrichment of PrLD-containing proteins within such 
structures, pointing towards a vital role for such domains in the formation and maintenance of these 
transitioned states. 
 
The nucleolus contains many proteins with disordered regions, including nucleophosmin (NPM1), 
which has an N-terminal oligomerisation domain and a central domain both exhibiting disorder101. This 
protein has structural polymorphism and is capable of adopting either a disordered state when 
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monomeric or a folded state when pentameric. This transition from disorder to order increases the 
valency of the oligomer, stabilising the structure and promoting phase transitions. Evidence from 
circular dichroism studies suggests that these N-terminal regions form a β-sheet-rich secondary 
structure102, thus bearing some resemblance to the structures formed by prion-like proteins, as previously 
described.  
 
As low complexity and intrinsic disorder are hallmarks of prion-like domains, many of the proteins 
involved with phase separation share similarities with these proteins. This similarity extends to their 
propensity for disease; hnRNPA1, for example, is a stress granule component that has been shown to 
transition into fibrillar disease states as a result of mutations in its low complexity, prion-like domain103. 
Akin to NPM1, hnRNPA1 also exhibits a predisposition to amyloid formation with a cross-b structure, 
reminiscent of the prion-like protein structures discussed earlier104. This aggregation-prone nature points 
towards a physiological role for IDRs and low complexity domains in state transitions – and indeed this 
appears to be the case. The purified IDR of hnRNPA1, for instance, is sufficient to drive LLPS alone in 
an RNA-independent fashion89. This coalescence of hnRNPA1 results in a high local protein 
concentration, thus biasing these phase-separated structures towards fibrillisation if insufficiently 
regulated. In this instance, this comes as a consequence of a steric zipper motif in the centre of the IDR 
that can drive this fibrillisation, aligning to form the spine of the fibril; this ability is abrogated if the 
steric zipper motif is removed103.  
 
These prion-like properties are also observed in a range of components involved in paraspeckle 
biogenesis. FUS and RBM14, for example, both contain prion-like domains that are essential for their 
formation; siRNA knockdown of either of these proteins in HeLa cells results in a dramatic reduction 
in paraspeckle number – a reduction that can only be rescued by the re-expression of FUS or RBM14 in 
their wild type forms. Expression of PrLD mutant variants of these proteins is unable to rescue this 
phenotype105. The importance of these domains can be further illustrated in vivo, with mutations to the 
prion-like domain of FUS resulting in diseases as a consequence of the mislocalisation of these protein 
components106, for example. 
 
On the whole, this points towards an important role for prion-like domains in both orchestrating protein 
interactions and helping to drive phase-transitioned states. These domains are often paired with RNA 
interacting domains, many of which fail to facilitate LLPS alone, unlike their PrLD counterparts – this 




Within a polymerising system, as the degree of bonding increases, the propensity for a sharp state 
transition is also increased, as formulated by theories of condensation polymerisation. In a biophysical 
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system, this translates to the valency of a biological molecule – with a greater valency predisposing the 
system towards phase transition. This can be demonstrated artificially by exploiting the modular nature 
of protein interaction domains; by engineering a host of proteins to contain different numbers of repeats 
of either the domain SRC homology 3 (SH3) or its proline-rich motif (PRM) ligand, the influence of 
multivalent protein interactions can be examined. In this case, as the number of repeats is increased, the 
critical concentration for LLPS is reduced107. This has been further validated in similar studies using 
constructs of repeating SUMO3 domains and its interaction partner, SIM, which similarly showed that 
an increased repetition of these domains led to an increase in the formation of phase separated cellular 
bodies87. Thus, overall, these experiments demonstrate that the physics of polymer condensation 
proposed for material states can indeed be applied to biophysical systems as well, confirming there is a 
role for multivalency in driving biological phase transitions. 
 
This phenomenon is observed in vivo as well, aided by the heterogeneous mix of biological molecules 
within cellular space. In particular, the importance of both protein and RNA interactions within a system 
can be intricately illustrated by the nucleolus. Nucleophosmin (NPM1), a key driver of nucleolar 
formation - specifically of the granular component – is highly multivalent. In its N terminus, this protein 
contains an oligomerisation domain (OD), followed by a central disordered region, and finally an RNA 
recognition motif (RRM). Removal of either the N or C-termini renders the protein incapable of phase 
transitioning, demonstrating the interdependence of these regions on one another101,108. Under wild type 
conditions, acidic tracts within the N-terminus can bind to short, linear, arginine (R)-rich motifs allowing 
NPM1 to form cross-linked homopentameric structures102. When in this pentameric form, the 
multivalency of NPM1 is increased, allowing for recruitment of further R-rich nucleolar proteins, as 
well as increasing the affinity of the RRM for rRNA101. This multivalent pentamer can facilitate phase 
transitions, whilst the interaction of the C-terminus with rRNA is vital for the correct localisation of 
these structures within the granular component of nucleolus. This reliance of NPM1 on both RNA and 
proteins interactions is an elegant example of how mutlivalency can powerfully modulate the formation 
of liquid condensates, this is particularly the case when factoring in the influence that posttranslational 
modifications can have on the formation of these phase transitioning pentamers (see section 1.2.3).  
 
1.2.4.3 RNA 
Beyond localising organelle components to the correct phase, RNA also plays an important modulatory 
role in the formation and dissolution of droplets, particularly in the nucleus. This is especially the case 
for prion-like RNA binding proteins that are often predisposed to transitioning into solid states and 
causing disease; RNA helps to mitigate these risks. The influence of nuclear conditions in this 
modulation can be demonstrated in a yeast model of ALS in which FUS is fused to a nuclear localisation 
signal, causing it to relocate from the cytoplasm into the nucleus. This results in a dramatic reduction in 
aggregate formation, suggesting that the nuclear environment does not promote phase transitions in the 
same way that the cytoplasm does109. In vitro phase separation assays have demonstrated that FUS, 
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amongst other prion-like RBPs, can undergo LLPS at nuclear concentrations – this is despite their 
presence in mostly diffuse states within the nucleus. Hence there must be another factor preventing the 
formation of these droplets in vivo. Indeed, this effect comes as a consequence of the high RNA 
concentration within the nucleus. Addition of RNA to the in vitro system, particularly of small RNA 
species, results in the dissolution of these droplets, an effect that can be easily reversed with the 
reformation of droplets following RNase A treatment. This solubilising effect can also be observed in 
vivo with injection of RNase A into the nuclei of HeLa cells containing GFP-fused FUS, showing a 
sudden formation of FUS-positive condensates106.  
 
This ability of RNA to buffer phase separation also reduces the ability of any phase separating structures 
that do form in this environment to transition into fibrillar states. Removal of RNA binding motifs from 
FUS results in a reduction in its mobility, thus, RNA functions to maintain the dynamic behaviour of 
prion-like RBPs, preventing their aberrant transition into a solid aggregate. 
 
Even within this highly solubilising environment, however, phase transitions can still occur, driven by 
specific RNAs capable of triggering LLPS. In the case of FUS, the long noncoding RNA Neat1 fulfils 
this role110, which can be recapitulated in vitro106, clearly illustrating the sufficiency of Neat1 RNA alone 
in nucleating this phase transition in the backdrop of high RNA solubilising conditions. This is enabled 
by the ability of Neat1 to form large RNA assemblies capable of acting as a scaffold for nucleation, with 
protein components associating with these assemblies and the process of phase separation thus being 
initiated. This ability of RNA to seed such transitions is not only seen in the nucleus, there is also 
evidence of such a mechanism at play in the formation of cytoplasmic stress granules, with trans-RNA-
RNA interactions between long transcripts acting as this scaffold. This ability has been demonstrated 
within protein-free lysates containing all cellular RNA; when incubated in conditions mimicking cellular 
stress, RNA can form liquid-like droplets and even more solid-like RNA tangles. Akin to the in vivo 
setting, these droplets are enriched for longer RNA, suggesting that length plays a role in facilitating the 
formation of these scaffold structures111. This is further evidenced in repeat expansion disorders – whilst 
traditionally thought of as diseases of protein disorder, these repetitive sequences also have an effect on 
RNA biology. As the number of repeats within an RNA transcript increases, their multivalent base-
pairing ability also increases, thus with it, the propensity for a phase transition112. It is likely that longer 
RNA transcripts are more likely to form phase-separated scaffolds due to the increased valency this 
length affords them.  
 
The importance of such RNA-RNA interactions in the formation of ribonucleoprotein complexes and 
their roles in normal physiology can be illustrated in Drosophila – for example, Drosophila 
embryogenesis, anterior patterning is reliant upon the asymmetric localisation of Bicoid mRNA. Its 
association with an RNP complex containing the protein Staufen facilitates this localisation. The 
nucleation of this RNP complex is dependent upon the oligomerisation of loop regions within the 3’ 
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UTR of Bicoid mRNA, without which, the association with Staufen is disrupted113. Thus, even beyond 
phase separating systems, it is commonplace for intermolecular RNA interactions to provide a platform 
for further protein interaction within RNP complexes. 
 
1.2.4.4 Multiphase Coexistence 
The microenvironment facilitated by liquid liquid phase separation can best be illustrated by the 
existence of multiple phases within a single system. These phases are capable of coexistence whilst also 
exhibiting immiscibility. Such behaviour has functional implications – for example, in the nucleolus, a 
sequential progression of liquid phases facilitates the multistep coordination of rRNA processing in 
preparation for ribosome biogenesis. The nucleolus itself has a tripartite structure, with three distinct 
sub-compartments localising different protein and RNA components within them. Namely, these are; 
(1) the fibrillar centre [FC]; (2) the dense fibrillar component [DFC]; and (3) the granular component 
[GC]. The immiscibility of these phases, and the intrinsic biophysical mechanisms driving this, can be 
demonstrated in vitro as nucleolar proteins purified from different phases will not coalesce101. Surface 
tension differences between these compartments prevent this coalescence into one large liquid organelle, 
whilst actin networks help to maintain structural integrity and minimise homotypic fusion events. This 
can be clearly demonstrated by disrupting these networks, leading to the fusion of all nucleolar sub-
compartments into a homogenous phase101,114.  
 
This core-shell architecture, whereby there is a denser, less liquid-like centre surrounded by a more fluid 
outer layer, is also seen in other phase separated organelles as well. Superresolution microscopy has 
identified stable substructures within both mammalian stress granules that fit this description. These 
core structures contain a greater density of protein and RNA interactions, resulting in a less mobile phase 
than the shell surrounding it. Isolation and proteomic analysis of these cores has allowed for components 
of the core to be identified, including many ATPase-dependent complexes that play regulatory roles in 
the assembly and disassembly of these granules115. The shell, however, is much more dynamic, allowing 
for a greater exchange of components from the cytoplasm. This further supports the existence of a 
spectrum of phases, with the immiscibility of each of these phases pointing at highly regulated 
mechanisms differentiating between these layers.  
 
1.2.5 Regulation of phase separated structures  
 
The functional significance of these phase-separated compartments is further validated by the tight 
physiological regulation of their assembly and dissolution. This process is facilitated via a multitude of 
mechanisms, and can lead to very precise spatiotemporal control of these organelles, allowing for 
targeted and effective responses to specific stimuli. 
 
1.2.5.1 Spatial Regulation  
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The ability to spatially regulate the formation of these condensates is vital for their effective 
functionality. This control often relies on the regulation of organelle components in their diffuse state – 
for example, protein localisation, or RNA synthesis. The best example of this exquisite spatial regulation 
comes from P granules in the developing C. elegans embryo – these begin uniformly distributed, 
however, after symmetry breaking, they begin to segregate along the anterior-posterior axis, with a bias 
towards formation posteriorly116. This process is tightly modulated by a PAR-1 kinase-dependent MEX-
5 concentration gradient that runs in the opposite direction to P granule asymmetry117. This regulation 
originates with the asymmetric cortical localisation of PAR-1, leading to preferential phosphorylation 
of MEX-5 in the posterior via serine 404. MEX-5 is an RNA-binding protein that is capable of 
associating with poly-U tract-containing RNA throughout the embryo118,119. Such associations with large 
RNA-containing complexes result in the slow diffusivity of this protein120 – however, upon 
phosphorylation of this C terminal serine, it is able to dissociate from such complexes and diffuse more 
freely, leading to greater mobility of posterior MEX-5 compared to anterior, leading to an enrichment 
in the anterior121. The intrinsically disordered protein, MEG-3, acts as a scaffold for RNA-induced phase 
separation and the formation of P granules. Co-incubation of purified MEG-3 with both MEX-5 and 
RNA demonstrates that ability of MEX-5 to inhibit the phase separation of MEG-3 in an RNA dependent 
manner, with MEX-5 outcompeting MEG-3 for RNA interaction122. This shows that the localisation of 
unphosphorylated MEX-5 triggers the preferential dissolution of MEG-3-mediated P granules in the 
anterior, whilst its absence in the posterior results in their preferential formation. The asymmetry 
observed in P granules illustrates the fine spatial control that an organism can exert on organelle 
dynamics – and is a clear demonstration of the functional consequences of this control; in this case, such 
spatial regulation positions P granules for their selective preferential inclusion in the posterior germline 
blastomere, P1, and exclusion from anterior blastomere, AB, following asymmetric cell division121. 
There are examples of similar spatial patterning in other phase separated systems as well, such as the 
formation of Cajal bodies around RNA during transcription123 – the requirement for RNA to phase 
transition means that their spatial regulation relies on the localisation of RNA synthesis, thus linking 
functionality and spatial control. 
 
1.2.5.2 ATP dependency 
The role of ATP in phase transitions is two-fold: as would be expected, it is capable of driving energy-
dependent processes that may be involved these transitions; however, beyond this, it has also been 
hypothesised that ATP can act as a biological hydrotrope, solubilising hydrophobic molecules within 
the aqueous environment of the cell. Akin to other hydrotropes, ATP is amphiphillic, containing both 
hydrophilic phosphates and a hydrophobic adenosine ring, lending support to this hypothesis. In vitro, 
this has indeed been shown to be the case, with ATP increasing the solubility of the hydrophobic 
compound fluorescein diacetate in a concentration dependent manner. Similar effects are observed with 
biologically aggregating species, with ATP preventing aggregate formation of FUS, amyloid-beta and 
the prion-like domain of Mot-3. It was even capable of dissolving preformed FUS aggregates124. Thus 
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this suggests that ATP can indeed act as a biological hydrotrope, potentially providing an explanation 
as to the magnitudinous surplus of ATP within the cell, which far exceeds its energy demands. 
 
In addition to this, the presence of ATP-dependent protein and RNA related complexes within many of 
these phase-separated organelles has provided a mechanism for their regulated assembly and 
dissolution. Proteomic analysis of isolated core regions of stress granules, for instance, identified a 
number of components involved in these processes; for example, the chaperonin-containing T (CCT) 
complex is involved in the inhibition of stress granule assembly, and manipulation of its ATPase domain 
results in a greater number of granules forming. Conversely, the mini-chromosome maintenance (MCM) 
complex and the RvuB-like helicase complex are both involved in inhibiting their disassembly; siRNA 
knockdown of these complexes results in a faster loss of granules during stress recovery. The reliance 
of these processes on ATP can be demonstrated in cell culture through the inhibition of glycolysis and 
oxidative phosphorylation, leading to a depletion of ATP. When applied concurrently with sodium 
arsenite, a stress granule inducer, formation of these stress granules is inhibited. Similarly, if applied 
after formation, the resulting stress granules lose their dynamic nature and become static, low mobility 
structures115. Thus, this illustrates the essential role that ATP plays in the biogenesis and dissolution of 
these granules, as well as in the maintenance of their liquid-like microenvironments.  
 
Due to the properties of many phase separation components, with their intrinsic disorder, prion-like 
nature, and their propensity for aggregate-like behaviour, it is perhaps unsurprising that chaperones can 
regulate the activity of these compartments, often in an ATP-dependent fashion. The AAA+ ATPase, 
Hsp104, already discussed in relation to yeast prion-like proteins, is of particular interest in this context. 
Working in conjunction with Hsp70 and Hsp40, this chaperone is able to dissolve aggregate-like 
formations and restore the constituent components to their functional, folded state125. Similar 
mechanisms are at play with the regulation of phase-transitioned organelles; stress granules, for 
example, show an increased assembly and decreased dissolution when Hsp104 is deleted. P-body 
formation, on the other hand, is not affected by Hsp104 deletion under basal conditions however, upon 
the application of an acute stress, P-body components such as Edc3 and Lsm4 mislocalise with stress 
granule components, forming irregularly shaped aggregate-like structures. The level of mislocalisation 
and aggregation of these assemblies correlates with the level of Hsp104 expression, demonstrating that 
this chaperone is required to maintain the liquid-like properties of P bodies90. On a mechanistic level, 
the action of Hsp104 relies on ATP hydrolysis to elicit a dramatic conformational change in its 
hexameric structure, resulting in a cyclic peristaltic pump motion126. This pumping motion drives the 
translocation of prion-like aggregates into the central channel of this hexamer – a process that is key for 
its disaggregase activity; this can be demonstrated by N-terminal domain deletion mutations that perturb 
this mechanism allowing substrates to escape this central channel. Without this mechanism, prion-like 
protein assemblies can be fragmented but not fully dissolved, as illustrated in the yeast prion Sup35, 
with mutant Hsp104 improving prionogenesis by driving fragmentation without dissolution126,127.  
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Although many chaperones have been identified as having regulatory influences over the life cycle of a 
phase separated entity, Hsp104 has some of the most diverse and wide-ranging effects, clearly 
demonstrating how ATP can be used to modulate these activities. 
 
On the whole, ATP can modulate the formation, maintenance and dissolution of phase-separated 
compartments in a multitude of ways. This diversity of action allows for such structures to be tightly 
controlled in response to specific physiological stimuli.  
 
1.2.5.3 Post-translational modifications 
Post-translational modifications (PTM) are a powerful mechanism through which cellular events can be 
temporally regulated. There are numerous types of PTM, often working in concert to fully orchestrate 
the coordinated subcellular environment. Such modifications have been implicated in the regulation of 
phase transitions. 
 
SUMOylation regulates the formation and dissolution of PML nuclear bodies128,129. The scaffold protein, 
PML, contains three lysine residues that allow for its modification by the ubiquitin-like modifier, 
SUMO-1. Mutagenesis of these SUMO sites results in NB disruption, demonstrating their importance 
for the formation and maintenance of these condensates130,131. This effect can be shown in a 
physiological context as well, with infection by the herpes simplex virus triggering the desumoylation 
of PML and, consequently, the dissolution of these phase separated structures132. The role of this 
modification in PML NB formation revolves around the ability of SUMO-modified proteins to interact 
with and recruit other proteins. This is best demonstrated by the presence of a SUMO binding motif 
within the PML protein – this domain can non-covalently interact with SUMOylated proteins and has 
been hypothesised to be the nucleation trigger for PML NB formation, with non-modified PML 
interacting with modified PML via its SUMO binding motif133. After this point, other SUMO interacting 
proteins, including Daxx, can interact and be recruited to the condensate134. Daxx is an interesting 
example of a client protein whose function is directly related to the SUMOylation state of other proteins. 
When diffuse, it can interact with SUMOylated transcription factors, preventing their transcriptional 
activity – however, upon recruitment to these inclusions via SUMOylated PML, this transcriptional 
activity can be restored and gene expression increased135. Thus, SUMO modifications are a useful 
mechanism to influence both formation and dissolution, as well as to modulate the activity of client 
proteins. Beyond these phase-separated structures, SUMOylation has also been implicated in the 
regulation of prion-like activity in proteins such as CPEB-362, suggesting some commonalities between 
their biology. 
 
The methylation of arginine residues has also been shown to contribute towards the regulation of phase-
separated organelles – specifically, in the regulated formation of Cajal bodies and nuclear gems. Coilin, 
a core component of CBs, contains symmetrical dimethylarginines (sDMAs) allowing it to interact with 
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complexes containing the protein SMN, retaining them in Cajal bodies as a consequence of their 
preferential affinity for sDMA-containing proteins136,137. However, when methylation is artificially 
inhibited, or there is a physiological hypomethylation, coilin can no longer efficiently interact with SMN 
complexes138,139, resulting in the formation of parallel condensates, known as nuclear gems. This has 
functional consequences, with reductions in pre-mRNA splicing and spliceosomal complex formation 
being observed in hypomethylated nuclear extracts as a result of this interaction loss137. On a clinical 
level, this also has profound effects; patients with mutations in SMN that prevent its interaction with the 
RG-rich, sDMA-containing sites of its partners develop spinal muscular atrophy, underscoring the vital 
role that this regulated interaction can have136,140. Thus, on the whole this demonstrates the importance 
of post-translational modifications, in this case methylation, on the regulation of a phase-separated 
organelle, namely Cajal bodies.  
 
Beyond these modifications, phosphorylation can also play a role in this regulatory process. Stress 
granule formation, for example, is triggered in response to an environmental stressor; the elicitation of 
this response involves a phosphorylation cascade ultimately resulting in the phosphorylation of the 
translation initiation factor, eIF2α141. This modification disrupts the normal activity of the protein by 
preventing the formation of pre-initiation complexes. Under basal conditions, this protein is 
unphosphorylated and interacts with GTP and tRNAMet to form a component of the complex involved 
in the loading of the initiator tRNA onto the 40s ribosomal subunit, thus driving translation. Upon 
phosphorylation, the affinity of eIF2α for eIF-2B, a guanidine nucleotide exchange factor, is increased 
– this interaction prevents the exchange of GDP for GTP and thus inhibits the formation of eIF2α-GTP-
tRNAMet and, subsequently, the formation of these pre-initiation complexes142. These stalled complexes 
are then involved in the nucleation of stress granule formation, via their interactions with the scaffold 
proteins TIA-1 and TIAR88. The direct influence that this phosphorylation event can have on stress 
granule formation can be demonstrated in phosphomimetic mutants of eIF2α – these mutants result in 
the constitutive formation of stress granules, even in basal conditions141. Conversely, mutants that cannot 
be phosphorylated show no stress granule formation before or after stress in most cases – though it is 
important to note that phosphorylation-independent reductions in eIF2α-GTP-tRNAMet can also elicit 
formation, albeit at a much lower frequency143. On the whole, however, this demonstrates the influence 
that phosphorylation can have on driving phase transitions in response to very specific stimuli. The 
reversibility of such modifications demonstrates a clear mechanism for reverse phase transitions in these 
contexts. 
 
1.2.6 Interactions driving phase transitions 
 
1.2.6.1 Dipole-dipole 
The influence that polar residue-rich intrinsically disordered regions (i.e. Q/N-rich domains) have on 
phase transitions can be modelled mathematically if the polymer-solvent environment is considered a 
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lattice, with each geospatial position (z) within the lattice occupied by either a solvent or polymer 
molecule (Figure 1.5A)86,144. The interactions of these residues along the polypeptide backbone of a 
protein result in a ‘chain of dipoles’. As the aqueous solvent environment is also dipolar, a number of 
potential dipolar interactions are possible; (1) solvent-polymer, 𝑢"#; (2) polymer-polymer, 𝑢""; and (3) 
solvent-solvent, 𝑢##. These potential interactions are in constant competition, with the interaction 
energies between such dipoles accounting for the enthalpic contribution to the free energy within the 
system. The effect that these dipoles have on the free energy state of the system can be approximated 
by a single mean-field value (Flory parameter, χ), averaging out the individual energies of each potential 
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Using these variables, the Flory-Huggin’s model of homopolymer physics can be applied145,146, resulting 
in a simple approximation of the energy state of mixing within the system and can describe simple phase 
separation dynamics, highlighting the importance of factors including polymer length (N), thermal 
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This equation illustrates the energetic cost involved in these polymer-solvent interactions. The greater 
the χ, the larger the energetic cost of mixing. Phase separation is favoured when χ > 0, indicating the 
polymer is in a poor solvent; past a critical threshold of χ, this energetic cost overcomes that of the 
mixing entropy, resulting in a phase transition. 
 
1.2.6.2 Charge-charge 
Other modes of interaction cannot be modelled with such a simple lattice, however. Charge-charge 
interactions, for example, result in a type of phase separation known as complex coacervation, driven 
by the various electrostatic properties of charged amino acids (Figure 1.5B). Such interactions are 
observed with polyampholytic intrinsically disordered proteins. In these cases, the effect of the short-
range interactions of neutral groups is significantly outweighed by the long-distance interactions of 
charged groups within the protein, thus rendering variables such as χ entirely negligible.  
 
Unlike before, where the fraction of polymer-to-solvent within a given environment was important, this 
time, charge-charge interactions consider the proportion of polycations (ø+) to polyanions (ø -) within a 
system. These electrostatic interactions can be modelled using the Overbeek-Voorn mean field theory147, 
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This equation summarises the factors that influence the phase separation dynamics of electrostatic-
induced transitions. In particular, the α value denotes a variable that is influenced by; (a) charge at the 
lattice site; (b) thermal energy (𝑘(𝑇); and (C) partial molar volume of the solvent. The 𝜎 variable, on 
the other hand, represents the linear charge density on each polyion. This theory hypothesises that when 
𝜎;𝑁 > 0.5 then phase separation will occur, with a condensation of these polyions.  
 
Electrostatic interactions within the nucleolar protein NPM1 play important roles in modulating the 
equilibrium between monomeric and oligomeric states148. As previously described, this protein 
undergoes LLPS when in a homopentameric conformation108; this conformation is stabilised by its 
configuration of electrostatic charges, with negatively charged residues arranged on one face of the 
oligomer, and mixed electrostatic residues on the other102. The influence of these electrostatic 
interactions can be demonstrated in vitro, with analytical ultracentrifugation studies demonstrating that 
NPM1 exists as a monomer in low-salt conditions, whilst pentamer formation is observed in high-salt 
conditions. In addition to this, the presence of Mg2+ and Ca2+ has also been shown to drive 
oligomerisation – possibly due to a proposed role of cations in shielding negative charges from repulsive 
electrostatic forces, thus stabilising the pentameric conformation148. 
 
The charge asymmetry of NPM1 can be exploited to allow for the dynamic modulation of monomeric 
to pentameric state via posttranslational modification. Phosphorylation of solvent exposed residues adds 
a negative charge to the pentamer, causing a thermodynamic destabilisation of NPM1 structure. This 
phosphorylation continues sequentially, with the destabilised structure exposing further sites for 
phosphorylation until eventually there is a structural switch and the pentamer is driven into its 
monomeric state102. Thus, charge-charge interactions can be utilised as a tool for both maintaining and 




Other electrostatic interactions can also modulate phase separation behaviour. Cation-p interactions, for 
instance, occur between aromatic rings and charged residues; these aromatic rings contain six p-orbitals 
corresponding with each of the six carbon atoms of the ring. These p-orbitals conjugate, resulting in one 
delocalised system, with p-orbital electrons forming a cloud above and below the aromatic ring plane, 
rather than being confined to their specific orbitals. In the presence of a positively charged residue, the 
electron cloud becomes polarised and the side facing the residue is attracted thus resulting in a cation-p 




Such interactions can be investigated in phase separating bodies by identifying components that are 
enriched in one of the three amino acids to contain such aromatic ring side chains – namely 
phenylalanine, tryptophan or tyrosine. FUS, for example, shows a large overrepresentation of tyrosine 
in its low complexity domain. Substitution experiments, in which tyrosine is replaced with alanine or 
phenylalanine, demonstrate the involvement of cation-p interactions in driving the phase separation 
properties of this protein. Alanine substitutions abolish the ability of FUS to phase separate either in 
vitro or in vivo – however, as phenylalanine also contains an aromatic ring, the phase separation 
behaviour of FUS is maintained in this replacement. Similarly, if the positively charged residue arginine 
is replaced with alanine or lysine, the phase separation ability is only observed with lysine substitutions, 
as this residue also has a cationic side chain, allowing for the maintenance of charge-p interactions. This 
has fascinating physiological repercussions, as these interactions can be disrupted by the methylation of 
arginine residues, thus reducing the propensity of FUS for phase separation – if this methylation is 
prevented, FUS more readily coalesces, forming more gel-like condensates149.   
   
This phenomenon has also been illustrated in Ddx4, an intrinsically disordered protein constituent of 
the phase-separated organelle, nuage. Similarly to FUS, this ability of this protein to form droplets is 
dependent upon the presence of repeating blocks of charged residues and enrichment of F or R 
containing dipeptides. Removal of either of these eliminates their phase transition abilities. Arginine 
methylation also plays a role in the regulation of these bodies as well, with this posttranslational 
modification triggering the dissolution of these droplets150. Thus, this demonstrates the importance of 
cation-p interactions in not only facilitating the formation of these condensates, but also for allowing a 
mechanism of regulation due to their sensitivity to reversible protein modification.  
 
1.2.6.4 p-p interactions 
In addition to this, p-bonds have also been implicated in the process of phase separation. Such 
interactions occur between the p-orbitals of neighbouring atoms, which run perpendicular to σ bonds 
formed between the same molecules. The formation of these bonds can occur following sp2 
hybridisation, whereby the s-orbital and p-orbitals are combined; this results in the creation of three new 
sp2-orbitals, involved in the formation of the sigma bond, and a spare p-orbital that goes on to form the 
p-bond (Figure 1.5D). Proteomic analysis has identified an enrichment of residues capable of such 
interactions in low complexity, intrinsically disordered regions and in RNA binding domains, both of 
which are commonly associated with phase transitions, suggesting that they might indeed play a role in 
driving the formation of these assemblies151.  
 
Arginine is one of these overrepresented residues, with sp2-hybridisation observed within the guanidium 
group of its side chain. The importance of this has been demonstrated using the N-terminal IDR of the 
phase separating protein Ddx4, which is enriched with arginine-glycine repeats. Due to the positive-
charge of arginine, it has been previously proposed that such transitions are driven by charge-charge 
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interactions, however, upon substitution experiments in which arginine was replaced with lysine, this 
was shown not be the case. Lysine, which holds the same positive-charge as arginine, is unable to form 
p-bonds due to its sp3-hybridised atoms – unlike the sp2-hybridised atoms of arginine, they do not have 
a spare p-orbital capable of forming such bonds. This R to K replacement prevents the phase separation 
of Ddx4, thus suggesting this transition is driven by p-interactions, rather than charge-interactions.  
Similar findings have been made for pathological fibril formation in Alzheimer’s disease, with p-
stacking of arginine side-chains thought to be involved tau fibril interactions152. This once again points 
towards a similar mechanism of assembly between pathological and physiological phase transitions.  
 
Figure 1.5 Interactions driving phase transitions (A) schematic of the Flory-Huggins model of dipole-dipole interactions; 
(B) schematic of the charge-charge interactions driving complex coacervation; (C) depiction of the fusion of adjacent orbital 
groups forming a conjugated pi-orbital system, with delocalised pi electrons forming clouds that become polarised during 
charge-pi interactions; (D) schematic depicting the process of sp2 hybridization that ultimate drives pi-pi interactions 
 
This was further investigated in studies assessing the influence of mixed charge domains (MCDs) within 
intrinsically disordered regions153; using similar R to K substitution experiments, synthetic dipeptide 
combinations were used to demonstrate the increased propensity for condensation resulting from an 
increase in net-positive charge driven by arginine residues. This effect was not observed for domains 
with a lysine-derived net-positive charge demonstrating that the guanidium side chain of arginine is the 
determinant of this phase behaviour. The multivalent nature of this guanidium ion, compared to the 
monovalent nature of the side chain amide of lysine, may be the driving force for this ability, as the 
arginine side chain is capable of p-p, cation-p and charge-charge interactions. 
 
It is important to note that, whilst many of these biophysical determinants of phase separation can 
individually have large influences on the transitional behaviour of individual components, it is likely 
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that a combination of all the above can influence these abilities. Within the example just mentioned, for 
instance, even within R-enriched MCDs, which show an increased propensity for phase separation, a 
net-negative charge can reduce condensation and incorporation into phase-separated bodies153. This is a 
clear demonstration of the complementary nature of these interactions in finely modulating the 
behaviour of these constituent components.  
 
1.3 Stress responses 
The ability to adapt to environmental challenges is vital for survival and, as such, a number of cellular 
stress response pathways have evolved to deal with these potential threats. As has been demonstrated, 
many phase-separated organelles are involved in dynamic responses to such environmental stimuli. 
Much of this relates to stress, such as the formation of stress granules and P bodies in response to protein 
misfolding or heat stress. There is increasing evidence that a whole host of novel phase separation events 
are able to facilitate responses to stressful stimuli. The existence of such a variety of structures points 
towards a much broader role for phase separation in physiology than perhaps first thought.  
 
The proteasome, for example, is a key mechanism in the maintenance of cellular proteostasis, with 
ubiquitinated substrates being targeted for protein degradation by proteasomal machinery. Recent 
evidence has identified a role for ubiquitin-chain-dependent phase separation in this process, condensing 
proteasomal components and their target proteins in transient, liquid-like foci, driven by the multivalent 
interactions made by the substrate-shuttling factor, RAD23B, with ubiquitin chains154.  
 
A role for phase separation has also been identified in modulating the response to tissue damage in C. 
elegans; the prion-like protein TIAR-2 forms granules capable of facilitating the inhibition of 
regeneration following axonal injury. This inhibition relies on the formation of these liquid-like 
assemblies, as demonstrated by the abolition of puncta formation via removal of the prion-like domain, 
which results in loss of this inhibition. As with all dynamic stress responses, the formation of these 
TIAR-2 condensates can be regulated – in this case, such regulation comes in the form of serine 
phosphorylation, with phospho-deficient mutants losing both the ability to form granules and the ability 
to inhibit regeneration155.  
 
An emerging role for phase transitions in the dynamic response to environmental stimuli is becoming 
increasingly clear – even amongst well-characterised stress responses. The following section explores 
stress response pathways within the nematode species Caenorhabditis elegans, although in most cases 
they represent highly evolutionarily conserved processes. Due to the often transient nature of these 
responses, it would be interesting to see if a further role for phase separation may be identified within 
these pathways. 
 




Caenorhabditis elegans is a soil-dwelling nematode species made up of a mere 959 somatic cells in the 
hermaphrodite. The simplicity of these animals is useful for investigating cellular processes and 
pathways within the physiologically relevant context of a multicellular, living organism (Figure 1.6A-
C). This is important as many in vivo influences cannot be recapitulated within an in vitro setting such 
as cell culture156–159.  
 
Figure 1.6 An introduction to the anatomy of the adult C. elegans hermaphrodite showing (A) major organs including the 
pharynx, intestine, uterus and gonad; (B) the epidermal (hypodermal) system, including the seam cells; (C) the nervous system 
(adapted from WormAtlas) 
 
These animals are capable of a diverse range of behaviours in response to the external environment. On 
an organismal level, this requires sensory processing and global motor coordination following reception 
of a cacophony of stimuli. This is facilitated by a small yet sophisticated nervous system made up of 
just 302 neurons in the hermaphrodite158,159, and 381 in the male160. Within the animal, neuronal cell 
bodies generally cluster in ganglia, often located in the head and tail regions, with neuronal processes 
extending out from there161. These neurons can be categorised by function, with circuits of sensory, 
motor and interneurons communicating and enabling appropriate stimuli-specific responses162. These 
neurons communicate both synaptically and extrasynaptically, utilising a similar diversity of 
neurotransmitters to that seen in mammalian species, with some exceptions – the biogenic amine, 
Cartoon of hermaphrodite C. elegans anatomy showing all the major organs removed. Copyright holder is WormAtlas. 
Cartoon of hermaphrodite C. elegans anatomy showing the epidermal system removed. Copyright holder is WormAtlas. 
 




octopamine, for example, is a tyramine-derivative that is much less abundant in vertebrate systems than 
in the nematode163. The nervous system is capable of the systemic coordination of stress responses – for 
example, splicing of the nematode ER stress-responsive transcription factor XBP-1 in neurons results 
in a global activation of cellular stress pathways via cell non-autonomous signaling164. 
 
Whilst the nervous system plays an important role in coordinating responses, it is not the only tissue 
that influences global states. The intestine, for example, is a highly metabolically active tissue, capable 
of altering global metabolic conditions in response to environmental stimuli and stress conditions165,166. 
In addition to this, intestinal tissue plays roles that are traditionally associated with the gut, such as 
secretion of digestive enzymes into the lumen for bacterial digestion, leading to uptake of appropriate 
nutrients167. In terms of stress responses, the intestine is also thought to be involved in the initiation of 
the innate immune response, due to it being one of the first sites of pathogenic invasion168.  
 
 
Figure 1.7 A schematic depicting the life cycle of C. elegans, beginning with in utero development of fertilised eggs in gravid 
adult animals, to gastrulation, embryonic development, larval development, and ultimately adulthood (adapted from 
WormAtlas) 
 
The anterior portion of the intestine is anchored to the pharynx. This epithelial organ is responsible for 
the initial bacterial uptake step via the buccal cavity. Within the pharynx, this bacteria is then ground 
and transported into the intestine for digestion. The pharyngeal grinder that facilitates this is made up of 




3 pairs of muscle cells – contraction of these muscles causes a rotation motion that acts to disrupt the 
bacteria169. These muscle cells are interspersed by marginal cells that act as a repository for nutrients in 
a sphingomyelin-dependent fashion170. In addition to this, the pharynx has a dedicated nervous system, 
with 20 neurons regulating both contractility of the pharyngeal muscles, but also communicating 
nutritional status and relaying signals from the external environment to the rest of the organism171,172.  
 
Surrounding these organs is a tough cuticle rich in structural extracellular matrix components, such as 
collagen173,174, that are secreted by epithelial cells including the hypodermis, the seam cells and the 
interfacial cells. This structure acts as an exoskeletal, aiding motility of animals, as well as providing a 
vital barrier function, protecting the animal from the external environment – as a result, it acts as a 
primary line of defence against environmental challenges such as pathogenic invasion. This ability to 
protect animals from pathogens is aided by the presence of a negatively charged epicuticular coating 
rich in lipids and glycoproteins175, with animals defective for genes encoding these epicuticular 
components displaying increased susceptibility to bacterial infection176,177. Beyond these functions, the 
cuticle is also important for the maintenance of body shape178, with a new cuticle grown after each larval 
stage upon shedding of the old179.  
 
The epithelial system that secretes these cuticular components is comprised of two different classes of 
epithelial tissue – either the hypodermis or specialised epithelial cells. The hypodermis encapsulates the 
entire organism, with the main hypodermal syncytium, hyp-7, spanning the main body of the animal, 
while smaller hypodermal cells lie in the anterior and posterior regions180. Throughout the life of an 
organism, these tissues take on different roles; during development, for example, they are involved in 
establishing the basic body plan and regulating cell fate determination, as well as guiding axonal 
migration181. In adulthood, however, the hypodermis adopts roles in nutrient storage and maintenance 
of cuticle integrity.  
 
There are a number of cell types that fall under the branch of specialised epithelial cell, including the 
seam cells, which form rows of 16 cells running longitudinally along both the left and right sides of the 
animal. Akin to the hypodermis, following larval development, these cells fuse and form a multinucleate 
syncytium159 that also plays a role in the secretion of cuticular components182. In addition to the main 
cuticle components, seam cells also produce cuticular ridges along the length of the animal known as 
alae158; formation of these structures is often used as a readout of seam cell terminal differentiation. 
Prior to this point, however, these cells are important in the specification of some neuronal and glial 





Compartment Localization Role 
Processing bodies Cytoplasm Regulation of mRNA translation and decay 
P granules Perinuclear Germlines compartments regulating posttranscriptional activity of RNA 
Stress granules Cytoplasm Form under stress, sequestering specific RNAs, stalling their translation 
Nucleoli Nuclear Formation of ribosomes, densely packed with RNA 
Paraspeckles Nuclear Unclear, but thought to localize specific proteins within the nucleus 
Cajal bodies Nuclear Sites of snRNP formation, involved with mRNA processing 
 
Figure 1.8 Phase-separated organelles within C. elegans (A-E) animals expressing IFE-2::GFP and DCAP-1::RFP as markers 
for stress granules and processing bodies respectively, before and after heat shock, demonstrating a degree of colocalization 
after this stress stimuli (adapted from Rieckher et al., 2013) 
 
Table 1.1 A summary of a number of conserved phase-separated structures observed in these nematode species, their 
localization within the cell, and their function 
 
This microscopic nematode, with a lifespan of only around 20 days, undergoes a number of recognisable 
developmental processes post-fertilisation, including periods of embryonic and larval development, 
before reaching fully fertile adulthood (Figure 1.7). As this process is relatively rapid, the generation 
time is short – this allows for large populations sizes to monitored in a relatively short space of time. 
 
The tractability of genetic manipulation in C. elegans makes this model organism attractive to work 
with, particularly in light of recent technological advancements that have allowed for the CRISPR-
mediated editing of endogenous loci. Unlike higher organisms, the short lifecycle of these animals 
allows age-related phenotypes to be investigated in real time – this is particularly useful when 
Fluorescent micrographs of labelled P-body and stress granule markers removed. Copyright 




investigating stress-related phenotypes, as these are often exacerbated in an age-dependent manner. In 
addition to this, these animals are transparent – a powerful characteristic for monitoring transient and 
dynamic effects visually, via fluorescence tagging for example, as these processes can be monitored in 
real time within an in vivo setting. When considering proteins structures that aggregate, coalesce, fuse 
and propagate, the ability to observe these processes in a living organism is invaluable. 
 
There are a number of phase-separated organelles that have already been identified and investigated in 
C. elegans (Figure 1.8A-B). Many of these are have homologs across biology and thus, information 
gained from this model organism can be translated into higher organisms. A number of these organelles 
have known roles in stress responses – understanding how these fit in with known stress response 
pathways will aid our understanding of the role that these structures play within those pathways, and 
how they are regulated as a part of coordinated responses to stress. 
 
1.3.2 Innate Immune Response 
In order to protect against the invasion of pathogens, C. elegans possess evolutionarily conserved innate 
immune pathways including the p38 MAPK and the DAF-2/DAF-16 pathways (Figure 1.9). A genetic 
screen for mutants that showed increased susceptibility to the pathogenic bacteria Pseudomonas 
aeruginosa (PA14) first led to the identification of genes involved in the phosphorylation cascade 
pathway of p38 MAPK. This screen identified sek-1, a MAP kinase kinase, and nsy-1, a MAP kinase 
kinase kinase, as being involved in this response183. Knockouts of either of these genes prevent the 
subsequent phosphorylation of PMK-1, the MAP kinase itself, thus demonstrating that this acts 
downstream from these proteins184. This pathway elicits an immune response by altering gene 
expression patterns to combat the pathogenic threat – upstream components of NSY-1 are able to detect 
such threats, driving this phosphorylation cascade and thus stimulating a remodelling of gene 
expression. For example, the murine homolog of NSY-1, ASK1, is activated downstream of 
lipopolysaccharide detection, thus demonstrating its direct stimulation by pathogen associated 
molecular patterns.  
 
The DAF-2/DAF-16 pathway has also been implicated in innate immune responses, with daf-2 mutants 
showing resistance to PA14 killing184. This is a DAF-16 dependent effect as daf-2;daf-16 double 
mutants do not have this reduced susceptibility185; this suggests that the immune response is facilitated 
via the canonical DAF-2/DAF-16 pathway, whereby DAF-2 activation results in DAF-16 
phosphorylation, inhibiting its movement into the nucleus where it would normally induce expression 
of target genes. Thus, antagonism of the DAF-2 receptor in innate immune responses can elicit DAF-





Figure 1.9 Innate immune response pathways in C. elegans (A) the p38 MAPK pathway; (B) the DAF-2/DAF-16 pathway 
 
1.3.3 Unfolded Protein Response 
Under normal functioning, the endoplasmic reticulum facilitates the proper folding of newly translated 
proteins via an array of molecular chaperones found within the ER lumen. An aberrant accumulation of 
misfolded or unfolded proteins within this compartment, however, can lead to the activation of a 
tripartite response system known as the unfolded protein response of the endoplasmic reticulum 
(UPRER), involving one of three transmembrane ER stress sensors; IRE1, PERK and ATF6, 
corresponding to IRE-1, PEK-1 and ATF-6 in C. elegans respectively (Figure 1.10)186. The molecular 
chaperone BiP is involved in the regulation of both IRE1 and PERK, functioning as an indirect readout 
of protein folding state within the ER. During unstressed, basal conditions, BiP associates with the 
luminal domains of both IRE1 and PERK, maintaining them in their monomeric forms and thus 
repressing their activation. Upon the accumulation of unfolded proteins, however, BiP can reversibly 
dissociate from these transmembrane proteins and bind to the unfolded protein instead. This dissociation 
derepresses both IRE1 and PERK, leading to their oligomerisation and activation187.  
 
In the case of IRE1, this activation is stimulated by the autophosphorylation of the dimer. In this state, 
the endonuclease activity of IRE1 is activated, resulting in the splicing of X box-binding protein 1 (xbp-
1) mRNA188. In its spliced form, xbp-1s can be translated into a functional transcription factor that 
translocates into the nucleus, driving the expression of UPRER target genes with the ultimate aim of 




PERK, meanwhile, triggers a translational attenuation, thus reducing the folding demands of the ER. 
Following its activation, PERK is able to phosphorylate the translation initiation complex eIF-2α, which, 
as previously described, prevents the formation of pre-initiation complexes involved with the loading 
of the initiator tRNA onto the 40s ribosomal subunit142. Consequently, protein synthesis is halted, 
allowing ER resident proteins to clear the accumulated unfolded proteins without further translation 
adding to the protein-folding burden. This effect can be demonstrated clearly in PERK-/- mouse 
embryonic stem cell lines – eIF-2α in these cells cannot be phosphorylated after treatment with 
pharmacological inducers of ER stress, such as the N-linked glycosylation inhibitor tunicamycin, and 
as a result display increased sensitivity to this stress189.  
 
ATF6, on the other hand, works in a similar fashion to XBP1 by regulating the expression of UPRER 
response genes. The N-terminal cytoplasmic domain of this protein contains a basic leucine zipper motif 
(bZIP) that protrudes into the cytoplasm, whilst the remainder of the protein is embedded in the ER 
membrane. Upon stress, this N terminal fragment undergoes a proteolytic cleavage, releasing it into the 
cytoplasm, from which point it is then able to translocate into the nucleus and induce the expression of 
genes including BiP190.  
 
Figure 1.10 Schematic outlining the three major pathways of the canonical unfolded protein response (UPR) of the 
endoplasmic reticulum, including the ATF-6. PEK-1 and IRE-1 branches (adapted from BioRender, courtesy of E. Madden) 
 
Although these branches are very much distinct in their own right, they do display a degree of cross talk, 
compensating for one another in case of deficiency. This can be demonstrated in mutants of ire-1/xbp-




1 paired with pek-1 or atf-6 mutations; whilst single mutant animals are viable, double mutants display 
larval lethality191,192. The underlying molecular underpinnings of this overlap have been investigated in 
animals with XBP-1-deficiencies. These xbp-1 mutant animals show an increased level of IRE-1 activity 
and PEK-1-mediated eIF-2α phosphorylation in unstressed conditions compared to wild type animals193. 
This suggests that xbp-1 mutation can trigger a constitutive activation of ER stress responses in basal 
conditions, thus allowing for alternative branches of the UPR to coordinately compensate for the loss of 
the IRE-1/XBP-1 axis. 
 
1.3.4 The “Non-Canonical” Unfolded Protein Response 
Upon inhibition of the xbp-1 branch of the UPRER, a non-canonical pathway can be stimulated to 
compensate for the loss of this response (Figure 1.11). The protein family involved in this pathway, 
known as the ABU family of proteins (Activated in Blocked UPR), is capable of eliciting a stress 
response in C. elegans under these conditions, mitigating against the loss of this key UPR component. 
Nine of these non-canonical components, namely abu-1 to abu-9, were first identified following a screen 
of genes upregulated in ER-stressed versus unstressed animals in an xbp-1 mutant background194. These 
nine genes, which all bear a close resemblance to one another with an N-terminal signal sequence and a 
transmembrane domain, can be knocked down simultaneously using RNAi against a highly related 3’ 
stretch of sequence. In keeping with this initial evidence, RNAi knockdown of these genes in an xbp-1 
or ire-1 mutant background reduces survivorship in cadmium-treated ER-stressed animals compared to 
those on control RNAi – this suggests that the abu gene family does indeed play a role in responding to 
ER stress when traditional pathways are compromised. However, the mechanisms underlying this 
protection are as yet unknown, with the function of individual ABU proteins still to be elucidated. 
 
1.3.5 UPR and Immunity 
A role for XBP-1 has been identified in protecting against pathogenic insult, thus highlighting a link 
between the UPR and the innate immune system. Under non-pathogenic conditions, xbp-1 mutants 
develop normally whilst those exposed to Pseudomonas aeruginosa (PA14) develop abnormal ER 
morphology and display larval lethality; these phenotypes are suppressed when PMK-1-mediated 
immunity is lost, and are exacerbated when this pathway is hyperactivated, demonstrating that this effect 
is mediated via the p38-MAPK pathway. The link between these two stress response systems is further 
validated by the expression of hsp-4p::gfp, a marker for ER stress, which is upregulated following PA14 
exposure, an effect that is lost in pmk-1 mutants195. This effect does not, however, protect against the 
immune threat itself but rather against the immune response; this has been demonstrated in xbp-1;pmk-
1 double mutants, which exhibit increased survival and development on PA14 compared to single xbp-
1 mutants. This suggests that the PMK-1-mediated immune response is having a detrimental impact 
upon the animal – an effect that XBP-1 mitigates against. It has been proposed that this is as a 
consequence of the increased demands placed upon the endoplasmic reticulum upon activation of such 
responses, with around half of the roughly 300 genes induced by the innate immune system shuttling 
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through the endomembrane system184. This large increase in nascent protein production can have 
negative effects on an organism due to the excessive strain it puts on the folding capacity of the system; 
the XBP-1 branch of the UPR can protect against this innate immune response-induced increase in ER 
stress195. 
 
Evidence has also emerged of a role for the ABU proteins in the innate immune response, with a set of 
abu/pqn (prion-like glutamine[Q]/asparagine[N]-rich domain-bearing protein]) genes being 
downregulated in mutants of the phagocytic receptor CED-1, pointing towards a cross over between 
these stress response pathways196,197. In keeping with its role in immunity, ced-1 mutants are deficient 
in bacterial clearance and are rapidly killed upon exposure to live bacteria. Genome expression analysis 
identified a group of genes highly upregulated by CED-1 – this group contained an enrichment of 
abu/pqn genes, suggesting that CED-1 can activate genes of the non-canonical UPR response. This has 
functional consequences, with abrogation of these genes reducing survival when exposed to live, but 
not dead, pathogenic bacteria. This can be visualised in vivo by the increased invasion of GFP-labelled 
S. enterica observed in ced-1 mutants when treated with RNAi against either abu-1 or abu-11. Hence, 
this demonstrates the role of CED-1 in activating the non-canonical UPR pathway to elicit an immune 
response. 
 
1.3.6 Regulation by OCTR-1 
Neuronal control of the innate immune response is vital for ensuring that such responses are not under- 
or over-activated; under-activation would exacerbate infection whilst over-activation could result in 
tissue damage. The p38 MAPK pathway, for example, is finely tuned to minimise such damage – this 
can be demonstrated in gain-of-function mutations in which positive regulators of this pathway, such as 
NSY-1, trigger an aberrant and heightened response, ultimately resulting in toxicity198. In C. elegans, a 
neuronal circuit involving the G-protein coupled receptor, NPR-1, has been shown to suppress innate 
immune responses, with loss of this receptor reducing survival upon exposure to Pseudomonas 
aeruginosa (PA14)199. This is a clear demonstration of the level of regulation that can be exerted on the 
immune system by the nervous system. Such regulatory effects have also been identified for OCTR-1, 
another neuronal GPCR. Unlike NPR-1, however, octr-1 mutants show a decreased susceptibility to 
PA14 killing compared to wild type animals, suggesting that this GPCR acts to inhibit the innate immune 
response. This improved survival phenotype of octr-1 mutants can be suppressed when treated with 
RNAi against pmk-1, thus demonstrating that OCTR-1 negatively regulates the innate immune response 
by inhibiting the p38 MAPK pathway200. Rescue of this phenotype can be elicited by expression of octr-
1 under control of the sra-6 promoter, which restricts expression to the neurons ASH, ASI and PVQ, 
although it is important to note that PVQ neurons do not endogenously express octr-1, thus suggesting 
that the expression of OCTR-1 in solely ASH and ASI drives this inhibition of the innate immune 
response downstream. This is further corroborated by the degeneration of the ASH neuron using neuron-
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specific polyQ expression, which recapitulated the enhanced resistance to PA14 observed in octr-1 
mutants. 
Analysis of the genes upregulated in octr-1 mutants compared to wild type animals highlights a subset 
of genes upregulated by CED-1, including some of the abu/pqn genes previously identified as being 
regulated by this phagocytic receptor196. Indeed, ced-1 mutants can inhibit the enhanced pathogen 
resistance of octr-1 mutants, implying that the inhibitory effect exerted by OCTR-1 is facilitated via 
CED-1. Similar suppression phenotypes are observed following RNAi knockdown of abu-1, -7, -8, -12 
and -13, although no additive effect was seen when this RNAi was paired with octr-1;ced-1 double 
mutants; this illustrates that, in the context of enhancing the pathogen resistance of octr-1 mutants, ced-
1 and the abu genes are in the same genetic pathway200.  
 
Figure 1.11 Schematic outlining the function of the ABU family in both a non-canonical ER stress response pathway and 
within the innate immune system, in response to CED-1 activation (created with BioRender) 
In addition to neuronal regulation of the non-canonical pathway via OCTR-1, there is also evidence of 
its role in the regulation of the canonical XBP-1 pathway in adulthood. During postembryonic 
development, octr-1 mutants show no difference in the XBP-1 splicing activity of IRE-1 compared to 
wild type animals, suggesting that OCTR-1 activity does not influence this pathway prior to adulthood. 
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In post-developmental stages, however, this does not seem to be the case, with expression of a number 
of XBP-1-target genes upregulated in octr-1 mutants following PA14 exposure. Similarly, these mutants 
also show a greater hsp-4p::gfp expression after exposure than wild type animals, suggesting an 
increased activity of the XBP-1 branch when OCTR-1 activity is lost201. 
Thus, on the whole, this demonstrates that both the canonical and non-canonical UPR pathways can be 
negatively regulated by the neuronal GPCR, OCTR-1, with the ABU family of proteins regulated via 
the phagocytic receptor CED-1.  
 
 
1.4 Aims of thesis 
Thus far, the role of prion-like proteins in the facilitation of stimuli-induced phase separation has been 
explored, but a further understanding of the diverse roles that these proteins play physiologically remains 
to be investigated. It is clear that the characteristics of prion-like domains - such as multivalency, low 
complexity and intrinsic disorder - incline these proteins towards such transitions. Identifying and 
understanding the function that these proteins play in phase separation has been enlightening in the 
pursuit of a mechanistic understanding of protein aggregation disorders. As has been illustrated, many 
of these aggregation disorders result from aberrant transitions of liquid- or hydrogel-like condensates as 
a consequence of misregulation of these structures. Developing our understanding of how these 
membraneless organelles are regulated, and in response to which stimuli, may help us to understand the 
mechanics of this prion-like aggregation both physiologically and pathologically.  
 
Using Caenorhabditis elegans as a model system, we will investigate a novel prion-like protein and 
characterise its functionality. This model system provides a great deal of physiological and molecular 
flexibility in this process, whilst maintaining the complexity of a multicellular, multi-tissue organism. 
 
In this thesis, I will aim to: 
 
1. Identify and functionally characterise a novel prion-like protein in C. elegans 
2. Investigate the characteristics of this prion-like protein in vitro and in vivo 
3. Understand both the protein and RNA interactions made by this protein, and the physiological 
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Whilst the role that many prion-like proteins play in pathology is well characterised, their involvement 
in cellular physiology is understood to a much lesser extent. Due to the stereotyped architecture of prion-
like domains (PrLDs), which often contain low complexity and intrinsically disordered sequences, it is 
possible to identify candidate prion-like proteins computationally. Using the Prion-Like Amino Acid 
Composition program, we have identified the stress-responsive protein ABU-13 as a potential prion in 
the nematode species, Caenorhabditis elegans. This protein scores more highly than many human and 
yeast prions across multiple comparable algorithms, lending credence to the possibility that this 
proposed PrLD does indeed confer prionogenic properties upon ABU-13. Analysis of predicted prion-
like sequences across species highlights an intraspecies clustering of prion-like protein prediction 
scores, suggesting that there may be differences in the frequency and sequence content of prion-like 
proteins between species.  
 
In general, the ABU family of proteins exhibit higher prediction scores than known non-prionogenic 
proteins, implying that a degree of low complexity and disorder may be an intrinsic feature of many of 
these proteins. Despite this, ABU-13 scores much higher than the rest of its family and thus remains the 
strongest candidate for further investigation. Phenotypic analysis of ABU-13 knockout animals has 
identified a non-redundant role for this protein in ER stress and innate immune responses. Whilst this 
suggests an interplay with the canonical unfolded protein response pathways, these knockout animals 
do not display defects in the activation of the ER stress response gene hsp-4 upon tunicamycin treatment, 
























2.1.1 Prion-like domains 
 
The properties of intrinsic disorder and low complexity that define prion-like domains allow for the 
conformational flexibility required for their activity. This ability to structurally switch between states is 
key for conformational templating, and thus for the propagation of prion-like states. Without this 
flexibility, prion-like states could not exist in their heritable form. Early studies demonstrated that such 
domains are discrete entities, capable of conferring these prion-like properties if the domain is 
transferred onto a non-prion1.  
 
The intrinsic ability of these domains to confer such properties is largely driven by amino acid 
composition - these abilities are not lost, for example, when the prion domain is scrambled, retaining 
the relative proportions of each amino acid constituent but in a different order, clearly demonstrating 
that residue position within the domain is less important than the basic composition2. Commonly, an 
overrepresentation of polar residues such as glutamine and asparagine (Q/N) is observed within such 
domains3,4. Some amino acids do, however, exhibit a very strong positional effect resulting from 
specific-residue properties; hydrophobic residues, for example, show a high degree of position 
dependency. These residues are underrepresented within these domains due to their strong propensity 
to trigger aggregation – however, their limited presence is beneficial in promoting prionogenicity5,6.  
 
2.1.2 Domain Predictions 
 
The predictable composition of these regions has allowed algorithms for the bioinformatic identification 
of novel prions to be developed, with mixed success. Initial algorithms, such as DIANA, focused on the 
Q/N-rich nature of these domains but neglected the influence of other residues, making it difficult to 
distinguish between prion and non-prion7. Such distinctions have been improved on since the 
development of DIANA. Alberti et al., for example, undertook a bioinformatic proteome-wide screen 
for prionogenic proteins in yeast, identifying and characterising around 100 novel candidates. By 
replacing the Sup35 prion domain with that of the candidate prions, they were able to demonstrate that 
19 of these candidates indeed functioned as prions, capable of transmitting their conformation onto naïve 
counterparts in a [PSI+] state8.  
 
Whilst this improved on previous predictions, the false positive rate observed in this screen remained 
high, suggesting that there are other factors influencing prion activity – possibly as a result of the 
systematic exclusion of underrepresented residues, such as those with hydrophobic properties, from 
these bioinformatic algorithms. Using mutagenesis data, Toombs et al. were able to reduce the false 
positive rate in their PAPA algorithm by quantifying the influence of the residues within these domains9. 
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The success of this algorithm was demonstrated in silico, with the design of synthetic prion forming 
domains (sPFDs), a number of which were shown to reconstitute prion activity to Sup3510.  
 
In this chapter, we utilise the Prion-Like Amino Acid Composition (PLAAC) algorithm to predict the 
presence of prion-like domains within the C. elegans proteome11. This algorithm relies primarily on the 
hidden Markov Model developed by Alberti et al., based on the composition of known yeast prions 
including Sup35p, Ure2p, Rnq1p and New1p8; it is important to note, however, that prions with 
dissimilar amino acid composition were not included in this model, as the mechanisms used by these 
domains to confer prionogenic activity are thought to differ.  This HMM parses sequences into one of 
two hidden states - either a prion-like or a non-prion state. Within the proteome, each amino acid is 
ascribed a transition probability, indicating the likelihood that the presence of that amino acid within the 
context of a pre-defined region would drive the protein in one of these two states. As standard, PLAAC 
defines prion-like domains as containing a minimum of 50 amino acids, using a region of this length as 
its pre-defined contextual query window for prion-like state in comparison to a background of 1000 
amino acids. These 50 amino acid query windows then undergo either a Viterbi or MAP parse – both of 
which are computational approaches to uncovering hidden states – to identify the cumulative probability 
of these regions representing prion-like or non-prion states. 
 
The PLAAC algorithm graphically depicts these hidden Markov Model results, plotting which protein 
regions are predicted to be prion-like and which are not. Beyond this, it also depicts the output from 
other algorithms, allowing for these readouts to be directly compared – strengthening the overall 
predictive power of these algorithms. A scaled version of the PAPA scores derived from the Toombs et 
al. algorithm12, for example, are plotted as well, following an adjustment of each score by a factor of -4 
– this allows lower values to become predictive of prionogenicity within the same numerical scale as 
the other readouts.  
 
In this chapter, we will apply and validate the use of the PLAAC algorithm on the C. elegans proteome, 
showing that, whilst there do appear to be species-specific differences in the prediction scores, the 
algorithm still strongly predicts the presence of prion-like domains in certain proteins. Specifically, 
ABU-13, a protein implicated in the unfolded protein response of the endoplasmic reticulum, scores 
















2.2.1 Species-specific validation of the PLAAC algorithm 
 
The PLAAC algorithm combines a number of different predictions of prion-like characteristics to 
identify potential PrLDs within the proteome of an organism. To normalise against the differential 
frequencies of amino acid usage between species, the algorithm uses a background frequency parameter 
for all proteomic data derived from non-yeast species. As the C. elegans proteome was used, the 
background frequency was set to 50 (out of 100), as recommended, compared to the 100 used for the 
yeast proteome, representing a total reliance on the background amino acid frequency of S. cerevisiae.  
 
Yeast Prions Yeast Non-Prions 















SUP35 51.215 0.1 -0.423 30.358 PBS2 N/A -0.051 -0.001 -0.716 
RNQ1 47.459 0.141 -0.324 79.598 HAC1 N/A -0.167 -0.076 -0.286 
MOT3 40.751 0.102 -0.116 152.584 GCN2 N/A 0.015 -0.04 -1.708 
URE2 29.225 0.103 -0.13 107.777 BCK1 N/A -0.069 -0.119 -1.527 
MOD5 N/A -0.045 -0.082 28.91 CDC28 N/A N/A N/A -0.346 
CYC8 57.104 -0.004 -0.49 -0.476 HCM1 N/A -0.134 -0.003 -0.687 
STD1 N/A -0.025 -0.13 116.93 SSA2 N/A -0.134 -0.003 -0.687 
PMA1 N/A -0.141 -0.007 0.691 IRE1 N/A -0.016 -0.007 -1.163 
SWI1 46.292 0.055 -0.02 -0.749 HSF1 N/A -0.012 -0.09 9.299 
NEW1 42.458 0.137 -0.546 133.073           
 
  
         
C. elegans Prion-like Proteins C. elegans Non-Prion-like Proteins 















LSM-4 N/A -0.099 0 -0.171 SEK-1 N/A -0.066 -0.002 -0.384 
TIAR-2 33.996 0.081 -0.269 26.867 CED-1 N/A -0.108 -0.003 -1.159 
HRP-1 28.649 0.014 -0.219 28.649 XBP-1 N/A 0.074 -0.038 -0.383 
MEG-3 N/A 0.063 -0.059 1.307 PEK-1 N/A -0.086 -0.003 -1.125 
LAF-1 24.835 -0.011 -0.244 28.705 ATF-6 N/A -0.059 -0.151 -0.637 
PAB-1 28.58 0.058 -0.22 42.691 NSY-1 N/A -0.068 -0.004 -1.547 
FUST-1 23.329 -0.099 -0.219 19.639 DAF-2 N/A -0.052 -0.004 -1.895 
CAR-1 22.331 0.02 -0.49 24.189 DAF-16 N/A -0.01 -0.002 -0.589 
          HSP-4 N/A -0.164 -0.004 -0.705 
          IRE-1 N/A -0.019 -0.002 -1.015 
          OCTR-1 N/A -0.012 -0.017 -0.456 
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Human Prion-like Proteins Human Non-Prion-like Proteins 















FUS 37.794 0.101 -0.21 91.609 MAP2K6 N/A -0.21 -0.008 -0.382 
TIA1 23.224 0.131 -0.089 20.805 MEGF10 N/A 0.041 0 -1.188 
RBM14 16.066 -0.134 -0.235 28.253 XBP1 N/A -0.048 -0.001 -0.309 
TDP-43 26.454 0.043 -0.001 30.133 EIF2AK3 N/A -0.054 -0.018 -1.164 
HNRNPA1 28.36 0.093 -0.091 19.715 ATF6 N/A 0.041 -0.009 -0.718 
CPEB3 N/A -0.071 -0.007 2.046 MAP3K15 N/A -0.002 -0.002 -1.361 
PrP N/A 0.02 -0.139 -0.301 IGF1R N/A -0.024 -0.01 -1.415 
HNRNPA2 30.064 0.043 -0.208 38.562 FOXO1 13.046 -0.013 -0.068 2.244 
TIAR 13.565 0.11 -0.096 10.265 FOXO3 N/A -0.058 -0.001 -0.721 
DDX4 N/A -0.089 -0.161 -0.986 FOXO4 N/A -0.109 -0.003 -0.553 
          HSPA5 (BiP) N/A -0.165 -0.003 -0.702 
          IRE1 N/A -0.06 -0.011 -1.025 
          ADRA2A N/A -0.106 -0.001 -0.513 
          HSF1 N/A -0.066 -0.002 -0.577 
Table 2.1 Summary of PLAAC results from known S. cerevisiae, human and C. elegans prions, with readouts from the Alberti 
algorithm (CORE score), Toombs algorithm (PAPA Prop), disorder prediction (FoldIndex) and Viterbi-parsed Hidden Markov 
Model scores 
 
To assess whether this resulted in an over- or underestimate of prion-like domains within these animals, 
we compared the PLAAC results from a number of known prion-like proteins from the yeast, human 
and C. elegans proteome, working on the assumption that such proteins would share similar results 
across these computational readouts (Table 2.1). Each of these proteins had previously been shown to 
have an intrinsically disordered region and/or a prion-like domain, or displayed prion-like capabilities 
such as the ability to act as a protein scaffold, nucleating phase separation. 
 
Comparison of scores across these three species demonstrates some of the differences arising from these 
algorithms. The prion propensity (PAPA prop) values, for example, show no significant differences 
between prion groups, regardless of species – however, only the yeast prions show any significant 
difference when compared to non-prion-like proteins of any other species (yeast, p=0.0167; human, 
p=0.0115; nematode, p=0.0202), whilst neither the human nor nematode prions showed any significant 
difference from non-prion proteins (Figure 2.1A). The CORE scores of yeast prions, on the other hand, 
are significantly greater than both human (p=0.0005) and nematode (p=0.0019) prions (Figure 2.1B). 
As would be expected, due to the lack of a predicted prion-like domain in many non-prion-like proteins, 
no CORE score could be determined and thus the difference between these results could not be assessed. 
Similarly, the Viterbi-parsed Hidden Markov Model shows a difference between yeast prions and the 
human and nematode prions, as well as between the yeast prions and all three species of non-prion-like 




Figure 2.1 Comparisons of PLAAC output scores between known yeast, human and nematode prions, as well as non-prion 
like proteins from all three species (A) Prion propensity (PAPA prop) values [Two way ANOVA, Yeast Prions v Yeast Non-
Prions, p=;0.0167; Yeast Prions v Human Non-Prion, p=0.0115; Yeast Prion v C. elegans Non-Prion, p=0.0202, C. elegans 
Prion v C. elegans Non-Prion, p=0.4657, ns; Human Prion v Human Non-Prion, p=0.0841; grey = significant PAPA value] 
(B) CORE scores [Two way ANOVA, Yeast Prions v Human Prions, p=0.0005; Yeast Prions v C. elegans Prions, p=0.0019; 
Yeast Prions v Yeast Non-Prion, p=0.000] (C) Viterbi-parsed HMM scores One way ANOVA, Yeast Prions v C. elegans 
prions, p=00140; Yeast Prions v Yeast Non-Prions,  p=<0.0001; Yeast Prions v C. elegans Prions, p=<0.0001;  Yeast Prions 
v Human Non-Prion, p<0.0001] 
 
2.2.2 ABU-13 is a strong candidate prion-like protein 
 
Application of the PLAAC algorithm to the full proteome of N2 animals – representing the laboratory 
standard wild type C. elegans strain - highlighted a number of potential prion-like candidates scoring 
highly across multiple readouts. The top hits amongst these candidates include UNC-10, the ortholog of 
the human RIMS1 protein, involved in synaptic transmission within the cholinergic system, and CEST-
12, a protein thought to function in the hydrolysis of carboxylic esters. In keeping with their 
overrepresentation amongst prion-like proteins, many of the top hits were PQN proteins previously 
identified by the DIANA algorithm, such as PQN-31, PQN-71 and PQN-84. It is interesting to observe 
that many of the PQN proteins identified in this computational screen do not have defined functions 
beyond domain-based predictions – this is likely a reflection of the technical difficulty of working with 
such proteins.  
 
Of these hits, the top-scoring candidate overall was ABU-13 (also known as PQN-46), a member of a 
protein family that has been previously been shown to be differentially regulated in response a number 
of environmental stress conditions, including activation of the innate immune system and the ER stress 
response. This protein has a CORE score of 73.571, far exceeding the next ranked candidate, PQN-32, 
with a rank of 59.467 (Table 1.2, Figure 2.2B), suggesting that ABU-13 has a significant glutamine-
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asparagine (Q/N)-rich domain that may confer prionogenic properties onto the protein. In support of 
this, ABU-13 also ranks highly and significantly on other readouts of prion propensity - in the Toombs 
algorithm (PAPA propensity), for example, it scores 0.206. This algorithm works in concert with the 
Alberti algorithm to fine-tune the identification of potentially prion-like domain proteins by assessing 
the relative contributions of residue interactions within these proposed domains, reducing the false 
positive rate. Within this system, any value above 0.05 is classed as significant, thus predicting that the 























Table 2.2 Summary of top PLAAC results from the C. elegans N2 proteome, with readouts from the Alberti algorithm (CORE 
score), Toombs algorithm (PAPA Prop), disorder prediction (FoldIndex) and Viterbi-parsed Hidden Markov Model  
 
This is further supported by the prediction of an amyloidogenic core in the middle of this proposed 
prion-like domain, spanning residues 199 to 219 (Figure 2.2A). This motif could represent the core set 
of amino acids necessary for fibrillisation of ABU-13, if such an aggregation occurs.  
 
2.2.3 Structural predictions of ABU-13 
Rank Protein CORE Score PAPA Propensity FoldIndex HMM Viterbi 
1 ABU-13 73.571 0.206 -0.581 103.79 
2 PQN-32 59.467 0.057 -0.326 143.97 
3 PQN-37 59.069 0.053 -0.28 99.584 
4 PQN-31 58.069 0.137 0 175.317 
5 CEST-12 56.978 0.167 -0.005 167.064 
6 PQN-71 56.781 0.143 -0.484 60.489 
7 PQN-84 55.072 0.074 -0.227 82.28 
8 PQN-88 54.645 0.14 -0.297 83.581 
9 UNC-10 53.467 0.031 -0.524 149.479 
10 PQN-8 52.97 0.143 -0.239 120.172 
11 PQN-42 51.475 0.018 -0.48 47.009 
12 PQN-83 51.228 0.077 -0.464 73.12 
13 PQN-27 51.034 0.101 -0.477 80.718 
14 PQN-15 50.923 0.072 -0.33 304.481 
15 ZC21.3 49.849 0.132 -0.293 149.056 
16 HGRS-1 49.653 0.104 -0.417 91.1 
17 TLK-1 49.234 0.107 -0.471 70.538 
18 IMPH-1 48.989 0.027 -0.149 112.117 
19 F13H8.5 48.682 0.124 -0.014 64.091 
20 F55A12.6 47.906 0.272 -0.276 47.808 
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Figure 2.2 The structural features of ABU-13 (A) a schematic highlighting a number of conserved domains features including 
a signal peptide, a Q/N-rich prion-like domain and a zinc-binding residue; (B) graphical representation of the PLAAC results, 
showing the two-state results of the hidden Markov Model (background vs. prion), with a residue by residue pictorial 
representation of the HMM results, as well as a map of the FoldIndex and PLAAC results across the whole protein; (C) 
IUPRED2A and ANCHOR2 results of disorder within ABU-13; (D) residue-by-residue charge distribution 
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As is true for most of the other PQN proteins, there is little known about the specific function of ABU-
13 itself. Analysis of conserved domains within this protein highlights an N-terminal region immediately 
adjacent to the proposed prion-like domain that shares a degree of similarity to a number of proteins 
involved with RNA and DNA binding (Figure 2.2A). This includes the gamma and tau subunits of DNA 
polymerase III (accession references PRK12323, p=4.79e-4; PRK14971, p=8.36e-4; PRK07764, 
p=1.44e-3) and the half-pint superfamily (accession reference TIGR01645, p=3.39e-3), which contains 
a number of RNA recognition motifs involved in the binding and splicing of poly-U sequences. This 
suggests that the N-terminal region of ABU-13 may be involved in RNA or DNA interactions. The 
presence of a zinc-binding cysteine in the C-terminus of the protein also points towards further 
interactions as well, potentially with a structurally stabilising effect suggesting that this terminus is more 
ordered and structured than its N-terminal counterpart.  
 
In addition to this, there is also a predicted signal peptide at the N-terminus of the protein (likeness 
probability = 0.9858), targeting ABU-13 to the Sec translocon before cleavage by Signal Peptidase I. 
This cleavage site is predicted to be between residues 14 and 15 (p=0.9477). Whilst this suggests that 
ABU-13 is targeted to the secretory pathway, it is unclear where the processed mature protein is 
ultimately localised – whether retained in the endoplasmic reticulum or Golgi apparatus, secreted into 
the extracellular environment, or inserted into a target membrane. The latter is unlikely, as, unlike the 
other members of the ABU protein family, ABU-13 does not contain a transmembrane domain.  
  
As would be hypothesised for proteins of this nature, applying the IUPRED and ANCHOR algorithms 
for prediction of unstructured domains identifies a large intrinsically disordered region within the centre 
of ABU-13, in alignment with the FoldIndex per residue scores and coinciding with the proposed prion-
like domain (Figure 2.2B, 2.2C). As previously discussed, these IDRs allow for conformational 
flexibility, facilitating the switch between different states required for prion formation and propagation. 
The ANCHOR algorithm suggests that within this unstructured region, there are a number of binding 
domains, including between residues 133 and 220, and 264 and 305. The nature of these binding regions, 
however, is unclear at this stage. 
 
The C-terminal region of ABU-13 contains blocks of alternating charge, extending all the way from the 
centre of the protein. These charge differences could be representative of charge-charge electrostatic 
interactions.  
 
2.2.4 Comparing ABU-13 with the wider ABU family of proteins 
 
The ABU family of proteins were first identified in C. elegans as a group of genes that were upregulated 
in response to treatment with tunicamycin, an inhibitor of N-linked glycosylation that causes ER stress, 
in an xbp-1 mutant background. The genes identified were named the abu genes due to their activation 
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in blocked UPR. In order to determine whether or not this predicted prion-like domain is unique to 
ABU-13 or whether it is an intrinsic feature of this protein family as a whole, we compared the ABU-
13 PLAAC results to those from the wider family and with the set of known C. elegans prion-like 
proteins. Interesting, whilst the known prion-like protein scores were wide ranging, many members of 
the ABU family score highly across a number of readouts (Table 2.3, Figures 2.3A-C). ABU-13, -12, -
2, -8, and -15, for example, all score above the 0.05 threshold for prion propensity, suggesting that they 
contain some inherent prionogenic ability (Figure 2.2B). Whilst there is no significant difference 
between the scores of known prion-like proteins and either the ABU family or the non-prion like 
proteins, the ABU family score significantly higher than the non-prion-like proteins (p=0.0005). This 
suggests that, in general, this family possesses prionogenic capacities with properties akin to those seen 
















Table 2.3 Summary of PLAAC results from the ABU family of proteins (Note that some proteins do not have values attributed 
to them – these represent outputs for which no domain of minimal core length could be identified) 
 
Of particular interest are those proteins that score highly across multiple readouts – for example, whilst 
ABU-2 scores highly in prion propensity (0.094), it scores much lower in terms of CORE score (11.235) 
compared to other members of this family. Hence, to maximise our chances at identifying a genuine 
prion-like domain-containing protein, we correlated scores between different algorithms to highlight 
proteins that scored consistently well across each of these programs (Figure 2.3D-G), including yeast 
and human proteins in this analysis for comparison.  
 
Protein CORE Score PAPA Prop FoldIndex HMM Viterbi 
ABU-13 73.571 0.206 -0.581 103.79 
ABU-12 45.179 0.108 -0.318 87.355 
ABU-8 30.014 0.07 -0.231 39.051 
ABU-11 27.361 0.021 -0.002 35.752 
ABU-7 25.847 0.042 -0.185 32.369 
ABU-6 25.645 0.059 -0.187 26.917 
ABU-15 23.771 0.059 -0.193 27.954 
ABU-1 12.098 0.063 -0.001 7.557 
ABU-2 11.235 0.094 -0.007 0.172 
ABU-10 N/A 0.003 -0.002 -0.423 
ABU-14 N/A N/A N/A -0.421 
ABU-4 N/A 0.005 -0.002 -0.387 
ABU-5 N/A -0.002 -0.004 -0.383 
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Figure 2.3 Comparison of nematode PLAAC scores (A-C) Comparisons of ABU family PLAAC results with C. elegans 
specific prions and non-prions, including (A) CORE score [One way ANOVA, no significant difference]; (B) Prion Propensity 
[One way ANOVA, ABU family v C. elegans Non-Prion, p=0.0005]; (C) Viterbi-parsed HMM scores [One way ANOVA, 
ABU family v C. elegans Non-Prion, p=0.0128] (D) Correlation between CORE score and Prion Propensity [Pearson 
correlation, r=0.4408; p=0.0167; grey = significant PAPA value]; (E) Correlation between Prion Propensity and FoldIndex 
[Pearson correlation, r=-0.4976, p=<0.0001; grey = significant PAPA value]; (F) Correlation between CORE score and the 
Viterbi-parsed HMM scores [Pearson correlation, r=0.4634, p=0.0113]; (G) Correlation between Prion Propensity and the 
Viterbi-parsed HMM scores [Pearson correlation, r=0.5610, p=<0.0001; grey = significant PAPA value] 
 
Within these correlations, species-specific clustering of prion scores becomes more evident with yeast 
prions consistently grouping together in regions highly predictive of prionogenic activity, whilst human 
and nematode scores tend to cluster at lower prediction scores. In keeping with some of the individual 
algorithms, the ABU family in general clusters with the prion-like proteins, rather than with the non-
prion-like proteins. Consistently, ABU-13 outperforms other prion-like proteins, including the yeast 
prion clusters, with the high scoring nature of this protein manifestly clear from these plots. As a result, 
we decided to investigate and characterise ABU-13, as the most promising candidate from our 
computational predictions. 
 









Figure 2.4 Knockout of abu-13 does not consistently alter lifespan of animals (A) Kaplan-Meier survival curves of abu-
13(tm6224) and N2 animals assessed at 20°C; (B) Table indicating median lifespans (in days) of each replicate, along with the 
p-values of these replicates, with significance calculated by Mantel-Cox log rank test  
 
As a role for the abu family in cellular stress responses has been implicated previously13,14, we sought 
to determine whether ABU-13 plays a non-redundant role in protection upon exposure to a number of 
environmental challenges. Using animals with a deletion mutation of abu-13 (allele tm6224, truncated 
at residue 177, compared to the full length of 493 amino acids) obtained from the Japanese Knockout 
Consortium, we assessed responses of these knockout animals to ER stress, pathogenic exposure, and 
heat shock. Stress response pathways and lifespan are intimately linked, with components of a variety 
of these pathways being implicated in the modulation of lifespan. Constitutive splicing of the UPRER 
transcription factor xbp-1 in neurons, for example, results in lifespan extension, whilst xbp-1 mutant 
animals have a reduced lifespan15.  
 
To determine whether abu-13 knockouts have a similarly shortened lifespan, we performed lifespan 
analyses on these animals, ultimately determining that they have a similar lifespan to wild type animals. 
This suggests that ABU-13 does not play a fundamental role in the maintenance of longevity, thus 
uncoupling any stress resistance observed in these animals from longevity (Figure 2.4A-B). Whilst 
similar effects have been observed before, this decoupling is unusual, potentially highlighting the 



















 Replicate 1 Replicate 2 Replicate 3 
N2 20 23 23 
abu-13(tm6224) 19 23 23 
p-value 0.2643 0.5307 0.0004 
A 
B 





Figure 2.5 ABU-13 plays a non-redundant role in the innate immune response (A) Schematic of the developmental assay used, 
with animals grown on either an OP50 control or pathogenic PA14; (B) Fraction of eggs developing to L4 after 72 hours when 
fed with either OP50 or PA14 in N2 (blue), abu-13(tm6224) (red) and xbp-1(zc12) (yellow) animals (Two way ANOVA, N2 
v abu-13(tm6224) on PA14 – p=0.0002, ***; N2 v xbp-1(zc12) – p=0.0091, **) 
 
We then assessed the role that ABU-13 plays in the innate immune response, by comparing the 
developmental times of N2 animals, abu-13(tm6224) animals, and xbp-1 (allele zc12) mutant animals 
that have a point mutation in codon 34 resulting in premature termination of XBP-1 upstream of its 
functional domains, on either a non-pathogenic E. coli (OP50) bacterial lawn or a pathogenic 
Pseudomonas aeruginosa (PA14) lawn (Figure 2.5B). Bacterial avoidance is a strategy that nematodes 
use to improve survival when exposed to such immune threats; to eliminate the confounding effects of 
this behaviour on our results, we used a large bacterial lawn, ensuring the entire NGM plate was covered, 
removing the ability of animals to avoid PA14.  
 
Xbp-1(zc12) animals are known to have an attenuated response to pathogens and, in keeping with this, 
show a significant reduction in developmental time when grown on PA14 in comparison to N2 animals, 
which only show a small defect in the fraction of eggs reaching the L4 postembryonic developmental 
stage after 72 hours. ABU-13 knockout animals also show reduced pathogen resistance, exhibiting a 
reduction in developmental time when compared to N2 (Figure 2.5B). This effect is driven by the 
pathogen itself, as these developmental differences are not observed when animals are grown on OP50.  
 
To determine their sensitivity to ER stress, abu-13(tm6224) animals were subjected to a tunicamycin 
development assay, with plates supplemented with 0, 1.5 or 3µg/mL of tunicamycin (Figure 2.6A). 
Similar to the PA14 assay, the fraction of eggs reaching L4 after 72 hours was scored and compared to 
the fractions of both N2 and xbp-1(zc12) mutant animals reaching this stage. Xbp-1(zc12) mutant 
animals exhibit significantly reduced survival and development upon exposure to tunicamycin 
compared to wild type. As expected, in our assay N2 animals show minimal developmental defects 
when exposed to 1.5µg/mL tunicamycin, whilst xbp-1(zc12) animals have an extreme developmental 
delay, with only a very small percentage reaching L4 after 72 hours. ABU-13 knockout animals have a 
moderate developmental delay upon tunicamycin treatment when compared to N2. Similar results were 
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observed at 3µg/mL, but the trend is much less obvious as this concentration of tunicamycin is sufficient 
to cause a significant developmental delay even in the N2 control animals (Figure 2.6B). This suggests 
that ABU-13 does indeed play a role in protecting against the effects of ER stress, though to a lesser 
degree than XBP-1.  
 
 
Figure 2.6 ABU-13 plays a non-redundant role in ER stress responses  (A) Schematic of the developmental assay used, with 
animals grown on either DMSO-supplemented plates or plates supplemented with varying concentrations of DMSO; (B)  
Fraction of eggs developing to L4 after 72 hours when grown on plates supplemented with either DMSO (represented at 
0µg/mL), 1.5µg/mL or 3µg/mL of tunicamycin in N2 (blue), abu-13(tm6224) (red) and xbp-1(zc12) (yellow) animals (Two 
way ANOVA, N2 v AGD972 on 0µg/mL – p=0.0423; N2 v abu-13(tm6224) on 1.5µg/mL tunicamycin – p=0.0011, **; N2 v 
AGD972 on 1.5µg/mL tunicamycin – p= <0.0001, ****; abu-13(tm6224) v xbp-1(zc12) on 1.5µg/mL – p=<0.0001, ****) 
 
We then examined resistance to a 2.5 hour 37°C heat shock treatment in N2, abu-13(tm6224) animals, 
and, as a positive control, animals with a substitution mutation in the heat shock factor hsf-1 (allele 
sy441) leading to a truncation mutant lacking its transactivation domain. There was, however, no 
significant difference between the heat shock survival of N2 and abu-13(tm6224), whereas hsf-1(sy441) 
animals showed a significant reduction in survival when compared to either of these strains (Figure 
2.7A-B). This suggests that ABU-13 is important in response to specific stresses, rather than to cellular 
stress in general. 
 
2.2.6 Interplay between the canonical and non-canonical UPRER pathway 
 
 As the ABU family were identified as being upregulated in response to inhibition of the IRE-1/XBP-1 
branch of the UPRER, we crossed abu-13(tm6224) animals into a strain containing a hsp-4p::gfp 
transgene. HSP-4 is the C. elegans ortholog of the mammalian ER stress sensor BiP, which is 
upregulated upon ER stress. Its induction depends entirely on the presence of IRE-1 and XBP-116 and 
this strain therefore acts as a readout for IRE-1/XBP-1 activation. Thus, using this transcriptional 
reporter, we were able to determine whether the activation of XBP-1 was changed in abu-13 knockout 
animals, using GFP expression as a surrogate for activation. 
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Figure 2.7 ABU-13 does not play a non-redundant role in responses to heat shock  (A) Schematic of the heat shock assay used, 
with survival of animals scored after a 2.5-hour heat shock treatment at 37°C; (B) Percent survival following a 2.5-hour heat 
shock at 37°C (One-way ANOVA, abu-13(tm6224) v hsf-1(sy441) – p=0.0439, *) 
 
In animals expressing the hsp-4p::gfp transgene in a wild type background (SJ4005), GFP levels are 
low under basal conditions as the UPR is not activated. Upon tunicamycin treatment, however, the 
expression of GFP is induced, resulting in a large increase in observable fluorescence, demonstrating 
the effective activation of these downstream targets. In an xbp-1 mutant background, however, this 
fluorescence cannot be seen either before or after tunicamycin treatment, demonstrating that these 
targets are not activated, as would be expected when this pathway is disrupted15. No significant effect 
on the activation of the hsp-4p::gfp transgene was observed in abu-13 knockout animals, with similar 
levels of fluorescence recorded in these animals compared to the control SJ4005 animals. This suggests 
that ABU-13 does not influence the expression of XBP-1 targets upon ER stress, and that the phenotypic 
effects observed are a consequence of a different pathway.  
 
In addition to this, as part of the innate immune system, proteostatic mechanisms are upregulated to 
mitigate the effects of the immune response itself. In keeping with this, existing evidence has 
demonstrated that hsp-4p::GFP expression is increased upon exposure to PA14. As we have identified 
a role for ABU-13 in both of these responses, we repeated this experiment in both the hsp-4p::GFP 
reporter control and those crossed into abu-13(tm6224) as well. We see a small increase in fluorescence 
in all animals following PA14 exposure, but no difference in reporter expression levels between these 
strains. This therefore further suggests that the role ABU-13 is playing in these responses is independent 






Figure 2.8 ABU-13 does not influence the expression of hsp-4, a readout of IRE-1/XBP-1 activationMicrographs of hsp-
4p::GFP (SJ4005) animals and hsp-4p::GFP;abu-13(tm6224) animals grown [i] OP50 for 6 hours; [ii] PA14 for 6 hours; [ii] 
Normalised fluorescence intensity values of the hsp-4p::GFP reporter after growth on OP50 or PA14 (SJ4005 v abu-
13(tm6224) on OP50, p = 0.8111, ns; SJ4005 v abu-13(tm6224) on PA14, p = 0.8226, ns; SJ4005 on OP50 v SJ4005 on PA14, 
p = 0.3290, ns; abu-13(tm6224) on OP50 v abu-13(tm6224) on PA14, p = 0.9998, ns) (B) Micrographs of hsp-4p::GFP 
(SJ4005) animals and hsp-4p::GFP;abu-13(tm6224) animals treated with [i] DMSO for 4 hours; [ii] 25ng/µL tunicamycin for 
4 hours [iii] Normalised fluorescence intensity values of the hsp-4p::GFP reporter after DMSO or 25ng/µL tunicamycin 
treatment (SJ4005 v abu-13(tm6224) treated with DMSO, p = 0.9984, ns; SJ4005 v abu-13(tm6224) treated with tunicamycin, 
p = 0.7705, ns; SJ4005 treated with DMSO v SJ4005 treated with tunicamycin, p = 0.0730, ns; abu-13(tm6224) treated with 











The primary determinant of a prion-like domain is amino acid composition, often in the form of Q/N-
rich sequences2,7. In yeast, this is particularly the case, with many prions within this species shown to 
contain an enrichment of these residues; as these prions form the basis of many computational 
predictions, this has resulted in a bias, with algorithms preferentially identifying domains with these 
characteristics to the neglect of prion-like domains that utilise different mechanisms to confer their 
prionogenic abilities. This is best illustrated by both the prion protein itself, as well as the fungal prion 
HET-s, both of which have strong prion activity whilst lacking a Q/N-rich domain17. Structural studies 
have shown that these proteins form beta-helical and beta-solenoid structures, capable of acting as 
prionogenic scaffolds – this suggests that any secondary structure domain capable of driving the 
formation of such a tertiary structure should be classed as a prion domain.  
 
This heterogeneity of prion domain composition is reflected in our PLAAC results, with many proteins 
known to possess prion-like characteristics scoring low in some of these algorithms. This suggests they 
do not conform to the standard Q/N-rich model for prion-like domains but rather they represent 
alternative mechanisms through which these characteristics can be conferred; RBM14 and DDX4, for 
example, are both proteins whose prion-like domains facilitate their involvement in the formation of the 
phase separated organelles paraspeckles and nuage, respectively18,19. Using these algorithms, however, 
they score low across multiple readouts, suggesting that they represent non-prion-like proteins – this is 
a clear demonstration of the omission of non-conforming prion domains from these computational 
results.  
 
This may also explain the differences observed between the scores of prions in different species, 
specifically between yeast prions, and their human and nematode counterparts. If there are a higher 
proportion of prions that use Q/N-rich domains in yeast compared to those in human and nematode 
species, then the average score of known, characterised prion-like domain proteins will be lower in 
latter, thus biasing the output towards higher average scores for the yeast prion datasets. However, this 
does not exclude the possibility that the Q/N-rich prion-like domains identified in the PLAAC algorithm 
for C. elegans do indeed represent genuine novel prion-like proteins; instead, it highlights the systematic 
underrepresentation of non-conforming prion-like domains in these results. 
 
In contrast to this omission, the false positive rate of many of these Q/N-rich domain prion predictions 
has been high with just 19 out of the 100 candidates screened in the initial validation of the Alberti 
algorithm possessing genuine prionogenic activity8. This has been mitigated by the development of 
algorithms such as that developed by Toombs et al.9,12, which predicts domains on their basis of residue 
interactions. Thus, by using multiple computational predictions in conjunction with one another, we 
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were able to cross-validate and strengthen high-ranking candidates in our screen of the C. elegans 
proteome.  
 
Amongst these highly ranked candidates, ABU-13 is one of the top hits across multiple outputs, scoring 
higher than well-characterised yeast prions by some readouts. This could be further validated moving 
forward using a Sup35 prion domain replacement assay, in which the prion-domain of Sup35 is swapped 
with that of the candidate prion. This chimeric protein is then tested for its ability to propagate the [PSI+] 
prion state – with successful propagation indicating the presence of a genuine prion-like domain. If the 
prion-like domain of ABU-13 is indeed capable of recapitulating these prionogenic effects then this 
would hugely strengthen the case for this protein acting as a prion in C. elegans. 
 
Based on the persuasively high score of ABU-13 across multiple readouts, however, we moved forward 
with exploring the functions of this protein as a promising candidate for a novel prion-like protein. 
Surprisingly, we identified a non-redundant role for ABU-13 in the response to tunicamycin treatment 
in a wild type background; this suggests that this protein is involved in the ER stress response pathway 
even when the IRE-1/XBP-1 branch of the UPR is intact. This must be functioning separately from the 
canonical pathway as, when crossed into an hsp-4 transcriptional reporter line, the expression of HSP-
4 was unaffected by knockout of abu-13. This suggests that under wild type conditions ABU-13 plays 
a role in stimulating a stress response; upon inhibition or disruption to xbp-1, however, this protein is 
highly upregulated, compensating for the loss of xbp-1. Alternatively, this could represent differential 
developmental effects of ABU-13 and XBP-1 pathways. Both have been shown to be regulated 
downstream of the neuronal GPCR, OCTR-1, but these influences differ between larval stages and 
adulthood. No regulation of XBP-1 by OCTR-1 is observed during larval development - this ability is 
gained in adulthood, as demonstrated by the dependence on xbp-1 for the enhanced survival of octr-1 
mutants upon PA14 in adulthood only.  
 
ABU-13, meanwhile, is negatively regulated by OCTR-1 throughout life in a CED-1-dependent fashion. 
As the effect of abu-13 knockout has been investigated in developmental assays, it remains possible that 
the fundamental, non-redundant role we have observed for ABU-13 in ER stress responses is only seen 
during development. Indeed, in data not shown, tunicamycin survival assays of abu-13 knockout 
animals initiated during L4 had highly variable survival rates – this is possibly as a result of inconsistent 
L4 staging, with those closer to adulthood surviving less than their slightly younger counterparts - 
however, controlled survival assays of adult animals would be required in order to draw any conclusions. 
This common neuronal regulation of ABU-13 and XBP-1 does, however, suggest an interesting 
relationship between the canonical and non-canonical UPR pathways. Further work is needed to 
characterise and clarify the nature of this relationship. 
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Whilst the role of the ABU family has been identified in the context of a compensatory response to xbp-
1 inhibition, its potential roles in respect to the other branches of the UPRER have been neglected. To 
investigate this, we would perform stress assays on ATF-6 and PEK-1 mutants, monitoring any changes 
in response when these animals are crossed into abu-13 knockouts. This would be in addition to the 
work performed with xbp-1;abu-13 double mutants - however, as these genes are both found on 
chromosome III, this would require editing of the endogenous locus via CRISPR to achieve this.  
 
In addition to this, the abu-13 knockout animal strain used (tm6224) contains a truncated form of the 
protein. Whilst this does abolish protein functioning entirely, it is not possible to determine whether the 
functional effects observed are a consequence of the prion-like domain specifically. To assess this, we 
will produce animals with deletion mutations of the entire predicted prion-domain, leaving the rest of 
the protein intact, and repeat the aforementioned phenotypic assays to determine whether these effects 
are still observed.  
 
Comparison of the ABU family of proteins suggests that this family is predisposed to prion-like features, 
with many of the proteins in this family scoring relatively high for prionogenicity. This suggests that 
low complexity might aid their involvement in stress response pathways – how this is brought about, 
however, is yet to be fully understood. There are, however, a number of intrinsically disordered proteins 
that have already been implicated in stress responses – for example, LSM-1 is involved in the formation 
of stress responsive phase separated organelles known as P-bodies20, whilst TIA-1 is involved with stress 
granule formation21. This potentially points towards a role for ABU-13 in the formation of phase 
separated organelles in response to stress. In vivo work will help to investigate this hypothesis further. 
 
In addition to this, it is also possible that the intrinsic disorder of the ABU family of proteins acts to 
‘mimic’ misfolded protein events within the ER. In the canonical UPRER, the chaperone HSP-4 (BiP in 
humans) is expressed in the endoplasmic reticulum and, under basal conditions, binds to the stress sensor 
IRE-1, maintaining this transmembrane protein in a monomeric, inactive state. When there is an 
accumulation of misfolded or unfolded proteins in the ER, however, HSP-4 preferentially binds to these 
proteins instead – this derepresses IRE-1, triggering its dimerization and subsequent activation, 
ultimately leading to a downstream stress response16,22,23. If the ABU family were acting to molecularly 
‘mimic’ misfolded protein events, this could stimulate an enhanced activation of the canonical pathway 
by sequestering HSP-4 away from IRE-1, leading to an increased activation of this stress response. If 
this were the case, then the increased expression of ABU proteins observed in xbp-1 mutant animals 
would represent a mechanism aimed at driving the increased activity of the non-xbp-1-related functions 
of IRE-1, as well as increasing the activation of the PEK-1 pathway, which also involves the chaperone 
HSP-4. Hence the ABU family could be functioning to upregulate compensatory UPR pathways, rather 
than stimulating a novel pathway entirely. There is, however, no observable change in the hsp-4::GFP 
reporter when combined with the abu-13(tm6224) mutants, as would be expected if this were the 
 
 76 
mechanism of action – this, however, might be reflection of redundancy amongst the ABU family, with 
the phenotypic deficiencies observed in abu-13(tm6224) animals a consequence of the activity of 
functional domains outside of intrinsically disordered regions. On the whole, this hypothesis could be 
tested further by assessing the expression of downstream target genes of these compensatory pathways 
in xbp-1;abu-13 double mutant backgrounds compared to xbp-1 single mutants.  
 
Alternatively, this prion-like characteristic of the ABU family might enable these proteins to bind to 
similarly unfolded regions found in misfolded proteins. This ability to has been observed in a number 
of prion-like proteins – often to a pathological end – however, in this case, this interaction might 
represent a physiological binding event. Akin to processes such as ubiquitination, in which proteins are 
targeted for degradation, binding of ABU proteins to misfolded proteins could act as a mechanism to 
identify and trigger their degradation. It would be interesting to investigate this further and identify 
whether there is any binding of the ABU proteins directly to misfolded proteins, and to compare the 
level of proteasomal activity in strains expression misfolding-prone proteins in both wild type and abu 
mutant backgrounds to determine whether such a binding event is used to stimulate degradation. It is 
important to note that, with the exception of ABU-13, the proteins within the ABU family all contain a 
transmembrane domain. This could point towards an alternative role – perhaps via recruitment of 
misfolded proteins to specific compartments, such as lysosomes, for degradation. In keeping with this, 
GFP-fused ABU-1 has been shown to localise in vesicular structures13. A better understanding of the 
cellular localisation of these proteins would improve our understanding of the role they might play.  
 
Although a defined role for the ABU family remains unclear, the unique properties of ABU-13 suggest 
it plays a distinct role within these responses, potentially one that differs significantly from the rest of 
the family. As mentioned previously, this protein is by far the most likely candidate for a prion in the C. 
elegans proteome. In addition to this, the presence of a potential RNA binding domain in the N-terminal 
region of this protein is highly reminiscent of the domain structure observed in phase separating proteins. 
The combination of a prion-like domain and an RNA interacting motif has been shown to play 
fundamental roles in the process of liquid liquid phase transitions due to the high valency that such 
protein architecture bestows. In fact, disruption of the RNA binding ability of the prion-like domains of 
such proteins can abolish their ability to form such structures at all. Multivalency is a key feature of 
these proteins, as this ability to interact with numerous molecules at once drives the coalescence of 
multiple of cellular components, allowing distinct regions of high concentration to form. The presence 
of these domains within ABU-13, as well as the prediction of binding sites within the intrinsically 
disordered region and a zinc-binding site in the C terminus of the protein add weight to the hypothesis 
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2.4 Material and Methods 
 
Maintenance of C. elegans 
 
Nematodes were maintained in accordance with standard protocols. Briefly, animals were grown on 
nematode growth media (NGM) plates seeded with the E. coli strain, OP50, at either 15°C for 
maintenance or at 20°C for experimental work. Prior to seeding, OP50 was cultured in Luria-broth 
overnight at 37°C, after which 100µL of bacteria was dispensed onto each plate and dried overnight at 




For predictions of prion-like domains, the PLAAC algorithm was used (http://plaac.wi.mit.edu/), using 
reference proteomes obtained from UniProt. All queries were programmed with the core length of 60 as 
standard. For the yeast proteome, the background frequency (a) was set to 100%, whilst the human and 
C. elegans proteomes were set to 50%. Output from this computation also gave residue-by-residue 
charge values from which a charge distribution plot was constructed. 
 
Domain conservation was determined using the NCBI Conserved Domain Search 
(https://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi), with settings maintained at default. ProinW 
was used to predict presence of nucleating amyloidogenic sequences (http://bioinf.uab.cat/prionw/). 
Signal sequences were identified using Signal-P5.0 (http://www.cbs.dtu.dk/services/SignalP/). The 
presence of zinc-binding residues was predicted by PredZinc (http://predzinc.bioshu.se/).  
 
For determination of disorder, the IUPRED2A and ANCHOR2 algorithms were applied 
(https://iupred2a.elte.hu/), with scores from the original ANCHOR algorithm used for prediction of 




Age-synchronised populations were grown at 20°C on OP50-seeded NGM plates and animals scored 
for viability every other day throughout adulthood (with the end of larval development corresponding 
with t = 0). To prevent offspring production and egg laying, animals were treated with 100µg/mL of 
FUDR at t = 0 and at day 5 of adulthood. Lifespan analyses were conducted using Prism 7 software, 






For tunicamycin development assays, NGM plates were supplemented with 1.5µg/mL or 3µg/mL of 
tunicamycin (Sigma Aldrich), or an equivalent volume of DMSO as a control. Beyond this point, plates 
were seeded with OP50 as per the standard protocol. For PA14 development assays, bacteria was 
cultured overnight at 37°C after which high peptone (0.35%) NGM plates were seeded with 100µL of 
bacteria evenly spread across the agar using a 10µL disposable inoculating loop (Thermo Scientific). 
PA14-seeded plates were incubated at 37°C overnight and then left at room temperature for 8 hours 
before use. 
 
Once ready for use, a timed egg lay was carried out on experimental plates to produce age-synchronised 
populations of animals. After this, plates were stored at 20°C for 72 hours before each plate was scored 
for developmental stage.  
 
Heat Shock Assay 
 
A timed egg lay was performed on seeded-NGM plates to age-synchronise populations. Once animals 
had reached the L4 stage of development, ~20 animals were transferred onto unseeded plates and 
wrapped in parafilm, ensuring they were fully watertight, before being placed into a 37°C water bath. 
After 2.5 hours, plates were removed and the survival of animals scored following an overnight period 
of recovery. 
 
Stress Reporter Treatment 
 
For tunicamycin imaging, age synchronised animals were collected at L4 and transferred into 1.5mL 
Eppendorf tubes containing either 25ng/µL of tunicamycin or an equivalent volume of DMSO. Animals 
were then incubated at room temperature on a rotating platform for 4 hours, before being transferred 
onto unseeded plates and immobilised with 50mM sodium azide. 
 
For Pseudomonas imaging, age synchronised animals were collected at L4 and transferred onto plates 
seeded with either OP50 or PA14, prepared as described above. Animals were then left on their 
respective bacterial lawns at 20°C for 6 hours, before being transferred onto unseeded plates and 
immobilised with 50mM sodium azide.  
 
Images were taken at 1X magnification using a Leica M205 FA microscope and LAS X software. 
Quantification of fluorescence was performed using ImageJ. 
 
Quantification of Fluorescence Imaging 
 
To determine the normalised fluorescence intensity values for each condition, the corrected total cell 
fluorescence (CTFC) for each individual animal was initially calculated. To do this, animals were 
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isolated within the image and measurements of integrated density and total area of the animal were 
taken, along with the average gray area of 3 different background regions. The CTFC was calculated as 
follows; 
 
𝐶𝑇𝐹𝐶 = 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑	𝐷𝑒𝑛𝑠𝑖𝑡𝑦 − (𝐴𝑟𝑒𝑎	𝑜𝑓	𝑎𝑛𝑖𝑚𝑎𝑙 ∗ 𝑀𝑒𝑎𝑛	𝑔𝑟𝑎𝑦	𝑎𝑟𝑒𝑎) 
 
An average CTFC value was determined for the control condition animals, and all CTFC values 





All statistical analyses were performed using Prism 8 software. One- and two-way ANOVA adjusted 
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Throughout biology, prion-like proteins are routinely overrepresented in pathology, with their 
propensity for aggregation promoting the formation of aberrant fibrillar species. More recently, 
however, evidence has emerged for a physiological role of these proteins, with many involved in the 
process of liquid-liquid phase separation. To determine whether ABU-13 acts as a scaffold for the 
formation of these phase-separated compartments, we produced both fluorescently labelled 
overexpression and endogenously-modified ABU-13 lines, allowing us to monitor the activity of our 
candidate prion-like protein in vivo. In line with our hypothesis, we do indeed see puncta formation 
throughout the body of the animal, reminiscent of these membraneless organelles, suggesting that ABU-
13 is indeed involved with formation of these transient structures. To determine whether these puncta 
were dependent on prionic mechanisms, we removed the prion domain from both of these lines, finding 
conflicting results, potentially suggesting that, whilst ABU-13 can act as a scaffold protein, there are 
other scaffold proteins expressed that play a compensatory role in these transitions in prion domain 
mutant animals. 
 
To investigate the biophysical properties of these puncta, we subjected them to FRAP to determine their 
mobility, finding that the larger puncta found within the overexpression line were largely immobile, 
whilst those within the endogenous line showed a broad range of mobility. Interesting, we observe a 
positive correlation between size and mobility, with larger puncta in the endogenously tagged line 
showing increased mobility compared to the smaller puncta. We propose that this is a consequence of 
multiphase coexistence, with smaller, low mobility structures representing core regions containing 
constitutive components of these compartment, whilst larger structures represent multiple core regions 
surrounded by a high mobility shell rich with more transient, highly turned over components.  
 
As we had already identified non-redundant roles for ABU-13 in both ER stress and innate immune 
responses, we next sought to understand how these puncta related to function. Whilst exposure of these 
animals to ER stress and heat shock conditions resulted in no observable change in puncta formation, 
we did see a highly significant change in puncta characteristics after exposure to the pathogenic bacteria 
Pseudomonas aeruginosa, with fewer yet larger puncta seen following invasion, as well as an 
upregulation of diffuse ABU-13 expression in the pharynx. This therefore led us to hypothesise that 
ABU-13 was acting via different mechanisms in response to these environmental stresses. 
 
To aid our understanding of how these compartments may be functioning, we investigated where ABU-
13 was expressed, with tissue predictions suggesting many hypodermal tissues. Indeed, an ABU-13 
transcriptional reporter line does appear to show expression in tissues including the hypodermis, seams 
cells, amphid sheath glia and the rectal epithelial cells. We then crossed our fluorescently tagged ABU-
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13 lines into a number of tissue marker strains, confirming expression in the seam cells, and potentially 
in the hypodermis, whilst excluding expression from a range of other tissues.  
 
There are a number of known stress-related phase separated organelles in C. elegans. To determine 
whether ABU-13 was localised to these, we crossed our tagged lines into stress granule and P-body 
marker strains, showing no colocalisation before and after the application of stress. This led us to 
propose that ABU-13 puncta may represent a novel form of phase separated compartment. 
 
To understand the mechanics of these phase separation properties without the confounding influence of 
the cellular environment, we moved into an in vitro system to determine whether ABU-13 was capable 
of driving phase transitions itself. Applying a range of buffer conditions to these purified proteins 
demonstrated an ability to reversibly form these puncta in vitro, thus supporting our previous hypothesis 
that ABU-13 can act as a scaffold protein for the formation of these structures. 
 
On the whole, we demonstrate that ABU-13 is involved in the formation of a dynamically responsive, 



































3.1.1 Phase separation 
 
Traditionally, cellular function is thought of as being compartmentalised within membrane-bound 
organelles1. This allows protein and nucleic acid-based molecules to be retained and regulated spatially, 
as the properties of the phospholipid bilayer largely restrict unregulated movement between the internal 
and external environments of the organelle. Instead, protein-based transporters are often relied upon to 
facilitate this movement - a process that is both energetically costly and time-consuming. As such, these 
organelles are often not rapidly dynamic. Even a rapid process such as the release of a neurotransmitter 
is reliant upon a cascade of processes. Phase separation, on the other hand, allows for rapid and 
responsive organelle dynamics, with organelle specificity deriving from the specificity of protein and 
nucleic acid interactions, rather than from the selective import and export of components.  
 
This act of coalescence is dependent upon the intrinsic biophysical properties of the constituent 
components themselves - often acting in response to changes in the cellular environment directly, or as 
a result of posttranslational modification2, for example. This removes some of the rate-limiting steps 
that membrane-bound organelles face when responding to stimuli. This is particularly true of liquid-like 
assemblies; these are often extremely transient, forming readily for the duration of their response before 
dissolving. Whilst many phase separated organelles undergo transitions into liquid-like states, not all do 
- some are capable of forming more solid-like structures known as hydrogels3,4. These are less transient 
than their liquid-like counterparts, with less free diffusion of components within them, and less exchange 
of molecules between them and the freely-diffusing surrounding environment. 
 
These liquid and hydrogel properties do not exist in a discrete system, but are rather part of a spectrum, 
with different phase separated organelles exhibiting a host of different properties. It has been 
hypothesised that this transition ability, when left unchecked, can result in pathological fibrillar states 
leading to the onset of disease5. 
 
There are a few mechanisms through which the biogenesis of these compartments is stimulated.  There 
is some evidence of RNA forming structural scaffolds onto which protein components can interact with 
and recruit further components6–8. The major route thought to drive this formation, however, is the 
intrinsic propensity of certain proteins, known as scaffold proteins, to coalesce9. Amongst scaffold 
proteins, there is an overrepresentation of prion-like proteins as their low complexity, intrinsically 
disordered domains facilitate such aggregatory behaviour10,11. However, this is not the only requirement 
for scaffold proteins - in order to promote the accumulation of many clients, this scaffold must have a 
degree of multivalency9,12. Some scaffolds achieve this through repetitive elements that promote 




Interactions with RNA, in particular, are hallmarks of phase separated organelles for a number of reasons 
– chiefly, many of these structures play roles in the regulation of RNA13 but, on top of this, RNA-species 
within these ribonucleoprotein complexes can help to maintain solubility and avoid aberrant transitions 
into fibrils14. Thus, the presence of both a prion-like domain and RNA interacting motifs within a protein 




In recent years, the ability to edit endogenous loci has improved in ease and efficiency. The advent of 
CRISPR technology has aided this process phenomenally. First identified as part of the bacterial 
adaptive immune system, this system involves the formation of ribonucleoprotein complexes capable of 
targeting specific DNA sequences and inducing double stranded breaks 3-4 nucleotides upstream of a 
protospacer adjacent motif (PAM), where the endonuclease Cas9 binds15.  
 
In the bacterial immune system, nucleotide sequences from invading DNA and RNA species are 
incorporated endogenously into clustered regularly interspaced short palindrome repeats (CRISPR) 
within the bacterial genome. These foreign incorporated sequences can then be expressed as CRISPR 
RNA (crRNA) capable of interacting with the Cas9 protein and guiding it to and cleaving DNA and 
RNA species upon re-invasion. Thus, these guide RNA sequences effectively allow the activity of Cas9 
to be reprogrammable for different genetic loci16–19. For genome editing, this has been exploited to 
induce double strand breaks at specific target sites. Unlike the bacterial immune system, however, the 
addition of a repair template can then be used to edit these specific-loci via homologous recombination.  
 
In C. elegans, CRISPR technology continues to be optimised. Akin to the insertion of extrachromosomal 
array lines, these endogenous edits can be achieved via microinjection - however the efficiency differs 
between approaches. For small edits and deletions, Paix et al. (2015) designed a basic protocol using 
pre-annealed site-specific Cas9-crRNA complexes in conjunction with single stranded donor 
oligonucleotide (ssODN) repair templates. For larger insertions, however, they recommend using double 
stranded PCR templates flanked by double stranded homology arms20.  
 
Alternative methods for insertions have been developed that purportedly improve efficiency in 
comparison to this approach. One such method is that of nested CRISPR, developed by Vicencio et al. 
(2019), that aims to improve the efficiency of large insertions by splitting them up into two smaller 
inserts (Figure 3.1)21. Initially, the full-size insert is split into three fragments; a small N terminal 
fragment, a large central fragment and a small C terminal fragment. An ssODN coding for these two 
small fragments flanked by appropriate homology arms, purposefully excluding the large central 
fragment, is then used for the first insertion. A double stranded PCR repair template of the full-size 
insert is then used for the next insertion - unlike the previous protocol, however, this does not require 
the addition of homology arms as the N and C terminal fragments already inserted fulfil this role. 
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The efficiency differences observed when using single stranded versus double stranded repair templates 
led Dokshin et al. (2019) to develop a method using partially single stranded repair templates22. This 
involves single stranded overhangs corresponding to homology arms sequences flanking the main 
double stranded repair template. This improves the efficiency of using dsPCR templates alone. 
 
 
Figure 3.1 A schematic outlining the multi-step process involved with Nested CRISPR 
 
Whilst these methods rely on the injection of pre-prepared Cas9-crRNA RNP complexes, this can 
present some technical difficulties, such as a tendency for these complexes to aggregate and block the  
needle during microinjection. As such, other methods rely on the formation of these complexes in vivo 
using a plasmid-based system to express components such as the repair template, homology arms and 
guide RNA. SapTrap, as this method is known, eliminates the need for complex cloning using a single 
tube ‘modular’ cloning strategy, allowing for the interchange of various fluorescent tags, linkers and 
self-excising cassettes using the SapI enzyme (Figure 3.2) 23,24. This enzyme results in a non-canonical 
digestion, with the resulting overhang found adjacent to the SapI recognition site, as opposed to the 
recognition and digestion sites being one and the same - as such, these overhangs can be made up of any 
combination of nucleotides. Exploiting this property of SapI allows components to be excised from PCR 
products and donor plasmids and inserted into a destination plasmid using a complementary 
combination of overhang sequences. This can then be injected into animals alongside a Cas9-expression 
vector or with the protein itself. Formation of the active RNP complex and the resulting edit then 
proceeds entirely in vivo. The inclusion of a self-excising cassette (SEC) allows for the positive selection 
of successfully edited animals - after which point, heat shock or hygromycin treatment can be used to 




Figure 3.2 Illustration of the modular nature of SapTrap, with exchangeable donor plasmids and overlapping SapI digestion 
overhangs (taken from Schwartz and Jorgenson, 2016)  
 
In this chapter, we will develop a number of fluorescently labelled ABU-13 transgenic animals, 
optimising the CRISPR/Cas9 protocols outlined above to produce endogenously edited lines in addition 
to extrachromosomal array lines. Using these strains, we will then characterise the biophysical properties 
of ABU-13 in vivo, demonstrating that, not only can this protein form puncta through the animal, but 
that these puncta vary in their mobility, suggesting that they represent both liquid-like and solid-like 
structures. Further characterisation of these structures will demonstrate a broad expression pattern, with 
higher expression levels in the hypodermis, as well as a dynamic change in these puncta in response to 
pathogenic bacteria. Finally, we will characterise the properties of ABU-13 in vitro, demonstrating that 
it retains the ability to form puncta in a range of conditions, further supporting our hypothesis that ABU-

















3.2.1 Construction of fluorescently tagged ABU-13 transgenic animals 
 
In order to determine the in vivo characteristics of ABU-13 and probe its potential prionogenicity, we 
produced transgenic lines expressing fluorescent proteins fused to ABU-13. Initially, we generated an 
extrachromosomal array line expressing tagRFP-fused ABU-13 under control of the abu-13 promoter 
(Figure 3.3A) - we chose this fluorescent protein due to its monomeric nature and low propensity for 
aggregation. This is of particular importance in the context of prion-like proteins due to their inherent 
propensity for such aggregatory behaviour. Visualisation of these animals showed clear punctate 
structures throughout the body, with these puncta varying in size but showing little variation over time 
(Figure 3.3B). The presence of these puncta does not negatively influence the health of the animal, with 
no overt structural or developmental phenotypes observed, indicating that these structures are not having 
an obvious adverse effect on these nematodes, as might be expected of pathological aggregation.  
 
One concern was that the distribution of ABU-13 in this system might be a result of overexpression. To 
circumvent the effects of overexpression, we sought to produce an endogenous insertion into the ABU-
13 locus using CRISPR/Cas9 technology. Whilst endogenous insertions are possible in C. elegans, the 
efficiency of such techniques remains low and, as such, we exhausted a number of insertion strategies 
before achieving a successful edit (Table 3.1). Initially, we relied on a protein-based strategy, whereby 
a pre-incubated Cas9-crRNA complex is injected directly into the gonad of maturing animals alongside 
a double-stranded PCR template of the insertion coding sequence flanked by 35 nucleotide overhangs 
corresponding to the locus of interest. The efficiency of this technique proved to be low, with no 
successful edits, despite success being achieved with the co-CRISPR marker, with a single-stranded 
oligonucleotide (ssODN) corresponding to the dpy-10 gene successfully editing the desired region and 
resulting in the appropriate roller phenotype for that small edit. This demonstrated that, whilst this 
method could produce small edits with a high efficiency, the efficiency for large insertions was 
significantly lower.  
 
We next moved to a different strategy, using a plasmid-based system alongside the Cas9 protein, known 
as SapTrap. Unlike the previous technique, the guide RNA and the repair template are cloned into an 
insertion plasmid, as opposed to the former being assembled into a complex with Cas9 prior to injection 
and the latter being injected alongside it. This technique purportedly results in high efficiency insertions 
in a high throughput fashion, with a modular ‘one-tube’ cloning system allowing for a simplistic 
interchange of fusion proteins, linkers and insertion sites within the plasmid by exploiting the non-
conventional endonuclease activity of the SapI enzyme. This, however, proved not to be the case in our 
hands, with no successful cloning events and thus we had no opportunity to test the efficiency of this 




Figure 3.3 Extrachromosomal array lines overexpressing tagRFP-fused ABU-13 show puncta throughout the animal (A) 
Schematic depicting the expression vector used to drive ABU-13::tagRFP overexpression (B) Confocal micrographs of ABU-
13::tagRFP overexpression animals (Scale bars, 100µm; 25µm) 
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We next attempted a nested CRISPR approach to mitigate the highly significant decline in efficiency 
observed as the insertion size increases (Figure 3.1). Indeed, we had some success with this approach. 
In particular, we saw a high insertion efficiency of the initial ssODN repair template sequence, which 
primes the locus for subsequent full insertion. We did then successfully edit the locus in this second 
insertion step, albeit with low efficiency. This was possibly due to the large insertion size of this 
fragment compared to the first. The insertion produced, however, contained many errors that rendered 
the fluorescent protein non-functional.  Many of these errors clustered around the site of Cas9 cleavage, 
and illustrated the importance of editing the PAM site within the repair template to minimise the risk of 
recutting and subsequent unnecessary, error-prone recombination events. Although we did attempt to 
repair these edits, our efforts proved unsuccessful, with more errors arising within the region of interest 
the more we edited. Despite further injections, no successful edits were achieved, demonstrating that, 
whilst this approach was indeed more successful than the initial strategy, the efficiency was still low. 
 
Method Reference Details 
Small ssODN or double-
stranded PCR repair template 
Paix et al. (2015) dsPCR template approach unsuccess for the 
endogenous insertion of tagRFP 
 
ssODN repair successful for PrLD deletion 
Nested CRISPR Vicencio et al. (2019) Initial insertion successful with a high efficiency  
 
Second with dsPCR repair template inefficient, with 
any successful inserts containing numerous errors  
SapTrap Schwartz & Jorgensen (2016)  
Dickinson et al. (2018) 
No success with initial cloning step  
Partially single-stranded 
repair template 
Dokshin et al. (2019) Full insert success, however small errors around the 
Cas9 cleavage site, repaired with a second ssODN edit 
 
Adapted protocol to use a co-CRISPR strategy with 
dpy-10 rather than a co-injection marker approach 
Table 3.1 A summary of the CRISPR approaches used for endogenous locus editing 
 
We next moved on to a more recently published methodology. This strategy was similar to those above, 
but instead of using double stranded PCR templates with double stranded homology arms, it used a 
double stranded repair template with single-stranded homology arms. Similarly to the other approaches 
taken, we initially saw little success - this led us to re-evaluate our strategy as a whole - specifically, the 




Figure 3.4 CRISPR-edited endogenously-tagged ABU-13::WormScarlet lines show puncta throughout the animal  (A) 
Schematic depicting the CRISPR-mediated insertion used for this ABU-13::WormScarlet endogenously-edited line (B) 
Confocal micrographs of ABU-13::WormScarlet endogenously-tagged animals (Scale bars, 100µm; 25µm) 
 
As with the extrachromosomal array line, we initially sought to introduce tagRFP endogenously. 
However, the coding sequence for this protein is ~ 900 base pairs long. As previously mentioned, the 
larger the insertion, the more difficult it becomes to insert it. As such, we moved to using a WormScarlet 
tag instead that, as well as being much smaller (~700bp instead), also has the advantage of being much 
brighter than tagRFP - which is particularly useful if ABU-13 is expressed at low levels. Indeed, after 
switching to this new fluorescent protein, we saw a higher success rate than with previous approaches, 
although the error rate remained high. To counteract this, we performed an additional editing step to 
repair the errors - a step that ultimately proved successful. Thus, with a WormScarlet endogenously 
tagged ABU-13 line, we were able to proceed and determine whether similar puncta formation was 
observed in these animals to that which we had seen in the overexpression line.  
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Figure 3.5 ABU-13 puncta in overexpression lines are larger and less numerous than in the endogenously tagged lines (A-E) 
Comparisons between overexpression and endogenous strain for (A) Normalised fluorescence intensity value (Unpaired t test, 
p =0.4365; ns); (B) Number of puncta (Unpaired t test, p = 0.0010; **); (C) Average size (Unpaired t test, p = 0.0079; **); 
(D) % area covered (Unpaired t test, p =0.0444; *); (E) Puncta/µm2 (Unpaired t test, p = 0.0118; *) 
 
Whilst these animals also contained punctate structures, these puncta were different from those observed 
in the ABU-13::tagRFP extrachromosomal array line (Figure 3.4A,B). The puncta in animals expressing 
endogenously-tagged ABU-13 were expressed more broadly than in the overexpression line - not 
necessarily a surprise, as the expression of the extrachromosomal array can vary across generations, and 
the overexpression construct may lack endogenous expression elements. In addition to this, the puncta 
themselves were also different in both number and size - the endogenous line contained significantly 
more puncta than the overexpression line, with these puncta generally being smaller in size but more 
plentiful in number (Figure 3.5A-E). This demonstrates that, whilst the overexpression does not itself 
drive puncta formation, it does alter the characteristics of these puncta. Overall, the presence of a prion-
like domain and a potential RNA binding domain alongside the inclusion of this protein into punctate 





































Figure 3.6 ABU-13DPrLD mutants show different distributions in the overexpression versus endogenously-tagged line  (A) 
Schematic depicting the modified expression vector used to generate the extrachromosomal array overexpression line (B) 
Experimental outline of the CRISPR/Cas9 edited ABU-13 locus to delete the prion domain from the genome (C-D) Confocal 
micrographs depicting (C) ABU-13DPrLD::tagRFP overexpression animals (Scale bar, 50µm); and (D) ABU-
13DPrLD::WormScarlet endogenously tagged animals (Scale bars, 100µm; 25µm) 
3.2.2 Removal of the prion-like domain abolishes the ability of ABU-13 to form puncta in the 
overexpression line but not the endogenously-tagged line 
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We next investigated the influence that the prion-like domain has on the formation of these punctate 
structures by removing the domain from both the overexpression and endogenously-tagged lines 
(Figures 3.6A-B). For the former, we produced another extrachromosomal array line, the injection 
plasmid used for which lacked the PrLD. For the latter, however, we used a CRISPR/Cas9 strategy 
outlined in Paix et al. (2015); this involved using two sgRNA sequences to target sites either side of the 
PrLD for cleavage. Once cleaved, this region was repaired using an ssODN template containing a 
GGGGS linker flanked by homology arms corresponding to the sequences adjacent to the removed 
prion-domain sequence – but not the PrLD itself, thus resulting in ABU-13 with the prion-domain 
removed and the N and C termini either side of it connected via a flexible linker. This is particularly 
useful when assessing the involvement of a protein in the formation of phase separated structures as 
prion domain-containing proteins often act as scaffold proteins for these transitions and, as such, if 
ABU-13 were indeed a scaffold protein, then we would expect the removal of this domain to prevent 
such transitions. 
 
To our surprise, the removal of the PrLD resulted in different effects in these two strains; the ability to 
form puncta was entirely abolished in the overexpression animals but was unaffected in the 
endogenously tagged animals. In the overexpression line, ABU-13 was diffuse across a range of tissue 
types, including the hypodermis, pharynx and intestine (Figure 3.6C). The endogenously tagged strain, 
however, showed a very similar punctate structure to that observed in the full-length variant (Figure 
3.6D). This difference may result as a consequence of a linker placed between the N and C terminal 
regions of ABU-13 in the endogenous line that is not present in the overexpression line (Figures 3.6A-
B). Without this linker, the functionality of the regions flanking the prion-like domain may be 
compromised. This potentially provides an interesting insight into the biogenesis of these puncta, as it 
may suggests that, whilst the prion-like domain is not necessary for puncta formation, either or both of 
the N and C termini play a role in either the formation or the localisation of ABU-13 to these puncta. 
 
3.2.3 Increased mobility of ABU-13 puncta in the endogenously-tagged compared to the 
overexpression strain 
 
Due to the large observable differences between the puncta found within the endogenous and 
overexpression lines, we next sought to identify whether these puncta displayed different biophysical 
properties. In particular, we used fluorescence recovery after photobleaching (FRAP) to determine the 




Figure 3.7 ABU-13 puncta have highly variable mobility  (A) FRAP recovery curves for individual puncta in endogenously-
tagged ABU-13::WormScarlet animals (green dashed line = photobleaching event); (B) FRAP recovery curves for individual 
puncta in ABU-13::tagRFP overexpression animals (green dashed line = photobleaching event); (C) Representative recovery 
plot of liquid-like stress granules (adapted from Molliex et al., (2015)); (D) Representative recovery plot of hnRNPA1 
hydrogels (adapted from Molliex et al., (2015)); (E) Confocal micrographs depicting the fluorescence recovery of an 
WormScarlet-tagged ABU-13 puncta  from endogenously tagged animals (Scale bar, 10µm); (F) Confocal micrographs 
depicting the fluorescence recovery of a tagRFP-tagged ABU-13 puncta from overexpression animals (Scale bar, 10µm); (G) 
Average FRAP recovery comparison between endogenously tagged and overexpression animals (Unpaired t test, p = 0.2247; 
ns); (H) Correlation between puncta size and percentage FRAP recovery between endogenously tagged animals (orange; r = 
0.6119; p=0.1967), overexpression animals (blue; r =0.9519; p=0.0481) and all puncta combined (black; r=0.5446; p 
=0.1036); (I) Representative confocal micrographs depicting ABU-13 puncta clustering together in a multiphase structure 
(Scale bar, 10µm)); (H) Schematic proposing multiphase coexistence in ABU-13 puncta, with recovery dynamics illustrated 
below 
variable rate of recovery between puncta, varying between puncta with mobile fractions of just 10.34%, 
and others with mobile fractions of 78.69% (Figure 3.7A,E). On the other hand, the puncta found within 
ABU-13::tagRFP overexpression animals showed consistently low mobility, suggesting that they are 
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largely immobile (Figure 3.7 B,F). Higher recovery is indicative of more liquid-like structures, with 
similar mobility observed in dynamic phase-separated compartments such as stress granules (Figure 
3.7C). Lower recovery, however, is associated with low mobility structures such as hydrogels (Figure 
3.7D). This suggests that the puncta within the endogenously-tagged strain exhibit a mixture of liquid- 
and hydrogel-like properties, whilst all of those in the overexpression strain adopt more hydrogel-like 
structures. The average mobility of the puncta between these strains is not significantly different (Figure 
3.7G), however, this is more a reflection of the high variation of mobility within the endogenously 
tagged animals - a larger sample size would likely clarify this difference.  
 
There was, however, a significant relationship between puncta size and mobility with larger puncta 
exhibiting a greater mobility (Figure 3.7H). This was contrary to expectations, as larger puncta are 
traditionally associated with uncontrolled solid-like aggregation and fibrillisation – a hallmark of 
pathology. Further imaging revealed that many of these puncta cluster together, forming small 
subpopulations of assemblies within one region (Figure 3.7I). The individual puncta within these 
clusterings appear less mobile, whilst the FRAP of the general cluster shows more mobility. This 
suggests that these clusters are made up of a number of low mobility ‘core’ structures surrounded by a 
more mobile, diffuse ‘shell’. As such, the ‘core’ regions of these puncta are reminiscent of the structures 
observed in the overexpression system. It is possible that these puncta represent hydrogel formations - 
such phase transition states show more solid-like properties than traditional liquid-like assemblies whilst 
retaining physiological function, as opposed to pathological dysfunction. 
 
3.2.4 PA14 exposure alters ABU-13 puncta dynamics, whilst tunicamycin treatment and heat shock 
do not 
 
To understand the relationship between these ABU-13 puncta and the phenotypic effects of abu-13 
knockout, we subjected endogenously tagged ABU-13::WormScarlet animals to a number of stress 
related stimuli. Initially, we treated animals with 25ng/mL of tunicamycin for 4 hours before imaging. 
Compared to DMSO-treated control animals, there were no observable differences in puncta properties. 
with the same number, size, and coverage of puncta observed between these conditions (Figure 3.8A-
G). This suggests that the role of ABU-13 in ER stress responses, as identified in abu-13 knockout 
animals upon tunicamycin treatment, does not involve gross changes in puncta dynamics, such as 





Figure 3.8 ABU-13 puncta do not change upon tunicamycin treatment  (A) Confocal micrographs of endogenously tagged 
ABU-13::WormScarlet animals treated with DMSO (Scale bars, 100µm; 25µm); (B) Confocal micrographs of endogenously 
tagged ABU-13::WormScarlet animals treated with 25ng/µL tunicamycin (Scale bars, 100µm; 25µm); (C-G) Comparisons 
between DMSO and tunicamycin treated animals for (C) Normalised fluorescence intensity value (Unpaired t test, p =0.5145; 
ns); (D) Number of puncta (Unpaired t test, p = 0.5210; ns); (E) Average puncta size (Unpaired t test, p = 0.8517; ns); (F) 
Puncta/µm2 (Unpaired t test, p = 0.6623; ns); (G) % area covered (Unpaired t test, p =0.7875; ns) 
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Figure 3.9 ABU-13 puncta do not change upon heat shock  (A) Confocal micrographs of endogenously tagged ABU-
13::WormScarlet animals grown at 20°C (Scale bars, 100µm; 25µm); (B) Confocal micrographs of endogenously tagged ABU-
13::WormScarlet animals subjected to a 6 hour 34°C heat shock (Scale bars, 100µm; 25µm); (C-G) Comparisons between 
20°C and 34°C treated animals for (C) Normalised fluorescence intensity value (Unpaired t test, p =0.4699; ns); (D) Number 
of puncta (Unpaired t test, p = 0.7575; ns); (E) Average puncta size (Unpaired t test, p = 0.9072; ns); (F) Puncta/µm2 (Unpaired 




Figure 3.10 ABU-13 puncta change following exposure to Pseudomonas aeruginosa (PA14)  (A) Confocal micrographs of 
endogenously tagged ABU-13::WormScarlet animals exposed to OP50 (Scale bars, 100µm; 25µm); (B) Confocal micrographs 
of endogenously tagged ABU-13::WormScarlet animals exposed to PA14. The arrow indicates pharyngeal expression (Scale 
bars, 100µm; 25µm); (C-G) Comparisons between animals exposed to OP50 and PA14 for (C) Normalised fluorescence 
intensity value (Unpaired t test, p =0.3911; ns); (D) Number of puncta (Unpaired t test, p = 0.0240; *); (E) Average puncta 
size (Unpaired t test, p = 0.0005; ***); (F) Puncta/µm2 (Unpaired t test, p = 0.0053; **); (G) % area covered (Unpaired t test, 
p =0.3420; ns)  
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Although no phenotypic effect was identified for knockout animals following heat stress, it is possible 
that there is redundancy compensating for loss of ABU-13 in this context, especially considering the 
unknown roles of many of the other ABU proteins. As such, we subjected ABU-13 endogenously tagged 
animals to a 34°C heat shock for 6 hours before imaging (Figure 3.9A-B). Similar to those treated with 
tunicamycin, we saw no gross changes to the ABU-13 puncta (Figure 3.9C-G), suggesting that there are 
no changes in ABU-13 dynamics upon heat stress. Paired with the lack of phenotypic readout for heat 
shock responses, this suggests that ABU-13 does not play a role in cellular responses to heat shock. 
Finally, we subjected animals to PA14 for 6 hours to identify any changes in ABU-13 dynamics upon 
exposure to a pathogenic bacteria. Compared to animals treated with the non-pathogenic E. coli strain, 
OP50, there were significant differences in puncta dynamics (Figure 3.10A-B). In animals treated with 
PA14, there was a dramatic reduction in puncta number, with a concurrent increase in the size of puncta 
(Figure 3.10C-G). This indicates that ABU-13 puncta are either fusing, or that some are being dissolved 
whilst others increase their recruitment allowing them to increase in size. In addition to this, we observed 
a significant increase in the diffuse expression of ABU-13 in the pharynx, potentially in the structural 
marginal cells (Figure 3.10B). This is interesting for a number of reasons: firstly, this expression is 
induced at the primary interface between the external environment and the animal, suggesting that the 
induction is driven as a direct consequence of pathogenic attack in the pharynx. Secondly, unlike in 
other regions, there is no obvious ABU-13 puncta formation - this potentially points towards different 
roles of ABU-13 in the pharynx compared to other tissues. 
 
On the whole, we have identified large structural changes to ABU-13 puncta in response to pathogenic 
insult but not in response to tunicamycin treatment. This suggests that these two stress-response 
pathways may depend upon ABU-13 via different mechanisms. 
 
3.2.5 ABU-13 is expressed in tissues including the hypodermis, seam cells & amphid sheath glia 
 
To predict the expression pattern of abu-13, we utilised an online tissue expression prediction algorithm 
that assigned specific prediction scores across all tissue types within the animal. This algorithm, 
developed by Kaletsky et al. (2008), combines datasets from a wide range of microarray and RNA-seq 
experiments to produce comprehensive tissue expression prediction scores. For ABU-13, the highest 
scoring tissue types in this output include many epidermal-derived tissues such as the hypodermis – in 
particular the hyp-7 syncytium, arcade cells, seam cells and the amphid sheath cells (Figure 3.11A-B). 
Due to the punctate nature of ABU-13 in vivo, it is difficult to determine tissue expression using the 
ABU-13::tagRFP fusion protein. To aid this process, we therefore constructed a transcriptional reporter 
line expressing tagRFP under the abu-13p promoter (Figure 3.11C). This reporter line appeared to 
support some of these tissue predictions, with tagRFP visible within seam cells, the hypodermis, in the 
amphid sheath cell and within the rectal epithelium. It is important to note, however, that the abu-13 
coding region contains large intronic sequences - this is often indicative of regulatory elements within 
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introns that influence expression of the gene itself. Thus, without these regulatory introns, the full 
endogenous expression pattern of abu-13 may not be fully realised using this reporter strain.  
 
 
Figure 3.11 ABU-13 is expressed widely in epidermally-derived tissues  (A) A heat map of ABU-13 expression prediction 
scores; (B) A schematic highlighting tissues of interest within the adult hermaphrodite; (C) Confocal micrographs of abu-
13p::tagRFP transcriptional reporter animals, highlighting expression in a number of tissues including the hypodermis and 
seam cells (Scale bar = 50µm) 
 
To further determine the expression pattern of ABU-13, we initially crossed the fluorescently tagged 
ABU-13 overexpression animals into a number of strains expressing fluorescent markers for specific 
tissues, to identify any colocalization between these markers. As ABU-13 puncta appear to be broadly 
visible across the animal, we performed a number of crosses, including with markers for tissue types in 
which ABU-13 expression was not predicted computationally.  
 
We first sought to determine whether ABU-13 puncta are present in neuronal cell bodies (Figure 3.12A) 
by crossing ABU-13::tagRFP animals into an unc-119p::GFP neuronal marker strain. Whilst the 
majority of puncta did not show any colocalization with unc-119p::GFP, there were some regions of 
overlap. This is particularly the case in the head region, where there is a high density of neuronal cell 
bodies. As a result, it is difficult to fully spatially resolve the colocalization between these two 
fluorescent proteins in this region. However, there does appear to be some proximal localisation 
observed around the amphid neurons, with several puncta surrounding this structure – this may represent 
expression of ABU-13 in the AMsh glia that support the neuron, in keeping with our previous 
computational predictions. In addition to this, there is potentially some colocalization along the ventral 
cord. 
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Figure 3.12 ABU-13::tagRFP colocalises with amphid neurons in overexpression line  (A) Confocal micrographs of ABU-
13::tagRFP overexpression animals crossed into (A) a neuronal marker strain (unc-119p::GFP), Scale bars = 50µm; (B) an 
intestinal marker strain (ges-1p::GFP), Scale bars = 50µm, 25µm; (C) a glial marker strain (pitx-1::GFP), Scale bars = 50µm, 
25µm 
We next crossed the ABU-13::tagRFP overexpression animals into ges-1p::GFP animals enabled us to 
identify any intestinal expression of ABU-13 (Figure 3.12B). Although there does appear to be a small 
degree of overlap, this is not consistent among animals and it is difficult to rule out large puncta from 
other planes bleeding through into the imaging plane of interest, giving a false impression of intestinal 
localisation. One point to note is the discrepancy between the prion-domain mutant overexpression 
animals and the transcriptional reporter line, the latter of which shows strong ABU-13 expression in the 
anterior intestine whilst the former shows none. As neither of these lines truly recapitulate the 
endogenous expression of ABU-13, with both strains lacking some if not all intronic sequences that 
regulate abu-13, repeating this imaging in the endogenously-tagged animals will likely be informative 
 
To investigate the expression of ABU-13 within glia, we constructed transgenic animals expressing GFP 
under the itx-1 promoter (Figure 3.12C). We found that, in this strain, posterior glia were well labelled 
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and anterior glial less so - this is likely a consequence of poor penetrance, and further work is needed to 
improve this expression. In the tail region, however, where glial cells were strongly labelled, we 
observed no colocalization between the ABU-13::tagRFP puncta and glia. Unfortunately, this analysis 
did not allow us to determine whether ABU-13 is indeed found within AMsh glia.  
 
It is important to recognise, however, that this imaging was performed in tagRFP extrachromosomal 
array lines, and thus expression of ABU-13 may be more variable and less complete than in the 
endogenously-tagged ABU-13::WormScarlet animals. As such, we have repeated some of these crosses 
and imaging in the endogenously-tagged strains. However, due to time constraints, we were unable to 
image the ABU-13::WormScarlet animals in all of these tissue marker strains.  
 
We initially repeated this imaging with ABU-13::WormScarlet animals crossed into the unc-119p::GFP 
neuronal marker strain (Figure 3.13A). As with the overexpression line, we did see colocalization 
between some neuronal structures and ABU-13::WormScarlet. This is notably the case in the head 
region where a substantial colocalization is identified with the amphid neurons. These neurons are 
involved in processing sensory outputs from the environment, and this localisation is in keeping with 
the role of ABU-13 in responding to external stress from the surrounding environment. That being said, 
it is curious that we see overlap with the amphid neurons specifically as we have previously found 
evidence of abu-13 expression in the amphid sheath glia. By nature, these glia surround the amphid 
neurons; we therefore may not be observing direct colocalization with the neuron itself, but rather with 
the sheath glia supporting it. Beyond this, we do not observe any further neuronal colocalization, apart 
from a small amount around the vulva that appears to represent juxtapositioned structures, as opposed 
to a direct overlap. Thus, this supports a role of ABU-13 in the amphid sheath neurons. 
 
We then crossed endogenously-tagged ABU-13::WormScarlet animals into an SCMp::GFP seam cell 
marker strain (Figure 3.13B). This seam cell marker is particularly well expressed during larval 
development, so we chose to image animals during the L3 developmental stage, slightly earlier than the 
other localisation analyses. These animals displayed a clear colocalization with the seam cells both 
dorsally and laterally, in keeping with our results using the transcriptional reporter line. This supports a 
role for ABU-13 within the seam cells as well as pointing towards a role for this protein in the 
hypodermal system in general, as these cells are closely anatomically linked to the hyp-7 syncytium, as 
well as sharing a great deal of functionality with the hypodermis. We were, however constrained by the 
quality of markers available for a tissue marker cross of the hypodermis; while we did make several 
attempts to produce our own transgenic GFP marker strain for the hypodermis, under the dpy-7 
promoter, these animals were difficult to maintain with many exhibiting anatomical defects, likely as a 
consequence of GFP overexpression. Similar issues were encountered with other hypodermal marker 
strains used, of which there is limited availability with GFP markers compared to red fluorophores - 
these animals tended to be difficult to maintain due to the low expression of the extrachromosomal array, 
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and attempts at crossing proved unsuccessful. As such, we were unable to perform a successful cross 
with a general marker for the hypodermis. 
 
Figure 3.13 ABU-13::WormScarlet colocalises with amphid neurons and seam cells in endogenously-tagged animals  (A) 
Confocal micrographs of endogenously-tagged ABU-13::WormScarlet animals crossed into (A) a neuronal marker strain (unc-
119p::GFP), Scale bars = 50µm, 25µm; (B) a seam cell marker strain (SCMp::GFP), Scale bars = 25µm 
 
3.2.6 ABU-13 puncta are juxtanuclear 
 
We next sought to determine a subcellular localisation for ABU-13. As ABU-13 forms punctate 
structures that might be consistent with a nuclear localisation, we stained animals with the nuclear dye 
DAPI to determine whether there was colocalization of nuclei with tagged ABU-13 (Figure 3.14). This 
was not the case, with no direct colocalization between DAPI-stained nuclei and the ABU-13 puncta in 
ABU-13::tagRFP overexpression animals. We did, however, notice that these puncta appeared 
juxtaposed with nuclei – that is, many were found adjacent to or surrounding nuclei, suggesting that 
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they represent juxta-nuclear bodies. One possibility is that this represents an endoplasmic reticulum 
localisation, which may support a role for ABU-13 in protection from ER stress.  
 
As we have already established, the puncta found in the overexpression strain are significantly larger on 
the whole than those found in the endogenously tagged strain. To address this, we attempted to stain 
endogenously-tagged animals with DAPI to determine whether this juxtaposition was maintained 
consistently across tissues. However, we encountered issues with this staining as the freeze-crack 
protocol used for DAPI-staining caused ABU-13 puncta to dissolve during the staining process. This 
dissolution of puncta after death possibly suggests that puncta maintenance is ATP-dependent in the 
endogenously-tagged line – this may not be the case in the overexpression line due to their potential 
propensity for aggregation. Alternative approaches to nuclear staining will be explored in the future to 
get around this issue and determine the relationship between ABU-13 and nuclei. 
 
Figure 3.14 ABU-13 is found in juxtanuclear positions, but shows no nuclear localisation  (A) Confocal micrographs of 
ABU-13::tagRFP overexpression animals stained with DAPI to mark nuclei (Scale bar = 25µm)  
 
To further explore the potential localisation of ABU-13 to the endoplasmic reticulum, we attempted 
staining of overexpression animals with an ER-sensitive dye, ER-Tracker™, following a similar freeze-
crack protocol. This staining, however, showed a high degree of background and non-specific staining, 
with no ER structures immediately visible during imaging. As such, we deemed ER-Tracker (Blue-
White)™ unsuitable for these animals. We then moved to using an ER-localised fluorescent marker; 
whilst most of these use red fluorophores, we found a limited number expressing GFP-tagged ER 
proteins as extrachromosomal array lines. The penetrance of these strains was low, and the markers 
themselves difficult to monitor and subsequently maintain. As such, no successful crosses could be 
performed. Moving forward, we will work to express an endogenous ER-resident GFP marker to 
eliminate issues with low penetrance and to facilitate successful crosses with ABU-13::WormScarlet 
animals. 
 
3.2.7 ABU-13 does not colocalize with known stress-related membraneless organelles 
 
In vivo and in vitro characterisation of ABU-13 
 109 
Following our hypothesis that ABU-13 is a scaffold protein involved with the formation of a phase 
separated compartment, we next explored whether this protein was a component of known stress-related 
membraneless organelles. Within C. elegans, the main stress-related compartments of this nature are 
stress granules and Processing bodies. Whilst P-bodies are constitutively present, they are also stress-
responsive, with increased formation upon the application of a stressful stimuli. Stress granules, on the 
other hand, do not form under basal conditions and are instead triggered upon such a stimulus. To 
identify whether ABU-13 was a constituent of either of these organelles, we imaged ABU-13::tagRFP 
overexpression animals crossed into ife-2p::IFE-2::GFP animals, marking stress granules, or dcap-
1::DCAP-1::GFP animals, marking P-bodies, before and after the application of a stress. 
 
Figure 3.15 ABU-13::tagRFP does not colocalise with P-bodies before or after heat shock in overexpression animals  (A) 
Confocal micrographs of ABU-13::tagRFP animals crossed into a P-body marker strain (dcap-1p::DCAP-1::GFP) before heat 
shock, Scale bars = 25µm ; (B) Confocal micrographs of ABU-13::tagRFP animals crossed into a P-body marker strain (dcap-
1p::DCAP-1::GFP) after heat shock, Scale bars = 25µm 
 
Heat shock is a traditional mechanism through which these stress-related organelles are stimulated, thus 
we initially subjected these crossed animals to a 34°C heat shock for 6 hours before imaging. In animals 
expressing a P-body marker, large P-bodies are evident prior to the heat shock (Figure 3.15A) - these 
constitute the constitutively-active P-body population that are present in basal conditions. Following 
this heat shock, there is a large increase in the formation of small P-bodies - these represent the stress-
responsive population (Figure 3.15B). Both before and after application of a heat stress stimuli, the 
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ABU-13 puncta are larger than the concurrent P-bodies with no colocalization observed between these 
structures. This suggests that within the overexpression model at least, these structures are unrelated.  
 
We then repeated this heat shock treatment in animals with the stress granule marker. As expected for 
these animals, there were initially very minimal GFP-positive puncta as these components are diffuse 
under basal conditions (Figure 3.16A). However, following heat shock treatment, there was a large 
coalescence of GFP into small puncta, indicative of stress granule formation (Figure 3.16B); these were 
present ubiquitously throughout the animal. However, as with the P-bodies, these stress granules are 
much smaller than the co-expressed ABU-13::tagRFP puncta and no colocalization is observed. As 
such, this also suggests that these two membraneless organelles do not overlap and supports the notion 
that ABU-13 puncta represent a novel species of stress-responsive phase-separated compartment in C. 
elegans. 
 
Figure 3.16 ABU-13::tagRFP does not colocalise with stress granules before or after heat shock in overexpression animals  
(A) Confocal micrographs of ABU-13::tagRFP animals crossed into a stress granule marker strain (ife-2p::IFE-2::GFP) before 
heat shock, Scale bars = 25µm ; (B) Confocal micrographs of ABU-13::tagRFP animals crossed into a stress granule marker 
strain (ife-2p::IFE-2::GFP) after heat shock, Scale bars = 25µm 
 
There are, however, limitations in the use of the overexpression animals. As we have already established, 
the puncta formed within these animals are significantly larger than those observed in the endogenously 
tagged animals. As such, we moved towards using these endogenously tagged animals to assess the 
potential interplay between these stress-related organelles.  
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Using these animals, we initially determined the effect of tunicamycin treatment. This was of particular 
interest as, unlike the PA14-treated animals, no observable changes to ABU-13 puncta were observed 
in these animals, and thus we hypothesised that the effect on ER stress resistance may be conferred via 
interactions with other membraneless organelles. Endogenously tagged animals crossed into the P-body 
marker strain showed a much more similar size distribution of P-body and ABU-13 puncta than in the 
overexpression model, as expected (Figure 3.17A-B). Despite this, however, there does not appear to 
be substantial colocalization between these puncta in either the DMSO-treated control animals nor the 
tunicamycin treated animals. It does appear, however, that some of the P-body puncta overlap with the 
larger ABU-13 puncta, potentially representing P-bodies engulfed by ABU-13 puncta or those in close 
physical proximity with them. This could be clarified using FRET to determine the proximity of these 
compartments, or using superresolution microscopy to improve spatial resolution.  
 
Figure 3.17 ABU-13::WormScarlet does not substantially colocalise with P-bodies before or after 25ng/µL tunicamycin 
treatment in endogenously-tagged animals (A) Confocal micrographs of ABU-13::WormScarlet animals crossed into a P-body 
marker strain (dcap-1p::DCAP-1::GFP) after DMSO treatment, Scale bars, 25µm ; (B) Confocal micrographs of ABU-
13::WormScarlet animals crossed into a P-body marker strain (dcap-1p::DCAP-1::GFP) after tunicamycin treatment, Scale 




Further work is needed to determine whether any interaction is observed between stress granules and 
the endogenously tagged ABU-13 puncta. In addition to this, assessing these interactions after treatment 
with a range of stress-stimuli may shed light on differential interactions in different conditions. As we 
have already established for ABU-13 and as has already been shown for stress granules and P-bodies, 
these stress-related organelles respond in a stimulus-specific fashion - as such, any potential inter-
organelle interaction may also be stimulus-specific; if this were indeed the case, it could help point 
towards molecular mechanisms conserved between these organelles.  
 
3.2.8 Purification of ABU-13 in preparation for in vitro phase separation assays 
 
To understand the dynamics of puncta formation and test our hypothesis that ABU-13 is involved in the 
formation of phase separated structures, we next sought to purify both ABU-13 and ABU13DPrLD and 
perform in vitro phase separation assays. However, substantial challenges were met during this 
purification process (Figure 3.18A). We began using a BL21 bacterial expression system, with the 
exonic coding region for abu-13 and abu-13DPrLD inserted in frame with GFP within a pET expression 
vector under control of a T7 promoter. Following induction, we saw no GFP signal within these bacteria. 
To determine whether this was as a consequence of low expression, we continued with the purification 
and, after SDS-PAGE, saw no band corresponding to the size of ABU-13. This issue persisted across 
numerous attempts.  
 
As bacteria lack some of the protein folding machinery compared to eukaryotes, we moved into an insect 
cell expression system, using Drosophila S2 cells, expressing abu-13 and abu-13DPrLD within a pMT 
vector, fused to GFP. Both sets of transformed cell cultures showed poor growth and could not be taken 
further for protein purification. 
 
As we knew that ABU-13 was expressed consistently within C. elegans, we attempted to purify directly 
from populations of worms in which ABU-13 was endogenously tagged. For this, we inserted a 3xFLAG 
tag into the C-terminus of abu-13 as to reduce the confounding effects that a larger fluorescent tag may 
have on the phase transition behaviour of ABU-13 in vitro. As such, we then attempted to purify both a 
FLAG-tagged and a WormScarlet-tagged form of ABU-13. We grew these animals in liquid culture 
before lysis and pull-down of the protein using FLAG or WormScarlet-specific beads before eluting the 
bound protein. However, upon visualisation of the purified protein via Western blot, we saw no bands 









Figure 3.18 Outline of ABU-13 protein purification work (A) Schematic detailing the various approaches taken to purify ABU-
13 in preparation for in vitro work ; (B) A plasmid map of the pRSET vector used for successful purification of GFP-tagged 
ABU-13 in which a MBP tag was used to solubilise the protein; (C) Western blot showing multiple attempts at protein 
purification from ABU-13::WormScarlet expressing C. elegans, or ABU-13::GFP expressing Rosetta 2 bacteria, probed with 
anti-GFP antibody (A = first attempt; B = second attempt; red arrow = correct ABU-13::GFP band) 
 
As it seemed likely that the prion-like nature of ABU-13 was causing issues with this purification, we 
moved to a protocol optimised for prion-like proteins. This involved the expression of ABU-13 fused to 
a 3C protease-cleavable maltose-binding protein tag, the addition of which aided the solubilisation of 
this protein in bacteria (Figure 3.18B). We then expressed this construct in Rosetta 2 bacteria, optimised 
for the expression of eukaryotic proteins. Following induction with IPTG and bacterial collection, the 
expression of GFP within bacteria expressing the control GFP-only construct was clear - however, the 
expression of ABU-13::GFP was not visible. We continued with this purification, and confirmed the 
presence of GFP-tagged ABU-13 in the final eluate by Western blot (Figure 3.18C).  
 
During this process, however, the aggregation-prone nature of ABU-13 became evident as it underwent 
substantial aggregation upon cleavage of the solubilising MBP tag. If the purified protein was too 
concentrated as this cleavage event occurred, we observed significant formation of GFP-positive 
aggregated structures visible to the naked eye. 
 




The presence of a prion-like domain and an RNA binding motif are indicative not only of components 
involved with phase separation compartments, but proteins with these characteristics often act as 
scaffolds, driving formation of these structures. Whilst in vivo data with prion-domain mutant animals 
is inconclusive, the ability of ABU-13 to phase separate in vitro would support a role for this protein in 
puncta formation. As such, using purified ABU-13, we conducted a series of in vitro phase separation 
assays to determine whether this protein possessed the intrinsic ability to nucleate a phase transition.  
 
One of the triggers of phase separation is an increase in molecular crowding conditions akin to those 
observed within the cytoplasm, which increases the propensity for phase separating proteins to coalesce. 
This can be mimicked in vitro using a molecular crowding agent such as dextran or polyethylene glycol 
(PEG). As would be expected for phase separating proteins, the formation of GFP-positive ABU-13 
puncta increases as the molecular crowding conditions are increased. This is not seen in the GFP control 
suggesting that this ability is intrinsic to ABU-13 itself rather than being driven by the GFP tag (Figure 
3.19A). 
 
Recently, it has been demonstrated that the chemical 1,6-hexanediol is capable of disrupting the weak 
interactions that hold phase separated compartments together. We tested this in our set up, imaging 
ABU-13 at either 50mg/mL or 100mg/mL PEG, with and without treatment with 5% 1,6-hexanediol 
Figure 3.19B). Whilst little difference is seen before and after treatment in the low molecular crowding 
conditions, there is a difference in the high molecular crowding condition sample. This suggests that 
some, but not all, puncta within these samples represent liquid-like phase separated compartments. It is 
possible that the remaining puncta possess more solid-like characteristics and cannot be dissolved with 
this treatment - whether this is a hydrogel or an aggregate is unclear, however, this could support 
previous evidence showing multiple species of ABU-13 puncta; one with more liquid-like properties 
and another with more solid-like properties. 
 
As mentioned previously, phase separating proteins are exquisitely sensitive to concentration - a 
property that has been illustrated in both our overexpression line and in the propensity of ABU-13 to 
aggregate during the purification process. Within a small concentration range, however, phase 
separating proteins are able to reversibly transition from diffuse to punctate and back again as the 
concentration is increased and then subsequently decreased. To determine whether ABU-13 is capable 
of this, we compared puncta formation in samples diluted from 100nM ABU-13 in 100mg/mL PEG to 
5nM in 5mg/mL to a baseline state of 5nM ABU-13 in 5mg/mL that had never been further concentrated 
(Figure 3.19C). In keeping with our hypothesis, we indeed observed a reversibility of puncta formation. 
As with the 1,6-hexanediol treatment, a small fraction of puncta remained in some of the imaging fields 
of view, potentially representing more solid-like structures; however, the majority of puncta were 
dissolved. 
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Figure 3.19 ABU-13 is able to form puncta in vitro, reminiscent of phase separated structures  (A) Confocal micrographs of 
purified ABU-13::GFP or GFP alone treated in varying molecular crowding conditions (Scale bar = 100µm) ; (B) Confocal 
micrographs of purified ABU-13::GFP in either 50mg/mL of PEG or 100mg/mL PEG, before and after 5% 1,6-hexanediol 
treatment (Scale bar = 100µm); (C) Confocal micrographs of purified ABU-13::GFP before and after dilution, showing the 






As we were only able to purify ABU-13 on a small scale, we could not further validate the conditions 
in which ABU-13 transitions - for example, phase separation also differs depending on factors such as 
salt concentration and temperature. However, further purifications have been performed, allowing us to 
construct a full phase diagram in the future.  
 
On the whole, the evidence thus far supports the role of ABU-13 in nucleating the formation of phase 
separated compartments, suggesting that it may indeed represent a scaffold protein, rather than a client 
protein. Further work to determine whether puncta formation is abolished upon removal of the prion 















































3.3.1 Phase separation properties of ABU-13 
 
Supporting our previous hypothesis that, due to its prion-like domain and predicted RNA binding 
properties, ABU-13 was involved in phase transitions, we observe punctate structures throughout the 
animal. Phase separated organelles often play a role in the regulation of RNA, which, as this protein has 
been implicated in ER stress responses25,26, could be a mechanism through which ABU-13 confers stress 
resistance. For example, ABU-13 may sequester specific RNA species upon stress, preventing their 
translation - or similarly, it may interact with other RNA species and promote translation. Understanding 
the protein and RNA interactors of ABU-13, particularly those localising to these biomolecular 
condensates, would help us to determine the molecular mechanisms operating within these puncta and 
establish exactly how this stress resistance might be conferred.  
 
Not all the components of a phase separating compartment have the intrinsic ability to drive their 
formation, however. Instead, many proteins are recruited by components already found within these 
structures - these are known as client proteins, whilst the proteins driving phase separation are known 
as scaffolds. A general role for prion-like proteins as scaffolds for the nucleation of these compartments 
has been proposed  - for example, TIA-1 and TDP-4327,28, and Lsm429 are all proteins containing a PrLD 
that are involved in the formation of stress granules and P-bodies respectively. As such, we might expect 
the removal of the prion-like domain of ABU-13 to abolish its ability to nucleate puncta formation. 
Whilst we do observe this in the overexpression model, we still see puncta formation in the endogenous 
line. We do not believe that this difference can be accounted for by differences in expression level 
between the overexpression line and the endogenously-tagged line; whilst this could be an influencing 
factor, we observe a much greater expression of ABU-13::tagRFP in the overexpression model by 
several orders of magnitude compared to the endogenously-tagged line. As we see diffuse ABU-13 
when there is higher expression, it is unlikely that the punctate structures in the endogenously-tagged 
line are driven by protein concentration. Instead, we hypothesise that this difference is a consequence 
of a flexible linker added between the N and C terminal regions flanking the removed prion-like domain 
in the endogenous line that is absent in the extrachromosomal array of the overexpression line. It is 
likely that, without this linker, the function of the remaining protein of ABU-13 is compromised. This 
is, however, insightful nonetheless as it suggests that localisation to ABU-13 puncta relies on regions 
outside of the prion-like domain.  
 
This can be interpreted in a number of ways; either ABU-13 is a client protein and incorporation into 
pre-existing condensates requires multivalent interaction with non-prionogenic domains, or there is 
redundancy amongst scaffold proteins and even without the prion-like domain, ABU-13 can continue 
to be incorporated due to its other interactions. This latter interpretation has been observed in a number 
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of organelles, with removal of single scaffold proteins not abolishing puncta formation30,31. Whilst it is 
common for phase-separated organelles to contain multiple scaffold proteins, many of which contain 
prion-like domains, it would be surprising to find a prion-like protein within these organelles that acted 
as a client protein. This predisposes us towards the interpretation that ABU-13 is acting as a scaffold, 
however more work is required to firmly come to this conclusion. For example, identifying whether 
transgenic lines expressing only the prion-domain can form puncta in vivo would help to clarify this 
further - though it is likely that these puncta may form non-specific aggregate-like structures in these 
conditions, as the multivalent interactions of these proteins play an important role in modulating the 
activity of these proteins. If this were indeed the case, alternative approaches to test this hypothesis in 
vivo could be employed - for example, identification of protein interactors would be useful in 
determining the molecular makeup of these puncta. This would allow puncta formation to be monitored 
by labelling another component - thus can be used to show whether there is still puncta formation in 
ABU-13DPrLD overexpression animals, even if ABU-13 is diffuse.  
 
A role of ABU-13 as a scaffold protein is further supported by our in vitro work with purified GFP-
tagged ABU-13. The formation of GFP-positive puncta demonstrates that coalescence is an inherent 
biophysical ability of ABU-13, whilst the reversibility of this formation indicates that these structures 
are not solid aggregates but rather dynamic assemblies truly reminiscent of phase separated organelles. 
Moving forward, purification of ABU-13DPrLD would allow us to determine more confidently whether 
this ability to form puncta is indeed reliant on the prion-like domain, with this in vitro setting removing 
any confounding interactions between existing puncta, and the N and C termini in vivo. It is also possible 
that, even if loss of the prion-domain does not abolish puncta formation, that these mutants have altered 
puncta dynamics and function – thus examining the functional consequences of prion-domain mutants 
would be of interest moving forward. 
 
3.3.2 Multiphase coexistence of ABU-13 
 
Traditionally, phase separation involves a transition from a diffuse to a liquid-like state, with many 
membraneless organelles exhibiting rapid recovery dynamics following a photobleaching event. The 
recovery rate of ABU-13 was variable, with larger puncta showing a more rapid recovery than smaller 
puncta. This variability suggests that some puncta are more dynamic than others. Further investigation 
of these differences demonstrated to us that these larger puncta were comprised of a clustering of smaller 
puncta. These smaller sub-punctae had lower mobility, whilst the area bounding them was more mobile. 
This is reminiscent of core-shell architecture seen in a number of phase-separating organelles, with core 
components forming a stable inner region, and more transient interactions occurring in the periphery32,33.  
 
Within these internal clusterings, very little fusion occurs, demonstrating that these phases can coexist 
whilst remaining immiscible. This is very similar to the behaviour of nucleoli, in which multiple phases 
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exist in a tripartite organisation, with differential surface tensions between compartments preventing 
their fusion32,34. Core-shell architecture has also been demonstrated in organelles considered incredibly 
liquid-like, including stress granules35. This therefore led us to suggest that ABU-13 puncta have 
variably mobility, with small core regions exhibiting hydrogel-like properties and representing a core 
set of compartment components, whilst the shell is more liquid-like and represents more transient 
interactions. It is important to note at this point that scaffold and client proteins can be found within 
either or both of the core and shell regions – the differential properties observed within these regions 
are determined by the intermolecular interactions in these different environments, rather than entirely 
different protein content. The presence of a scaffold in the core, for example, does not preclude it from 
being in the shell region as well.  
 
There are fascinating implications of this supramolecular organisation for stress responses - for example, 
it is possible that within a stress response, the core components of these assemblies do not change, but 
those within the outer layer do. If this were the case, the core components would represent those that are 
necessary for puncta functionality, whilst the outer components acting as dynamic ‘adaptors’, 
modulating the activity of the puncta in response to environmental stimuli. Determining both the 
mobility of these puncta in various physiological stress conditions, and identifying potential core versus 
shell proteins in these contexts would be useful for gaining a deeper understanding of puncta dynamics 
and function.  
 
3.3.3 Role in ER stress responses 
 
Despite identifying a role for ABU-13 in the response to tunicamycin treatment, we did not see any 
observable effects on puncta dynamics upon ER stress. This suggests that the role of this protein in ER 
stress responses does not involve large structural changes to these assemblies, as is observed in some 
stress-responsive organelles. Instead, we hypothesise that these responses are facilitated via the 
differential recruitment of components to these structures. This would allow the activity of these 
constitutively active puncta to be modulated dynamically, with client proteins recruiting RNA and 
protein specific to the stress response. 
 
At the moment, it is unclear whether the role that ABU-13 plays in ER stress responses is dependent on 
puncta formation. While we know that puncta formation still occurs in endogenously-edited prion-
domain mutants, it is unclear whether these animals exhibit the same phenotypic deficits seen in abu-
13 knockout animals. Similarly, we do not know whether these abu-13(tm6224) knockout animals, 
which express a truncated form of the protein, are capable of forming puncta in vivo or not. Repeating 
these phenotypic assays in abu-13DPrLD mutants would clarify whether or not these animals retain 
their ability to facilitate an ER stress response. If they do not exhibit the same phenotypic effects, this 
suggests that their presence within puncta is sufficient in enabling their function. Thus, identifying 
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alternative ways to prevent association of ABU-13 with puncta (i.e. by mutating RNA binding domains) 
would be necessary to further understand the link between the function of ABU-13 and its inclusion in 
these compartments.  
 
As many phase separated organelles are involved in the regulation of RNA, it is possible that ABU-13 
exerts its action via a similar mechanism. As such, determining the RNA species within these puncta, 
and specifically those that ABU-13 interacts with, will help to elucidate whether this protein is involved 
with the regulation of RNA. This hypothesis could be further tested by identifying and subsequently 
mutating any RNA binding motifs within ABU-13. As with the prion-like domain mutants, it would be 
interesting to determine whether the phenotypic deficits observed in abu-13(tm6224) animals are 
recapitulated when these RNA binding motifs are mutated. It is, however, possible that the two 
compensate for one another – as such, if no phenotypic effect is observed in either of these mutants, it 
might be the case that mutants for both the RNA binding domain and the prion-domain are necessary 
for actualisation of these deficits. 
 
In addition to this, to further explore the role that ABU-13 puncta play in the ER stress response, we are 
in the process of producing ABU-13::WormScarlet animals with an xbp-1(zc12) mutation, thus 
replicating the conditions in which abu-13 was first identified as a modulator of the non-canonical 
unfolded protein response. As these genes both reside on chromosome III, however, we are working on 
a CRISPR-derived mutant to monitor this effect. 
 
3.3.4 Role in the immune response 
 
The changes observed in ABU-13 puncta upon exposure to Pseudomonas aeruginosa indicate 
significant changes in their dynamics. The reduction in puncta number paired with the increase in size 
suggests one of two possibilities – that either puncta are fusing and thus overcoming their immiscible 
nature, or that some puncta are being dissolved whilst others are increasing their recruitment. The switch 
from a state of immiscibility to fusion would indicate that there is an unknown factor modulating the 
free mixing of these puncta in their basal state. There is evidence that both RNA and ATP can buffer 
these condensates, preventing their solid-like transition14,36 - thus this switch may be a reflection of 
increased ATP interaction or RNA recruitment that in turn overcomes the immiscible nature of these 
puncta and ultimately facilitates their fusion. 
 
Beyond these puncta, we also observe an increase in diffuse expression of ABU-13 within a sub-region 
of the pharynx, possibly within the marginal cells. These cells line the pharynx in three segments, 
surrounded by pharyngeal muscle. Little is known about their function, however, they do appear to 
possess the ability to scavenge cholesterol and small hydrophobic molecules, known as wactives, from 
bacteria being fed upon in a sphingomyelin-dependent fashion37. This scavenging behaviour is 
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particularly interesting in the context of ABU-13, which is known to be activated downstream of the 
scavenger receptor, CED-138,39. Whilst there is no evidence of ced-1 expression in these marginal cells, 
it is possible that ABU-13 is responsive to scavenger processes within this tissue via another mechanism. 
Although no such function has been identified as of yet, as the marginal cells are amongst the first cells 
to contact potentially pathogenic ingested material, it is logical for these to play a role in immune 
surveillance, activating an early innate immune response. Perhaps, for example, these cells are capable 
of scavenging bacterial components that can act as antigens and adjuvants, stimulating this immune 
response. For such a mechanism to be useful, however, these marginal cells would need to signal to 
other tissues. 
 
Interestingly, within these cells, ABU-13 is diffuse. This was surprising to us as we had expected ABU-
13, as a potential scaffold protein, to nucleate puncta formation when expressed. The lack of coalescence 
observed could point towards a different cellular environment within these cells that increases the 
critical concentration required for a phase transition. This is possible, for example, by modulating the 
buffering capacity of the aqueous environment by increasing salt concentration or, as previously 
mentioned, increasing RNA concentration. Alternatively, this could support a role for ABU-13 as a 
client protein, rather than a scaffold, with the lack of condensation resulting from no expression of a 
nucleating scaffold protein. Whilst we cannot fully exclude this possibility, given our in vitro evidence, 
this explanation seems unlikely.  
 
Overall, we propose that pharyngeal ABU-13 expressed within marginal cells functions to process 
scavenged bacterial antigens, potentially stimulating a downstream immune response. To fully 
investigate this hypothesis further, a greater understanding of the physiology of marginal cells in the 
context of the immune system is required, and then ultimately how ABU-13 might fit into this. 
 
3.3.5 Long-term immune protection?   
 
With many environmental stresses, an initial exposure to a threat can have a hormetic effect and result 
in a bolstering of future responses against the future stress. This has been observed in nematodes 
following heat shock40,41, for example, with improved survival of animals subjected to an initial stress 
earlier in life compared to those experiencing a stress for the first time. This points towards an ability of 
stress response pathways to ‘prime’ themselves for recurrent stress. Within the immune system, there 
are a number of mechanisms through which such priming can be achieved - in higher organisms, for 
example, the adaptive immune system can facilitate this.  
 
Whilst C. elegans lacks the specialised, mobile immune cells required for an adaptive immune system, 
there are examples of primitive responses in invertebrates that play a comparable role. Although 
discussed in another context, the bacterial CRISPR/Cas9 system is an excellent example of this, using 
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Cas9-crRNA ribonucleoprotein complexes to stimulate a form of adaptive immune response in bacteria 
against specific invading DNA and RNA species17,19. This, however, relies on insertion of foreign DNA 
elements into CRISPR motif regions within the bacterial genome16. Whilst ABU-13 does not play a 
homologous role within C. elegans, as demonstrated by its lack of nuclear localisation, it is possible that 
the constitutive presence of ABU-13 structures may allow for priming of the immune response, 
protecting animals against reinfection later.  This constitutive presence within animals enables more 
long-term interactions to be forged, unlike those that can be made within the limited lifespan of more 
transient phase separated structures. As such, responses of these puncta to bacterial invasion could 
prompt a form of ‘molecular memory’ that is propagated beyond the immune response itself. There is 
evidence for similar long-lived effects in other membraneless organelles as well - for example, the prion-
like scaffold protein CPEB3 is capable of forming functional aggregate-like structures whose long-term 
persistence within synapses is involved in the facilitation of a fear conditioned memory42–44. Thus, it is 
possible that retention of immune system components within these assemblies post-infection may act as 
a ‘molecular imprint’ of previous exposure, and thus protect animals against reinfection.  
 
This hypothesis, however, is contingent on a number of unknown factors that require future 
experimental work. Firstly, it would be interesting to determine whether the changes in puncta dynamics 
observed in response to PA14 treatment are maintained post-infection - if so, this would suggest a 
persistence of this response.  In addition to this, determining the molecular interactions that ABU-13 
makes within these puncta in different stress conditions - particularly post PA14 exposure - would allow 
us to determine how these puncta fit into the C. elegans immune system in general.  It would be 
particularly interesting to identify if any immune system components are retained within these puncta 
post-exposure and, if this were the case, whether they might be involved in priming the animal for a 
future response. Similarly, in the spirit of a truly ‘proto’-adaptive immune response, it is possible that, 
in keeping with the role that these puncta play in sequestering components from the environment, 
bacterial components may also be sequestered within these puncta, allowing for them to be more readily 
identified upon re-exposure. This underscores the pertinence of performing co-immunoprecipitation 
studies with ABU-13 to identify protein interactors in different environmental contexts, as this could 
unveil potential novel mechanisms of stress response. 
 
3.3.6 Role of the epithelial system in stress responses 
 
A number of epithelial-derived cell types were predicted as potential tissues for abu-13 expression, 
including the hypodermis, the amphid sheath (AMsh) glia and the arcade cells. The arcade cells, of 
which there are 9, form two separated epithelial syncytia and contain very little endoplasmic reticulum45. 
ABU-13 expression in these cells was not observed in our transcriptional reporter line, so we did not 
explore the role that arcade cells might play in ABU-13 function any further. We did, however, see 
localisation of ABU-13 around amphid neurons in the neuronal marker strain, as well structures 
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reminiscent of the AMsh glia within the transcriptional reporter, suggesting that we may indeed see 
ABU-13 expression within these sheath cells. These cells have been primarily linked with maintenance 
of the amphid neurons, with ablation of the AMsh glia causing morphological abnormalities in the 
dendritic tips of these neurons and preventing the detection of the dauer pheromone46–48. Although these 
functions do not seem related to functions we have identified for ABU-13, recent evidence has proposed 
a broad role for the cephalic sheath glia in coordinating global responses to ER stress49; thus, it is 
possible that the AMsh glia also play unidentified roles in systemic signalling of stress - a mechanism 
through which ABU-13 might act within these cells. 
 
The widespread expression of ABU-13 within what appears to be the hypodermis and seam cells is of 
particular interest in the context of immune responses. These tissues possess a barrier function, 
protecting animals from the invasion of potentially harmful pathogens. This protection derives in part 
from the formation of the cuticle, which acts as a physical barrier to the outside world protecting against 
a range of environmental threats including bacterial infection and osmotic shock. Alongside other 
specialised epithelial cells, the hypodermis and seam cells secrete cuticle components including 
collagen, structural glycoproteins and many insoluble proteins, allowing for the formation of an 
exoskeleton-like structure to form50. Whilst some of the ABU-13 expressed does appear to be located 
towards the body surface, a lot is expressed throughout the syncytial hypodermis suggesting that, even 
though this prion-like protein may have a propensity for insolubility, its main function is not as a part 
of the cuticle. This does not, however, exclude a role for these puncta in the processing of cuticular 
components.  
 
Beyond a role in the production and maintenance of the cuticle, these tissues play a role in immune 
signalling of invasive pathogens. This is particularly the case for pathogens that adhere to the cuticle 
surface, leading to the downstream activation of an innate immune response51,52. However, the primary 
route of Pseudomonas infection is via gut invasion53 and thus, this suggests a cell non-autonomous 
mechanism is involved in the response of hypodermal ABU-13 puncta to PA14 exposure. Such a 
mechanism would allow other tissues to pre-emptively prepare for bacterial invasion, thus improving 
the chances of survival. Pre-emptive immune responses such as this have been identified in C. elegans 
previously - for example, upon cuticular injury, antimicrobial peptide expression is increased in 
anticipation of any opportunistic pathogenic invasion54,55. Hence, moving forward, it would be of 
interest to determine whether there is indeed a signalling pathway mediating the link between bacterial 
invasion in the gut and the structural changes observed in ABU-13 puncta, or whether there is a more 
direct mode of activation. 
 
Overall, we propose that ABU-13 represents a scaffold protein capable of driving the assembly of 
multiphase biomolecular condensates capable of facilitating both ER stress and immune responses. The 
former may involve the context-dependent association of client molecules with the phase-separated 
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body, whilst the latter involves large structural changes to the overall puncta. Further work to determine 
the molecular interactions within these puncta in different environmental conditions will elucidate the 
mechanisms underlying these functions.  
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3.4 Material and Methods 
 
Construction of transgenic strains expressing extrachromosomal arrays 
 
To construct the pRT11[abu-13p::abu-13::tagRFP] plasmid, animals were first lysed in nematode lysis 
buffer (1X Platinum™ Taq High Fidelity DNA Polymerase (Invitrogen); 200µg/mL Proteinase K 
(Promega);  MgCl2 (New England Biolabs)), before amplification of the abu-13p::abu-13 locus from 
the isolated genomic DNA. This PCR amplification was performed in 5 fragments, with each fragment 
flanked by overhangs complementary to the adjacent region.  
 
To prepare these fragments for insertion into the expression vector pPD30.38, the plasmid was digested 
with HpaI and EcoRV following an hour-long incubation at 37°C. These fragments and the digested 
plasmid were then run on a 1% low-melting point agarose gel at 90V before excision and purification 
using a QiaQUICK Gel Purification Kit (Qiagen). The purified components were then combined, with 
50ng of vector added along with a two-fold molar excess of each fragment. 10µL of Gibson Assembly 
Master Mix (NEB) was then added to this mix, and the total volume brought up to 20µL with the addition 
of deionised water. The sample was then incubated in a thermocycler for 60 minutes at 50°C before 
electroporation into DH5α electrocompetent cells. These transformed cells were plated onto ampicillin-
containing TYE plates and incubated overnight at 37°C. Colonies were then singled out and grown in 
2XTY for 8 hours before being spun down and collected. Recombinant plasmids were then purified 
from bacteria using a QIAprep Spin Miniprep Kit (Qiagen) and sequenced to confirm identity.  
 
Following this, the full length abu-13p::abu-13 transcript was amplified from this plasmid and tagRFP 
amplified from pDD286. The expression vector pPD30.38 was digested using HpaI and SalI. The 
fragments and vector were ligated and the subsequent recombinant plasmid purified as per the protocol 
outlined above. 
 
For construction of the abu-13p::tagRFP transcriptional reporter plasmid (pRT31[abu-13p:: 
tagRFP::unc-54 3’UTR]), abu-13p and tagRFP were both amplified from pRT11 and inserted into 
pPD30.38 via Gibson assembly following digestion of the plasmid with HpaI and SalI. 
 
For construction of pRT26, the plasmid containing abu-13 without the prion domain (pRT26[abu-
13p::abu-13DPrLD::tagRFP::unc-54 3’UTR]), the regions either side of the prion-like domain were 
amplified from pRT11 before insertion into a HpaI/SalI digested pPD30.38. 
 
For construction of the pRT27[pitx-1::gfp::unc-54 3’UTR], the glial reporter line plasmid, the glial-
specific promoter itx-1 was amplified from nematode genomic DNA whilst C. elegans codon-optimised 
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gfp was amplified from pPD95.77. These fragments were then cloned into HpaI/EcoRV-digested 
pPD30.38 using Gibson Assembly, as outlined above. 
 
These plasmids were then injected into L4 animals mounted on 2% agarose pads at 100ng/µL using a 
Femtojet® 4x (Eppendorf) and InjectMan® 4 (Eppendorf). Nematodes were recovered in M9 media 
and transferred to OP50-seeded NGM plates for recovery. F1 progeny were then screened for transgenic 
animals - these animals were then singled out onto individual plates and propagated on for several 
generations before use to maximise the penetrance of the extrachromosomal array.  
  
SapTrap cloning for endogenous insertion 
 
To produce the insertion plasmid for the SapTrap protocol, both 5’ and 3’ homology arms flanking the 
insert region were amplified in preparation, with the former amplified from pRT11 and the latter 
amplified following a nested PCR directly from genomic DNA. These homology arms were 57 bps in 
length, with an additional 3 bps added adjacent to the SapI recognition site, corresponding to the specific 
overhang sequences exposed following digestion. In addition to this, 10µM of complementary single-
stranded oligonucleotides (ssODN) coding for the sgRNA sequence were mixed in 1X oligo annealing 
buffer (from a 1.25X buffer: 300uL of 1M HEPES [pH 7.5]; 1mL of 1M potassium acetate; 6.7mL of 
H2O)  and annealed following incubation of the mixture at 95°C in a thermocycler for 5 minutes. The 
annealed oligos were then cooled at room temperature for 10 minutes before diluting to 150nM in TE 
buffer. Note that within the annealed sgRNA duplex, each strand contained a similar 3 bp overhang to 
allow ligation into the destination vector later on. 
 
Following this, a DNA mix was prepared of all components in preparation for cloning into a destination 
vector (pPDD379). This included 300fmol of the annealed sgRNA duplex, 100fmol of the 5’ and 3’ 
homology arms, 100fmol of the mKate2-containing plasmid pDD375, 100fmol of the self-excising 
cassette-containing plasmid pDD363, 100fmol of the C-terminal linker-containing plasmid pMLS287 
and 100fmol of pDD379. The reaction mix was then made up of 1µL of DNA mix, 1µL of SapTrap 
reaction buffer (for 6X SapTrap reaction buffer: 24µL of 10X T4 DNA ligase buffer (NEB); 1uL of 1M 
potassium acetate; 15uL of H2O), 1µL of SapTrap enzyme mix (for 6X SapTrap enzyme mix: 28µL of 
SapI (NEB); 6µL T4 polynucleotide kinase (NEB); 6µL 400U/uL T4 DNA ligase (NEB)) and 3µL of 
nuclease free water. This mixture was then incubated at room temperature overnight before bacterial 
transformation, performed via electroporation, as outlined previously. 
 
Protein-based CRISPR  
 
Adapted protocol described in Paix et al. (2015)20. Briefly, the repair template was prepared by 
amplifying tagRFP from pDD286, flanked by 35 bp homology arms on either side of the transcript. The 
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PCR product was subsequently gel purified. Before preparation of the injection mix, the crRNA was 
designed using the CCTop algorithm (https://crispr.cos.uni-heidelberg.de/), which predicts off and on 
target scores for that specific crRNA. The crRNA itself made up of a 20 nucleotide crRNA sequence 
corresponding to the region immediately upstream of a PAM motif (NGG) - the site of Cas9 cleavage - 
along with a universal sequence that allows the crRNA to anneal with a tracrRNA to make the full 
sgRNA. The tracrRNA interacts with Cas9 itself, facilitating the formation of ribonucleoprotein 
complexes that target specific genomic loci. Hence, the 1uL of 8ug/µL target crRNA (IDT), 0.4µL of 
the co-CRISPR dpy-10 crRNA (IDT) and 5µL of 4ug/uL tracrRNA (IDT) were incubated together for 
5 minutes at 95°C in the thermocycler, followed by a gradient cooling to 4°C.  
 
After this, 10µL of 5µg/µL TrueCut™  Cas9 Protein v2 (Invitrogen) was added to the mix and incubated 
at 37°C for a further 10 minutes before leaving the RNP mix at room temperature for 10 minutes. Once 
cooled, 0.55µL of 500ng/µL dpy-10 ssODN repair template (IDT) and up to 500ng/µL of the PCR repair 
template was added, along with nuclease free water to bring the volume of the injection mix up to 20µL, 
if necessary. The mix was then spun down at 13,000rpm for 10 minutes and the injection mixed used to 
inject early adult animals.  
 
F1 progeny displaying the dumpy phenotype were single plated and, upon egg laying, subjected to PCR 




This protocol is adapted from Vicencio et al. (2019)21 and shares many similarities with the Paix et al. 
(2015) protocol described above. It differs fundamentally its two-step nature, however, with an initial 
small insertion followed by a second larger insertion. The preparation of the sgRNA-Cas9 complex is 
the same as outlined previously. However, when adding the repair templates, rather than using a PCR 
repair template the initial insertion uses a 200 nucleotide 4nmol ultramer ssODN repair template (IDT) 
instead. This ssODN consists of a 45 bp 5’ homology arm with the PAM from this first insertion 
mutated, a N terminal fragment from tagRFP, a C terminal fragment, and then a 45 bp 3’ homology arm. 
Mutating the initial PAM site prevents recutting. The constituent components of the initial injection mix 
differ from that used previously; 
 
Component Initial Concentration Final Concentration  Volume (µL) 
TrueCut™ Cas9 v2 10000ng/µL 250ng/µL 0.75 
tracrRNA 320µM 6.40µM 0.60 
dpy-10 crRNA 50µM 1.25µM 0.75 
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abu-13 crRNA 100µM 5µM 1.5 
dpy-10 ssODN 32.7µM 0.92µM 0.84 
tagRFP ssODN 100µM 2.20µM 0.66 
Nuclease free water   24.9 
Total volume   30 
 
The injection mix was prepped as before, and early adults singled out if they displayed the dumpy 
phenotype. Following egg lay, these animals were then lysed and genotyped via PCR, with gel 
electrophoresis using a 2% agarose gel used to identify any insertions. Non-dumpy offspring from 
homozygous animals were then singled out, and the genotyping repeated until homozygous animals 
identified. From this point, the second insertion step could proceed. Unlike the first insertion, a PCR 
product of tagRFP was used as the repair template; this repair template did not require the addition of 
abu-13-specific homology arms as the N and C terminal fragments inserted in the first step act as 
homology arms in this second step. The injection mix was prepared as before, using the following 
concentrations; 
 
Component Initial Concentration Final Concentration  Volume (µL) 
TrueCut™ Cas9 v2 10000ng/µL 250ng/µL 0.75 
tracrRNA 320µM 10.25µM 0.96 
dpy-10 crRNA 100µM 2µM 0.6 
tagRFP crRNA 100µM 8µM 2.4 
dpy-10 ssODN 32.7µM 0.92µM 0.84 
tagRFP PCR 1000ng/µL* 570ng/µL 17.1* 
Nuclease free water   7.35 
Total volume   30 
*Volume of tagRFP PCR product added depended on the concentration of the PCR product after gel 
excision and purification.  
 
As with the initial step, following injection, F1 animals with the dumpy phenotype were singled out and 
genotyped following egg lay, with correct genotyping bands purified and sent for sequencing for further 
validation (Eurofins Genomics). 
 
Long, partially single-stranded DNA-based CRISPR 
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This protocol utilises a dual PCR amplification process to produce double stranded products of 
differential sizes. Either tagRFP or WormScarlet was amplified from pDD286 or pSEM87 respectively, 
producing one set of PCR products the length of the fluorescent protein coding sequence itself and 
another using ultramer primers made up of 120 bp homology arms and 20 bps of the fluorophore 
sequence (IDT). Due to their length, a 1µM working concentration of each primer was used, diluted 
1:100 from a 100µM stock solution, along with 20ng/µL of plasmid to optimise this amplification. 
 
These products were purified using the QIAquick PCR Purification Kit (Qiagen), combined at a 1:1 
ratio and incubated in a thermocycler at 95°C for 2 minutes to melt the double stranded DNA, before a 
gradient cooling to 4°C to allow reannealing of single strands from different PCR products. This resulted 
in a population of double stranded DNA flanked by single-stranded ends corresponding to the 120 bp  
5’ and 3’ homology arms.  
 
The injection mix was then prepared following the same protocol as the second insertion stop of the 
nested CRISPR protocol outlined above. Note that in the original Dokshin et al. (2019) protocol, rather 
than using a co-CRISPR marker, a co-injection marker was used - instead of this, we used the dpy-10 
co-CRISPR marker as before.  
 
Due to the high error rate observed during this process, we proceeded to correct a small error in 
positively edited animals that resulted in a lack of fluorescent protein expression using the protocol for 




Animals were mounted on 2% agarose pads and imaged under a Zeiss 710 confocal microscope at 40X 
or 63X. To minimise imaging time and allow for maximal temporal resolution, the imaging window 
was restricted to small areas within the field of view. An initial region of interest (ROI) was highlighted 
corresponding to the area to be bleached, along with two further ROIs corresponding both a reference 
and a background region. Upon imaging, the first ROI was bleached 5 times consecutively using the 
514nm and 561nm lasers set to 100% power following an initial imaging step to visualise the pre-bleach 
fluorescence intensity. A series of imaging steps were then repeated post-bleaching to monitor the 
changes in fluorescence of these regions over time. 
 
For FRAP analysis, the background intensity was subtracted from both the fluorescence intensity values 
of the bleached and the reference regions. The bleached region was then normalised to the reference 
region, counteracting the effects of general bleaching during the imaging process. These values were 




𝑦 = 𝑎 ∗ W
1
𝑒XY∗Z
[ + 𝑐 
 
Within this exponential recovery curve, a + c corresponds to the mobile fraction of the bleached region. 




For tunicamycin and Pseudomonas exposure, animals were treated as outlined in Section 2.4. For heat 
shock, however, age synchronized animals were collected at L4 and transferred onto unseeded plates. 
These plates were then placed in a 20˚C or 34˚C incubator for 6 hours prior to imaging. 
 
Following induction of stress, animals were mounted on 2% agarose pads and imaged using a Zeiss 710 
Confocal microscope, with either a 10X, 20X, 40X Oil, or 63X Oil objective. Images were then analysed 
using Fiji (ImageJ) software. To determine the normalised fluorescence intensity values for each 
condition, we first determined the corrected total cell fluorescence (CTFC) for each individual animal. 
To do this, animals were isolated within the image and measurements of integrated density and total 
area of the animal were taken, along with the average gray area of 3 different background regions. The 
CTFC was calculated as follows; 
 
𝐶𝑇𝐹𝐶 = 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑	𝐷𝑒𝑛𝑠𝑖𝑡𝑦 − (𝐴𝑟𝑒𝑎	𝑜𝑓	𝑎𝑛𝑖𝑚𝑎𝑙 ∗ 𝑀𝑒𝑎𝑛	𝑔𝑟𝑎𝑦	𝑎𝑟𝑒𝑎) 
 
An average CTFC value was determined for the control condition animals, and all CTFC values 
normalised to this average.  
 
For puncta measurements, images were initially thresholded using Autothreshold settings. Whole 
animals were then isolated in the image and the Analyse Particles function used to measure the 
properties of these puncta. For all these measurements, Prism 8 software was used for statistical analysis. 
 
Expression prediction software 
 
To predict the expression pattern of abu-13, an online ‘tissue-ome’ database was used 
(http://worm.princeton.edu/), developed by Kaletsky et al. (2018). These prediction values were then 
inputted into Prism 8 software and a heat map generated. 
 
Freeze-crack and DAPI staining  
 
Prior to preparation of nematodes, a flat metal plate was cooled on a bed of dry ice to ensure ice-cold. 
Day 1 animals were then collected in M9 and washed 3 times to remove all bacteria, aspirating and 
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discarding the M9 after each wash. Animals were then resuspended in ddH2O and 10 - 20µL transferred 
onto polylysine coated slides, with individual animals being ‘drawn out’ using a pipette tip as to separate 
out individual nematodes. A coverslip was then added to the slide before placing it onto the pre-cooled 
metal plate for 2 hours. The coverslip was then carefully removed from the slide. Acetone was then 
added and incubated with nematode samples in a humid chamber for 30 minutes, after which, the slide 
was gently washed with PBS twice, making sure to remove as much liquid as possible without disrupting 
the prepared animals on the slide. DAPI was then added to the sample and left to stain animals for a 
further 30 minutes in a humid chamber. After a final set of PBS washes, a coverslip was secured to the 
slide and animals were imaged using a Zeiss 710 Confocal microscope. 
 
Protein purification from BL21 E. coli 
 
In preparation for protein expression, we amplified out the exonic sequences of abu-13 and abu-
13DPrLD from pRT11 and pRT26 respectively and, using Gibson assembly, cloned these into 
pPD30.38. For bacterial purification, we then amplified out the full open reading frames for these genes 
and, using FseI and AscI digestion sites, cloned them sequence into an adapted pET 28b expression 
vector. The resulting recombinant expression vectors (pRT28 and pRT29 respectively) were then 
transformed into BL21(DE3) E. coli, adding 1µL of plasmid to 50µL of bacteria. This mixture was 
placed on ice for 30 minutes before heat shock was applied at 42C for 10 seconds. The sample was then 
immediately placed back onto ice for 5 minutes before recovering bacteria in 950µL of SOC media. 
Following incubation of this mixture at 37C for 60 minutes in a shaking incubator, the liquid culture 
was spread on kanamycin selection plates and left at 37C overnight.  
 
The resulting colonies were then scraped into 60mL of 2XTY and grown overnight to prepare a pre-
culture. This pre-culture was added to 3L of 2XTY and grown in a shaking incubator set to 37°C until 
OD 0.8. Following a period of cooling at 4°C, 0.5µM of IPTG was added to induce expression of abu-
13 and incubated at 20°C overnight in a shaking incubator. Bacteria was then pelleted down at 6000rpm 
for 20 minutes at 4°C, supernatant discarded, and the remaining pellet resuspended in 30mL PBS. After 
spinning down at 3900rpm for 30 minutes at 4°C and discarding the supernatant once more, this washed 
pellet was then resuspended in 200mL of lysis buffer (20mM HEPES; 150mM KCl; 5% glycerol; 20mM 
imidazole, pH 7.7; 1% Triton X-100; 5mM MgCl2; 10ug/mL DNase I; 1xcOmplete protease inhibitor 
cocktail (Roche); 1mM PMSF). The bacteria was then sonicated for 5 minutes, using a programme set 
to 5 seconds on/5 seconds off at a 40% amplitude. This sonicated bacteria was then pelleted at 
16,000rpm for 30 minutes at 4°C to clear any remaining debris. The clarified supernatant was then 
collected. 
 
For every 3mL of Ni-NTA agarose resin (Qiagen), 25mL of lysis buffer was added to equilibrate the 
beads, before spinning them down at 1000rpm. The buffer was then removed, replaced with the bacterial 
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lysate and left rotating overnight at 4°C. After this point, the incubated beads were left to settle for 30 
minutes, the supernatant discarded before resuspending and washing in 1x extract buffer (for 10xXB: 
1M KCl; 1mM CaCl2; 10mM MgCl2; 50mM sucrose; 100mM HEPES, pH 7.8) supplemented with 
20mM imidazole, 4 times. 1mM DTT and 0.5mM EDTA was then added along with 1:50 v/v of TEV 
protease (NEB) and rocked overnight at 4°C. The sample was then dialysed twice with XB before 
incubating with 20mM imidazole for 2 hours.  
 
The beads were then loaded into an Econo-Pac Chromatography Column (Biorad) pre-equilibrated with 
lysis buffer and the flow through collected before concentration of the sample to 1mL using an Amicon® 
Ultra-15 Centrifugal Filter Unit (Millipore). This concentrated sample was then ultracentrifuged at 
100,000g for 5 minutes and the supernatant collected before being flask frozen and stored at -80°C. 
 
Protein purification from S2 cells 
 
In preparation for expression in S2 cells, the abu-13 and abu-13DPrLD open reading frame sequences 
were amplified out of pRT28 and pRT29, and cloned into an adapted gfp-containing pMT expression 
vector gifted by Joseph Watson (Derivery lab, MRC LMB) following FseI and AscI digestion. The 
resulting recombinant plasmids (pRT29 and pRT30 respectively) were transfected into S2 cells using 
Lipofectamine® 3000 as follows. S2 cells were initially seeded and grown to between 70 and 90% 
confluence. Lipofectamine® 3000 Reagent (Invitrogen) was then diluted in Opti-MEM® Medium 
(Invitrogen), whilst 5µg of plasmid was diluted in Opti-MEM® Medium and P3000™ Reagent 
(Invitrogen) added. These two diluted reagents were then combined at a ratio of 1:1 and incubated for 5 
minutes at 4°C before being added to cells. These cells were then incubated for 3-4 days at 37°C and 
then visualised to monitor growth.  
 
Protein purification from C. elegans 
 
For preparation of liquid culture, 3L of OP50 were grown in LB overnight at 37°C before being pelleted 
at 2500g for 10 minutes. This concentrated OP50 was then used to inoculate S-medium (1L S Basal 
[5.85g NaCl; 1g K2HPO4; 6 g KH2PO4; 1mL of 5mg/mL cholesterol; 999mL H2O]; 10mL of 1M 
potassium citrate, pH 6 [for 1L: 20g citric acid monohydrate, 293.5g tri-potassium citrate monohydrate; 
1L H2O]; 10mL trace metals solution (for 1L: 1.86g disodium EDTA; 0.69g FeSO4•7 H2O; 0.2 g 
MnCl2•4 H2O; 0.29 g ZnSO4•7 H2O; 0.025 g CuSO4•5 H2O; 1L H2O]; 3mL 1M CaCl2; 3 mL 1M 
MgSO4). Several large plates of ABU-13::WormScarlet or ABU-13::3xFLAG animals recently cleared 
of bacteria were washed into this inoculated S-media and flasks transferred into a shaking incubator set 
at 20C.  
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These liquid cultures were monitored daily to ensure no bacterial growth or depletion of the food source. 
By the fourth or fifth day, when there were a significant number of adult animals for harvesting, these 
flasks were put on ice and cooled for 15 minutes allowing animals to settle. The liquid was then aspirated 
and animals washed in M9, before aspirating off the liquid once more and resuspending animals in RIPA 
buffer (10mM Tris-HCl, pH 7.5; 150mM NaCl; 0.5mM EDTA; 0.1% SDS; 1% Triton X-100; 1% 
deoxycholate; 1x cOmplete protease inhibitor cocktail (Roche); 1mM PMSF) before flash freezing in 
liquid nitrogen. These samples were then thawed on ice before being lysed by sonication. Lysis was 
then spun down at 4000g for 15 minutes and the clarified supernatant collected. The sample used with 
the RFP-Trap beads was then diluted in a dilution buffer (10mM Tris-HCl, pH 7.5; 150mM NaCl; 0.5nM 
EDTA; 1x cOmplete protease inhibitor cocktail (Roche); 1mM PMSF) at a ratio of 2:3, sample:buffer.  
 
Prior to purification of the tagged protein, RFP-Trap® agarose beads (Chromotek) and ANTI-FLAG® 
M2 magnetic beads (Sigma) were vortexed to resuspend beads in their storage buffer. A 500µL bead 
slurry of each was then diluted in 10mL of dilution buffer. RFP-Trap beads were then spun down at 
2500g for 2 minutes at 4°C, whilst anti-FLAG beads were separated using a magnetic separator before 
removing the supernatant and resuspending the beads in the same volume once again. This was repeated 
twice more. After the final wash, diluted lysate was added to the RFP-Trap beads, whilst undiluted lysate 
was added to the anti-FLAG beads. The lysate-bead mix was then left on a rotator overnight at 4°C. 
 
Beads were then collected as described previously and supernatant discarded. After two further rounds 
of washing in dilution buffer, we aspirated off the supernatant and eluted the bound protein from the 
beads. For the RFP-Trap beads, we added 1mL of 0.2M glycine, pH 2.5 to the beads, mixing constantly 
for 30 seconds before immediately spinning down at 2500g for 2 minutes, collecting the supernatant 
and neutralizing it in 100µL of 1M Tris, pH 10.4. For the anti-FLAG beads, 1mL of 0.1 glycine, pH 3.0 
was added and incubated with the beads for 10 minutes on a rotator before separating with a magnetic 
separator, collecting the supernatant and neutralizing with 200uL of 0.5M Tris-HCl, pH 7.4 with 1.5M 
NaCl. Collected eluate was then flash frozen and stored at -80°C until use. 
 
Protein purification for prion-like proteins 
 
Protocol adapted from Alberti et al. (2018)56. The 6xHis::MBP::3C::ABU-13::TEV::GFP expression 
vector was constructed in two stages; initially, the individual components were combined in pPD30.38 
by Gibson Assembly. The MBP sequence was cloned out of pMal c5X gifted by Dr. Ketan Malhotra 
(Bertolotti lab, MRC LMB) with a 6xHis::3C protease site sequence added to the forward primer. The 
abu-13 open reading frame was cloned from pRT28, with the addition of the 3C protease target site 
sequence at the 5’ end whilst the gfp sequence was cloned out of an adapted pMT-GFP expression vector 
gifted by Joseph Watson (Derivery lab, MRC LMB), with the TEV-cleavage site and a flexible linker 
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sequence added to the forward primer. These were then assembled as previously described into 
pPD30.38 following a SalI/HpaI digestion. 
 
Using this intermediate recombinant plasmid, either the full 6xHis::MBP::3C::ABU-13::TEV::GFP 
sequence or a GFP-only sequence were amplified and inserted into an adapted pRSET expression vector 
gifted by Joseph Watson (Derivery lab, MRC LMB), following digestion of all components with FseI 
and AscI, via T4 DNA ligase-mediated ligation overnight at 15C before being transformed into DH5α 
electrocompetent cells and prepped for use using methods previously outlined. Once prepared, 1uL of 
purified plasmid was added to 50µL of Rosetta™ 2(DE3)pLysS Singles™ Competent Cells (Novagen) 
and incubated on ice for 5 minutes. The mix was then heated for exactly 30 seconds at 42°C in a 
stationary thermoshaker and transferred back onto ice immediately for 2 minutes before being suspended 
in 950µL of SOC media and incubated at 37C for 1 hour in a shaking incubator. This liquid culture was 
then spread onto ampicillin-containing TYE plates and incubated overnight at 37°C.  
 
Colonies from this plate were then scraped into 60mL of 2XTY and grown overnight at 37°C. 20mL of 
this pre-culture was then added to each litre of 2XTY (3 litres made overall), and grown in a shaking 
incubator until OD 0.8. The culture was then cooled at 4°C before the addition of 0.5µM of IPTG. These 
induced cultures were then grown in the shaking incubator overnight at 20C. The next day, bacteria was 
spun down at 4500rpm for 20 minutes at 4°C, the supernatant removed and the bacterial pellet 
resuspended in 30mL PBS. These resuspending bacterial pellets were then spun down once again, this 
time at 3900rpm for 30 minutes.  
 
These washes pellets were then resuspended in lysis buffer (50mM Tris-HCl, pH 7.4; 1M KCl; 5% 
glycerol; 10mM imidazole; 1x cOmplete protease inhibitor cocktail (Roche); 1mM PMSF) and lysed by 
sonication. The lysis was then cleared of debris following centrifugation at 4500rpm for 20 minutes at 
4°C and the supernatant incubated with pre-equilibrated Ni-NTA agarose resin (Qiagen) overnight. 
Agarose beads were collected via centrifugation at 1500rpm for 2 minutes and washed three times in 
lysis buffer, with the beads spun down once more after each wash. After the final wash, the beads were 
resuspended once more and added to pre-equilibrated Econo-Pac Chromatography Columns (Biorad). 
The beads were then washed once more with two columns worth of lysis buffer. Bound protein was then 
eluted from the beads using elution buffer (50nM Tris-HCl, pH 7.4; 1M KCl; 5% glycerol; 500nM 
imidazole).  
 
This eluted protein was then incubated for 1 hour at room temperature with PreScission protease 
(Promega) at a ratio of 1:50 to cleave off the 6xHis-MBP tag. Buffer exchange and concentration of the 
purified protein samples was then performed using Amicon® Ultra-4 Centrifugal Filter Units 
(Millipore), subjecting the sample to an initial spin at 4500rpm for 15 minutes, and then three additional 
spins following addition of storage buffer to the concentrated sample (50mM Tris-HCl, pH 7.4; 500mM 
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KCl; 1mM DTT; 5% glycerol). These samples were then aliquoted, frozen in liquid nitrogen and stored 
at -80°C until use.  
  
SDS-PAGE and Western blot 
 
Initially, 10uL of 4x LDS Sample Buffer (Invitrogen) was added 30µL of purified protein sample and 
incubated for 10 minutes at 95°C. Samples were not standardised prior to electrophoresis. These heated 
samples were then loaded in duplicate onto a NuPage 4-12% Bis-Tris precast gel (Invitrogen) alongside 
a Precision Plus Protein Dual Color Standard (Biorad) protein ladder and run at 200V in 1x MOPS-SDS 
running buffer for 30 minutes. 
 
Once run, the gel was removed from the plastic casing. The gel was then split in half, with the first set 
of samples being fixed in 40%EtOH/10% acetic acid for 15 minutes, rinsed in water and stained 
overnight in QC Colloidal Coomassie Stain (Biorad). This gel was then rinsed in water once more and 
imaged using a Chemidoc Touch Imaging System (Biorad), with the settings set to detect Coomassie.  
 
The second set of samples was then subjected to a dry transfer onto an iBlot™ Transfer Stack PVDF 
membrane (Invitrogen) using iBlot® Dry Blotting System (Invitrogen). This membrane was then 
blocked for 2 hours in 5% bovine serum albumin dissolved in PBS-T, before the addition of either an 
RFP antibody (6G6, Chromotek) against WormScarlet at a 1:1000 concentration, or an anti-GFP 
antibody (ab290, Abcam) at a 1:10000 concentration. This membrane was then incubated at 4°C 
overnight before being washed 3 times in PBS-T and 5% BSA solution containing secondary antibody 
added. For the RFP antibody-probed membrane, 1:5000 of anti-mouse secondary antibody, whilst 
1:10000 of anti-Rabbit HRP-conjugated secondary antibody (W401B, Promega) was used against the 
anti-GFP antibody. After a 2 hour incubation at room temperature, membranes were washed 3 times in 
PBS-T and then a final time in PBS. Imaging was then performed using a Chemidoc Touch Imaging 
System (Biorad), with the settings set to detect Chemiluminescence, following visualisation of HRP-
conjugated antibodies with Pierce™ ECL Western Blotting Substrate (Thermo Scientific).  
 
In vitro phase separation assays 
 
The concentration of purified GFP and GFP-fused ABU-13 was calculated using an Eppendorf 
Biospectrometer® set to 488nm before standardising samples with storage buffer. Prior to imaging, 
airtight chambers were prepared using glass coverslips passivated with PLL-g-PEG (20K) at 1mg/mL 
in buffer containing 10mM Tris-HCl, pH 7.5 and 150mM KCl for 1 hour at room temperature. 
Experimental conditions were tested in a standard phase separation buffer (50mg/mL 20K PEG (Sigma); 
25nM Tris-HCl, pH 7.4; 150mM KCl), with any deviation from this standard specified. 5µL of sample 
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The formation of phase-separated structures is reliant on the multivalent interactions of a number of 
scaffold proteins, facilitating the coalescence of a wide range of protein and RNA components. These 
structures compartmentalise cellular function akin to a membrane-bound compartment, albeit lacking 
the membrane. Often these structures are involved in RNA processing of some kind – whether through 
the sequestration of relevant RNA machinery, preventing translation or other related processes, or via 
active RNA processes such as mRNA decapping.  
 
Thus far, we have demonstrated that ABU-13 is capable of forming punctate structures that resemble 
those observed within phase-separated organelles. As such, gaining an insight into the nature of protein 
and RNA interactions within these structures is likely to aid our mechanistic understanding of their role 
within C. elegans. Although the ability to bind RNA has been predicted by domain conservation 
predictions in the N terminus of the protein, this ability has not been verified experimentally and thus, 
we initially sought to determine whether ABU-13 was an RNA binding protein. Using an adapted cross-
linking and immunoprecipitation protocol, we show that this is indeed the case, further supporting the 
involvement of ABU-13 within phase-separated structures. 
 
We next investigated the protein-protein interactions of ABU-13 by co-immunoprecipitating ABU-
13::tagRFP and performing mass spectrometry on the pulled down proteins. In keeping with our 
hypothesis that this protein plays a role in ER stress responses and RNP complex formation, we see an 
overrepresentation of gene ontology terms relating to these processes.  
 
As we hypothesised that ABU-13 is involved in the formation of hydrogel-like structures, we performed 
a biotinylated isoxazole precipitation of hydrogel-forming proteins to determine if ABU-13 is found 
amongst these proteins. This was not the case, and ABU-13 was not identified within this precipitate. 
This dataset, however, provides a novel insight into hydrogel-forming proteins in C. elegans, 














4.1.1 RNA Binding Domains 
 
Multivalency is a powerful driver of phase separation due to the inherent propensity of multivalent 
proteins to interact with a variety of other cellular components, including proteins and RNA. This 
facilitates the coalescence of numerous components into a restricted cellular space, ultimately driving 
this process of phase transition. Amongst these phase separating proteins, there is an enrichment of both 
proteins with prion-like domains and those with RNA binding domains. Whilst the former is vital for 
driving self-assembly of these proteins due to their intrinsic proclivity for aggregation-like behaviour1, 
the presence of RNA binding can act as a modulator of these processes, with evidence suggesting that 
RNA can act to buffer these transitions, keeping them in a more liquid-like state and preventing their 
transition to solid-like pathological aggregates2.  
 
Beyond this, however, these RNA associations often play important functions in the regulation of RNA 
– from sequestration to degradation – and thus understanding the specificity of RNA binding under 
different physiological circumstances can be a powerful tool for determining molecular function of these 
biological condensates. Furthermore, determining the sites of interaction with specific RNAs can point 
towards different types of regulation; for example, the RNA binding protein TIS11B is involved in the 
formation of TIS granules that form a meshwork around the endoplasmic reticulum. Within a 
subcompartment of this membraneless compartment, known as the TIGER domain, TIS11B facilitates 
the differential regulation of mRNA transcripts based on their 3’UTRs3. Thus, understanding both the 
identity of the RNA involved and the site of interaction can be useful for determining the molecular 




Physiological hydrogels allow phase-separated structures to stably persist within a cellular environment, 
as opposed to the often-transient formations observed with liquid-liquid phase transitions. Many of these 
structures are involved in multiphase systems, such as the nucleolus, where a tripartite structure of 
phases facilitates a sequential processing of ribosomal components. Similarly, biphasic structures are 
commonplace amongst some of the more transient compartments too – for example, stress granules 
contain a core-shell architecture whereby the outer layer has more liquid-like properties and the inner 
layer has more solid-like properties. This allows for retention of vital components of these condensates, 
whilst the outer layer allows for weaker associations of more transient components to occur.  
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It is possible to isolate proteins with a propensity for forming hydrogels by selectively precipitating 
them out from lysate using the chemical biotinylated isoxazole (b-isox) (Figure 4.1). This has allowed 
the sequence determinants of such transitions to be explored. Notably, low complexity domains were 
shown to be both necessary and sufficient for this precipitation. This has been illustrated using the stress 
granule-associated protein, TIA1; evidence from mice has shown that this protein is precipitated from a 
range of cell and tissue types following homogenisation and b-isox treatment. This precipitation is 
abolished, however, if the low complexity domain is removed – this is not the case when the RNA 
recognition motifs are removed, with precipitation occurring as before in this context. Despite this, RNA 
binding proteins are highly enriched amongst this dataset, with a highly significant representation of 
RNA granule proteins found within these precipitated protein groups in comparison to the much lower 
frequency of such proteins within the mouse proteome in general4. 
 
Figure 4.1 Schematic depicting the experimental process allowing biotinylated isoxazole precipitation of hydrogel forming 
proteins 
 
Within these low complexity domains, there is also a correlation between hydrogel formation and the 
presence of [G/S]Y[G/S] motifs. This has been shown in vitro by the abolition of hydrogen formation 
of purified FUS and hnRNPA2 LC domains upon mutation of these tyrosine residues. These in vitro 
hydrogel structures exhibit diffraction rings of 4.6-4.7Å and 10Å, suggesting they form cross-β 
structures, similar to those seen in a range of prion-like and amyloid-like protein fibrils. However, unlike 
pathogenic amyloid fibrils, these structures are readily disassembled and display a more dynamic nature, 
capable of heterotypic incorporation of other RNA binding proteins into pre-existing polymers. Similar 
findings have also been shown for the prion-like domain of RBM14, involved in paraspeckle formation, 
which can form an amyloidogenic hydrogel as well5. As with FUS and hnRNPA2, these hydrogels show 
diffraction reflections at around 4.6Å and 10Å, highly reminiscent of the amyloid structures previously 
discussed. Thus, it is clear that low complexity domains play a role in driving the transition of RNA 




In this chapter we will demonstrate that ABU-13 is indeed an RNA binding protein, capable of 
interacting with RNA whilst the protein is in its full-length state – but not when the prion-like domain 
is removed. This further supports the role of this protein in phase transitions, as RNA binding proteins 
are overrepresented in such processes. Beyond RNA, we next sought to identify the protein interaction 
partners of ABU-13, showing an enrichment of other RNA interacting proteins immunoprecipitated 
alongside ABU-13, suggesting a role for this protein in the regulation of RNA. In addition to this, a 
number of glycosylation-related proteins were pulled down as well, pointing towards a further role for 
ABU-13 in the folding quality control of glycosylated proteins. To investigate the hypothesis that ABU-
13 represents a species of hydrogel-forming proteins, we took an unbiased approach, precipitating 
hydrogel-forming protein en mass from wild type animals using b-isox. We did not find ABU-13 
amongst these precipitated proteins suggesting that it may not in fact drive the formation of a hydrogel-
like structure in vivo. This dataset, however, represents a novel characterisation of the hydrogel 
proteome of C. elegans, with a number of interesting candidate proteins identified that warrant further 





























4.2.1 ABU-13 is an RNA binding protein 
 
To test whether ABU-13 represents a species of RNA binding protein, as predicted by conserved domain 
searches, we adapted protocols for crosslinking and immunoprecipitation (CLIP)6, and nucleic acid end-
labelling7, allowing us to pull-down ABU-13 following UV crosslinking of the protein to any RNA 
interactors in vivo (Figure 4.2A). 
 
Figure 4.2 ABU-13 is capable of binding RNA, (A) a schematic illustrating the adapted CLIP protocol used to determine 
whether ABU-13 is an RNA binding protein; (B) SDS-PAGE of ABU-13::tagRFP, ABU-13 Δ::tagRFP and tagRFP alone, 




This RNA could then be chemically altered, using polynucleotide kinase to facilitate the transfer of a 
gamma phosphate group from ATP-γ-S to the 5’-hydroxyl end of any bound RNA, priming this 5’ end 
for conjugation with 5-iodacetamidofluorescein (5-IAF). SDS-PAGE of these immunoprecipitated 
samples allowed any RNA-bound protein complexes to be directly visualised due to the fluorescent 
properties of this compound. Using extrachromosomal array lines, ABU-13::tagRFP, ABU-
13ΔPrLD::tagRFP and tagRFP alone were tested for their abilities to bind RNA. Out of these three 
samples, only the full length ABU-13 co-precipitated with RNA, suggesting that ABU-13 is indeed 
capable of binding RNA. ABU-13ΔPrLD::tagRFP and tagRFP, on the other hand, showed no ability to 
bind RNA (Figure 4.2B). This suggests that the RNA binding abilities observed by the ABU-13::tagRFP 
animals were not a consequence of the fluorescent tag and may also be dependent upon the prion-like 
domain.  
 
These RNA binding results could not, however, be tested in our endogenous expression systems due to 
the inability of the anti-FLAG or anti-RFP immunoprecipitation beads to successfully pull down 
sufficient ABU-13::3xFLAG or ABU-13::WormScarlet.  
 
4.2.2 ABU-13 interacts with a range of proteins 
 
To determine the protein interactions of ABU-13, we co-immunoprecipitated tagRFP-fused ABU-13 
using RFP-Trap beads (Chromotek) and performed mass spectrometry to identity any proteins pulled 
down alongside this protein, compared to those in a tagRFP control. Whilst there were many proteins 
identified in both samples, we applied thresholds of detection to eliminate background proteins that 
represented non-specific hits shared between both conditions. This involved filtering out all the proteins 
that showed a less than 50% increase between tagRFP and ABU-13::tagRFP. Within this filtered dataset, 
a number of proteins relating to particular processes were significantly overrepresented (Figure 4.3). 
Many of these were processes involved in ER-localised processes, RNA processing and translation; this 
is in keeping with our previous findings that ABU-13 contains a signal sequence for ER targeting and 
plays a non-redundant role in ER homeostasis. In addition to this, many terms relating to occyte 
development were significantly overrepresented – whilst these could represent a role for ABU-13 in the 
development of eggs, they may also suggest a slight difference in the developmental stage at which 
nematode populations were harvested for the co-IP. The harvesting of animals at Day 1 of adulthood 
could explain this result – at this stage, animals are still undergoing significant oogenesis and thus any 
mismatch - even if minor - in the ages between the nematodes of each sample group could result in a 
significant overrepresentation of genes involved with these responses. 
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Figure 4.3 Gene Ontology terms for proteins identified as overrepresented within the mass spectrometry results of a tagRFP-
fused ABU-13 pull-down compared to a tagRFP control, as determined using PANTHER Overrepresentation Test, with 
proteins ranked by significance (Fisher test, with FDR adjustments to correct for multiple comparisons); red = terms relating 







4.2.3 ABU-13 interacts with stress related proteins, including those of the IRE-1 branch of the UPR 
 
Following our initial results that ABU-13 plays a non-redundant role in the ER stress response, as 
demonstrated by the developmental deficits observed in knockout animals exposed to tunicamycin, we 
sought to determine if any known ER stress response proteins were identified as interacting with ABU-
13. This was indeed the case, with many proteins related to stress responses shown to be overrepresented 
(Table 4.1). The presence of ER resident proteins, alongside those involved with ER stress responses, 
suggests that ABU-13 is indeed localised to this compartment.  
 
Components of the ERAD pathway were also pulled down, including UBXN-4, which positively 
regulates RNA Polymerase II transcription as part of the ER stress and ERAD responses. This is 
particularly interesting due to the homology of the N-terminal region of ABU-13 with RNA Polymerase 
II – if this homology region shares structural similarity to RNA Polymerase II, UBXN-4 may also be 
involved in its regulation too. In addition to this, a number of interactors associated with the IRE-1 
branch of the unfolded protein response were identified; these represent promising candidates when 
considering the role of ABU-13 in the non-canonical UPR pathway following inhibition of xbp-1. 
UGGT-1, for example, is an UDP-glucose glycoprotein glucosyltransferase found in the lumen of the 
ER. As well as playing a role in the IRE-1-mediated UPR, this protein also functions in larval 
development. Among the ER stress responsive proteins identified, a number of IRE-1 pathway-related 
proteins were also pulled down – these include the GTP binding protein, TAG-335, and the ribosomal 
binding protein, K12H4.2. 
 
















trap-3 TRanslocon-Associated Protein - 
K12H4.4 Probable signal peptidase complex subunit 3 protease 
asna-1 ATPase asna-1 nucleotide phosphatase 
transporter 









mans-3 alpha-1,2-Mannosidase chaperone 
F44B9.5 Ancient ubiquitous protein 1 homolog acyltransferase 
erl-1 ERLin (ER lipid raft associated protein) homolog - 
ubxn-4 UBX domain-containing protein 4 - 












ubc-13 Ubiquitin-conjugating enzyme E2 13 - 
tag-335 Mannose-1-phosphate guanyltransferase beta - 
Y54G2A 4D656 membrane traffic protein 
transporter 
K12H4.4 Probable signal peptidase complex subunit 3 protease 
mans-3 alpha-1,2-Mannosidase chaperone 
F44B9.5 Ancient ubiquitous protein 1 homolog acyltransferase 
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K12H4.2 Uncharacterized protein K12H4.2 - 
erl-1 ERLin (ER lipid raft associated protein) homolog - 
gale-1 UDP-glucose 4-epimerase - 
Y54G2A.23 MANF/CDNF-like protein - 
ubxn-4 UBX domain-containing protein 4 - 














ubc-13 Ubiquitin-conjugating enzyme E2 13 - 
his-3 Histone H2A - 
tag-335 Mannose-1-phosphate guanyltransferase beta - 
Y54G2A 4D656 membrane traffic protein 
transporter 
him-1 Structural maintenance of chromosomes protein 1 - 
rpa-2 Replication Protein A homolog - 
K12H4.4 Probable signal peptidase complex subunit 3 protease 
mans-3 alpha-1,2-Mannosidase chaperone 
F44B9.5 Ancient ubiquitous protein 1 homolog acyltransferase 
smk-1 SMEK (Dictyostelium Suppressor of MEK null) homolog - 
K12H4.2 Uncharacterized protein K12H4.2 - 
erl-1 ERLin (ER lipid raft associated protein) homolog - 
gale-1 UDP-glucose 4-epimerase - 
haf-1 HAlF transporter (PGP related) cysteine protease 
serine protease 
flr-4 Serine/threonine-protein kinase flr-4 - 
Y54G2A.23 MANF/CDNF-like protein - 
ubxn-4 UBX domain-containing protein 4 - 
Y54G2A.50 Uncharacterized protein DNA helicase 
uggt-1 UDP-Glucose Glycoprotein glucosylTransferase glycosyltransferase 
ragc-1 RAs-related GTP binding protein C homolog small GTPase 
smc-6 Structural maintenance of chromosomes protein 6 homolog smc-6 - 
Table 4.1 Summary of ER and stress related gene ontology terms corresponding to the proteins significantly overrepresented 
amongst ABU-13::tagRFP samples following mass spectrometry of co-immunoprecipitated interaction partners 
 
4.2.4 ABU-13 interacts with proteins involved with RNA processing 
 
In addition to the ER-related terms, there is also an overrepresentation of terms relating to RNA 
processing (Table 4.2) – and within these, of particular interest, are terms relating to ribonucleoprotein 
complex assembly. As we have previously established, ABU-13 forms punctate structures within 
nematodes reminiscent of phase separated organelles – as such, the presence of other RNP complex 
components is consistent with the hypothesis that ABU-13 forms phase separated structures. Amongst 
these potential interactors are a number of translation initiation factors and ribosome biogenesis factors 
– this suggests that that ABU-13 may play a role in sequestering translation machinery to alleviate 
























eif-2d Eukaryotic Initiation Factor receptor 
eif-3.E Eukaryotic translation initiation factor 3 subunit E translation initiation factor 
eif-3.C Eukaryotic translation initiation factor 3 subunit C translation initiation factor 
pptr-2 Serine/threonine protein phosphatase 2A regulatory subunit protein phosphatase 
C43E11.9 60S ribosome subunit biogenesis protein NIP7 homolog - 
ZC434.4 Ribosomal RNA-processing protein 7 homolog ribosomal protein 
lpd-6 LiPid Depleted - 
Y54E10A.10 Ribosome production factor 2 homolog nuclease 
snr-4 Probable small nuclear ribonucleoprotein Sm D2 mRNA processing factor 









elpc-1 Elongator complex protein 1 kinase activator 





mRNA splicing factor 
riok-1 Serine/threonine-protein kinase RIO1 - 





snu-23 Putative zinc finger matrin-type protein snu-23 - 
ssb-1 Sjogren Syndrome antigen B homolog ribonucleoprotein 
rbd-1 RBD (RNA binding domain) protein mRNA splicing factor 
Y54G2A.12 Uncharacterized protein mRNA splicing factor 
B0024.11 Putative pseudouridine synthase B0024.11 - 
ZC434.4 Ribosomal RNA-processing protein 7 homolog ribosomal protein 
dcr-1 Endoribonuclease dcr-1 endodeoxyribonuclease 
lsm-1 LSM Sm-like protein mRNA splicing factor 
    nuclease 
Y54E10A.10 Ribosome production factor 2 homolog nuclease 
ZK686.2 Putative ATP-dependent RNA helicase ZK686.2 - 
snr-4 Probable small nuclear ribonucleoprotein Sm D2 mRNA processing factor 
Y54G2A.75 Uncharacterized protein - 
B0511.7 Uncharacterized protein - 
B0511.6 RNA helicase - 
rps-7 40S ribosomal protein S7 ribosomal protein 
Table 4.2 Summary of RNA-related gene ontology terms corresponding to the proteins significantly overrepresented amongst 
ABU-13::tagRFP samples following mass spectrometry of co-immunoprecipitated interaction partners 
Beyond these RNP components, there are also a number of mRNA splicing factors that coIP alongside 
ABU-13. This includes splicing factors involved in nematode development such as RBD-1, which 
coincidentally is also found within the phase-separated structure, the nucleolus, once more hinting at the 
potential involvement of ABU-13 in phase transitions. This is further supported by the presence of LSM-
1 in that dataset – this protein, involved in RNA capping and degradation, has also been shown to localise 
in P-bodies and stress granules. Overall, these overrepresented RNA-related terms are in keeping with 
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our hypothesis that ABU-13 is involved with multivalent interactions with other RNA interacting 
proteins, potentially through the coalescence of phase-separating components. It is important, however, 
to recognize the possibility that some of these co-immunoprecipitated proteins represents non-
physiological interactions occurring post-lysis. Further validation and characterisation of these 
candidate interactors would clarify this further. 
 
4.2.5 Identification of hydrogel forming proteins in C. elegans  
 
As our in vivo work suggested involvement of ABU-13 in both liquid-like and hydrogel-like structures, 
we decided to take an unbiased approach to identifying hydrogel-forming proteins in wild type animals. 
This involved selective precipitation of these proteins using biotinylated isoxazole (b-isox), before 
subjecting the precipitate to mass spectrometry. Although this approach has been undertaken in a 
number of species-derived cells and tissue homogenates, including Drosophila S2 cells, mouse NIH 
3T3 embryonic stem cells, as well as mouse brain and testis homogenate4, this approach has never been 
performed in C. elegans. As we hypothesised that ABU-13 was capable of forming a hydrogel-like 
structure, extracting this information from N2 animals would allow us to determine this in the absence 
of any genetic modification or protein tagging, ensuring that all protein components were in their native 
conformation. 
 
Unlike the original b-isox precipitation study4, we did not identify the same 106 ‘core’ proteins – 
however, this may reflect species-specific differences between proteins involved in the formation of 
hydrogels. On the other hand, however, the proteins precipitated from the nematode lysate showed a 
strong overrepresentation of RNA binding terms when compared to the DMSO control treated animals 
(Figure 4.4A), a finding that is in keeping with these previous experimental datasets. RNA binding 
proteins are highly enriched amongst proteins that facilitate phase separation, thus their enrichment 
within proteins involved in solid-like phase separation makes sense. This population likely represents a 
subset of scaffold proteins that possess a propensity for pathological transition – indeed, within our 
dataset, TDP-1 is identified, the C. elegans homolog of the ALS-associated protein TDP-43. However, 
among these hydrogel-forming proteins precipitated by b-isox, ABU-13 was not identified, suggesting 
that ABU-13 may not act as a hydrogel-forming protein.  
 
Despite the absence of ABU-13, this dataset of b-isox precipitated hydrogel-forming proteins from C. 
elegans is novel and as such we explored these results further. Initially we compared the ‘prion-like’ 
abilities of these proteins, plotting Prion Propensity (PAPAprop) against the output values from the 
Viterbi-parsed HMM (Figure 4.4B). The majority of the results cluster in low scoring regions, indicating 
that they do not represent prion-like proteins as predicted by these algorithms. There are, however, a 
few that score higher, indicating that these may indeed represent protein with prionogenic abilities – 
these include MDT-15, MUT-16, GLD-2, PBRM-1, AMA-1, DUR-1, HUM-1, MSI-1, SMG-6 and 
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PUF-6. These proteins may therefore be hydrogel-forming scaffold proteins that utilise prion-like 
domains to drive their phase transitions, although further work is needed to verify this. 
 
Figure 4.4 Summary of results from biotinylated isoxazole precipitation of N2 animals showing (A) Gene Ontology terms for 
proteins identified as being overrepresented within the mass spectrometry results of b-isox precipitated samples compared to 
DMSO control samples, as determined using PANTHER Overrepresentation Test, with proteins ranked by significance (Fisher 
test, with FDR adjustments to correct for multiple comparisons); (B) Prion-like domain scores for b-isox samples, black = non-
RNA associated proteins, red = RNA-related protein (Unpaired t-test, p = 0.5234, no significant difference); (C) Venn diagram 
comparing the proteins identified following co-immunoprecipitation of ABU-13::tagRFP (purple), with CORE scores within 
the PLAAC algorithm output (yellow), and with those proteins precipitated following b-isox treatment (green) 
 
As prionogenic proteins tend to contain both a prion-like domain and RNA interacting motifs, we next 
sought to determine whether the RNA binding proteins overrepresented within this dataset were more 
likely to be predicted prion-like proteins. Whilst a limited number of these did crop up in the highest 
scoring candidates within this dataset (MDT-15, AMA-1, SMG-6 and PUF-6), the majority clustered 
alongside the other low scoring candidates and demonstrated no significant difference in the prion-like 
prediction scores from the non-RBPs amongst this set of proteins (p = 0.5234). This suggests that 
hydrogel forming proteins within C. elegans do not rely on the presence of a prion-like domain to 
facilitate their liquid-to-solid transitions. 
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We then went on to compare the proteins identified from a number of these approaches to see if there 
was any overlap that might prove physiologically promising (Figure 4.4C). Specifically we compared; 
(1) co-immunoprecipitation of ABU-13::tagRFP; (2) b-isox precipitation; and (3) PLAAC algorithm 
results. Whilst there were no proteins shared between all three of these datasets, there are a number that 
were shared between individual categories. For example, there are a number of RNA-related proteins 
shared between the b-isox dataset and the PLAAC scores, including AMA-1 and GLD-2, involved with 
RNA polymerisation and polyadenylation respectively. In addition to this, there are also a number of 
proteins involved that are flagged as common between the ABU-13 pull-down and the b-isox precipitate, 
suggesting that these might represent hydrogel-forming proteins associated with ABU-13 puncta – these 
include AAGR-4, CHT-3, INOS-1 and NPP-4 amongst others. NPP-4, for example, is particularly 
interesting as this is the ortholog of a human nucleoporin that, as previously discussed, is involved in 
the formation of physiological hydrogels. Finally, we also compared the ABU-13 co-
immunoprecipitation results to the PLAAC scores, identifying a small number of proteins, some of 
which exhibited promising functionality – PUF-9, for example, has been predicted to possess mRNA 
3’UTR binding activity8, reminiscent of TIS11B in TIGER domains. LET-711, on the other hand, has 
been implicated in larval development and the regulation of gene expression through its involvement in 
P-body activity, via recruitment of LSM-1 and LSM-39 – this is particularly interesting considering the 
presence of LSM-1 within these pulled down proteins as well, implicating a role for ABU-13 with P-
body components. Overall, there do appear to be candidate proteins shared between these groups that 
represent interesting avenues for future investigation, with some of these candidates pointing towards 






















4.3.1 Protein-RNA Interactions 
 
The ability of ABU-13 to bind RNA validates the prediction of nucleic acid interaction domains in the 
N terminus of the protein, although the exact sites of interaction are yet to be determined. This is in 
keeping with our hypothesis that ABU-13 is a prion-like protein involved in phase transitions, as the 
combination of PrLDs and RNA binding domains are highly represented amongst proteins involved 
with this process. It is, however, particularly interesting to note the lack of RNA binding ability of ABU-
13ΔPrLD. There are a number of possible explanations for this result. Most likely, removal of this 
domain disrupts proper folding of the rest of the protein, ultimately preventing RNA binding due to a 
general structural perturbation. Alternatively this could indicate that the prion-like domain is necessary 
for RNA binding either directly, via interactions with residues within this intrinsically disordered region, 
or indirectly as a consequence of the reliance of the overexpressing animals on the prion-domain for 
incorporation into phase separated compartments. For example, it is possible that ABU-13 does not bind 
RNA in its diffuse state, as is observed in ABU-13ΔPrLD::tagRFP animals, and instead requires 
recruitment to phase separated structures before this can occur. If this were the case, this would suggest 
that target RNAs are ‘shepherded’ to ABU-13, rather than this protein acting as a recruiter of RNA itself. 
This would indicate that ABU-13 is acting to stabilise these structures via a multivalent array of 
interactions, or that it is potentially playing a functional role with its RNA interactions. Optimisation of 
endogenous ABU-13 pull-downs would aid this understanding – this is particularly the case considering 
the different behaviours of the ABU-13ΔPrLD species observed between our two models. If failure to 
localise ABU-13 within these phase separated compartments is indeed why the ABU-13ΔPrLD::tagRFP 
animals do not exhibit any RNA binding activity following CLIP, then, for this theory to be true, we 
would hypothesise that the endogenous ABU-13ΔPrLD::WormScarlet animals would demonstrate 
RNA-binding ability due to their localisation within these structures. 
 
Differential binding of RNA species under specific physiological conditions could be a mechanism 
through which ABU-13 exerts its functional effects. The optimisation of the pull down technique using 
endogenously tagged ABU-13 would also enable us to identify which RNAs are bound under a range 
of conditions – i.e. in basal conditions, under ER stress and after exposure to an immune threat. If these 
were indeed variable, the identity of these RNA species would help to elucidate the role of ABU-13 and 
the puncta in which it is found. 
 
4.3.2 Protein-Protein Interactions 
 
The use of overexpression models in co-immunoprecipitation studies presents some challenges in 
extracting biologically relevant information. This is especially the case in light of recent evidence 
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demonstrating that phase separated organelles adopt different morphologies when their scaffold 
components are overexpressed compared to expression at endogenous levels3. However, as we have 
shown with our in vivo endogenous tagging, ABU-13 does appear to be upregulated in situations of 
stress – thus an overexpression system may be recapitulating some of the interactions involved in such 
responses. This is supported by the identification of a number of components relevant to the pathways 
that ABU-13 has been implicated in. Some of the most interesting hits resulting from these mass 
spectrometry results are those implicated in the IRE-1 branch of the UPRER, due to the role of the ABU 
family of proteins in responding to a blockage in the IRE-1/XBP-1 branch - these candidates potentially 
represent physiologically-relevant interactors.  
 
One of these candidates of interest is the UDP-glucose glycoprotein glucosyltransferase, UGGT-1; this 
protein has been identified as an ER stress responsive protein, upregulated following tunicamycin 
treatment in an IRE-1-dependent fashion, and is thought to play a role in monitoring the folding quality 
of glycoproteins10. Although GFP-fused UGGT-1 reporter lines only show expression within the 
nervous system, it has been noted that, due to the lack of introns and 3’UTR sequence within the 
construct used to produce these transgenic animals, this may not be truly representative of its true 
expression pattern; this is particularly the case as no changes in the amount or expression pattern of this 
GFP reporter was observed in these animals upon the induction of ER stress – a result that is in 
contradiction to qPCR data that shows a significant increase in uggt-1 expression in these conditions. 
Thus, it is possible that uggt-1 is indeed expressed beyond the nervous system, particularly following 
ER stress, although this has yet to be determined. As such, this does not exclude the possibility that 
UGGT-1 is indeed a physiological interactor of ABU-13 in extra-neuronal tissues. 
 
The presence of an XBP-1 binding site in the promoter of uggt-1 suggests its expression is negatively 
correlated with abu-13 expression – i.e. inhibited XBP-1 activity would reduce uggt-1 expression but 
increase abu-13 expression. This negative correlation between the expression patterns of these two 
genes, paired with their potential protein-protein interaction, could point towards a mechanism of 
regulation, with UGGT-1 binding to and negatively regulating the activity of ABU-13. If ABU-13 is 
involved with a positive feedback loop to increase its own expression, it is possible that UGGT-1 
prevents this, acting as a downstream readout of XBP-1 activity and thus inhibiting the further 
expression of ABU-13. Conversely, when XBP-1 is inhibited, uggt-1 would not be expressed, thus 
disinhibiting this feedback loop and leading to an increase in abu-13 expression. Crucially, this 
hypothesis neglects the requirement for an ER stress signal – thus, there must be other stress-responsive 
modulators that are involved independently of the XBP-1 pathway, perhaps via the secondary non-xbp-
1 pathway driven by IRE-1, potentially acting as enhancers of gene expression. This hypothesis could 
be tested by constitutive expression of uggt-1 in an xbp-1 mutant background and monitoring abu-13 
transcript levels following tunicamycin treatment; if this regulation were indeed occurring, there would 




Following evidence that ABU-13 is indeed an RNA binding protein, its role in RNA processing and in 
ribonucleoprotein complexes make an attractive hypothesis. In support of this, we have also observed a 
significant overrepresentation of RNA-related terms within these mass spectrometry results. The 
presence of other RNP components, in particular, may help point towards a molecular understanding of 
what ABU-13 is doing, if it is indeed involved in the formation of such complexes. Within these 
components includes a number of translation initiation factors, including EIF-2D, EIF-3.E and EIF-3.C, 
and ribosome biogenesis factors, such as K12H4.3 and Y54E10A.10 – sequestering of such components 
can reduce translational rates during periods of proteostatic stress, alleviating protein folding burden 
and helping restore protein homeostasis to the organism. LSM-1 and LET-711 also represent promising 
RNP-related proteins pulled down alongside ABU-13 – these proteins are involved in Processing-body 
activity in the development embryo, with LET-711 recruiting the decapping proteins LSM-1 and LSM-
3 to these condensates within somatic blastomeres, resulting in the degradation of maternally derived 
mRNA. As we have previously shown, P-bodies are constitutively active, stress-responsive organelles 
within C. elegans – however, we see no association between ABU-13 puncta and P-bodies in vivo. It is, 
however, possible that components of these organelles are shared, even if the organelles themselves do 
not overlap, potentially representing some common functionality.  
 
In addition to this, candidates within this dataset also hint at a mechanistic regulation of any potential 
phase separation that might occur in our system. PPTR-2, for example, is a protein phosphatase 
previously identified as having a redundant role in the regulation of P granule formation, 
dephosphorylating MEG proteins and facilitating their involvement in P granule biogenesis. An initial 
screen of its redundant partner, PPTR-1 identified interactions with MEG-1, MEG-3 and MEG-4 – a 
finding that was demonstrated in PPTR-2 as well, with these MEG proteins being pulled down alongside 
PPTR-211. As PPTR-1 is not immunoprecipitated alongside ABU-13, it is possible that PPTR-2 is 
playing a non-redundant role in this system, regulating ABU-13 to modulate dynamics of its puncta. 
Identification of a physiologically relevant phosphorylation site would elucidate the role that this 
posttranslational modification might have on ABU-13. Thus far, we have been unable to successfully 
detect ABU-13 after endogenous tagging with a 3xFLAG motif or WormScarlet tag, for reasons that 
remain elusive. Optimisation of this protocol would allow us to initially determine whether ABU-13 is 
indeed phosphorylated, and if so, under what conditions. From here, it would then be possible to 
determine whether pptr-2 knockouts prevented this dephosphorylation and, alongside imaging data, 
demonstrate whether this resulted in changes in puncta dynamics. If this were indeed the case, 
identification of the relevant phosphorylation site could then provide direct evidence of this regulation 
using phospho-mimetic and phospho-deficient mutants of ABU-13. 
 
Identification of protein-protein interactions within an endogenous expression system would be useful 
to delineate which, if any, of these hits represent proteins of physiological interest. As briefly mentioned, 
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the overexpression of ABU-13 may result in protein interactions that are normally observed upon stress, 
when abu-13 is physiologically upregulated. As with the RNA interaction work, optimisation of the 
endogenous pull down will help determine the protein interactome of ABU-13 under different 
conditions, helping us to further characterise its mechanism of action.  
 
4.3.3 The hydrogel-forming proteome of C. elegans 
 
The low mobility nature of some ABU-13 puncta indicated to us that this protein might be involved in 
the formation of hydrogel-like structures – particularly considering the presence of a prion-like domain 
within the centre of this protein, often indicative of proteins involved in the biogenesis of such puncta. 
However, the absence of this protein amongst the biotinylated isoxazole precipitated proteins calls this 
hypothesis into question. There are a number of possible explanations for these contradictory results; 
firstly, we cannot rule out the possibility that our precipitation protocol was not entirely successful. This 
is especially relevant considering the absence of the majority of shared ‘core’ proteins precipitated 
following b-isox treatment in previous datasets – these proteins represent many recognisable phase-
separation related proteins including hnRNPA1 and TIA-1. While this absence may reflect evolved 
differences in the propensity of species-specific proteins for solid transitions, repetition of this 
precipitation would help to clarify these dataset differences, although we have been restricted in this 
pursuit by the very limited supply of biotinylated isoxazole.  
 
There are, of course, a multitude of potential physiological explanations for the lack of ABU-13 within 
this dataset as well. The tagging of ABU-13, for example, may drive the protein towards more solid-
like transitions; we did attempt to mitigate this effect using a tagRFP fluorescent protein, which has 
been specifically developed to be monomeric as to prevent fluorophore aggregation. However, we were 
unable to use this tag for our endogenous tagging system and thus the solid-like formations observed in 
the ABU-13::WormScarlet animals may result from the tag rather than the protein itself. Meanwhile, in 
the ABU-13::tagRFP animals, we may be observing an overexpression effect resulting in punctae 
appearing to be more solid than they would be under physiological conditions. As has been previously 
discussed, prion-like proteins involved in phase transitions are acutely sensitive to protein concentration 
and thus any abnormal expression of these components could drive these structures into non-
physiological states. 
 
Another explanation for these contradictory results could be that ABU-13 is not the only protein 
component within these compartments capable of driving phase separation, with other proteins driving 
the liquid to solid transition.  Hence, rather than relying on a single protein component to drive synthesis 
of these structures, a number of scaffold proteins instead work in concert to modulate the dynamic nature 
of these puncta – so, whilst ABU-13 may be involved in more liquid-like phase separation, others may 




Besides the absence of ABU-13, the low scoring nature of the majority of pulled down proteins when 
subjected to prion-prediction algorithms is particularly interesting. It might be expected, due to their 
roles in facilitating phase transitions, that these proteins would represent candidate prionogenic species. 
However, according to these algorithms, this is not the case. Whilst this may be a consequence of an 
underrepresentation of hydrogel-forming proteins – for example, as already mentioned, many of the 
‘core’ proteins precipitated by b-isox in mammalian cells are not seen in this dataset – it may also be 
indicative of a different mechanism through which hydrogel-forming proteins phase separate. Unlike 
proteins involved in liquid-liquid phase transitions, these proteins may rely on different domain 
structures to drive solid transitions. Further computational analysis of liquid-like versus solid-like 
scaffold proteins would be useful in elucidating these differences. For example, as has already been 
shown in previous work, the number of hydrophobic residues within prion domains is tightly controlled 
to increase the propensity for coalescence and phase separation without prompting aberrant 
fibrillisation. Thus, if these hydrogel-forming proteins do contain a ‘prion-like domain’, it is possible 
that they possess different residue compositions to drive the biogenesis of more solid-like structures.  
 
Alternatively, it is possible that hydrogel proteins are not necessarily themselves the nucleating, scaffold 
proteins that drive initial assembly of these phase-separated condensates. Instead, these organelles may 
require sequential progression through different phase transitioned states, from diffuse to liquid to 
hydrogel. As such, there is not necessarily a need for a prion-like domain within these proteins. They 
do, however, clearly play roles more fundamental to these assemblies than other client proteins, capable 
of fine-tuning and modulating the dynamic natures of these structures. As such, they may represent an 
intermediate between scaffold and client proteins, a species of protein that we have termed transitional 
proteins. Whilst these proteins do not necessarily represent fundamental core components that drive 
initial phase separation events, they do push the organelle towards more solid-like states. Crucially, 
these proteins enact this transition as a consequence of their secondary structure, rather than through 
biologically active processes that regulate other protein components within these condensates. Whilst 
this might not be the case for all hydrogel-forming proteins, we propose this sequential phase transition 
model as a potential mechanism through which b-isox precipitated proteins in C. elegans facilitate their 
intrinsic hydrogel forming abilities, as opposed to a direct action of these proteins to drive hydrogel 
formation from diffuse states. Further work to determine the modulatory activity of these proteins is 
necessary to understand the exact influence they have on existing or de novo phase-separated structures. 
Such a model would fit with the absence of ABU-13 from this precipitation data – rather than driving 
hydrogel formation itself, ABU-13 may instead be involved in the biogenesis of these biological 
condensates as a scaffold protein for liquid-like phase transitions. Once in these liquid-like states, a 
further ‘transitional’ component may be responsible for the switch into a hydrogel state later on.  
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To determine what the identity of this transitional component might be, we compared the proteins 
precipitated by biotinylated isoxazole treatment to those pulled down with ABU-13::tagRFP. Of the 14 
crossover candidates, there are a number that warrant further investigation. NPP-4 is one of these 
candidates of interest; this protein is the ortholog of the human Nucleoporin 6212. As we have previously 
described, nucleoporins are involved in the formation of physiological hydrogel structures, with NPP-4 
and its homologs interacting with other nucleoporins to drive the formation of nuclear pore complexes. 
This is supported by evidence that, in Xenopus, Nup62 contains an FG-rich domain that, when purified, 
is capable of rapidly forming hydrogel structures in vitro13. These structures show a low permeability, 
with movement of molecules through this hydrogel showing a highly selectivity. In addition to an FG-
rich repeat region, this protein has also been shown to contain a serine-threonine-rich linker region that 
acts as a site of glycosylation, with the addition of N-acetylglucosamine residues modulating the activity 
of this protein14–16. This modification weakens inter-FG-repeat connections, reducing the selectivity of 
this barrier and facilitating the entry of larger nuclear transport receptors13. The regulation of 
Nucleoporin 62 via glycosylation is particularly interesting in the context of ABU-13, which has been 
shown to co-immunoprecipitate alongside the glycosylation-related protein UGGT-1 and a glucosidase 
II alpha subunit ortholog, AAGR-4, both of which are involved with the folding of nascent 
glycoproteins. This points towards a general role for ABU-13 in the regulation of glycosylation. In the 
context of NPP-4, it is possible that ABU-13 may be acting in concert with glycosylation components 
and subsequently with NPP-4 to regulate the movement of specific molecules through the nuclear pore 
complex, helping to alleviate the protein-folding burden upon stress via this regulation. 
 
Adding weight to the involvement of ABU-13 in glycosylation is the presence of CHT-3 within this 
limited set of crossover proteins. CHT-3 is the ortholog of the human proteins CHI3L1, a secreted 
glycoprotein containing a chitinase-like domain, and the glycoprotein OVGP1, involved in reproductive 
health. This is particularly interesting contextually as CHI3L1 expression is increased during 
inflammation, suggesting a role for this protein in immune responses. In keeping with this, the presence 
of a chitinase-like domain17 points towards an interaction with chitin-containing structures, of which the 
fungal cell wall is a prime candidate. It is important to note, however, that no active chitinolytic 
behaviour has been identified from this protein – whether this is also the case for CHT-3 remains unclear. 
The co-immunoprecipitation of CHT-3 alongside ABU-13 could suggest a mechanism through which 
ABU-13 is involved in the innate immune response, perhaps via the regulated glycosylation of immune 
proteins upon stress.  
 
An alternative mechanism through which ABU-13 may be exerting its stress-responsive effects through 
CHT-3 is via its ability to modulate the PI3K-AKT pathway. Although not studied in nematodes, 
increased expression of CHI3L1 has been shown to increase the kinase activity of PI3K following 
gamma-irradiation in U87 cells, resulting in the increased phosphorylation of AKT and subsequent 
increased inhibition of FOXO-mediated transcription18. In C. elegans, the FOXO homolog DAF-16 has 
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been shown to restore ER proteostasis in an IRE-1/XBP-1-independent manner, with reduced 
insulin/IGF-1 signalling rescuing the effects of xbp-1 and ire-1 mutations following tunicamycin 
treatment. This is facilitated by the improved degradation of misfolded lumenal protein following their 
EDEM-1-mediated release from the ER folding cycle and subsequent export into the cytosol for 
degradation via autophagy19. This could provide a mechanistic pathway through which ABU-13 and the 
non-canonical UPR pathway acts upon inhibition of the canonical UPR – using the DAF-2/DAF-16 IIS 
pathway to drive alternative degradation systems. However, such a strong restoration of proteostasis is 
not observed in xbp-1 mutants, despite components of the non-canonical pathway being upregulated in 
these circumstances. It may be that the influence of ABU-13 on this DAF-16 pathway is minimal in 
comparison to the experimental paradigm utilising daf-2 mutants to mimic reduced IIS – an intervention 
that represents a much larger perturbation and elicits a much greater downstream effect than an 
endogenous pathway might induce physiologically. Either way, this branch warrants more exploration 
to determine if this is indeed mechanism of action for ABU-13 – crossing these animals into cht-3 
mutants, for example, could be useful for determining whether such mutants display similar phenotypes 
to the abu-13 knockout animals.  
 
There are, however, a number of proteins identified from this precipitation that do have predicted prion-
like properties. Whilst these are not likely to be involved with ABU-13-related processes, they do 
represent an interesting group of proteins whose intrinsic hydrogel-forming ability intrinsic may arise 
as a consequence of a prion-like domain. Within this list of candidate proteins, certain functions are 
overrepresented – particularly those relating to the regulation of RNA, whether through RNA 
polymerase activity, such as with AMA-1, or with the regulation of mRNA post-transcriptionally – MSI-
1, for example, regulates mRNA within the cytoplasm. Of these RNA regulating proteins, GLD-2 is of 
particularly note due to its association with the developmental phase-separated organelle, P granules. 
This protein contains a cytoplasmic poly(A) polymerase (PAP) motif, enabling it to polyadenylate 
mRNA within the cytoplasm, increasing its expression. Unlike conventional PAP motifs, GLD-2 does 
not contain an RNA recognition motif but rather interacts with the RNA binding protein GLD-3, which 
shepherds appropriate RNA to it20. This mechanism is akin to that which we proposed for ABU-13, 
whereby removal of the prion-like domain abolished RNA binding ability, suggesting that it was only 
able to bind RNA when within localised within puncta – it is possible that GLD-2 is acting in a similar 
way, with RNA being shuttled to it by another component.  
 
Although not pulled down with ABU-13, the hydrogel-forming protein candidate RLE-1 stands out 
amongst this list due to its role in protein homeostasis and the effect that this protein has on organismal 
longevity. RNAi against this E3 ubiquitin ligase in metastable mutants that exhibit paralysis phenotypes 
due to a loss of proteostasis and subsequent protein aggregation results in a reduction in this paralysis, 
suggesting a role for RLE-1 in protein homeostasis21. Beyond this, RLE-1 functions as a modulator of 
lifespan, catalysing the ubiquitination of DAF-16 and triggering its degradation. Consequently, 
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downstream transcriptional pathways cannot be expressed, ultimately reducing lifespan. The 
identification of RLE-1 as a potential hydrogel-forming protein is particularly interesting in the context 
of its involvement in the ubiquitination-proteosomal system, with recent evidence suggesting a role for 
phase separation in these processes22. Whilst the UPS components within this study were shown to form 
liquid-like condensates, it is possible that RLE-1 represents a component of this system involved in less 
transient, more solid-like assemblies that are constitutively present within C. elegans. Further work to 
understand the influence of RLE-1 on hydrogel formation in vivo would be required to determine this, 
and whether or not this propensity plays a role in its function as an E3 ubiquitin ligase. 
 
Overall, this enrichment of nucleotide binding proteins within CORE-scoring biotinylated isoxazole 
precipitated proteins is further validation of the role that many phase separating organelles and their 



























4.4 Material and Methods 
 
Crosslinking and Immunoprecipitation (CLIP) 
 
Nematodes were grown to day 1 of adulthood before transfer onto unseeded NGM plates ready for UV 
irradiation using a UV Stratalinker 2400 (254nm), set to 300µJ(x100). Following irradiation, 
populations were harvested in M9 and pelleted down, aspirating off the supernatant and resuspending 
animals in RIPA buffer before transferring to Precellys tubes and flash freezing samples in liquid 
nitrogen. After thawing, animals were lysed at 4°C using a Precellys 24 (Bertin Instruments) 
programmed for 3 spins of 15 seconds, with a 30 second interval between each spin. To clear any debris, 
samples were then spun down at 8000g for 15 minutes at 4°C and transferred to fresh precooled 1.5mL 
Eppendorf tubes.  
 
RNase I (Ambion, AM2295) was prepared in a 1/500 dilution, after which 10µL of diluted RNase I was 
added to the lysate alongside 2µL Turbo DNase. Samples were incubated for 3 minutes at 37°C, shaking 
at 1100rpm before being transferred immediately to ice. A further spin was then performed at 22,000g 
for 20 minutes at 4°C to clear the lysate once more, and subsequently the supernatant collected. 
 
In preparation for the immunoprecipitation step, RFP-Trap Agarose beads (Chromotek, rta-20) were 
vortexed and 2µL of beads mixed with 500µL of cooled dilution buffer (10mM Tris-HCl, pH 7.5; 
150mM NaCl; 0.5mM EDTA; 1x cOmplete protease inhibitor cocktail (Roche); 1mM PMSF). This 
bead mix was then centrifuged at 2500g for 2 minutes at 4°C and the supernatant discarded before 
resuspending in 500µL of dilution buffer once more and repeating this step a further two times. Once 
the supernatant had been removed a final time, the prepared lysate was added and the sample incubated 
with the beads for 1 hour at 4°C. Beads were then collected by centrifugation at 2500g for 2 minutes at 
4°C and the supernatant discarded. 500µL of dilution buffer added and spun down using the same 
conditions a further two times to wash the beads. 
 
Once the supernatant had been discarded, beads were resuspended in 20µL of PNK mix (15µL water; 
4µL 5x PNK buffer, pH 6.5 [350mM Tris-HCl; 50mM MgCl2; 25mM dithiothreitol]; 0.5µL PNK 
enzyme (NEB); 0.5µL RNasin (Promega)) and incubated for 20 minutes at 37°C. After this, 500µL of 
high-salt buffer (50mM Tris-HCl, pH 7.4; 1M NaCl; 1mM EDTA; 1% NP-40; 0.1% SDS; 0.5% sodium 
deoxycholate) was added before collecting the beads via centrifugation at 2500g for 2 minutes at 4°C 
and resuspending in high-salt buffer and spinning down once more. These wash steps were then repeated 
twice more with wash buffer (20mM Tris-HCl, pH 7.4; 10mM MgCl2; 0.2% Tween-20) before removing 
the supernatant and adding 8µL of hot PNK mix (0.4µL PNK; 0.8µL ATPγS; 0.8µL 10x PNK buffer 
(NEB); 6µL water) and incubating overnight at 37°C. 
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Immediately prior to use, prepare a 10mM stock solution of 5-iodacetamidofluorescein (Thermo 
Scientific) in DMSO. Spin down beads and remove the hot PNK mix before resuspending beads in 50µL 
of fluorescein mix (7.5µL of 10mM 5-IAF; 42.5µL of 2mM HEPES, pH 7.4). Mix gently at room 
temperature for 2 – 3 hours in the dark before centrifuging the beads and discarding the supernatant. 
Beads were then resuspending in 20µL of 1x NuPage LDS Sample Buffer (Invitrogen) and incubated 
for 10 minutes at 70°C. Beads were then spun down a final time and the supernatant loaded onto a 
NuPage 4-12% Bis-Tris precast gel (Invitrogen) and run at 200V in 1X MOPS running buffer alongside 
a Precision Plus Protein Dual Color Standard (Biorad) protein ladder. Once the gel had run, it was 
removed from its casing and rinsed in PBS before being imaged using a Chemidoc Touch Imaging 




Day 1 adult animals were lysed in RIPA using a Preceylls 24, as previously described. Lysates were 
spun down at 8000g for 15 minutes at 4°C and cleared supernatant transferred into pre-cooled 1.5mL 
Eppendorf tubes. As with CLIP, 25 µL of RFP-Trap Agarose beads were prepared after vortexing in 
500 µL of ice-cold dilution buffer. Following three wash steps, the details of which are detailed above, 
lysate was added to the beads and incubated overnight at 4°C, after which, three further washes were 
performed. After the final wash, beads were spun down at 2500g a final time and the supernatant 
discarded before resuspending the washed beads in 100 µL of 2x LDS Sample Buffer and incubating 
the mix for 10 minutes at 95C. Following this boiling step, beads were collected by centrifugation at 
2500x g for 2 minutes and the supernatant loaded onto a NuPage 4-12% Bis-Tris precast gel (Invitrogen) 
and run as above.  
 
Once run, the gel was removed from the plastic casing and fixed in 40%EtOH/10% acetic acid for 15 
minutes before rinsing in water and staining overnight in QC Colloidal Coomassie Stain (Biorad). The 
gel was then rinsed in water once more and imaged using a Chemidoc Touch Imaging System (Biorad), 
with the settings set to detect Coomassie. The full gel lane was then fragmented and excised from the 
gel, and prepped for mass spectrometry.  
 
Biotinylated isoxazole precipitation 
 
Day 1 adult animals were homogenised in lysis buffer (20mM Tris buffer; 150mM NaCl; 5mM MgCl2; 
20mM β-mercaptoethanol; 0.5% NP-40; 10% glycerol; 1x cOmplete protease inhibitor cocktail (Roche); 
1:100 RNasin ribonuclease inhibitor (Promega); 2mM vanadyl ribonucleoside complex (NEB); 0.1mM 
PMSF), using the Preceylls 24 system as described previously. Cleared lysates were then divided in two 
– one to be used as the experimental sample, the other as the control. Biotinylated isoxazole (Sigma-
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Aldrich) was prepared as a 10mM stock solution in DMSO and a 1/100 dilution added to one of the 
lysates, resulting in a final b-isox concentration of 10uM. An equivalent volume of DMSO was added 
to the control sample. Both were then tumbled at 4°C for 90 minutes before spinning down at 10,000x 
g for 10 minutes at 4°C. Supernatant from both samples was discarded and pellets washed twice in lysis 
buffer before suspending in 2x LDS Sample Buffer and loading on to a NuPage 4-12% Bis-Tris precast 





Samples underwent tandem mass spectrometry following proteolysis of excised gel fragments. The 
resulting peptide fragments were subjected to LC-MS/MS using a Velos Orbitrap mass spectrometer 
(Thermo Scientific). Protein identity was attributed to peptides using the MASCOT database (Matrix 
Science) and results collated using Scaffold4 (Proteome Software).  
 
Results from mass spectrometry were compared between experimental and control conditions (i.e. 
ABU-13::tagRFP versus tagRFP only; B-isox versus DMSO). Experimental samples that demonstrated 
a greater than 50% increase in Exclusive Unique Peptide Count compared to their DMSO counterparts 
were taken forward for further analysis. Using the PANTHER Overrepresentation Test 
(http://www.pantherdb.org/), gene ontology terms relating to the proteins identified could be determined 
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Within this thesis, I have established that the C. elegans protein ABU-13 is a prion-like domain-
containing component of a phase separated compartment that plays important roles in immune responses 
and ER stress resistance (Figure 5.1). 
 
After subjecting the nematode proteome to computational analysis to identify prionogenic candidates1–
4, we cross-validated multiple algorithms and found that ABU-13, a previously uncharacterised protein, 
scored consistently high across computations. The ABU family in general exhibit a higher prion 
propensity than the average non-prion-like protein within these animals, however, on the whole, ABU-
13 ranks the highest amongst both this family and the rest of the proteome, even outperforming other 
well-characterised prion-like proteins already identified in C. elegans.  
 
This family has previously been shown to be upregulated within innate immune responses and in the 
non-canonical unfolded protein response of the endoplasmic reticulum, however little has been known 
about the function of the ABU proteins individually5–7. Using a series of stress resistance assays, we 
compared abu-13(tm6224) animals to N2 animals, identifying developmental delays in abu-13(tm6224) 
mutants when treated with the ER stress-inducing agent tunicamycin, and when exposed to the 
pathogenic bacteria Pseudomonas aeruginosa. 
 
To gain mechanistic insight into how ABU-13 might be involved with such functions, we proceeded to 
produce transgenic strains expressing fluorescently-tagged forms of this protein. Initially this involved 
using extrachromosomal array lines, however, after a process of optimisation, we were successful in 
establishing a line of endogenously-tagged animals using a CRISPR/Cas9-mediated genome insertion 
as well. In vivo visualisation of this protein demonstrated a localisation to discrete punctate structures 
throughout the animals. Along with the presence of a prion-like domain and a potential RNA binding 
domain, as evidenced by conserved domain predictions that suggest nucleotide binding activity in the 
N-terminus, we hypothesise that these puncta represent phase-separated compartments. 
 
The puncta within the endogenously-tagged line are smaller and more numerous than those in the 
overexpression line. FRAP analyses from both of these strains demonstrate that the ABU-13 puncta 
show a greater variation in mobility within endogenously-tagged animals than within overexpression 
line animals, with the latter exhibiting consistently low FRAP recovery. Whilst a high mobility is 
indicative of more diffuse, liquid-like assemblies, lower mobility is associated with more solid, 
hydrogel-like formations. As such, we proposed that the ABU-13 puncta within the endogenously-




Akin to other biomolecular condensates, these structures may display multiphase coexistence, with 
hydrogel forming puncta clustering within larger, less viscous assemblies8–10. If this were the case, little 
fusion of these smaller hydrogel-like structures would occur in a basal state. Instead, these more 
immiscible solid states likely represent a coalescence of ‘core’ proteins vital for the functionality of the 
organelle. Meanwhile, the surrounding liquid-like environment potentially represents ‘adaptor’ 
components that are interchanged depending on the cellular context, thus allowing for the function of 
these constitutively active puncta to be dynamically modulated. As ABU-13 is not precipitated 
following treatment with biotinylated isoxazole, we propose that it does not represent the ‘scaffold’ of 
such hydrogel formations. The role of this protein in nucleating liquid-liquid phase transitions, however, 
is unclear, with in vitro phase separation assays demonstrating an inherent biophysical ability to phase 
separate, whilst in vivo data from endogenously-edited prion-domain mutants showing retention of 
ABU-13 within punctate compartments. Taking this into consideration we propose that ABU-13 plays 
a redundant role as a scaffold protein for liquid-liquid phase separation, whilst a secondary ‘transitional’ 
co-scaffold protein interacting with ABU-13 puncta is responsible for the liquid to hydrogel phase 
transition. 
 
To assess the involvement of these puncta in the functions we identified for ABU-13, we subjected 
endogenously-tagged animals to a range of environmental stresses. In response to ER stress, ABU-13 
puncta exhibit no significant change, with similar puncta number, size and distribution observed 
between DMSO-treated controls and tunicamycin-treated animals. We hypothesise that these puncta are 
dynamically exchanging components with the diffuse environment, bringing together stress-specific 
clients to facilitate a downstream sub-branch of the ER stress response. This exchange results in no 
observable net gain or loss of puncta, suggesting that many of the components required are already 
located within these structures under basal conditions. Although initially identified as representing a 
non-canonical unfolded protein response of the endoplasmic reticulum6,7, our evidence points towards 
ABU-13 playing a role in the ER stress response when the canonical pathway is operational. Moving 
forward, it would be interesting to investigate whether the response of ABU-13 in xbp-1 mutant animals 
represents an upregulation of the response seen in wild type conditions, or whether ABU-13 is involved 
in other mechanisms to compensate for the loss of XBP-1. 
 
The response of ABU-13 puncta to pathogenic bacteria, however, is different, with significant growth 
and fusion of puncta following exposure to P. aeruginosa. We propose that, in response to pharyngeal 
and gut invasion of PA14, cell non-autonomous stress signals coordinate a global immune response, 
priming the organism to deal with an ongoing pathogenic attack as it spreads. Within the pharynx, we 
observe an upregulation of diffuse ABU-13 upon exposure to this bacteria, potentially within the 
marginal cells – however, these cells do not have any well-characterised global signalling capacity. We 
do, however, see potential expression within the amphid sheath glia – whilst the role of expression of 
ABU-13 in this support cell is unclear, it is possible it is involved in a form of stress signalling in 
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coordination with the amphid neurons, which are involved in processing sensory information from the 
environment. 
 
Beyond the pharynx, it is also possible that other sites of bacterial invasion may be involved. The 
intestine, for example, has been shown to modulate metabolism systemically11, as well as recent 
evidence demonstrating a role for this tissue in the transmission of ER stress signals between cells12. 
Thus, we hypothesise that PA14 invasion of the intestine may stimulate a global stress state, leading to 
downstream activation of ABU-13 puncta. This activation might involve a change in transition state of 
these compartments, with immiscible structures adopting less viscous properties, allowing for their 
subsequent fusion. This likely results from recruitment of client molecules that buffer these assemblies, 
such as RNA or hydrotropic ATP13,14.  
 
Although a number of phase-separated compartments have been linked to stress responses previously, 
we do not see any colocalization of ABU-13 with stress granules nor P-bodies before or after exposure 
to an environmental stress, suggesting that these ABU-13 puncta may represent novel phase-separated 
organelles.  
 
In both of the relevant stress response conditions, recruitment of client molecules to ABU-13 
compartments is likely a mechanism through which these puncta can facilitate their downstream effects 
on stress responses. This is observed in many phase separated organelles, with recruitment of particular 
protein and nucleic acid components having functional consequences. These functional consequences 
often involve the regulation of RNA – for example, through the benign sequestration of specific RNA 
species or through the active processing of these transcripts. In keeping with this, we have determined 
that ABU-13 is indeed an RNA binding protein. As we have already postulated, the involvement of 
RNA in these assemblies is potentially vital for preventing aberrant transitions into pathological fibrils 
due to the aggregation-prone behaviour of prion-like proteins13,15. However, beyond this, it is likely that 
the RNA species recruited to these ABU-13 puncta are involved in the downstream stress response in 
some capacity. 
 
As such, further work is necessary to determine the protein-protein and protein-RNA interactions with 
ABU-13 in different cellular stress conditions. This will shed light on the molecular mechanisms at hand 
and help elucidate the pathways that might govern the function of these puncta. Preliminary 
coimmunoprecipitation studies of ABU-13 from the overexpression model identified a number of 
proteins involved in RNA regulation, supporting this hypothesis. Beyond this, a number of components 
pulled down are involved in the quality control of glycosylated proteins, suggesting that ABU-13 may 
play a role in monitoring the folding of glycoproteins. This has important implications for ABU-13-
mediated stress responses – for example, glycoproteins are a vital component of the cuticle, maintenance 
of which is important for protecting the animal against pathogenic invasion. Performing these studies in 
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endogenously tagged animals in these stress contexts will further clarify how some of these components 
relate to the downstream stress response. This is similar for RNA interactions; whilst protein interactions 
may help to identify the function of these puncta – i.e. in mRNA decapping, for example – understanding 
the RNA species that are processed will allow us to gain molecular details of the stress pathway 
involved.   
 
Prion-like proteins are proving to play functional roles in the biology of phase separation with their 
multivalent, intrinsically disordered nature providing the ideal biophysical conditions for these 
biomolecular assemblies to form16,17. Whilst many of these organelles represent transient structures 
responding dynamically to specific stimuli, others are more persistent. These persistent structures have 
been implicated in epigenetic regulation, with the heritability of some prion species suggesting that these 
compartments may be able to pass on information transcellularly and transgenerationally18–20. Whilst 
this is most clearly evident in yeast species due to their asexual reproduction by budding, similar effects 
have also been observed in eukaryote organisms too, with phase separated organelles being implicated 
in transgenerational epigenetic inheritance21. 
 
It would be interesting moving forward to determine whether the persistence of ABU-13 puncta enables 
the transmittance of stress-related information either via a ‘molecular memory’ mechanism within an 




Figure 5.5 A schematic summarising the role of ABU-13, showing the responses of ABU-13 puncta (red) in response to ER 
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6.0 Experimental Contributions 
 
In Chapter 2, the lifespan analysis performed on abu-13(tm6224) animals was performed and statistical 
analysed by Dr. Rebecca Taylor 
 
In Chapter 3, the bacterial purification of ABU-13 from BL21 E. coli and from Drosophila S2 cells was 
performed in conjunction with Joseph Watson. 
 
In Chapter 3, imaging chambers for in vitro phase separation assays were prepared by and imaging 
performed in conjunction with Joseph Watson. 
 














































 6.1 Supplemental Tables 
 
Summary of strains 






Strain Genotype Comment 
N2 Wild type, Bristol strain Obtained from CGC 
RCT214 abu-13(tm6224)III Obtained from Japanese 
Knockout Consortium; 
outcrossed to N2 6x 
SJ4005 zcls4(hsp-4::GFP)V Obtained from CGC 
RCT215 zcls4(hsp-4::GFP)V; abu-13(tm6224)III SJ4005 crossed into 
RCT214 
AGD972 xbp-1(zc12)III; zcls4(hsp-4::GFP)V SJ17 further outcrossed to 
N2 4x 




RCT200 abu-13(rms12[abu-13::WormScarlet])III  
RCT201 abu-13(rms-13[*rms12])III Prion-like domain deletion 
RCT93 rmsEx11[abu-13p::tagRFP::unc-54 3’UTR]  
RCT37 edIs6[unc-119p::gfp + rol-6(su1006)]IV DP132 (CGC) outcrossed 
to N2 6x 
RCT216 edIs6[unc-119p::gfp + rol-6(su1006)]IV; 
rmsEx12[abu-13p::abu-13::tagRFP::unc-54 
3’UTR] 
RCT37 crossed into 
RCT96 
RCT217 edIs6[unc-119p::gfp + rol-6(su1006)]IV; abu-
13(rms12[abu-13::WormScarlet])III 
RCT37 crossed into 
RCT200 
RCT51 zcIs18[ges-1p::gfp] SJ4144 (CGC) outcrossed 
to N2 6x 
RCT218 zcIs18[ges-1p::gfp]; abu-13(rms12[abu-
13::WormScarlet])III 
RCT51 crossed into 
RCT200 
RCT142 rmsEx13[pitx-1::gfp::unc-54 3’UTR] Glial marker strain 
RCT219 rmsEx13[pitx-1::gfp::unc-54 3’UTR]; abu-
13(rms12[abu-13::WormScarlet])III 
RCT142 crossed into 
RCT200 
HZ470 wIs51[SCMp::gfp + unc-119(+)] Seam cell marker strain 
RCT220 wIs51[SCMp::gfp + unc-119(+)]; abu-
13(rms12[abu-13::WormScarlet])III 
HZ470 crossed into 
RCT200 
BRF70 synEx115[pife-2::ife-2::gfp::unc-54 3’UTR; 
rol-6(su1006)] 
Gifted by the Syntichaki 
lab 
RCT221 synEx115[pife-2::ife-2::gfp::unc-54 3’UTR; 
rol-6(su1006)]; rmsEx12[abu-13p::abu-
13::tagRFP::unc-54 3’UTR] 
BRF70 crossed into 
RCT96 
BRF261 synEx19[pdcap-1::dcap-1::gfp::dcap-1 3’UTR; 
rol-6(1006)] 
Gifted by the Syntichaki 
lab 
RCT222 synEx19[pdcap-1::dcap-1::gfp::dcap-1 3’UTR; 
rol-6(1006)]; rmsEx12[abu-13p::abu-
13::tagRFP::unc-54 3’UTR] 
BRF261 crossed into 
RCT96 
RCT223 synEx19[pdcap-1::dcap-1::gfp::dcap-1 3’UTR; 
rol-6(1006)]; abu-13(rms12[abu-
13::WormScarlet])III 




Summary of CRISPR reagents 
 





































































et al., 2015) 
sgRNA #1 GTTGTGGAACAAATGCGTATGGG 
























Supplementary Table 2 CRISPR reagents used for successful editing events (underlined = flexible linker sequence; bold = 








Summary of genotyping primers 
 
Target Type of Primer Sequence 
C-terminal 





Forward 1 TGTTTCAGCCCATACGCATTT 
























































Summary of proteins co-immunoprecipitated with ABU-13::tagRFP 
 
Gene ID Details 
eef-1B Probable elongation factor 1-beta/1-delta 2 OS=Caenorhabditis elegans GN=eef-
1B.2 PE=1 SV=4 
act-4 Actin-4 OS=Caenorhabditis elegans GN=act-4 PE=3 SV=2 
CELE_R08E5 R08E5.3 OS=Caenorhabditis elegans GN=CELE_R08E5.3 PE=1 SV=1 
C46G7 C46G7.2 OS=Caenorhabditis elegans GN=C46G7.2 PE=1 SV=1 
abu-13 ABU-13 OS=Caenorhabditis elegans GN=abu-13 PE=1 SV=3 
sodh-1 Alcohol dehydrogenase 1 OS=Caenorhabditis elegans GN=sodh-1 PE=2 SV=2 
dnj-13 DNJ-13 OS=Caenorhabditis elegans GN=dnj-13 PE=1 SV=1 
CELE_F53F4 F53F4.11 OS=Caenorhabditis elegans GN=CELE_F53F4.11 PE=1 SV=2 
CELE_F31D4 F31D4.9 OS=Caenorhabditis elegans GN=CELE_F31D4.9 PE=1 SV=2 
rpia-1 Probable-ribose 5-phosphate isomerase OS=Caenorhabditis elegans GN=rpia-1 
PE=3 SV=1 
elpc-1 Elongator complex protein 1 OS=Caenorhabditis elegans GN=elpc-1 PE=1 
SV=2 
B0564 B0564.7, isoform a OS=Caenorhabditis elegans GN=B0564.7 PE=1 SV=2 
C43E11 60S ribosome subunit biogenesis protein NIP7 homolog OS=Caenorhabditis 
elegans GN=C43E11.9 PE=1 SV=1 
cal-5 CAL-5 OS=Caenorhabditis elegans GN=cal-5 PE=1 SV=2 
CELE_F18C12 F18C12.3 OS=Caenorhabditis elegans GN=CELE_F18C12.3 PE=1 SV=1 
C36E6 C36E6.1, isoform b OS=Caenorhabditis elegans GN=C36E6.1 PE=1 SV=1 
asp-13 ASP-13 OS=Caenorhabditis elegans GN=asp-13 PE=1 SV=1 
CELE_Y92H12
A 
Y92H12A.5, isoform a OS=Caenorhabditis elegans GN=CELE_Y92H12A.5 
PE=1 SV=1 
him-1 Structural maintenance of chromosomes protein 1 OS=Caenorhabditis elegans 
GN=him-1 PE=1 SV=4 
unc-96 UNC-96, isoform b OS=Caenorhabditis elegans GN=unc-96 PE=1 SV=1 
CELE_F55B11 F55B11.2 OS=Caenorhabditis elegans GN=CELE_F55B11.2 PE=1 SV=2 
fipr-21 FIPR-21 OS=Caenorhabditis elegans GN=fipr-21 PE=1 SV=1 
CELE_F17E9 F17E9.5 OS=Caenorhabditis elegans GN=CELE_F17E9.5 PE=1 SV=2 
ucr-2 UCR-2.1, isoform a OS=Caenorhabditis elegans GN=ucr-2.1 PE=1 SV=1 
B0511 B0511.6 OS=Caenorhabditis elegans GN=B0511.6 PE=1 SV=2 
cgr-1 CGR-1 OS=Caenorhabditis elegans GN=cgr-1 PE=1 SV=3 
CELE_ZC477 ZC477.3, isoform a OS=Caenorhabditis elegans GN=CELE_ZC477.3 PE=1 
SV=1 
tag-163 TAG-163, isoform a OS=Caenorhabditis elegans GN=tag-163 PE=1 SV=1 
B0416 B0416.5, isoform b OS=Caenorhabditis elegans GN=B0416.5 PE=1 SV=1 
rmd-6 RMD-6 OS=Caenorhabditis elegans GN=rmd-6 PE=4 SV=1 
emb-4 EMB-4, isoform a OS=Caenorhabditis elegans GN=emb-4 PE=1 SV=4 
CELE_T04C9 T04C9.1, isoform a OS=Caenorhabditis elegans GN=CELE_T04C9.1 PE=1 
SV=1 
C49C3 C49C3.9 OS=Caenorhabditis elegans GN=C49C3.9 PE=1 SV=1 
Y54E10A Ribosome production factor 2 homolog OS=Caenorhabditis elegans 
GN=Y54E10A.10 PE=3 SV=1 
nlp-24 NLP-24 OS=Caenorhabditis elegans GN=nlp-24 PE=1 SV=2 
 
 208 
gly-4 Polypeptide N-acetylgalactosaminyltransferase 4 OS=Caenorhabditis elegans 
GN=gly-4 PE=2 SV=2 
CELE_Y37D8A Y37D8A.19 OS=Caenorhabditis elegans GN=CELE_Y37D8A.19 PE=1 SV=1 
CELE_Y43D4A Y43D4A.5, isoform c OS=Caenorhabditis elegans GN=CELE_Y43D4A.5 PE=4 
SV=1 
CELE_F40F4 F40F4.7 OS=Caenorhabditis elegans GN=CELE_F40F4.7 PE=1 SV=4 
pph-4 Serine/threonine-protein phosphatase 4 catalytic subunit 1 OS=Caenorhabditis 
elegans GN=pph-4.1 PE=1 SV=1 
F40F8 UMP-CMP kinase 2 OS=Caenorhabditis elegans GN=F40F8.1 PE=1 SV=1 
F44E2 Uncharacterized protein F44E2.8 OS=Caenorhabditis elegans GN=F44E2.8 
PE=4 SV=2 
F14E5 Golgi apparatus protein 1 homolog OS=Caenorhabditis elegans GN=F14E5.2 
PE=1 SV=1 
gei-15 GEI-15 OS=Caenorhabditis elegans GN=gei-15 PE=1 SV=1 
cpna-1 CPNA-1, isoform b OS=Caenorhabditis elegans GN=cpna-1 PE=1 SV=1 
pch-2 Putative pachytene checkpoint protein 2 OS=Caenorhabditis elegans GN=pch-2 
PE=1 SV=1 
ugt-50 Putative UDP-glucuronosyltransferase ugt-50 OS=Caenorhabditis elegans 
GN=ugt-50 PE=1 SV=2 
npp-1 NPP-1, isoform a OS=Caenorhabditis elegans GN=npp-1 PE=1 SV=3 
mppb-1 MPPB-1 OS=Caenorhabditis elegans GN=mppb-1 PE=1 SV=2 
soc-2 Leucine-rich repeat protein soc-2 OS=Caenorhabditis elegans GN=soc-2 PE=1 
SV=3 
rsu-1 RSU-1 OS=Caenorhabditis elegans GN=rsu-1 PE=1 SV=1 
trpp-8 TRPP-8, isoform a OS=Caenorhabditis elegans GN=trpp-8 PE=1 SV=1 
ZK177 Uncharacterized protein ZK177.8 OS=Caenorhabditis elegans GN=ZK177.8 
PE=4 SV=2 
pptr-2 PPTR-2, isoform c OS=Caenorhabditis elegans GN=pptr-2 PE=1 SV=1 
vps-45 VPS-45, isoform a OS=Caenorhabditis elegans GN=vps-45 PE=1 SV=1 
CELE_F30F8 F30F8.9, isoform b OS=Caenorhabditis elegans GN=CELE_F30F8.9 PE=1 
SV=1 
CELE_W04A4 W04A4.5 OS=Caenorhabditis elegans GN=CELE_W04A4.5 PE=1 SV=2 
clec-153 CLEC-153 OS=Caenorhabditis elegans GN=clec-153 PE=1 SV=1 
symk-1 SYMK-1 OS=Caenorhabditis elegans GN=symk-1 PE=1 SV=2 
CELE_Y56A3A Y56A3A.7, isoform a OS=Caenorhabditis elegans GN=CELE_Y56A3A.7 PE=1 
SV=2 
dap-3 DAP-3 OS=Caenorhabditis elegans GN=dap-3 PE=1 SV=1 
CELE_W02H5 W02H5.8 OS=Caenorhabditis elegans GN=CELE_W02H5.8 PE=1 SV=1 
CELE_T23E7 T23E7.2, isoform a OS=Caenorhabditis elegans GN=CELE_T23E7.2 PE=1 
SV=2 
mans-3 alpha-1,2-Mannosidase OS=Caenorhabditis elegans GN=mans-3 PE=1 SV=2 
hpo-5 HPO-5 OS=Caenorhabditis elegans GN=hpo-5 PE=1 SV=2 
CELE_F53C11 F53C11.1, isoform b OS=Caenorhabditis elegans GN=CELE_F53C11.1 PE=1 
SV=1 
C44E4 C44E4.4 OS=Caenorhabditis elegans GN=C44E4.4 PE=1 SV=1 
scav-4 SCAV-4 OS=Caenorhabditis elegans GN=scav-4 PE=1 SV=2 
C34C6 C34C6.4 OS=Caenorhabditis elegans GN=C34C6.4 PE=1 SV=1 
mrp-5 MRP-5, isoform b OS=Caenorhabditis elegans GN=mrp-5 PE=1 SV=1 
ugt-58 Putative UDP-glucuronosyltransferase ugt-58 OS=Caenorhabditis elegans 
GN=ugt-58 PE=3 SV=2 
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lgc-28 LGC-28 OS=Caenorhabditis elegans GN=lgc-28 PE=1 SV=1 
CELE_M05D6 M05D6.6 OS=Caenorhabditis elegans GN=CELE_M05D6.6 PE=1 SV=1 
magu-4 MAGU-4, isoform a OS=Caenorhabditis elegans GN=magu-4 PE=1 SV=1 
ani-2 Anillin-like protein 2 OS=Caenorhabditis elegans GN=ani-2 PE=2 SV=1 
CELE_Y43F4B Y43F4B.5, isoform a OS=Caenorhabditis elegans GN=CELE_Y43F4B.5 PE=1 
SV=1 
CELE_ZC416 ZC416.6, isoform a OS=Caenorhabditis elegans GN=CELE_ZC416.6 PE=1 
SV=2 
F13H6 Esterase CM06B1 OS=Caenorhabditis elegans GN=F13H6.3 PE=3 SV=3 
erfa-3 ERFA-3, isoform a OS=Caenorhabditis elegans GN=erfa-3 PE=1 SV=2 
iff-2 Eukaryotic translation initiation factor 5A-2 OS=Caenorhabditis elegans 
GN=iff-2 PE=2 SV=1 
arx-2 Actin-related protein 2 OS=Caenorhabditis elegans GN=arx-2 PE=3 SV=1 
CELE_T07D3 T07D3.9, isoform a OS=Caenorhabditis elegans GN=CELE_T07D3.9 PE=1 
SV=3 
fli-1 Protein flightless-1 homolog OS=Caenorhabditis elegans GN=fli-1 PE=2 SV=2 
CELE_F55A4 F55A4.7 OS=Caenorhabditis elegans GN=CELE_F55A4.7 PE=1 SV=4 
CELE_T02H6 T02H6.1, isoform b OS=Caenorhabditis elegans GN=CELE_T02H6.1 PE=1 
SV=1 
pmp-1 PMP-1 OS=Caenorhabditis elegans GN=pmp-1 PE=1 SV=1 
CELE_F25G6 F25G6.9 OS=Caenorhabditis elegans GN=CELE_F25G6.9 PE=1 SV=2 
CELE_T28D6 T28D6.6, isoform a OS=Caenorhabditis elegans GN=CELE_T28D6.6 PE=1 
SV=1 
CELE_T08H10 T08H10.1 OS=Caenorhabditis elegans GN=CELE_T08H10.1 PE=1 SV=2 
hpo-34 HPO-34, isoform a OS=Caenorhabditis elegans GN=hpo-34 PE=1 SV=3 
CELE_M01E11 M01E11.2 OS=Caenorhabditis elegans GN=CELE_M01E11.2 PE=1 SV=1 
ugt-26 UDP-glucuronosyltransferase OS=Caenorhabditis elegans GN=ugt-26 PE=1 
SV=1 
aagr-3 AAGR-3, isoform a OS=Caenorhabditis elegans GN=aagr-3 PE=1 SV=1 
ZK512 Probable ATP-dependent RNA helicase DDX55 homolog OS=Caenorhabditis 
elegans GN=ZK512.2 PE=3 SV=2 
asp-3 Aspartic protease 3 OS=Caenorhabditis elegans GN=asp-3 PE=1 SV=3 
CELE_M4 M4.1, isoform b OS=Caenorhabditis elegans GN=CELE_M4.1 PE=1 SV=1 
Y54G2A MANF/CDNF-like protein OS=Caenorhabditis elegans GN=Y54G2A.23 PE=3 
SV=2 
metr-1 Probable methionine synthase OS=Caenorhabditis elegans GN=metr-1 PE=3 
SV=1 
acdh-11 ACDH-11, isoform b OS=Caenorhabditis elegans GN=acdh-11 PE=1 SV=1 
sac-1 SAC-1 OS=Caenorhabditis elegans GN=sac-1 PE=1 SV=1 
T26C12 Acetolactate synthase-like protein OS=Caenorhabditis elegans GN=T26C12.1 
PE=3 SV=2 
puf-9 PUF-9 OS=Caenorhabditis elegans GN=puf-9 PE=1 SV=2 
C42C1 C42C1.11, isoform c OS=Caenorhabditis elegans GN=C42C1.11 PE=1 SV=1 
CELE_F42C5 F42C5.9 OS=Caenorhabditis elegans GN=CELE_F42C5.9 PE=1 SV=1 
alh-7 ALH-7, isoform a OS=Caenorhabditis elegans GN=alh-7 PE=1 SV=2 
CELE_R09H10 R09H10.5 OS=Caenorhabditis elegans GN=CELE_R09H10.5 PE=1 SV=2 




E04D5 Eukaryotic translation initiation factor 2A OS=Caenorhabditis elegans 
GN=E04D5.1 PE=3 SV=2 
CELE_F21D5 F21D5.7 OS=Caenorhabditis elegans GN=CELE_F21D5.7 PE=1 SV=1 
hum-9 HUM-9 OS=Caenorhabditis elegans GN=hum-9 PE=1 SV=2 
tni-4 Troponin I 4 OS=Caenorhabditis elegans GN=tni-4 PE=2 SV=2 
ani-1 Anillin-like protein 1 OS=Caenorhabditis elegans GN=ani-1 PE=2 SV=2 
vha-19 VHA-19 OS=Caenorhabditis elegans GN=vha-19 PE=1 SV=1 
aagr-4 AAGR-4 OS=Caenorhabditis elegans GN=aagr-4 PE=1 SV=3 
CELE_Y71H10
B 
Y71H10B.1, isoform c OS=Caenorhabditis elegans GN=CELE_Y71H10B.1 
PE=1 SV=1 
CELE_F32D8 F32D8.5, isoform a OS=Caenorhabditis elegans GN=CELE_F32D8.5 PE=1 
SV=1 
art-1 Probable very-long-chain enoyl-CoA reductase art-1 OS=Caenorhabditis elegans 
GN=art-1 PE=3 SV=1 
mop-25 MO25-like protein 2 OS=Caenorhabditis elegans GN=mop-25.2 PE=3 SV=1 
abce-1 ABCE-1 OS=Caenorhabditis elegans GN=abce-1 PE=1 SV=1 
kin-3 Casein kinase II subunit alpha OS=Caenorhabditis elegans GN=kin-3 PE=1 
SV=1 
acdh-7 ACDH-7 OS=Caenorhabditis elegans GN=acdh-7 PE=1 SV=2 
CELE_ZK1058 ZK1058.9, isoform b OS=Caenorhabditis elegans GN=CELE_ZK1058.9 PE=1 
SV=1 
pgam-5 Serine/threonine-protein phosphatase Pgam5, mitochondrial OS=Caenorhabditis 
elegans GN=pgam-5 PE=3 SV=2 
clec-56 CLEC-56 OS=Caenorhabditis elegans GN=clec-56 PE=1 SV=3 
gsk-3 Glycogen synthase kinase-3 OS=Caenorhabditis elegans GN=gsk-3 PE=1 SV=1 
ula-1 NEDD8-activating enzyme E1 regulatory subunit OS=Caenorhabditis elegans 
GN=ula-1 PE=3 SV=2 
CELE_ZC247 ZC247.1 OS=Caenorhabditis elegans GN=CELE_ZC247.1 PE=1 SV=1 
H24K24 Alcohol dehydrogenase class-3 OS=Caenorhabditis elegans GN=H24K24.3 
PE=2 SV=1 
trap-3 TRAP-3 OS=Caenorhabditis elegans GN=trap-3 PE=1 SV=1 
nex-3 Annexin OS=Caenorhabditis elegans GN=nex-3 PE=1 SV=1 
air-1 AIR-1 OS=Caenorhabditis elegans GN=air-1 PE=1 SV=1 
ttr-25 TTR-25, isoform a OS=Caenorhabditis elegans GN=ttr-25 PE=1 SV=1 
acdh-3 ACDH-3 OS=Caenorhabditis elegans GN=acdh-3 PE=1 SV=1 
chup-1 CHUP-1, isoform b OS=Caenorhabditis elegans GN=chup-1 PE=1 SV=1 
gna-2 GNA-2 OS=Caenorhabditis elegans GN=gna-2 PE=1 SV=1 
CELE_F19B6 Uridine kinase OS=Caenorhabditis elegans GN=CELE_F19B6.1 PE=1 SV=1 
agef-1 AGEF-1, isoform a OS=Caenorhabditis elegans GN=agef-1 PE=1 SV=1 
CELE_R09B3 R09B3.3 OS=Caenorhabditis elegans GN=CELE_R09B3.3 PE=1 SV=1 
CELE_T16G1 T16G1.9 OS=Caenorhabditis elegans GN=CELE_T16G1.9 PE=1 SV=1 
grld-1 GRLD-1, isoform a OS=Caenorhabditis elegans GN=grld-1 PE=1 SV=1 
rme-2 RME-2, isoform a OS=Caenorhabditis elegans GN=rme-2 PE=1 SV=3 
CELE_T03G6 T03G6.3 OS=Caenorhabditis elegans GN=CELE_T03G6.3 PE=1 SV=2 
snr-4 Probable small nuclear ribonucleoprotein Sm D2 OS=Caenorhabditis elegans 
GN=snr-4 PE=1 SV=1 
CELE_Y82E9B
R 




let-711 LET-711 OS=Caenorhabditis elegans GN=let-711 PE=1 SV=3 
faah-1 Fatty acid amide hydrolase 1 OS=Caenorhabditis elegans GN=faah-1 PE=2 
SV=1 
rpb-2 DNA-directed RNA polymerase II subunit RPB2 OS=Caenorhabditis elegans 
GN=rpb-2 PE=2 SV=2 
lpd-6 LPD-6 OS=Caenorhabditis elegans GN=lpd-6 PE=1 SV=2 
F44B9 Probable replication factor C subunit 5 OS=Caenorhabditis elegans 
GN=F44B9.8 PE=3 SV=3 
ZK686 Probable dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 
3 OS=Caenorhabditis elegans GN=ZK686.3 PE=3 SV=2 
haf-3 HAF-3 OS=Caenorhabditis elegans GN=haf-3 PE=1 SV=2 
riok-1 Serine/threonine-protein kinase RIO1 OS=Caenorhabditis elegans GN=riok-1 
PE=1 SV=5 
odr-8 Ufm1-specific protease OS=Caenorhabditis elegans GN=odr-8 PE=1 SV=1 
CELE_R74 R74.8, isoform a OS=Caenorhabditis elegans GN=CELE_R74.8 PE=1 SV=2 
mtm-1 MTM-1 OS=Caenorhabditis elegans GN=mtm-1 PE=1 SV=2 
pfd-6 Probable prefoldin subunit 6 OS=Caenorhabditis elegans GN=pfd-6 PE=2 SV=1 
iffb-1 Eukaryotic translation initiation factor eIF5B OS=Caenorhabditis elegans 
GN=iffb-1 PE=1 SV=1 
CELE_JC8 JC8.2 OS=Caenorhabditis elegans GN=CELE_JC8.2 PE=1 SV=2 
kars-1 Lysine--tRNA ligase OS=Caenorhabditis elegans GN=kars-1 PE=1 SV=1 
pat-10 PAT-10 OS=Caenorhabditis elegans GN=pat-10 PE=1 SV=1 




Y71H2AM.5 OS=Caenorhabditis elegans GN=CELE_Y71H2AM.5 PE=1 SV=1 
unc-89 Muscle M-line assembly protein unc-89 OS=Caenorhabditis elegans GN=unc-89 
PE=1 SV=3 
F37C4 Protein F37C4.5 OS=Caenorhabditis elegans GN=F37C4.5 PE=1 SV=3 
CELE_ZK418 ZK418.9, isoform b OS=Caenorhabditis elegans GN=CELE_ZK418.9 PE=1 
SV=1 
pas-4 Proteasome subunit alpha type-7 OS=Caenorhabditis elegans GN=pas-4 PE=1 
SV=1 
smk-1 SMK-1, isoform a OS=Caenorhabditis elegans GN=smk-1 PE=1 SV=1 
inos-1 INOS-1 OS=Caenorhabditis elegans GN=inos-1 PE=1 SV=1 
cdc-37 CDC-37, isoform b OS=Caenorhabditis elegans GN=cdc-37 PE=1 SV=1 
skpo-1 Peroxidase skpo-1 OS=Caenorhabditis elegans GN=skpo-1 PE=2 SV=1 
plst-1 PLST-1, isoform a OS=Caenorhabditis elegans GN=plst-1 PE=1 SV=1 
C31B8 C31B8.8 OS=Caenorhabditis elegans GN=C31B8.8 PE=1 SV=1 
fasn-1 FASN-1 OS=Caenorhabditis elegans GN=fasn-1 PE=1 SV=2 
B0024 Putative pseudouridine synthase B0024.11 OS=Caenorhabditis elegans 
GN=B0024.11 PE=3 SV=1 
ifb-2 Intermediate filament protein ifb-2 OS=Caenorhabditis elegans GN=ifb-2 PE=1 
SV=1 
sur-6 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B 
OS=Caenorhabditis elegans GN=sur-6 PE=1 SV=1 
lin-40 LIN-40, isoform a OS=Caenorhabditis elegans GN=lin-40 PE=1 SV=2 
nrs-1 Asparagine--tRNA ligase, cytoplasmic OS=Caenorhabditis elegans GN=nrs-1 
PE=3 SV=1 
gpd-1 Glyceraldehyde-3-phosphate dehydrogenase 1 OS=Caenorhabditis elegans 
GN=gpd-1 PE=3 SV=1 
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ttr-24 TTR-24, isoform a OS=Caenorhabditis elegans GN=ttr-24 PE=1 SV=1 
eif-3 Eukaryotic translation initiation factor 3 subunit C OS=Caenorhabditis elegans 
GN=eif-3.C PE=3 SV=2 
let-721 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 
OS=Caenorhabditis elegans GN=let-721 PE=3 SV=2 
myo-6 MYO-6, isoform a OS=Caenorhabditis elegans GN=myo-6 PE=1 SV=2 
tpp-2 Tripeptidyl-peptidase 2 OS=Caenorhabditis elegans GN=tpp-2 PE=2 SV=1 
hipr-1 Huntington interacting protein related 1 OS=Caenorhabditis elegans GN=hipr-1 
PE=3 SV=3 
lrs-1 Leucine--tRNA ligase OS=Caenorhabditis elegans GN=lrs-1 PE=3 SV=2 
zyg-9 Zygote defective protein 9 OS=Caenorhabditis elegans GN=zyg-9 PE=1 SV=1 
lfi-1 LFI-1, isoform a OS=Caenorhabditis elegans GN=lfi-1 PE=1 SV=1 
ZC434 Probable arginine kinase ZC434.8 OS=Caenorhabditis elegans GN=ZC434.8 
PE=3 SV=1 
vha-8 VHA-8 OS=Caenorhabditis elegans GN=vha-8 PE=1 SV=1 
CELE_Y57G11
C 
Y57G11C.33, isoform b OS=Caenorhabditis elegans GN=CELE_Y57G11C.33 
PE=1 SV=1 
ret-1 Reticulon-like protein OS=Caenorhabditis elegans GN=ret-1 PE=1 SV=1 
cmd-1 Calmodulin OS=Caenorhabditis elegans GN=cmd-1 PE=1 SV=3 
vha-16 VHA-16 OS=Caenorhabditis elegans GN=vha-16 PE=1 SV=1 
kin-19 Casein kinase I isoform alpha OS=Caenorhabditis elegans GN=kin-19 PE=3 
SV=1 
iff-1 Eukaryotic translation initiation factor 5A OS=Caenorhabditis elegans GN=iff-1 
PE=1 SV=1 
CELE_F57F5 F57F5.1 OS=Caenorhabditis elegans GN=CELE_F57F5.1 PE=1 SV=2 
mlc-2 Myosin regulatory light chain 2 OS=Caenorhabditis elegans GN=mlc-2 PE=3 
SV=1 
sel-9 Suppressor/enhancer of lin-12 protein 9 OS=Caenorhabditis elegans GN=sel-9 
PE=1 SV=1 
mccc-1 MCCC-1 OS=Caenorhabditis elegans GN=mccc-1 PE=1 SV=2 
fbp-1 FBP-1, isoform a OS=Caenorhabditis elegans GN=fbp-1 PE=1 SV=1 
ard-1 ARD-1, isoform a OS=Caenorhabditis elegans GN=ard-1 PE=1 SV=1 
rps-30 RPS-30 OS=Caenorhabditis elegans GN=rps-30 PE=1 SV=1 
nuo-1 NUO-1 OS=Caenorhabditis elegans GN=nuo-1 PE=1 SV=1 
pdhb-1 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 
OS=Caenorhabditis elegans GN=pdhb-1 PE=1 SV=2 




Y18D10A.11 OS=Caenorhabditis elegans GN=CELE_Y18D10A.11 PE=1 
SV=1 
rpl-28 60S ribosomal protein L28 OS=Caenorhabditis elegans GN=rpl-28 PE=1 SV=3 
CELE_F42G8 F42G8.10 OS=Caenorhabditis elegans GN=CELE_F42G8.10 PE=1 SV=1 
ugt-19 UGT-19 OS=Caenorhabditis elegans GN=ugt-19 PE=1 SV=2 
asna-1 ATPase asna-1 OS=Caenorhabditis elegans GN=asna-1 PE=1 SV=1 
CELE_F45H10 F45H10.3 OS=Caenorhabditis elegans GN=CELE_F45H10.3 PE=1 SV=1 
asns-2 ASNS-2, isoform a OS=Caenorhabditis elegans GN=asns-2 PE=1 SV=1 
CELE_M153 M153.1 OS=Caenorhabditis elegans GN=CELE_M153.1 PE=1 SV=1 
hpo-18 HPO-18 OS=Caenorhabditis elegans GN=hpo-18 PE=1 SV=1 
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ubxn-4 UBX domain-containing protein 4 OS=Caenorhabditis elegans GN=ubxn-4 
PE=3 SV=1 
uggt-1 UGGT-1 OS=Caenorhabditis elegans GN=uggt-1 PE=1 SV=1 
rho-1 Ras-like GTP-binding protein rhoA OS=Caenorhabditis elegans GN=rho-1 
PE=1 SV=1 
rpa-2 60S acidic ribosomal protein P2 OS=Caenorhabditis elegans GN=rpa-2 PE=3 
SV=2 
CELE_ZK1055 ZK1055.7 OS=Caenorhabditis elegans GN=CELE_ZK1055.7 PE=1 SV=1 
CELE_F36F2 F36F2.1, isoform a OS=Caenorhabditis elegans GN=CELE_F36F2.1 PE=1 
SV=1 
set-27 SET-27 OS=Caenorhabditis elegans GN=set-27 PE=1 SV=2 
gale-1 GALE-1, isoform a OS=Caenorhabditis elegans GN=gale-1 PE=1 SV=1 
pfd-5 Probable prefoldin subunit 5 OS=Caenorhabditis elegans GN=pfd-5 PE=2 SV=1 
acdh-10 Probable medium-chain specific acyl-CoA dehydrogenase 10, mitochondrial 
OS=Caenorhabditis elegans GN=acdh-10 PE=2 SV=1 
C30H6 C30H6.7, isoform a OS=Caenorhabditis elegans GN=C30H6.7 PE=1 SV=1 
dhs-30 DHS-30 OS=Caenorhabditis elegans GN=dhs-30 PE=1 SV=1 
cpna-2 Copine family protein 2 OS=Caenorhabditis elegans GN=cpna-2 PE=2 SV=4 
aqp-8 AQP-8, isoform b OS=Caenorhabditis elegans GN=aqp-8 PE=3 SV=1 
C01H6 C01H6.2 OS=Caenorhabditis elegans GN=C01H6.2 PE=1 SV=2 
puf-5 Pumilio domain-containing protein 5 OS=Caenorhabditis elegans GN=puf-5 
PE=2 SV=1 
mrpl-12 MRPL-12 OS=Caenorhabditis elegans GN=mrpl-12 PE=1 SV=1 
phy-2 Prolyl 4-hydroxylase subunit alpha-2 OS=Caenorhabditis elegans GN=phy-2 
PE=1 SV=1 
CELE_F49E2 F49E2.2, isoform c OS=Caenorhabditis elegans GN=CELE_F49E2.2 PE=1 
SV=1 
ttll-5 TTLL-5, isoform b OS=Caenorhabditis elegans GN=ttll-5 PE=1 SV=1 
C30H6 C30H6.7, isoform a OS=Caenorhabditis elegans GN=C30H6.7 PE=1 SV=1 
CELE_DC2 DC2.5 OS=Caenorhabditis elegans GN=CELE_DC2.5 PE=1 SV=4 
spp-10 SPP-10, isoform b OS=Caenorhabditis elegans GN=spp-10 PE=1 SV=3 




Y46E12BL.2, isoform a OS=Caenorhabditis elegans GN=CELE_Y46E12BL.2 
PE=1 SV=1 
tbc-14 TBC-14 OS=Caenorhabditis elegans GN=tbc-14 PE=1 SV=2 
deps-1 DEPS-1, isoform a OS=Caenorhabditis elegans GN=deps-1 PE=1 SV=1 
lov-1 Location of vulva defective 1 OS=Caenorhabditis elegans GN=lov-1 PE=1 
SV=4 
K12H4 Probable signal peptidase complex subunit 3 OS=Caenorhabditis elegans 
GN=K12H4.4 PE=1 SV=1 
CELE_T19D12 T19D12.4, isoform a OS=Caenorhabditis elegans GN=CELE_T19D12.4 PE=1 
SV=1 
CELE_Y7A5A Y7A5A.1 OS=Caenorhabditis elegans GN=CELE_Y7A5A.1 PE=1 SV=1 
qns-1 QNS-1, isoform a OS=Caenorhabditis elegans GN=qns-1 PE=1 SV=1 
tba-1 TBA-1, isoform b OS=Caenorhabditis elegans GN=tba-1 PE=1 SV=1 
CELE_K04F10 K04F10.7 OS=Caenorhabditis elegans GN=CELE_K04F10.7 PE=1 SV=1 
snb-1 Synaptobrevin-1 OS=Caenorhabditis elegans GN=snb-1 PE=1 SV=1 
CELE_F35D11 F35D11.4 OS=Caenorhabditis elegans GN=CELE_F35D11.4 PE=1 SV=2 
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klp-18 Kinesin-like protein OS=Caenorhabditis elegans GN=klp-18 PE=1 SV=1 
C25H3 C25H3.9, isoform b OS=Caenorhabditis elegans GN=C25H3.9 PE=1 SV=1 
sptl-2 Serine palmitoyltransferase 2 OS=Caenorhabditis elegans GN=sptl-2 PE=3 
SV=1 
C18E9 C18E9.4 OS=Caenorhabditis elegans GN=C18E9.4 PE=1 SV=1 
bag-1 BAG family molecular chaperone regulator 1 OS=Caenorhabditis elegans 
GN=bag-1 PE=1 SV=1 
mmaa-1 Methylmalonic aciduria type A homolog, mitochondrial OS=Caenorhabditis 
elegans GN=mmaa-1 PE=3 SV=2 
rbd-1 RBD-1, isoform a OS=Caenorhabditis elegans GN=rbd-1 PE=1 SV=1 
CELE_Y23H5B Y23H5B.5 OS=Caenorhabditis elegans GN=CELE_Y23H5B.5 PE=1 SV=2 
CELE_F54E2 F54E2.1 OS=Caenorhabditis elegans GN=CELE_F54E2.1 PE=1 SV=2 
ragc-1 RAGC-1, isoform a OS=Caenorhabditis elegans GN=ragc-1 PE=1 SV=1 
eif-1 EIF-1 OS=Caenorhabditis elegans GN=eif-1 PE=1 SV=1 
mpst-1 Putative thiosulfate sulfurtransferase mpst-1 OS=Caenorhabditis elegans 
GN=mpst-1 PE=3 SV=1 
ddo-2 D-aspartate oxidase 2 OS=Caenorhabditis elegans GN=ddo-2 PE=1 SV=1 
CELE_T24C12 T24C12.3 OS=Caenorhabditis elegans GN=CELE_T24C12.3 PE=1 SV=2 
gpx-7 Glutathione peroxidase OS=Caenorhabditis elegans GN=gpx-7 PE=1 SV=1 
F09B12 Putative phospholipase B-like 2 OS=Caenorhabditis elegans GN=F09B12.3 
PE=1 SV=2 
npp-4 NPP-4 OS=Caenorhabditis elegans GN=npp-4 PE=1 SV=1 
mrps-15 28S ribosomal protein S15, mitochondrial OS=Caenorhabditis elegans 
GN=mrps-15 PE=3 SV=1 
ZK177 Uncharacterized protein ZK177.8 OS=Caenorhabditis elegans GN=ZK177.8 
PE=4 SV=2 
CELE_ZK1307 ZK1307.8 OS=Caenorhabditis elegans GN=CELE_ZK1307.8 PE=1 SV=1 
dod-19 DOD-19 OS=Caenorhabditis elegans GN=dod-19 PE=1 SV=2 
mdt-9 MDT-9, isoform b OS=Caenorhabditis elegans GN=mdt-9 PE=1 SV=1 
F54D5 Probable glutaryl-CoA dehydrogenase, mitochondrial OS=Caenorhabditis 
elegans GN=F54D5.7 PE=1 SV=1 
unc-61 UNC-61, isoform c OS=Caenorhabditis elegans GN=unc-61 PE=1 SV=2 
aipl-1 AIPL-1 OS=Caenorhabditis elegans GN=aipl-1 PE=1 SV=1 
CELE_F28B3 F28B3.10 OS=Caenorhabditis elegans GN=CELE_F28B3.10 PE=1 SV=1 
cht-3 Chitinase-like protein C25A8.4 OS=Caenorhabditis elegans GN=cht-3 PE=1 
SV=3 
moag-4 MOAG-4 OS=Caenorhabditis elegans GN=moag-4 PE=1 SV=1 
dad-1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit dad-1 
OS=Caenorhabditis elegans GN=dad-1 PE=3 SV=1 
CELE_W04C9 W04C9.4 OS=Caenorhabditis elegans GN=CELE_W04C9.4 PE=1 SV=1 
pfd-4 Probable prefoldin subunit 4 OS=Caenorhabditis elegans GN=pfd-4 PE=2 SV=1 
CELE_R09E10 R09E10.6 OS=Caenorhabditis elegans GN=CELE_R09E10.6 PE=1 SV=1 
flu-2 Kynureninase OS=Caenorhabditis elegans GN=flu-2 PE=2 SV=1 
mei-1 Meiotic spindle formation protein mei-1 OS=Caenorhabditis elegans GN=mei-1 
PE=1 SV=1 
ttr-14 TTR-14 OS=Caenorhabditis elegans GN=ttr-14 PE=1 SV=1 
ugt-16 UDP-glucuronosyltransferase OS=Caenorhabditis elegans GN=ugt-16 PE=1 
SV=1 
pmp-2 PMP-2 OS=Caenorhabditis elegans GN=pmp-2 PE=1 SV=1 
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teg-4 TEG-4 OS=Caenorhabditis elegans GN=teg-4 PE=1 SV=1 
CELE_D1086 D1086.6 OS=Caenorhabditis elegans GN=CELE_D1086.6 PE=1 SV=5 
CELE_ZK546 ZK546.14, isoform b OS=Caenorhabditis elegans GN=CELE_ZK546.14 PE=1 
SV=1 
pafo-1 RNA polymerase II-associated factor 1 homolog OS=Caenorhabditis elegans 
GN=pafo-1 PE=2 SV=2 
tre-3 Trehalase OS=Caenorhabditis elegans GN=tre-3 PE=1 SV=1 
T23D8 Protein LTV1 homolog OS=Caenorhabditis elegans GN=T23D8.3 PE=3 SV=1 
Supplemental Table 4 Summary of all proteins co-immunoprecipitated with ABU-13::tagRFP from overexpression animals 
that show a greater than 50% change in abundance compared to abu-13p::tagRFP animals (OS = Organism Name; GN = Gene 
















































Summary of proteins precipitated from N2 animals following biotinylated isoxazole treatment  
 
 
Gene ID Details 
ttc-7 Y39A3CR.3, isoform a OS=Caenorhabditis elegans GN=ttc-7 PE=1 SV=1 
CELE_K11D2 K11D2.5 OS=Caenorhabditis elegans GN=CELE_K11D2.5 PE=4 SV=2 
CELE_Y43F8B Y43F8B.1, isoform e OS=Caenorhabditis elegans GN=CELE_Y43F8B.1 PE=1 
SV=1 
C04F12 C04F12.1 OS=Caenorhabditis elegans GN=C04F12.1 PE=1 SV=1 
CELE_F07F6 F07F6.8 OS=Caenorhabditis elegans GN=CELE_F07F6.8 PE=1 SV=1 
calu-1 CALU-1, isoform a OS=Caenorhabditis elegans GN=calu-1 PE=1 SV=1 
jmjd-1 Lysine-specific demethylase 7 homolog OS=Caenorhabditis elegans GN=jmjd-
1.2 PE=1 SV=1 
cdc-6 CDC-6 OS=Caenorhabditis elegans GN=cdc-6 PE=1 SV=1 
dhhc-8 Palmitoyltransferase OS=Caenorhabditis elegans GN=dhhc-8 PE=3 SV=3 
cdf-1 Cation diffusion facilitator family protein 1 OS=Caenorhabditis elegans 
GN=cdf-1 PE=1 SV=1 
Y53F4B Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 
OS=Caenorhabditis elegans GN=Y53F4B.13 PE=3 SV=3 
CELE_W02D7 W02D7.4 OS=Caenorhabditis elegans GN=CELE_W02D7.4 PE=1 SV=1 
H03A11 Extracellular serine/threonine protein kinase CeFam20 OS=Caenorhabditis 
elegans GN=H03A11.1 PE=1 SV=1 
CELE_K08D9 K08D9.4 OS=Caenorhabditis elegans GN=CELE_K08D9.4 PE=4 SV=1 
ech-1 T08B2.7, isoform a OS=Caenorhabditis elegans GN=ech-1.2 PE=1 SV=1 
C49F5 C49F5.6 OS=Caenorhabditis elegans GN=C49F5.6 PE=4 SV=1 
nol-10 NOL-10 OS=Caenorhabditis elegans GN=nol-10 PE=1 SV=1 
sem-5 Sex muscle abnormal protein 5 OS=Caenorhabditis elegans GN=sem-5 PE=1 
SV=1 
xpf-1 XPF-1 OS=Caenorhabditis elegans GN=xpf-1 PE=1 SV=1 
myo-6 MYO-6, isoform a OS=Caenorhabditis elegans GN=myo-6 PE=1 SV=2 
spon-1 SPON-1 OS=Caenorhabditis elegans GN=spon-1 PE=1 SV=2 
sqv-1 SQV-1, isoform a OS=Caenorhabditis elegans GN=sqv-1 PE=1 SV=1 
CELE_F26F12 F26F12.3, isoform a OS=Caenorhabditis elegans GN=CELE_F26F12.3 PE=1 
SV=1 
CELE_F56D5 F56D5.3 OS=Caenorhabditis elegans GN=CELE_F56D5.3 PE=1 SV=1 
pid-1 21U-RNA biogenesis factor pid-1 OS=Caenorhabditis elegans GN=pid-1 PE=1 
SV=1 
parn-1 PARN-1 OS=Caenorhabditis elegans GN=parn-1 PE=4 SV=2 
C32E8 C32E8.9 OS=Caenorhabditis elegans GN=C32E8.9 PE=1 SV=2 
cids-1 CID domain-containing protein 1 OS=Caenorhabditis elegans GN=cids-1 
PE=3 SV=2 
Y48A6B Putative H/ACA ribonucleoprotein complex subunit 2-like protein 
OS=Caenorhabditis elegans GN=Y48A6B.3 PE=3 SV=1 
CELE_R10H10 R10H10.7 OS=Caenorhabditis elegans GN=CELE_R10H10.7 PE=1 SV=5 
T27F2 Uncharacterized protein T27F2.1 OS=Caenorhabditis elegans GN=T27F2.1 
PE=1 SV=1 
dsbn-1 Dysbindin protein homolog OS=Caenorhabditis elegans GN=dsbn-1 PE=1 
SV=1 




CELE_ZC410 ZC410.5, isoform a OS=Caenorhabditis elegans GN=CELE_ZC410.5 PE=1 
SV=1 
maoc-1 MAOC-1 OS=Caenorhabditis elegans GN=maoc-1 PE=1 SV=1 
gpa-12 Guanine nucleotide-binding protein alpha-12 subunit OS=Caenorhabditis 
elegans GN=gpa-12 PE=1 SV=2 
C25H3 C25H3.9, isoform a OS=Caenorhabditis elegans GN=C25H3.9 PE=1 SV=1 
aap-1 AAP-1 OS=Caenorhabditis elegans GN=aap-1 PE=1 SV=1 
inx-22 Innexin OS=Caenorhabditis elegans GN=inx-22 PE=3 SV=2 
CELE_Y73C8B Y73C8B.3 OS=Caenorhabditis elegans GN=CELE_Y73C8B.3 PE=1 SV=1 
CELE_M18 M18.3 OS=Caenorhabditis elegans GN=CELE_M18.3 PE=1 SV=1 
CELE_F53H1 F53H1.1, isoform a OS=Caenorhabditis elegans GN=CELE_F53H1.1 PE=1 
SV=1 
F42A8 Uncharacterized protein F42A8.1 OS=Caenorhabditis elegans GN=F42A8.1 
PE=4 SV=1 
mls-1 MLS-1 OS=Caenorhabditis elegans GN=mls-1 PE=4 SV=1 
sds-22 Protein phosphatase 1 regulatory subunit SDS22 homolog OS=Caenorhabditis 
elegans GN=sds-22 PE=3 SV=1 
golg-4 F59A2.6 OS=Caenorhabditis elegans GN=golg-4 PE=1 SV=1 
C06A6 Thioredoxin domain-containing protein C06A6.5 OS=Caenorhabditis elegans 
GN=C06A6.5 PE=1 SV=2 
laat-1 Lysosomal amino acid transporter 1 OS=Caenorhabditis elegans GN=laat-1 
PE=1 SV=2 
C50D2 Probable ADP-dependent glucokinase OS=Caenorhabditis elegans 
GN=C50D2.7 PE=1 SV=1 
CELE_Y54E5A Y54E5A.5 OS=Caenorhabditis elegans GN=CELE_Y54E5A.5 PE=1 SV=1 
rba-1 Probable histone-binding protein rba-1 OS=Caenorhabditis elegans GN=rba-1 
PE=3 SV=1 
mdt-15 Mediator of RNA polymerase II transcription subunit 15 OS=Caenorhabditis 
elegans GN=mdt-15 PE=1 SV=3 
C33A12 Probable NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 
OS=Caenorhabditis elegans GN=C33A12.1 PE=3 SV=1 
CELE_K01C8 K01C8.1 OS=Caenorhabditis elegans GN=CELE_K01C8.1 PE=1 SV=2 
CELE_ZK484 ZK484.4, isoform b OS=Caenorhabditis elegans GN=CELE_ZK484.4 PE=1 
SV=1 
R107 ATP-dependent (S)-NAD(P)H-hydrate dehydratase OS=Caenorhabditis 
elegans GN=R107.2 PE=3 SV=3 
syx-18 SYX-18 OS=Caenorhabditis elegans GN=syx-18 PE=1 SV=1 
C05D11 Uncharacterized protein C05D11.1 OS=Caenorhabditis elegans GN=C05D11.1 
PE=4 SV=2 
rabn-5 RABN-5 OS=Caenorhabditis elegans GN=rabn-5 PE=1 SV=1 
pssy-2 PSSY-2 OS=Caenorhabditis elegans GN=pssy-2 PE=4 SV=4 
ipla-7 T04B2.5 OS=Caenorhabditis elegans GN=ipla-7 PE=1 SV=1 
rle-1 Regulation of longevity by E3 ubiquitin-protein ligase OS=Caenorhabditis 
elegans GN=rle-1 PE=1 SV=4 
arl-5 ADP-ribosylation factor-like protein 5 OS=Caenorhabditis elegans GN=arl-5 
PE=3 SV=3 
sars-2 SARS-2, isoform a OS=Caenorhabditis elegans GN=sars-2 PE=1 SV=1 
CELE_R09F10 R09F10.8 OS=Caenorhabditis elegans GN=CELE_R09F10.8 PE=1 SV=3 




tut-2 Cytoplasmic tRNA 2-thiolation protein 2 OS=Caenorhabditis elegans GN=tut-
2 PE=3 SV=2 
rab-33 Rab-33 (Fragment) OS=Caenorhabditis elegans GN=rab-33 PE=2 SV=1 
exos-7 EXOS-7 OS=Caenorhabditis elegans GN=exos-7 PE=1 SV=1 
CELE_Y46G5A Y46G5A.34 OS=Caenorhabditis elegans GN=CELE_Y46G5A.34 PE=4 SV=1 
taf-5 TAF-5 OS=Caenorhabditis elegans GN=taf-5 PE=1 SV=1 
ccnk-1 CCNK-1 OS=Caenorhabditis elegans GN=ccnk-1 PE=1 SV=2 
dur-1 DUR-1, isoform k OS=Caenorhabditis elegans GN=dur-1 PE=1 SV=1 
B0495 Putative endoplasmic reticulum metallopeptidase 1-A OS=Caenorhabditis 
elegans GN=B0495.7 PE=1 SV=2 
CELE_Y48G1C Y48G1C.6 OS=Caenorhabditis elegans GN=CELE_Y48G1C.6 PE=4 SV=1 
CELE_Y54E5A Y54E5A.5 OS=Caenorhabditis elegans GN=CELE_Y54E5A.5 PE=1 SV=1 
ced-6 Cell death protein 6 OS=Caenorhabditis elegans GN=ced-6 PE=1 SV=1 
cdr-1 CDR-1 OS=Caenorhabditis elegans GN=cdr-1 PE=1 SV=1 
CELE_Y63D3A Y63D3A.7 OS=Caenorhabditis elegans GN=CELE_Y63D3A.7 PE=1 SV=2 
T03F6 Probable glucosamine-6-phosphate isomerase OS=Caenorhabditis elegans 
GN=T03F6.3 PE=3 SV=1 
gosr-2 Probable Golgi SNAP receptor complex member 2 OS=Caenorhabditis elegans 
GN=gosr-2.1 PE=3 SV=1 
grp-1 GTP exchange factor for ARFs 1 OS=Caenorhabditis elegans GN=grp-1 PE=3 
SV=2 
CELE_W10C8 W10C8.5 OS=Caenorhabditis elegans GN=CELE_W10C8.5 PE=1 SV=1 
cdd-1 CDD-1 OS=Caenorhabditis elegans GN=cdd-1 PE=1 SV=1 
lact-1 LACT-1 OS=Caenorhabditis elegans GN=lact-1 PE=4 SV=2 
anmt-2 ANMT-2 OS=Caenorhabditis elegans GN=anmt-2 PE=1 SV=2 
C01H6 C01H6.2 OS=Caenorhabditis elegans GN=C01H6.2 PE=1 SV=2 
wdr-5 WD repeat-containing protein wdr-5.1 OS=Caenorhabditis elegans GN=wdr-
5.1 PE=1 SV=1 
CELE_K04G7 K04G7.1 OS=Caenorhabditis elegans GN=CELE_K04G7.1 PE=1 SV=1 
CELE_W01B11 W01B11.6, isoform a OS=Caenorhabditis elegans GN=CELE_W01B11.6 
PE=1 SV=2 
Y39B6A Uncharacterized protein Y39B6A.33 OS=Caenorhabditis elegans 
GN=Y39B6A.33 PE=3 SV=1 
B0024 B0024.10 OS=Caenorhabditis elegans GN=B0024.10 PE=1 SV=2 
lgg-3 Ubiquitin-like protein ATG12 OS=Caenorhabditis elegans GN=lgg-3 PE=3 
SV=1 
cyc-2 Cytochrome c 2.1 OS=Caenorhabditis elegans GN=cyc-2.1 PE=1 SV=2 
CELE_Y4C6B Y4C6B.7, isoform b OS=Caenorhabditis elegans GN=CELE_Y4C6B.7 PE=1 
SV=1 
CELE_F41D9 F41D9.2, isoform b OS=Caenorhabditis elegans GN=CELE_F41D9.2 PE=1 
SV=1 
dve-1 DVE-1, isoform a OS=Caenorhabditis elegans GN=dve-1 PE=1 SV=1 
gst-21 GST-21, isoform b OS=Caenorhabditis elegans GN=gst-21 PE=1 SV=1 
M142 Protein-lysine N-methyltransferase M142.8 OS=Caenorhabditis elegans 
GN=M142.8 PE=3 SV=1 
CELE_K09E4 K09E4.3, isoform a OS=Caenorhabditis elegans GN=CELE_K09E4.3 PE=1 
SV=1 
CELE_F47G3 F47G3.3 OS=Caenorhabditis elegans GN=CELE_F47G3.3 PE=1 SV=1 




gos-28 Golgi SNAP receptor complex member 1 OS=Caenorhabditis elegans 
GN=gos-28 PE=2 SV=1 
mif-1 MIF-1 OS=Caenorhabditis elegans GN=mif-1 PE=1 SV=1 
paqr-1 Progestin and adipoQ receptor-like protein 1 OS=Caenorhabditis elegans 
GN=paqr-1 PE=3 SV=2 
T19B4 Adenine phosphoribosyltransferase OS=Caenorhabditis elegans GN=T19B4.3 
PE=2 SV=1 
CELE_F59E11 F59E11.5 OS=Caenorhabditis elegans GN=CELE_F59E11.5 PE=4 SV=2 
gly-13 Putative alpha-1,3-mannosyl-glycoprotein 2-beta-N-
acetylglucosaminyltransferase OS=Caenorhabditis elegans GN=gly-13 PE=2 
SV=2 
lron-10 LRON-10 OS=Caenorhabditis elegans GN=lron-10 PE=1 SV=1 
fbxa-156 FBXA-156 OS=Caenorhabditis elegans GN=fbxa-156 PE=4 SV=2 
pud-2 PUD-2.1 OS=Caenorhabditis elegans GN=pud-2.1 PE=1 SV=1 
C13F10 C13F10.5 OS=Caenorhabditis elegans GN=C13F10.5 PE=4 SV=2 
dgk-2 Diacylglycerol kinase OS=Caenorhabditis elegans GN=dgk-2 PE=1 SV=1 
ras-2 GTP binding protein OS=Caenorhabditis elegans GN=ras-2 PE=1 SV=1 
cept-1 CEPT-1, isoform b OS=Caenorhabditis elegans GN=cept-1 PE=1 SV=1 
ZK632 Probable mannose-6-phosphate isomerase OS=Caenorhabditis elegans 
GN=ZK632.4 PE=3 SV=3 
CELE_Y87G2A Y87G2A.19 OS=Caenorhabditis elegans GN=CELE_Y87G2A.19 PE=1 SV=1 
puf-8 PUF-8 OS=Caenorhabditis elegans GN=puf-8 PE=1 SV=3 
CELE_E04D5 E04D5.2 OS=Caenorhabditis elegans GN=CELE_E04D5.2 PE=4 SV=2 
CELE_Y53C12A Protein YIPF OS=Caenorhabditis elegans GN=CELE_Y53C12A.3 PE=1 
SV=2 
CELE_Y119D3B Y119D3B.12, isoform a OS=Caenorhabditis elegans GN=CELE_Y119D3B.12 
PE=1 SV=1 
strd-1 STE20-related kinase adapter protein strd-1 OS=Caenorhabditis elegans 
GN=strd-1 PE=1 SV=1 
CELE_D1069 D1069.3, isoform b OS=Caenorhabditis elegans GN=CELE_D1069.3 PE=1 
SV=1 
alh-3 10-formyltetrahydrofolate dehydrogenase OS=Caenorhabditis elegans 
GN=alh-3 PE=1 SV=1 
hum-1 HUM-1 OS=Caenorhabditis elegans GN=hum-1 PE=1 SV=1 
iglr-2 Immunoglobulin domain and leucine-rich repeat-containing protein 2 
OS=Caenorhabditis elegans GN=iglr-2 PE=1 SV=2 
C49A9 C49A9.9, isoform a OS=Caenorhabditis elegans GN=C49A9.9 PE=1 SV=1 
CELE_D1069 D1069.3, isoform b OS=Caenorhabditis elegans GN=CELE_D1069.3 PE=1 
SV=1 
ugt-39 UGT-39, isoform a OS=Caenorhabditis elegans GN=ugt-39 PE=1 SV=1 
CELE_K02F6 K02F6.7 OS=Caenorhabditis elegans GN=CELE_K02F6.7 PE=1 SV=2 
let-413 Protein lap1 OS=Caenorhabditis elegans GN=let-413 PE=1 SV=3 
ugt-47 Putative UDP-glucuronosyltransferase ugt-47 OS=Caenorhabditis elegans 
GN=ugt-47 PE=1 SV=2 
npp-4 NPP-4 OS=Caenorhabditis elegans GN=npp-4 PE=1 SV=1 
aagr-4 AAGR-4 OS=Caenorhabditis elegans GN=aagr-4 PE=1 SV=3 
pdcd-2 PDCD-2, isoform a OS=Caenorhabditis elegans GN=pdcd-2 PE=1 SV=2 
CELE_Y37A1B Y37A1B.17, isoform a OS=Caenorhabditis elegans GN=CELE_Y37A1B.17 
PE=1 SV=1 
prp-3 PRP-3 OS=Caenorhabditis elegans GN=prp-3 PE=1 SV=1 
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mrpl-1 MRPL-1 OS=Caenorhabditis elegans GN=mrpl-1 PE=1 SV=1 
syx-5 Putative syntaxin-5 OS=Caenorhabditis elegans GN=syx-5 PE=3 SV=1 
CELE_T14B4 T14B4.1 OS=Caenorhabditis elegans GN=CELE_T14B4.1 PE=1 SV=3 
wdr-48 WD repeat-containing protein 48 homolog OS=Caenorhabditis elegans 
GN=wdr-48 PE=1 SV=2 
CELE_F21H7 Major sperm protein OS=Caenorhabditis elegans GN=CELE_F21H7.5 PE=1 
SV=1 
coq-3 COQ-3, isoform a OS=Caenorhabditis elegans GN=coq-3 PE=1 SV=1 
CELE_T26A5 T26A5.6 OS=Caenorhabditis elegans GN=CELE_T26A5.6 PE=1 SV=3 
C05C8 KRR1 small subunit processome component OS=Caenorhabditis elegans 
GN=C05C8.2 PE=1 SV=1 
rad-51 RAD-51, isoform b OS=Caenorhabditis elegans GN=rad-51 PE=1 SV=1 
smc-6 SMC-6 OS=Caenorhabditis elegans GN=smc-6 PE=1 SV=1 
tdp-1 Tar DNA-binding protein homolog 1 OS=Caenorhabditis elegans GN=tdp-1 
PE=1 SV=1 
C13B4 C13B4.1, isoform a OS=Caenorhabditis elegans GN=C13B4.1 PE=1 SV=3 
CELE_F10G7 F10G7.10, isoform a OS=Caenorhabditis elegans GN=CELE_F10G7.10 PE=1 
SV=1 
CELE_Y34B4A Y34B4A.9 OS=Caenorhabditis elegans GN=CELE_Y34B4A.9 PE=1 SV=1 
gad-3 GAD-3 OS=Caenorhabditis elegans GN=gad-3 PE=1 SV=3 
arf-1 ADP-ribosylation factor 1-like 2 OS=Caenorhabditis elegans GN=arf-1.2 
PE=2 SV=2 
cyp-14a5 CYP-14A5 OS=Caenorhabditis elegans GN=cyp-14a5 PE=1 SV=1 
kin-1 cAMP-dependent protein kinase catalytic subunit OS=Caenorhabditis elegans 
GN=kin-1 PE=1 SV=3 
ero-1 ERO-1, isoform c OS=Caenorhabditis elegans GN=ero-1 PE=1 SV=1 
inos-1 INOS-1 OS=Caenorhabditis elegans GN=inos-1 PE=1 SV=1 
CELE_Y51A2D Y51A2D.7, isoform b OS=Caenorhabditis elegans GN=CELE_Y51A2D.7 
PE=1 SV=2 
CELE_W04B5 W04B5.5 OS=Caenorhabditis elegans GN=CELE_W04B5.5 PE=1 SV=1 
CELE_F40F4 F40F4.7 OS=Caenorhabditis elegans GN=CELE_F40F4.7 PE=1 SV=4 
CELE_Y6B3B Y6B3B.9, isoform a OS=Caenorhabditis elegans GN=CELE_Y6B3B.9 PE=1 
SV=2 
rsp-2 Probable splicing factor, arginine/serine-rich 2 OS=Caenorhabditis elegans 
GN=rsp-2 PE=3 SV=1 
mrpl-35 Probable 39S ribosomal protein L35, mitochondrial OS=Caenorhabditis 
elegans GN=mrpl-35 PE=3 SV=2 
tra-3 Calpain-5 OS=Caenorhabditis elegans GN=tra-3 PE=1 SV=1 
mrrf-1 Ribosome-recycling factor, mitochondrial OS=Caenorhabditis elegans 
GN=mrrf-1 PE=3 SV=2 
CELE_F32H2 F32H2.10 OS=Caenorhabditis elegans GN=CELE_F32H2.10 PE=4 SV=1 
parg-1 PME-3, isoform f OS=Caenorhabditis elegans GN=parg-1 PE=1 SV=1 
acl-3 ACL-3 OS=Caenorhabditis elegans GN=acl-3 PE=1 SV=2 
W09C3 Probable DNA-directed RNA polymerase III subunit RPC6 
OS=Caenorhabditis elegans GN=W09C3.4 PE=3 SV=1 
mdt-20 Mediator of RNA polymerase II transcription subunit 20 OS=Caenorhabditis 
elegans GN=mdt-20 PE=3 SV=2 
C34E10 C34E10.10 OS=Caenorhabditis elegans GN=C34E10.10 PE=1 SV=1 




CELE_Y94H6A Y94H6A.10 OS=Caenorhabditis elegans GN=CELE_Y94H6A.10 PE=1 SV=1 
C56C10 C56C10.11 OS=Caenorhabditis elegans GN=C56C10.11 PE=1 SV=2 
C05D12 C05D12.3, isoform a OS=Caenorhabditis elegans GN=C05D12.3 PE=1 SV=1 
clk-1 5-demethoxyubiquinone hydroxylase, mitochondrial OS=Caenorhabditis 
elegans GN=clk-1 PE=1 SV=1 
nhr-35 Nuclear hormone receptor family member nhr-35 OS=Caenorhabditis elegans 
GN=nhr-35 PE=2 SV=3 
erl-1 ERL-1 OS=Caenorhabditis elegans GN=erl-1 PE=1 SV=1 
tag-257 TAG-257 OS=Caenorhabditis elegans GN=tag-257 PE=1 SV=1 
jac-1 JAC-1, isoform e OS=Caenorhabditis elegans GN=jac-1 PE=1 SV=1 
CELE_F58H1 F58H1.8 OS=Caenorhabditis elegans GN=CELE_F58H1.8 PE=1 SV=1 
trpp-4 TRPP-4 OS=Caenorhabditis elegans GN=trpp-4 PE=1 SV=1 
hat-1 HAT-1 OS=Caenorhabditis elegans GN=hat-1 PE=1 SV=2 
clec-78 CLEC-78 OS=Caenorhabditis elegans GN=clec-78 PE=1 SV=2 
CELE_Y7A9A Y7A9A.1 OS=Caenorhabditis elegans GN=CELE_Y7A9A.1 PE=1 SV=2 
rae-1 mRNA export factor rae-1 OS=Caenorhabditis elegans GN=rae-1 PE=1 SV=1 
tufm-2 Mitochondrial elongation factor Tu homologue OS=Caenorhabditis elegans 
GN=tufm-2 PE=1 SV=1 
sup-35 SUP-35 OS=Caenorhabditis elegans GN=sup-35 PE=1 SV=1 
CELE_Y69H2 Y69H2.7, isoform a OS=Caenorhabditis elegans GN=CELE_Y69H2.7 PE=1 
SV=3 
CELE_H43I07 H43I07.3 OS=Caenorhabditis elegans GN=CELE_H43I07.3 PE=1 SV=1 
C17G10 C17G10.2 OS=Caenorhabditis elegans GN=C17G10.2 PE=1 SV=2 
cht-3 Chitinase-like protein C25A8.4 OS=Caenorhabditis elegans GN=cht-3 PE=1 
SV=3 
xpb-1 XPB-1 OS=Caenorhabditis elegans GN=xpb-1 PE=1 SV=1 
exc-4 Chloride intracellular channel exc-4 OS=Caenorhabditis elegans GN=exc-4 
PE=1 SV=2 
pbrm-1 PBRM-1, isoform a OS=Caenorhabditis elegans GN=pbrm-1 PE=1 SV=1 
sun-1 Sun domain-containing protein 1 OS=Caenorhabditis elegans GN=sun-1 PE=3 
SV=1 
CELE_M01B12 M01B12.4, isoform b OS=Caenorhabditis elegans GN=CELE_M01B12.4 
PE=1 SV=1 
CELE_F17H10 F17H10.1 OS=Caenorhabditis elegans GN=CELE_F17H10.1 PE=1 SV=1 
tim-16 Mitochondrial import inner membrane translocase subunit tim-16 
OS=Caenorhabditis elegans GN=tim-16 PE=3 SV=1 
CELE_ZK418 ZK418.9, isoform a OS=Caenorhabditis elegans GN=CELE_ZK418.9 PE=1 
SV=2 
acl-9 ACL-9 OS=Caenorhabditis elegans GN=acl-9 PE=1 SV=2 
gly-9 Probable N-acetylgalactosaminyltransferase 9 OS=Caenorhabditis elegans 
GN=gly-9 PE=2 SV=1 
CELE_F30F8 F30F8.9, isoform a OS=Caenorhabditis elegans GN=CELE_F30F8.9 PE=1 
SV=1 
C04H5 Multifunctional methyltransferase subunit TRM112-like protein 
OS=Caenorhabditis elegans GN=C04H5.1 PE=3 SV=1 
CELE_Y75B8A Y75B8A.24 OS=Caenorhabditis elegans GN=CELE_Y75B8A.24 PE=1 SV=2 
did-2 DID-2 OS=Caenorhabditis elegans GN=did-2 PE=1 SV=1 
CELE_T08B1 T08B1.1 OS=Caenorhabditis elegans GN=CELE_T08B1.1 PE=1 SV=2 
CELE_Y87G2A Y87G2A.19 OS=Caenorhabditis elegans GN=CELE_Y87G2A.19 PE=1 SV=1 
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smg-6 SMG-6, isoform a OS=Caenorhabditis elegans GN=smg-6 PE=1 SV=3 
B0205 B0205.6 OS=Caenorhabditis elegans GN=B0205.6 PE=1 SV=2 
CELE_F33G12 F33G12.3 OS=Caenorhabditis elegans GN=CELE_F33G12.3 PE=1 SV=1 
C15C7 C15C7.5 OS=Caenorhabditis elegans GN=C15C7.5 PE=1 SV=1 
CELE_Y55F3AR Y55F3AR.2 OS=Caenorhabditis elegans GN=CELE_Y55F3AR.2 PE=1 SV=2 
orc-5 ORC-5, isoform a OS=Caenorhabditis elegans GN=orc-5 PE=4 SV=2 
rpb-11 Probable DNA-directed RNA polymerase II subunit RPB11 
OS=Caenorhabditis elegans GN=rpb-11 PE=3 SV=1 
CELE_VF13D12
L 
VF13D12L.3 OS=Caenorhabditis elegans GN=CELE_VF13D12L.3 PE=1 
SV=1 
C34F6 C34F6.9 OS=Caenorhabditis elegans GN=C34F6.9 PE=1 SV=1 
riok-3 Putative RIO-type serine/threonine-protein kinase 3 OS=Caenorhabditis 
elegans GN=riok-3 PE=3 SV=1 
rpc-25 RPC-25 OS=Caenorhabditis elegans GN=rpc-25 PE=1 SV=1 
tag-10 P52CeGA (Fragment) OS=Caenorhabditis elegans GN=tag-10 PE=2 SV=1 
CELE_F53C3 F53C3.13, isoform c OS=Caenorhabditis elegans GN=CELE_F53C3.13 PE=1 
SV=1 
mut-16 MUT-16, isoform a OS=Caenorhabditis elegans GN=mut-16 PE=1 SV=4 
mrps-11 MRPS-11 OS=Caenorhabditis elegans GN=mrps-11 PE=1 SV=1 
CELE_F59A3 F59A3.12 OS=Caenorhabditis elegans GN=CELE_F59A3.12 PE=4 SV=2 
nuaf-3 NUAF-3, isoform a OS=Caenorhabditis elegans GN=nuaf-3 PE=1 SV=2 
lin-61 Protein lin-61 OS=Caenorhabditis elegans GN=lin-61 PE=1 SV=1 
jmjc-1 Bifunctional lysine-specific demethylase and histidyl-hydroxylase NO66 
OS=Caenorhabditis elegans GN=jmjc-1 PE=3 SV=2 
pho-5 Putative acid phosphatase 5 OS=Caenorhabditis elegans GN=pho-5 PE=1 
SV=3 
abts-2 ABTS-2 OS=Caenorhabditis elegans GN=abts-2 PE=1 SV=1 
D1044 Uncharacterized kinase-like protein D1044.1 OS=Caenorhabditis elegans 
GN=D1044.1 PE=3 SV=2 
fbxa-101 FBXA-101 OS=Caenorhabditis elegans GN=fbxa-101 PE=1 SV=1 
gst-41 GST-41 OS=Caenorhabditis elegans GN=gst-41 PE=1 SV=1 
F54D5 Probable glutaryl-CoA dehydrogenase, mitochondrial OS=Caenorhabditis 
elegans GN=F54D5.7 PE=1 SV=1 
aph-1 Gamma-secretase subunit aph-1 OS=Caenorhabditis elegans GN=aph-1 PE=1 
SV=1 
CELE_R144 R144.13 OS=Caenorhabditis elegans GN=CELE_R144.13 PE=1 SV=1 
dox-1 DOX-1 OS=Caenorhabditis elegans GN=dox-1 PE=1 SV=1 
CELE_Y110A7A Y110A7A.15, isoform a OS=Caenorhabditis elegans GN=CELE_Y110A7A.15 
PE=1 SV=1 
Y67D2 Probable ATP-dependent RNA helicase DHX35 homolog OS=Caenorhabditis 
elegans GN=Y67D2.6 PE=3 SV=1 
cbs-1 CBS-1, isoform a OS=Caenorhabditis elegans GN=cbs-1 PE=1 SV=1 
C49A9 C49A9.9, isoform a OS=Caenorhabditis elegans GN=C49A9.9 PE=1 SV=1 
adbp-1 2L737 OS=Caenorhabditis elegans GN=adbp-1 PE=1 SV=1 
CELE_W02G9 W02G9.3 OS=Caenorhabditis elegans GN=CELE_W02G9.3 PE=1 SV=1 
tag-131 Neuferricin homolog OS=Caenorhabditis elegans GN=tag-131 PE=3 SV=1 
exl-1 Chloride intracellular channel exl-1 OS=Caenorhabditis elegans GN=exl-1 
PE=2 SV=2 
exos-9 EXOS-9, isoform a OS=Caenorhabditis elegans GN=exos-9 PE=1 SV=2 
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aps-3 APS-3 OS=Caenorhabditis elegans GN=aps-3 PE=1 SV=1 
acbp-5 ACBP-5 OS=Caenorhabditis elegans GN=acbp-5 PE=1 SV=2 
C06H2 C06H2.2 OS=Caenorhabditis elegans GN=C06H2.2 PE=1 SV=3 
tnt-3 TNT-3, isoform b OS=Caenorhabditis elegans GN=tnt-3 PE=1 SV=1 
CELE_Y39A1A Y39A1A.22 OS=Caenorhabditis elegans GN=CELE_Y39A1A.22 PE=1 SV=1 
CELE_F59B1 F59B1.8 OS=Caenorhabditis elegans GN=CELE_F59B1.8 PE=1 SV=2 
CELE_Y69A2AR Y69A2AR.18, isoform a OS=Caenorhabditis elegans 
GN=CELE_Y69A2AR.18 PE=1 SV=1 
ZK1098 Probable translation initiation factor eIF-2B subunit alpha OS=Caenorhabditis 
elegans GN=ZK1098.4 PE=1 SV=1 
rfp-1 E3 ubiquitin-protein ligase bre-1 OS=Caenorhabditis elegans GN=rfp-1 PE=1 
SV=2 
hint-1 Histidine triad nucleotide-binding protein 1 OS=Caenorhabditis elegans 
GN=hint-1 PE=3 SV=1 
CELE_F10C1 F10C1.9, isoform b OS=Caenorhabditis elegans GN=CELE_F10C1.9 PE=1 
SV=1 
B0513 Proline dehydrogenase 1, mitochondrial OS=Caenorhabditis elegans 
GN=B0513.5 PE=3 SV=2 
trpp-10 TRPP-10, isoform b OS=Caenorhabditis elegans GN=trpp-10 PE=1 SV=2 
crls-1 Probable cardiolipin synthase (CMP-forming) OS=Caenorhabditis elegans 
GN=crls-1 PE=3 SV=1 
pir-1 PIR-1, isoform a OS=Caenorhabditis elegans GN=pir-1 PE=1 SV=2 
CELE_ZK1320 ZK1320.9 OS=Caenorhabditis elegans GN=CELE_ZK1320.9 PE=1 SV=1 
alh-12 ALH-12, isoform a OS=Caenorhabditis elegans GN=alh-12 PE=1 SV=1 
CELE_Y57A10A Y57A10A.23 OS=Caenorhabditis elegans GN=CELE_Y57A10A.23 PE=1 
SV=1 
zig-1 Secreted 2-immunoglobulin-domain protein ZIG-1 OS=Caenorhabditis elegans 
GN=zig-1 PE=1 SV=1 
ran-4 Probable nuclear transport factor 2 OS=Caenorhabditis elegans GN=ran-4 
PE=3 SV=1 
ppk-2 PPK-2 OS=Caenorhabditis elegans GN=ppk-2 PE=1 SV=1 
tre-1 Trehalase OS=Caenorhabditis elegans GN=tre-1 PE=1 SV=1 
nekl-3 Serine/threonine-protein kinase nekl-3 OS=Caenorhabditis elegans GN=nekl-3 
PE=1 SV=1 
CELE_F32D8 F32D8.5, isoform b OS=Caenorhabditis elegans GN=CELE_F32D8.5 PE=1 
SV=1 
F25B4 Hydroxymethylglutaryl-CoA synthase OS=Caenorhabditis elegans 
GN=F25B4.6 PE=2 SV=2 
aat-3 AAT-3 OS=Caenorhabditis elegans GN=aat-3 PE=1 SV=2 
parn-2 PARN-2 OS=Caenorhabditis elegans GN=parn-2 PE=1 SV=1 
ZK652 Uncharacterized protein ZK652.6 OS=Caenorhabditis elegans GN=ZK652.6 
PE=3 SV=2 
CELE_T08B6 T08B6.4 OS=Caenorhabditis elegans GN=CELE_T08B6.4 PE=1 SV=2 
CELE_F58B3 F58B3.4 OS=Caenorhabditis elegans GN=CELE_F58B3.4 PE=1 SV=3 
CELE_F25B5 5'-nucleotidase OS=Caenorhabditis elegans GN=CELE_F25B5.3 PE=1 SV=1 
cacn-1 Cactin OS=Caenorhabditis elegans GN=cacn-1 PE=1 SV=1 
F52B11 Probable phosphomannomutase OS=Caenorhabditis elegans GN=F52B11.2 
PE=3 SV=2 




dhrs-4 Dehydrogenase/reductase SDR family member 4 OS=Caenorhabditis elegans 
GN=dhrs-4 PE=1 SV=1 
CELE_T22B7 T22B7.7 OS=Caenorhabditis elegans GN=CELE_T22B7.7 PE=1 SV=1 
aakb-1 AAKB-1 OS=Caenorhabditis elegans GN=aakb-1 PE=1 SV=1 
CELE_Y41C4A Y41C4A.9 OS=Caenorhabditis elegans GN=CELE_Y41C4A.9 PE=1 SV=1 
fbxa-64 FBXA-64 OS=Caenorhabditis elegans GN=fbxa-64 PE=1 SV=2 
C49A9 C49A9.9, isoform a OS=Caenorhabditis elegans GN=C49A9.9 PE=1 SV=1 
ugt-9 UGT-9, isoform b OS=Caenorhabditis elegans GN=ugt-9 PE=1 SV=1 
dct-11 DCT-11 OS=Caenorhabditis elegans GN=dct-11 PE=1 SV=2 
cdk-7 Cyclin-dependent kinase 7 OS=Caenorhabditis elegans GN=cdk-7 PE=1 SV=1 
CELE_F59D12 F59D12.5 OS=Caenorhabditis elegans GN=CELE_F59D12.5 PE=1 SV=1 
CELE_F18H3 F18H3.1 OS=Caenorhabditis elegans GN=CELE_F18H3.1 PE=1 SV=2 
tftc-3 TFTC-3 OS=Caenorhabditis elegans GN=tftc-3 PE=1 SV=1 
hda-3 Histone deacetylase OS=Caenorhabditis elegans GN=hda-3 PE=1 SV=1 
lbp-5 Fatty acid-binding protein homolog 5 OS=Caenorhabditis elegans GN=lbp-5 
PE=3 SV=1 
ptr-11 PTR-11, isoform a OS=Caenorhabditis elegans GN=ptr-11 PE=1 SV=1 
ooc-5 Torsin-like protein OS=Caenorhabditis elegans GN=ooc-5 PE=1 SV=1 
C39B5 C39B5.5 OS=Caenorhabditis elegans GN=C39B5.5 PE=1 SV=1 
CELE_F22B8 F22B8.7 OS=Caenorhabditis elegans GN=CELE_F22B8.7 PE=1 SV=2 
snf-3 Sodium- and chloride-dependent betaine transporter OS=Caenorhabditis 
elegans GN=snf-3 PE=1 SV=1 
CELE_T20F5 T20F5.6 OS=Caenorhabditis elegans GN=CELE_T20F5.6 PE=1 SV=2 
npp-22 Nucleoporin ndc-1 OS=Caenorhabditis elegans GN=npp-22 PE=3 SV=1 
adr-2 Probable double-stranded RNA-specific adenosine deaminase 
OS=Caenorhabditis elegans GN=adr-2 PE=2 SV=2 
C45G9 Uncharacterized protein C45G9.5 OS=Caenorhabditis elegans GN=C45G9.5 
PE=4 SV=1 
wapl-1 WAPL-1, isoform b OS=Caenorhabditis elegans GN=wapl-1 PE=1 SV=1 
E02H1 Probable dimethyladenosine transferase OS=Caenorhabditis elegans 
GN=E02H1.1 PE=3 SV=2 
skr-4 SKR-4 OS=Caenorhabditis elegans GN=skr-4 PE=1 SV=1 
CELE_Y71H2B Y71H2B.5 OS=Caenorhabditis elegans GN=CELE_Y71H2B.5 PE=1 SV=4 
plk-1 Serine/threonine-protein kinase plk-1 OS=Caenorhabditis elegans GN=plk-1 
PE=1 SV=3 
ama-1 DNA-directed RNA polymerase II subunit RPB1 OS=Caenorhabditis elegans 
GN=ama-1 PE=1 SV=3 
CELE_D1081 D1081.7, isoform b OS=Caenorhabditis elegans GN=CELE_D1081.7 PE=1 
SV=1 
bub-1 Mitotic checkpoint serine/threonine-protein kinase BUB1 OS=Caenorhabditis 
elegans GN=bub-1 PE=1 SV=1 
Y66H1A Probable H/ACA ribonucleoprotein complex subunit 1-like protein 
OS=Caenorhabditis elegans GN=Y66H1A.4 PE=3 SV=2 
CELE_Y82E9BR Y82E9BR.18 OS=Caenorhabditis elegans GN=CELE_Y82E9BR.18 PE=1 
SV=2 
gld-2 Poly(A) RNA polymerase gld-2 OS=Caenorhabditis elegans GN=gld-2 PE=1 
SV=2 
rab-5 Rab-5 (Fragment) OS=Caenorhabditis elegans GN=rab-5 PE=2 SV=1 
ger-1 GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase 
OS=Caenorhabditis elegans GN=ger-1 PE=1 SV=1 
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pfd-2 Prefoldin subunit 2 OS=Caenorhabditis elegans GN=pdf-2 PE=3 SV=1 
pus-1 tRNA pseudouridine synthase OS=Caenorhabditis elegans GN=pus-1 PE=1 
SV=1 
skr-3 SKR-3 OS=Caenorhabditis elegans GN=skr-3 PE=1 SV=1 
tac-1 2P40 OS=Caenorhabditis elegans GN=tac-1 PE=1 SV=1 
CELE_Y79H2A Y79H2A.3, isoform f OS=Caenorhabditis elegans GN=CELE_Y79H2A.3 
PE=1 SV=1 
swsn-2 SWSN-2.2 OS=Caenorhabditis elegans GN=swsn-2.2 PE=1 SV=2 
F32A5 Uncharacterized serine carboxypeptidase F32A5.3 OS=Caenorhabditis elegans 
GN=F32A5.3 PE=1 SV=1 
CELE_T05B9 T05B9.1 OS=Caenorhabditis elegans GN=CELE_T05B9.1 PE=1 SV=1 
lact-9 LACT-9, isoform a OS=Caenorhabditis elegans GN=lact-9 PE=1 SV=1 
tbc-2 TBC-2 OS=Caenorhabditis elegans GN=tbc-2 PE=1 SV=2 
acs-2 ACS-2 OS=Caenorhabditis elegans GN=acs-2 PE=1 SV=1 
ech-8 ECH-8 OS=Caenorhabditis elegans GN=ech-8 PE=1 SV=2 
gst-20 GST-20 OS=Caenorhabditis elegans GN=gst-20 PE=1 SV=1 
alh-6 ALH-6, isoform a OS=Caenorhabditis elegans GN=alh-6 PE=1 SV=1 
C14A4 Putative glycosyltransferase C14A4.3 OS=Caenorhabditis elegans 
GN=C14A4.3 PE=1 SV=2 
wago-4 Piwi-like protein OS=Caenorhabditis elegans GN=wago-4 PE=1 SV=1 
F40A3 Phosphatidylethanolamine-binding protein homolog F40A3.3 
OS=Caenorhabditis elegans GN=F40A3.3 PE=3 SV=1 
kin-20 Casein kinase I isoform delta OS=Caenorhabditis elegans GN=kin-20 PE=2 
SV=3 
unc-94 Tropomodulin OS=Caenorhabditis elegans GN=unc-94 PE=1 SV=2 
rpoa-49 RPOA-49 OS=Caenorhabditis elegans GN=rpoa-49 PE=1 SV=1 
CELE_K12C11 K12C11.1, isoform a OS=Caenorhabditis elegans GN=CELE_K12C11.1 PE=1 
SV=2 
CELE_H20J04 H20J04.4, isoform b OS=Caenorhabditis elegans GN=CELE_H20J04.4 PE=1 
SV=1 
F08C6 Putative choline-phosphate cytidylyltransferase OS=Caenorhabditis elegans 
GN=F08C6.2 PE=3 SV=2 
pkn-1 PKN-1, isoform b OS=Caenorhabditis elegans GN=pkn-1 PE=1 SV=1 
chat-1 CHAT-1, isoform a OS=Caenorhabditis elegans GN=chat-1 PE=1 SV=1 
CELE_T08G11 T08G11.1, isoform a OS=Caenorhabditis elegans GN=CELE_T08G11.1 PE=1 
SV=1 
cyn-12 Peptidyl-prolyl cis-trans isomerase OS=Caenorhabditis elegans GN=cyn-12 
PE=1 SV=1 
dhs-12 DHS-12 OS=Caenorhabditis elegans GN=dhs-12 PE=1 SV=1 
C34B2 C34B2.8 OS=Caenorhabditis elegans GN=C34B2.8 PE=1 SV=1 
unc-43 UNC-43, isoform r OS=Caenorhabditis elegans GN=unc-43 PE=1 SV=1 
rpac-40 RPAC-40 OS=Caenorhabditis elegans GN=rpac-40 PE=1 SV=2 
CELE_F53H1 F53H1.1, isoform a OS=Caenorhabditis elegans GN=CELE_F53H1.1 PE=1 
SV=1 
rpl-28 60S ribosomal protein L28 OS=Caenorhabditis elegans GN=rpl-28 PE=1 
SV=3 
msi-1 MSI-1 OS=Caenorhabditis elegans GN=msi-1 PE=1 SV=1 
T19C3 Uncharacterized protein T19C3.4 OS=Caenorhabditis elegans GN=T19C3.4 
PE=3 SV=1 
CELE_M01G5 M01G5.3 OS=Caenorhabditis elegans GN=CELE_M01G5.3 PE=1 SV=2 
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C35C5 Putative selT-like protein C35C5.3 OS=Caenorhabditis elegans GN=C35C5.3 
PE=3 SV=2 
cmd-1 Calmodulin OS=Caenorhabditis elegans GN=cmd-1 PE=1 SV=3 
ubr-1 E3 ubiquitin-protein ligase ubr-1 OS=Caenorhabditis elegans GN=ubr-1 PE=1 
SV=2 
CELE_W07E6 W07E6.2 OS=Caenorhabditis elegans GN=CELE_W07E6.2 PE=1 SV=1 
cyp-37a1 CYP-37A1 OS=Caenorhabditis elegans GN=cyp-37a1 PE=1 SV=2 
C02F5 Uncharacterized GTP-binding protein C02F5.3 OS=Caenorhabditis elegans 
GN=C02F5.3 PE=3 SV=2 
CELE_F21C10 F21C10.9 OS=Caenorhabditis elegans GN=CELE_F21C10.9 PE=1 SV=3 
CELE_F17A9 F17A9.4 OS=Caenorhabditis elegans GN=CELE_F17A9.4 PE=1 SV=1 
ehbp-1 EHBP-1 OS=Caenorhabditis elegans GN=ehbp-1 PE=1 SV=1 
mec-7 Tubulin beta-1 chain OS=Caenorhabditis elegans GN=mec-7 PE=2 SV=1 
CELE_F42A10 F42A10.5 OS=Caenorhabditis elegans GN=CELE_F42A10.5 PE=1 SV=1 
gex-3 Membrane-associated protein gex-3 OS=Caenorhabditis elegans GN=gex-3 
PE=1 SV=2 
C18E9 C18E9.4 OS=Caenorhabditis elegans GN=C18E9.4 PE=1 SV=1 
acs-14 ACS-14 OS=Caenorhabditis elegans GN=acs-14 PE=1 SV=1 
ncl-1 B-box type zinc finger protein ncl-1 OS=Caenorhabditis elegans GN=ncl-1 
PE=2 SV=1 
C39D10 C39D10.8, isoform a OS=Caenorhabditis elegans GN=C39D10.8 PE=1 SV=1 
klc-1 KLC-1, isoform a OS=Caenorhabditis elegans GN=klc-1 PE=1 SV=2 
smc-5 SMC-5 OS=Caenorhabditis elegans GN=smc-5 PE=1 SV=2 
CELE_Y48G10A Y48G10A.3 OS=Caenorhabditis elegans GN=CELE_Y48G10A.3 PE=1 SV=1 
Y48B6A Ribosome biogenesis protein BOP1 homolog OS=Caenorhabditis elegans 
GN=Y48B6A.1 PE=3 SV=1 
C27F2 C27F2.8 OS=Caenorhabditis elegans GN=C27F2.8 PE=1 SV=4 
dis-3 Probable exosome complex exonuclease RRP44 OS=Caenorhabditis elegans 
GN=dis-3 PE=3 SV=2 
ND1 NADH-ubiquinone oxidoreductase chain 1 OS=Caenorhabditis elegans 
GN=ND1 PE=3 SV=1 
str-101 STR-101 OS=Caenorhabditis elegans GN=str-101 PE=4 SV=3 
glt-1 Excitatory amino acid transporter OS=Caenorhabditis elegans GN=glt-1 PE=1 
SV=2 
CELE_T28C6 T28C6.7, isoform b OS=Caenorhabditis elegans GN=CELE_T28C6.7 PE=1 
SV=1 
cyk-3 CYK-3, isoform a OS=Caenorhabditis elegans GN=cyk-3 PE=1 SV=1 
soap-1 SOAP-1 OS=Caenorhabditis elegans GN=soap-1 PE=1 SV=1 
C27H6 UPF0160 protein C27H6.8 OS=Caenorhabditis elegans GN=C27H6.8 PE=3 
SV=2 
atg-2 ATG-2 OS=Caenorhabditis elegans GN=atg-2 PE=1 SV=3 
lbp-6 Fatty acid-binding protein homolog 6 OS=Caenorhabditis elegans GN=lbp-6 
PE=1 SV=1 
cyp-29a2 CYP-29A2 OS=Caenorhabditis elegans GN=cyp-29a2 PE=1 SV=1 
him-10 Kinetochore protein Nuf2 homolog OS=Caenorhabditis elegans GN=him-10 
PE=1 SV=1 
sec-16 Protein transport protein Sec16 OS=Caenorhabditis elegans GN=sec-16 PE=3 
SV=1 
CELE_F18F11 F18F11.1 OS=Caenorhabditis elegans GN=CELE_F18F11.1 PE=1 SV=1 
ani-1 Anillin-like protein 1 OS=Caenorhabditis elegans GN=ani-1 PE=2 SV=2 
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eif-3 Eukaryotic translation initiation factor 3 subunit C OS=Caenorhabditis elegans 
GN=eif-3.C PE=3 SV=2 
csn-6 CSN-6, isoform b OS=Caenorhabditis elegans GN=csn-6 PE=1 SV=1 
mrps-5 Putative 28S ribosomal protein S5, mitochondrial OS=Caenorhabditis elegans 
GN=mrps-5 PE=3 SV=3 
CELE_Y17G9B Y17G9B.5 OS=Caenorhabditis elegans GN=CELE_Y17G9B.5 PE=1 SV=1 
COX1 Cytochrome c oxidase subunit 1 OS=Caenorhabditis elegans GN=COX1 PE=3 
SV=1 
farl-11 FARL-11 OS=Caenorhabditis elegans GN=farl-11 PE=1 SV=2 
chd-7 CHD-7 OS=Caenorhabditis elegans GN=chd-7 PE=1 SV=3 
mel-28 MEL-28 OS=Caenorhabditis elegans GN=mel-28 PE=1 SV=2 
frl-1 FRL-1 OS=Caenorhabditis elegans GN=frl-1 PE=1 SV=3 
hpo-3 HPO-3, isoform b OS=Caenorhabditis elegans GN=hpo-3 PE=1 SV=2 
umps-1 UMPS-1 OS=Caenorhabditis elegans GN=umps-1 PE=1 SV=1 
CELE_F35G12 F35G12.12 OS=Caenorhabditis elegans GN=CELE_F35G12.12 PE=1 SV=3 
CELE_Y23H5B Y23H5B.5 OS=Caenorhabditis elegans GN=CELE_Y23H5B.5 PE=1 SV=2 
ugt-13 UGT-13 OS=Caenorhabditis elegans GN=ugt-13 PE=1 SV=2 
djr-1 Glutathione-independent glyoxalase DJR-1.1 OS=Caenorhabditis elegans 
GN=djr-1.1 PE=1 SV=1 
lin-33 LIN-33, isoform a OS=Caenorhabditis elegans GN=lin-33 PE=1 SV=1 
asf-1 Probable histone chaperone asf-1 OS=Caenorhabditis elegans GN=asf-1 PE=3 
SV=2 
bet-1 BET-1, isoform a OS=Caenorhabditis elegans GN=bet-1 PE=1 SV=3 
C52A10 Carboxylic ester hydrolase OS=Caenorhabditis elegans GN=C52A10.1 PE=1 
SV=1 
kcc-2 KCC-2, isoform a OS=Caenorhabditis elegans GN=kcc-2 PE=1 SV=1 
pbs-2 Proteasome subunit beta type OS=Caenorhabditis elegans GN=pbs-2 PE=1 
SV=1 
C08F8 C08F8.3, isoform a OS=Caenorhabditis elegans GN=C08F8.3 PE=1 SV=2 
CELE_F31D4 F31D4.2 OS=Caenorhabditis elegans GN=CELE_F31D4.2 PE=1 SV=1 
rpl-24 60S ribosomal protein L24 OS=Caenorhabditis elegans GN=rpl-24.1 PE=3 
SV=1 
CELE_F49C12 F49C12.7, isoform a OS=Caenorhabditis elegans GN=CELE_F49C12.7 PE=1 
SV=1 
CELE_F13E9 F13E9.1 OS=Caenorhabditis elegans GN=CELE_F13E9.1 PE=1 SV=1 
CELE_F17C11 F17C11.12, isoform b OS=Caenorhabditis elegans GN=CELE_F17C11.12 
PE=1 SV=1 
3E324 3E324 OS=Caenorhabditis elegans GN=3E324 PE=1 SV=1 
C05D11 Uncharacterized protein C05D11.1 OS=Caenorhabditis elegans GN=C05D11.1 
PE=4 SV=2 
nbet-1 BET1 OS=Caenorhabditis elegans GN=nbet-1 PE=1 SV=1 
ugt-25 UDP-glucuronosyltransferase OS=Caenorhabditis elegans GN=ugt-25 PE=1 
SV=1 
egg-6 Leucine-rich repeat-containing protein egg-6 OS=Caenorhabditis elegans 
GN=egg-6 PE=2 SV=2 
B0495 Putative endoplasmic reticulum metallopeptidase 1-A OS=Caenorhabditis 
elegans GN=B0495.7 PE=1 SV=2 
gld-4 Poly(A) RNA polymerase gld-4 OS=Caenorhabditis elegans GN=gld-4 PE=1 
SV=1 
hyl-1 Ceramide synthase hyl-1 OS=Caenorhabditis elegans GN=hyl-1 PE=1 SV=1 
 
 228 
C09G9 C09G9.1, isoform b OS=Caenorhabditis elegans GN=C09G9.1 PE=1 SV=1 
CELE_Y113G7C Protein-tyrosine-phosphatase OS=Caenorhabditis elegans 
GN=CELE_Y113G7C.1 PE=1 SV=1 
asp-2 ASP-2, isoform a OS=Caenorhabditis elegans GN=asp-2 PE=1 SV=1 
wrk-1 WRK-1, isoform a OS=Caenorhabditis elegans GN=wrk-1 PE=1 SV=1 
CELE_Y76B12C Y76B12C.6, isoform b OS=Caenorhabditis elegans GN=CELE_Y76B12C.6 
PE=1 SV=1 
tut-1 Cytoplasmic tRNA 2-thiolation protein 1 OS=Caenorhabditis elegans GN=tut-
1 PE=1 SV=1 
ceh-44 Protein CASP OS=Caenorhabditis elegans GN=ceh-44 PE=3 SV=1 
CELE_F48E8 F48E8.4 OS=Caenorhabditis elegans GN=CELE_F48E8.4 PE=1 SV=4 
cyp-35a3 CYP-35A3 OS=Caenorhabditis elegans GN=cyp-35a3 PE=1 SV=1 
rep-1 REP-1, isoform a OS=Caenorhabditis elegans GN=rep-1 PE=1 SV=1 
C01G10 C01G10.8 OS=Caenorhabditis elegans GN=C01G10.8 PE=1 SV=1 
mau-2 Maternal uncoordinated protein 2 OS=Caenorhabditis elegans GN=mau-2 
PE=1 SV=1 
far-1 Fatty-acid and retinol-binding protein 1 OS=Caenorhabditis elegans GN=far-1 
PE=3 SV=1 
sup-1 Protein SUP-1 OS=Caenorhabditis elegans GN=sup-1 PE=1 SV=1 
iws-1 IWS1-like protein OS=Caenorhabditis elegans GN=iws-1 PE=3 SV=1 
CELE_F13B9 F13B9.1, isoform a OS=Caenorhabditis elegans GN=CELE_F13B9.1 PE=1 
SV=1 
gsp-4 Serine/threonine-protein phosphatase OS=Caenorhabditis elegans GN=gsp-4 
PE=3 SV=1 
sna-2 SNA-2 OS=Caenorhabditis elegans GN=sna-2 PE=1 SV=1 
CELE_Y53G8AR Y53G8AR.9 OS=Caenorhabditis elegans GN=CELE_Y53G8AR.9 PE=1 
SV=1 
snb-2 SNB-2 OS=Caenorhabditis elegans GN=snb-2 PE=1 SV=3 
ctg-1 CTG-1, isoform a OS=Caenorhabditis elegans GN=ctg-1 PE=1 SV=2 
lpd-6 LPD-6 OS=Caenorhabditis elegans GN=lpd-6 PE=1 SV=2 
mrps-23 Probable 28S ribosomal protein S23, mitochondrial OS=Caenorhabditis 
elegans GN=mrps-23 PE=3 SV=1 
rnp-2 RNP-2 OS=Caenorhabditis elegans GN=rnp-2 PE=1 SV=2 
ndx-3 Nudix hydrolase 3 OS=Caenorhabditis elegans GN=ndx-3 PE=3 SV=2 
plrg-1 PLRG-1, isoform a OS=Caenorhabditis elegans GN=plrg-1 PE=1 SV=1 
cni-1 Protein cornichon homolog 1 OS=Caenorhabditis elegans GN=cni-1 PE=1 
SV=2 
mrps-25 Probable 28S ribosomal protein S25, mitochondrial OS=Caenorhabditis 
elegans GN=mrps-25 PE=3 SV=1 
alkb-8 ALKB-8 OS=Caenorhabditis elegans GN=alkb-8 PE=1 SV=2 
bcat-1 Branched-chain-amino-acid aminotransferase, cytosolic OS=Caenorhabditis 
elegans GN=bcat-1 PE=2 SV=2 
CELE_W05H9 W05H9.1, isoform a OS=Caenorhabditis elegans GN=CELE_W05H9.1 PE=1 
SV=1 
cdc-73 Cell division cycle protein 73 OS=Caenorhabditis elegans GN=cdc-73 PE=3 
SV=4 
sto-1 Stomatin-1 OS=Caenorhabditis elegans GN=sto-1 PE=3 SV=2 
F13C5 Uncharacterized protein F13C5.5 OS=Caenorhabditis elegans GN=F13C5.5 
PE=1 SV=1 
tba-4 TBA-4 OS=Caenorhabditis elegans GN=tba-4 PE=1 SV=1 
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CELE_F44E7 F44E7.4, isoform c OS=Caenorhabditis elegans GN=CELE_F44E7.4 PE=1 
SV=1 
CELE_F45F2 F45F2.9, isoform b OS=Caenorhabditis elegans GN=CELE_F45F2.9 PE=1 
SV=1 
CELE_F35H10 F35H10.6 OS=Caenorhabditis elegans GN=CELE_F35H10.6 PE=1 SV=2 
F59E10 Probable coatomer subunit zeta OS=Caenorhabditis elegans GN=F59E10.3 
PE=3 SV=1 
CELE_F49E8 F49E8.7, isoform a OS=Caenorhabditis elegans GN=CELE_F49E8.7 PE=1 
SV=1 
cku-80 ATP-dependent DNA helicase II subunit 2 OS=Caenorhabditis elegans 
GN=cku-80 PE=1 SV=1 
CELE_W06B4 W06B4.1 OS=Caenorhabditis elegans GN=CELE_W06B4.1 PE=1 SV=1 
chs-1 CHS-1 OS=Caenorhabditis elegans GN=chs-1 PE=2 SV=1 
mdt-9 MDT-9, isoform b OS=Caenorhabditis elegans GN=mdt-9 PE=1 SV=1 
hsp-43 HSP-43, isoform b OS=Caenorhabditis elegans GN=hsp-43 PE=1 SV=2 
mrps-26 MRPS-26 OS=Caenorhabditis elegans GN=mrps-26 PE=1 SV=1 
dhs-20 DHS-20 OS=Caenorhabditis elegans GN=dhs-20 PE=1 SV=3 
npp-8 NPP-8, isoform b OS=Caenorhabditis elegans GN=npp-8 PE=1 SV=4 
CELE_F32A5 F32A5.8 OS=Caenorhabditis elegans GN=CELE_F32A5.8 PE=1 SV=2 
CELE_T05E7 T05E7.3 OS=Caenorhabditis elegans GN=CELE_T05E7.3 PE=1 SV=1 
aph-2 APH-2, isoform a OS=Caenorhabditis elegans GN=aph-2 PE=1 SV=1 
capg-1 CAPG-1 OS=Caenorhabditis elegans GN=capg-1 PE=1 SV=1 
CELE_F56D3 F56D3.1 OS=Caenorhabditis elegans GN=CELE_F56D3.1 PE=1 SV=2 
wrm-1 Armadillo repeat-containing protein wrm-1 OS=Caenorhabditis elegans 
GN=wrm-1 PE=1 SV=2 
CELE_F15G9 F15G9.1, isoform c OS=Caenorhabditis elegans GN=CELE_F15G9.1 PE=1 
SV=1 
mos-2 Protein mos-2 homolog OS=Caenorhabditis elegans GN=mos-2 PE=1 SV=1 
mec-17 Alpha-tubulin N-acetyltransferase 1 OS=Caenorhabditis elegans GN=mec-17 
PE=2 SV=1 
C27A7 C27A7.6, isoform c OS=Caenorhabditis elegans GN=C27A7.6 PE=4 SV=1 
F12F6 Probable DNA polymerase delta small subunit OS=Caenorhabditis elegans 
GN=F12F6.7 PE=3 SV=1 
CELE_T10E9 T10E9.4 OS=Caenorhabditis elegans GN=CELE_T10E9.4 PE=1 SV=2 
cpg-2 Chondroitin proteoglycan-2 OS=Caenorhabditis elegans GN=cpg-2 PE=1 
SV=3 
CELE_F56G4 F56G4.6 OS=Caenorhabditis elegans GN=CELE_F56G4.6 PE=1 SV=3 
C24D10 C24D10.6 OS=Caenorhabditis elegans GN=C24D10.6 PE=1 SV=1 
exos-1 EXOS-1 OS=Caenorhabditis elegans GN=exos-1 PE=1 SV=1 
Sep-01 SEP-1 OS=Caenorhabditis elegans GN=sep-1 PE=1 SV=1 
trcs-2 TRCS-2 OS=Caenorhabditis elegans GN=trcs-2 PE=1 SV=3 
trpp-1 TRPP-1 OS=Caenorhabditis elegans GN=trpp-1 PE=1 SV=2 
CELE_F58F9 F58F9.3, isoform b OS=Caenorhabditis elegans GN=CELE_F58F9.3 PE=1 
SV=2 
ced-4 Cell death protein 4 OS=Caenorhabditis elegans GN=ced-4 PE=1 SV=2 
C35D10 C35D10.5 OS=Caenorhabditis elegans GN=C35D10.5 PE=1 SV=2 
CELE_Y49F6B Y49F6B.2 OS=Caenorhabditis elegans GN=CELE_Y49F6B.2 PE=1 SV=1 
cpsf-1 Probable cleavage and polyadenylation specificity factor subunit 1 
OS=Caenorhabditis elegans GN=cpsf-1 PE=3 SV=2 
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CELE_Y110A2AR Y110A2AR.3, isoform a OS=Caenorhabditis elegans 
GN=CELE_Y110A2AR.3 PE=1 SV=1 
CELE_F55A11 F55A11.6, isoform c OS=Caenorhabditis elegans GN=CELE_F55A11.6 PE=1 
SV=1 
wrb-1 WRB-1, isoform a OS=Caenorhabditis elegans GN=wrb-1 PE=1 SV=2 
C48B4 Probable peroxisomal acyl-coenzyme A oxidase OS=Caenorhabditis elegans 
GN=C48B4.1 PE=3 SV=1 
F10E9 Uncharacterized protein F10E9.4 OS=Caenorhabditis elegans GN=F10E9.4 
PE=4 SV=1 
T23D8 Protein LTV1 homolog OS=Caenorhabditis elegans GN=T23D8.3 PE=3 SV=1 
shc-1 SHC-transforming protein homolog 1 OS=Caenorhabditis elegans GN=shc-1 
PE=1 SV=2 
CELE_Y71H2AM Y71H2AM.4 OS=Caenorhabditis elegans GN=CELE_Y71H2AM.4 PE=1 
SV=1 
B0495 Putative endoplasmic reticulum metallopeptidase 1-A OS=Caenorhabditis 
elegans GN=B0495.7 PE=1 SV=2 
gstk-2 Glutathione s-transferase kappa 2 OS=Caenorhabditis elegans GN=gstk-2 
PE=2 SV=1 
Y48A5A Protein SHQ1 homolog OS=Caenorhabditis elegans GN=Y48A5A.1 PE=3 
SV=4 
CELE_D2085 D2085.3 OS=Caenorhabditis elegans GN=CELE_D2085.3 PE=1 SV=1 
dnj-21 Mitochondrial import inner membrane translocase subunit TIM14 
OS=Caenorhabditis elegans GN=dnj-21 PE=3 SV=1 
CELE_R144 R144.13 OS=Caenorhabditis elegans GN=CELE_R144.13 PE=1 SV=1 
CELE_M60 M60.4, isoform b OS=Caenorhabditis elegans GN=CELE_M60.4 PE=1 SV=1 
CELE_Y43F8A Y43F8A.2 OS=Caenorhabditis elegans GN=CELE_Y43F8A.2 PE=1 SV=1 
otub-3 OTUB-3, isoform b OS=Caenorhabditis elegans GN=otub-3 PE=1 SV=1 
CELE_F43G9 F43G9.4 OS=Caenorhabditis elegans GN=CELE_F43G9.4 PE=1 SV=1 
CELE_Y57G11B Y57G11B.5 OS=Caenorhabditis elegans GN=CELE_Y57G11B.5 PE=1 SV=1 
zhit-3 ZHIT-3 OS=Caenorhabditis elegans GN=zhit-3 PE=1 SV=2 
lron-9 LRON-9, isoform a OS=Caenorhabditis elegans GN=lron-9 PE=1 SV=1 
hoe-1 Ribonuclease Z OS=Caenorhabditis elegans GN=hoe-1 PE=2 SV=2 
CELE_T26E3 T26E3.4 OS=Caenorhabditis elegans GN=CELE_T26E3.4 PE=1 SV=3 
ify-1 IFY-1 OS=Caenorhabditis elegans GN=ify-1 PE=1 SV=1 
cnb-1 CNB-1 OS=Caenorhabditis elegans GN=cnb-1 PE=1 SV=1 
CELE_F54E12 F54E12.2 OS=Caenorhabditis elegans GN=CELE_F54E12.2 PE=1 SV=1 
paf-2 Platelet-activating factor acetylhydrolase homolog 2 OS=Caenorhabditis 
elegans GN=paf-2 PE=2 SV=2 
ugt-5 UDP-glucuronosyltransferase OS=Caenorhabditis elegans GN=ugt-5 PE=1 
SV=2 
CELE_R07E5 R07E5.7 OS=Caenorhabditis elegans GN=CELE_R07E5.7 PE=1 SV=1 
CELE_F28C1 F28C1.3, isoform c OS=Caenorhabditis elegans GN=CELE_F28C1.3 PE=1 
SV=1 
CELE_F17E9 F17E9.4 OS=Caenorhabditis elegans GN=CELE_F17E9.4 PE=1 SV=2 
mrpl-11 Probable 39S ribosomal protein L11, mitochondrial OS=Caenorhabditis 
elegans GN=mrpl-11 PE=3 SV=1 
ent-2 ENT-2 OS=Caenorhabditis elegans GN=ent-2 PE=1 SV=1 
gfi-2 GFI-2, isoform a OS=Caenorhabditis elegans GN=gfi-2 PE=1 SV=1 
nsun-5 Y53F4B.4, isoform b OS=Caenorhabditis elegans GN=nsun-5 PE=1 SV=2 
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ZK20 Cytochrome c oxidase assembly factor 7 homolog OS=Caenorhabditis elegans 
GN=ZK20.4 PE=3 SV=1 
CELE_T09B4 T09B4.8 OS=Caenorhabditis elegans GN=CELE_T09B4.8 PE=1 SV=3 
C34B2 C34B2.8 OS=Caenorhabditis elegans GN=C34B2.8 PE=1 SV=1 
CELE_F53E10 F53E10.1 OS=Caenorhabditis elegans GN=CELE_F53E10.1 PE=1 SV=1 
pssy-1 PSSY-1 OS=Caenorhabditis elegans GN=pssy-1 PE=1 SV=1 
ubc-7 Probable ubiquitin-conjugating enzyme E2 7 OS=Caenorhabditis elegans 
GN=ubc-7 PE=1 SV=1 
CELE_Y47G6A Y47G6A.18 OS=Caenorhabditis elegans GN=CELE_Y47G6A.18 PE=1 SV=2 
CELE_F33C8 F33C8.4 OS=Caenorhabditis elegans GN=CELE_F33C8.4 PE=1 SV=3 
kbp-5 KBP-5 OS=Caenorhabditis elegans GN=kbp-5 PE=1 SV=1 
CELE_F32A7 F32A7.5, isoform d OS=Caenorhabditis elegans GN=CELE_F32A7.5 PE=1 
SV=1 
CELE_R186 R186.3 OS=Caenorhabditis elegans GN=CELE_R186.3 PE=1 SV=1 
acs-6 ACS-6 OS=Caenorhabditis elegans GN=acs-6 PE=1 SV=1 
CELE_T07A9 T07A9.10 OS=Caenorhabditis elegans GN=CELE_T07A9.10 PE=1 SV=1 
cdc-14 Probable tyrosine-protein phosphatase cdc-14 OS=Caenorhabditis elegans 
GN=cdc-14 PE=1 SV=2 
Oct-02 OCT-2, isoform a OS=Caenorhabditis elegans GN=oct-2 PE=1 SV=4 
CELE_Y38C1AA Y38C1AA.7 OS=Caenorhabditis elegans GN=CELE_Y38C1AA.7 PE=1 
SV=1 
arf-6 ARF-6 OS=Caenorhabditis elegans GN=arf-6 PE=1 SV=1 
erv-46 ERV-46 OS=Caenorhabditis elegans GN=erv-46 PE=1 SV=1 
CELE_Y57G11A Y57G11A.2 OS=Caenorhabditis elegans GN=CELE_Y57G11A.2 PE=1 SV=1 
C34C6 C34C6.4 OS=Caenorhabditis elegans GN=C34C6.4 PE=1 SV=1 
CELE_Y37D8A Y37D8A.19 OS=Caenorhabditis elegans GN=CELE_Y37D8A.19 PE=1 SV=1 
CELE_F43C9 F43C9.2 OS=Caenorhabditis elegans GN=CELE_F43C9.2 PE=1 SV=2 
CELE_D1086 D1086.8, isoform a OS=Caenorhabditis elegans GN=CELE_D1086.8 PE=1 
SV=1 
pcp-4 PCP-4 OS=Caenorhabditis elegans GN=pcp-4 PE=1 SV=1 
pes-4 PES-4 OS=Caenorhabditis elegans GN=pes-4 PE=1 SV=3 
fmo-5 Dimethylaniline monooxygenase [N-oxide-forming] OS=Caenorhabditis 
elegans GN=fmo-5 PE=1 SV=1 
Y56A3A Zinc finger protein 593 homolog OS=Caenorhabditis elegans GN=Y56A3A.18 
PE=3 SV=1 
nepr-1 NEPR-1, isoform b OS=Caenorhabditis elegans GN=nepr-1 PE=1 SV=1 
mrps-24 28S ribosomal protein S24, mitochondrial OS=Caenorhabditis elegans 
GN=mrps-24 PE=3 SV=1 
tnc-2 Troponin C, isoform 2 OS=Caenorhabditis elegans GN=tnc-2 PE=2 SV=1 
CELE_K08E7 K08E7.8, isoform a OS=Caenorhabditis elegans GN=CELE_K08E7.8 PE=4 
SV=1 
F09G8 Uncharacterized protein F09G8.7 OS=Caenorhabditis elegans GN=F09G8.7 
PE=4 SV=1 
F44B9 Probable replication factor C subunit 5 OS=Caenorhabditis elegans 
GN=F44B9.8 PE=3 SV=3 
CELE_Y66A7A Ribonuclease P/MRP protein subunit POP5 OS=Caenorhabditis elegans 
GN=CELE_Y66A7A.2 PE=1 SV=1 
tbh-1 Tyramine beta-hydroxylase OS=Caenorhabditis elegans GN=tbh-1 PE=1 
SV=3 
teg-1 TEG-1 OS=Caenorhabditis elegans GN=teg-1 PE=1 SV=2 
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zig-9 ZIG-9 OS=Caenorhabditis elegans GN=zig-9 PE=1 SV=3 
ugt-64 UGT-64 OS=Caenorhabditis elegans GN=ugt-64 PE=1 SV=1 
hrpf-2 HRPF-2, isoform a OS=Caenorhabditis elegans GN=hrpf-2 PE=1 SV=1 
CELE_F37B12 F37B12.3 OS=Caenorhabditis elegans GN=CELE_F37B12.3 PE=1 SV=2 
CELE_W08E3 W08E3.2 OS=Caenorhabditis elegans GN=CELE_W08E3.2 PE=1 SV=1 
CELE_F58E6 F58E6.13, isoform d OS=Caenorhabditis elegans GN=CELE_F58E6.13 PE=1 
SV=1 
aly-1 ALY-1 OS=Caenorhabditis elegans GN=aly-1 PE=1 SV=1 
VPS34 Phosphatidylinositol 3-kinase OS=Caenorhabditis elegans GN=VPS34 PE=2 
SV=1 
CELE_K07A1 K07A1.9, isoform a OS=Caenorhabditis elegans GN=CELE_K07A1.9 PE=1 
SV=2 
dsh-1 DSH-1, isoform c OS=Caenorhabditis elegans GN=dsh-1 PE=1 SV=1 
taf-1 TAF-1 OS=Caenorhabditis elegans GN=taf-1 PE=1 SV=1 
cccp-1 CCCP-1 OS=Caenorhabditis elegans GN=cccp-1 PE=2 SV=1 
M01F1 Lipoyl synthase, mitochondrial OS=Caenorhabditis elegans GN=M01F1.3 
PE=3 SV=1 
CELE_Y56A3A Acyl carrier protein OS=Caenorhabditis elegans GN=CELE_Y56A3A.19 
PE=1 SV=1 
C06A8 C06A8.3 OS=Caenorhabditis elegans GN=C06A8.3 PE=1 SV=1 
ttr-26 TTR-26 OS=Caenorhabditis elegans GN=ttr-26 PE=1 SV=1 
ttr-32 TTR-32 OS=Caenorhabditis elegans GN=ttr-32 PE=1 SV=1 
C49F8 C49F8.3 OS=Caenorhabditis elegans GN=C49F8.3 PE=1 SV=1 
CELE_F10C1 F10C1.9, isoform b OS=Caenorhabditis elegans GN=CELE_F10C1.9 PE=1 
SV=1 
syp-3 SYP-3 OS=Caenorhabditis elegans GN=syp-3 PE=1 SV=2 
gst-35 GST-35 OS=Caenorhabditis elegans GN=gst-35 PE=1 SV=2 
CELE_R144 R144.13 OS=Caenorhabditis elegans GN=CELE_R144.13 PE=1 SV=1 
CELE_F29C6 F29C6.1, isoform a OS=Caenorhabditis elegans GN=CELE_F29C6.1 PE=1 
SV=1 
CELE_Y49E10 Y49E10.21, isoform a OS=Caenorhabditis elegans GN=CELE_Y49E10.21 
PE=1 SV=1 
san-1 SAN-1 OS=Caenorhabditis elegans GN=san-1 PE=1 SV=2 
F21D5 Uncharacterized protein F21D5.5 OS=Caenorhabditis elegans GN=F21D5.5 
PE=2 SV=2 
C17C3 C17C3.1, isoform e OS=Caenorhabditis elegans GN=C17C3.1 PE=1 SV=1 
CELE_T01G1 T01G1.2 OS=Caenorhabditis elegans GN=CELE_T01G1.2 PE=1 SV=1 
CELE_ZK899 ZK899.2 OS=Caenorhabditis elegans GN=CELE_ZK899.2 PE=1 SV=2 
mvb-12 MVB-12 OS=Caenorhabditis elegans GN=mvb-12 PE=1 SV=1 
syx-16 SYX-16 OS=Caenorhabditis elegans GN=syx-16 PE=1 SV=2 
klo-1 KLO-1 OS=Caenorhabditis elegans GN=klo-1 PE=1 SV=1 
pfkb-1 PFKB-1.1, isoform a OS=Caenorhabditis elegans GN=pfkb-1.1 PE=1 SV=2 
sek-3 SEK-3, isoform a OS=Caenorhabditis elegans GN=sek-3 PE=1 SV=3 
CELE_Y37H9A Y37H9A.1, isoform b OS=Caenorhabditis elegans GN=CELE_Y37H9A.1 
PE=4 SV=1 
acs-11 ACS-11 OS=Caenorhabditis elegans GN=acs-11 PE=1 SV=3 




CELE_Y62H9A Y62H9A.6 OS=Caenorhabditis elegans GN=CELE_Y62H9A.6 PE=1 SV=1 
mig-23 Nucleoside-diphosphatase mig-23 OS=Caenorhabditis elegans GN=mig-23 
PE=1 SV=2 
B0513 Proline dehydrogenase 1, mitochondrial OS=Caenorhabditis elegans 
GN=B0513.5 PE=3 SV=2 
C46F11 C46F11.4 OS=Caenorhabditis elegans GN=C46F11.4 PE=1 SV=2 
CELE_Y37E11AL Y37E11AL.3, isoform a OS=Caenorhabditis elegans GN=CELE_Y37E11AL.3 
PE=4 SV=1 
CELE_F45G2 F45G2.7 OS=Caenorhabditis elegans GN=CELE_F45G2.7 PE=4 SV=1 
CELE_Y43C5B Y43C5B.3 OS=Caenorhabditis elegans GN=CELE_Y43C5B.3 PE=1 SV=1 
tads-1 TADS-1 OS=Caenorhabditis elegans GN=tads-1 PE=1 SV=1 
adpr-1 ADPR-1, isoform a OS=Caenorhabditis elegans GN=adpr-1 PE=1 SV=1 
his-3 Histone H2A OS=Caenorhabditis elegans GN=his-3 PE=1 SV=2 
rga-1 RGA-1, isoform a OS=Caenorhabditis elegans GN=rga-1 PE=1 SV=1 
CELE_F54A3 F54A3.2 OS=Caenorhabditis elegans GN=CELE_F54A3.2 PE=1 SV=5 
algn-14 HPO-16, isoform b OS=Caenorhabditis elegans GN=algn-14 PE=1 SV=1 
B0001 Probable uridine-cytidine kinase OS=Caenorhabditis elegans GN=B0001.4 
PE=3 SV=2 
CELE_F44G4 F44G4.3 OS=Caenorhabditis elegans GN=CELE_F44G4.3 PE=4 SV=1 
mak-1 MAK-1, isoform a OS=Caenorhabditis elegans GN=mak-1 PE=1 SV=1 
BE0003N10 BE0003N10.1 OS=Caenorhabditis elegans GN=BE0003N10.1 PE=1 SV=3 
gst-40 GST-40 OS=Caenorhabditis elegans GN=gst-40 PE=1 SV=2 
C41D11 Uncharacterized protein C41D11.5 OS=Caenorhabditis elegans GN=C41D11.5 
PE=4 SV=2 
prp-4 PRP-4 OS=Caenorhabditis elegans GN=prp-4 PE=1 SV=1 
CELE_R01B10 R01B10.6 OS=Caenorhabditis elegans GN=CELE_R01B10.6 PE=1 SV=1 
dmd-8 DMD-8 OS=Caenorhabditis elegans GN=dmd-8 PE=4 SV=2 
CELE_K07C5 K07C5.2 OS=Caenorhabditis elegans GN=CELE_K07C5.2 PE=1 SV=1 
CELE_E01B7 E01B7.1 OS=Caenorhabditis elegans GN=CELE_E01B7.1 PE=1 SV=1 
Supplemental Table 5 Summary of all proteins precipitated from N2 animals following biotinylated isoxazole treatment that 
show a greater than 50% change in abundance compared to DMSO treated control animals (OS = Organism Name; GN = Gene 
Name; PE = Evidence of Protein Existence; SV = Sequence Version) 
 
 
 
